1- (1H- INDOL- 1-YL) -3- (METHYLAMINO) -1- PHENYLPROPAN-2 -OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) CROSS REFERENCE TO RELATED. APPLICATIONS This application claims priority to U.S. Application No 60/721,676 filed September 29, 2005, the entire disclosure of which is incorporated herein by reference. FIELD OF THE INVENTION The present invention relates to phenylaminopropanol derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, schizophrenia, and combinations thereof. BACKGROUND OF THE INVENTION Vasomotor symptoms (VMS), referred to as hot flushes and night sweats, are the most common symptoms associated with menopause, occurring in 60% to 80% of all women following natural or surgically-induced menopause. VMS are likely to be an adaptive response of the central nervous system (CNS) to declining sex steroids. To date, the most effective therapies for VMS are hormone-based treatments, including estrogens and/or some progestins. Hormonal treatments are very effective at alleviating VMS, but they are not appropriate for all women. It is well recognized that VMS are caused by fluctuations of sex steroid levels and can be disruptive and disabling in both males and females. A hot flush can last up to thirty minutes and vary in their frequency from several times a week to multiple occurrences per day. The patient experiences a hot flash as a sudden feeling of 'hea't Ma?sprea'ds^qtitc'Kty"ffom the faoe to the chest and back and then over the rest of the body. It is usually accompanied by outbreaks of profuse sweating. It may sometimes occur several times an hour, and it often occurs at night. Hot flushes and outbreaks of sweats occurring during the night can cause sleep deprivation. Psychological and emotional symptoms observed, such as nervousness, fatigue, irritability, insomnia, depression, memory loss, headache, anxiety, nervousness or inability to concentrate are considered to be caused by the sleep deprivation following hot flush and night sweats (Kramer et a/., In: Murphy et at., 3rd Infl Symposium on Recent Advances in Urological Cancer Diagnosis and Treatment-Proceedings, Paris, France: SCI: 3-7 (1992)). Hot flushes may be even more severe in women treated for breast cancer for several reasons: 1) many survivors of breast cancer are given tamoxifen, the most prevalent side effect of which is hot flush, 2) many women treated for breast cancer undergo premature menopause from chemotherapy, 3) women with a history of breast cancer have generally been denied estrogen therapy because of concerns about potential recurrence of breast cancer (Loprinzi, et a/., Lancer, 2000, 356(9247): 2059-2063). Men also experience hot flushes following steroid hormone (androgen) withdrawal. This is true in cases of age-associated androgen decline (Katovich, et a/., Proceedings of the Society for Experimental Biology & Medicine, 1990, 193(2): 129-35) as well as in extreme cases of hormone deprivation associated with treatments for prostate cancer (Berendsen, et at., European Journal 'of Pharmacology, 2001, 419(1): 47-54. As many as one-third of these patients will experience persistent and frequent symptoms severe enough to cause significant discomfort and inconvenience. The precise mechanism of these symptoms is unknown but generally is thought to represent disturbances to normal homeostatic mechanisms controlling thermoregulation and vasomotor activity (Kronenberg, et a/., "Thermoregulatory Physiology of Menopausal Hot Flashes: A Review," Can. J. Physiol. Pharmacol., 1987,65:1312-1324). The fact that estrogen treatment (e.g., estrogen replacement therapy) relieves the symptoms establishes the link between these symptoms and an estrogen deficiency. For example, the menopausal stage of life is associated with a wide range of other acute symptoms as described above and these symptoms are generally estrogen responsive. It has been suggested that estrogens may stimulate the activity of both the norepinephrine (NE) and/or serotonin (5-HT) systems (J. Pharmacology & Experimental Therapeutics, 1986, 236(3) 646-652). It is hypothesized that estrogens modulate NE and 5-HT levels providing homeostasis in the thermoregulatory center of the hypothalamus. The descending pathways from the hypothalamus via brainstem/spinal cord and the adrenals to the skin are involved in maintaining normal skin temperature. The action of NE and 5-HT reuptake inhibitors is known to impinge on both the CNS and peripheral nervous system (PNS). The pathophysiology of VMS is mediated by both central and peripheral mechanisms and, therefore, the interplay between the CNS and PNS may account for the efficacy of dual acting SRI/NRIs in the treatment of thermoregulatory dysfunction. In fact, the physiological aspects and the CNS/PNS involvement in VMS may account for the lower doses proposed to treat VMS (Loprinzi, et al., Lancet, 2000, 356:2059-2063; Steams et al., JAMA, 2003, 289:2827-2834) compared to doses used to treat the behavioral aspects of depression. The interplay of the CNS/PNS in the pathophysiology of VMS and the presented data within this document were used to support the claims that the norepinephrine system could be targeted to treat VMS. It has been reported that serotonin 2A (S-HTsA) receptors play a role in temperature regulation (Berendsen, Maturitas, 2000, 36, 155). A low blood estrogen level has been shown to correlate with a high concentration of the 5-HT;>A receptor subtype on blood platelets (Biegon, Effects of steroid hormones on the serotonergic system. In: Whitaker-Azmitia, Peroutka editors. The Neuropharmacology of Serotonin. 1990, 427-34) and an upregulation of central S-HTaA receptors (Fink et al., Nature, 1996, 383, 306). The 5-HT2 and 5-HT3 receptor antagonist mirtazapine, was reported to be effective in reducing the frequency and intensity of hot flushes tf.^WISMfltas, 2000, 36, 165). The 5-HT2 receptor antagonist mianserin was also shown to be effective in treating hot flushes (Takagi, et al., Sanfujinka No Sekai (World Obstet Gynecof) 1986, 36, 853). The combination of a norepinephrine reuptake inhibitor with a 5-HTaA receptor antagonist has also been reported to result in enhanced activity in animal models of thermoregulatory dysfunction (Deecher, et al., WO 2004/035036). Although VMS are most commonly treated by hormone therapy (orally, transdermally, or via an implant), some patients cannot tolerate estrogen treatment (Berendsen, Maturitas, 2000, 36(3): 155-164, Fink et al., Nature, 1996, 383(6598): 306). In addition, hormone replacement therapy is usually not recommended for women or men with or at risk for hormonally sensitive cancers (e.g. breast or prostate cancer). Thus, non-hormonal therapies (e.g. fluoxetine, paroxetine [SRIs] and clonidine) are being evaluated clinically. WO9944601 discloses a method for decreasing hot flushes in a human female by administering fluoxetine. Other options have been studied for the treatment of hot flashes, including steroids, alpha-adrenergic agonists, and beta-blockers, with varying degree of success (Waldinger et al., Maturitas, 2000, 36(3): 165-168). . It has been reported that a2-adrenergic receptors play a role in thermoregulatory dysfunctions (Freedman et a/., Fertility & Sterility, 2000, 74(1): 20-3). These receptors are located both pre- and post-synaptically and mediate an inhibitory role in the central and peripheral nervous system. There are four distinct subtypes of the adrenergic^ receptors, i.e., are a2A, ocas, cizc and 0.20 (Mackinnon et al., TIPS, 1994, 15: 119; French, Pharmacol. Ther, 1995, 68: 175). It has been reported that a non-select ot2-adrenoceptor antagonist, yohimbine, induces a flush and an a2-adrenergic receptor agonist, clonidine, alleviates the yohimbine effect (Katovich, et al., Proceedings of the Society for Experimental Biology & Medicine, 1990, 193(2): 129-35, Freedman et al., Fertility & Sterility, 2000, 74(1): 20-3). Clonidine has been used to treat hot flush. However, using such treatment is associated with a number of undesired side effects caused by high doses necessary to abate hot flash described herein and known in the related arts. Given the complex multifaceted nature of thermoregulation and the interplay between the CMS and PNS in maintaining thermoregulatory homeostasis, multiple therapies and approaches can be developed to target vasomotor symptoms. The present invention focuses on novel compounds and compositions containing these compounds directed to these and other important uses. SUMMARY OF THE INVENTION The present invention is directed to phenylaminopropano! derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, schizophrenia, and combinations thereof. In one embodiment, the invention is directed to compounds of formula I: (Rl)m- Wa'Tp'HafrfiS'ceutically acceptable sait thereof; wherein: the dotted line between Y and Z represents an optional second bond; the dotted line between the two R4 groups represents an optional heterocyclic ring of 4 to 6 ring atoms that may be formed between the two R* groups, together with the nitrogen through which they are attached; X is -(C(Ri2)2)o-, -0(C(R12)2)o-, -(C(Ri2)2)oO-, -S(O)p(C(R12)2)o-, -(C(Ri2)2)0S(0)p-, -N(R13)C(0)(C(R12)2)0-, -(C(R12)2)0C(O)N(R13)-, -C(0)N(R13)(C(R12)2)0-, -(C(Ri2)2)0N(Ri3)C(0)-, -(C(R12)2)0N(R13)S(O)2-, -S(0)2N(R13)(C(R12)2)0-, -N(R,3)S(0)2(C(R12)2)o-, -(C(Ri2)2)0S(O)2N(R13)-, -NR7(C(R12)2)o-, -(C(R12)2)oNR7-, or-OC-; Y is N, C(R6)2, CRe, or C=O; Z is O, S(0)p, N, NR7, CRs, or C(Rs)2; RI is, independently at each occurrence, alkyl, alkoxy, halo, CF3l OCF3, hydroxy, alkanoyloxy, nitro, cyano, alkenyl, alkynyl, alkylsulfoxide, alkylsulfone, alkylsulfonamide, or alkylamido; or two adjacent RI also represent methylenedioxy; R2 is aryl substituted with 0-3 R-u or heteroaryl substituted with 0-3 R14; R3 is H or d-C4 alkyl; R4 is, independently at each occurrence, H, Ci-C4 alkyl, C3-C6 cycloalkyl, arylalkyl, heteroarylmethyl, cycloheptylmethyl, cyclohexylmethyl, cyclopentylmethyl, or cyclobutylmethyl, or both RA groups, together with the nitrogen through which they are attached, form a heterocyclic ring of 4 to 6 ring atoms, where one carbon may be optionally replaced with N, O, S, or SOz, and where any carbon ring atom or additional N atom may be optionally substituted with CrC4 alkyl, F, or CF3; R5 is, independently at each occurrence, H, Ci-C4 alkyl, aryl substituted with 0-3 Ru, heteroaryl substituted with 0-3 Ri4, or cyano; or when two R5 are present, they may form a carbocydic ring of 3-5 carbons; RG is, independently at each occurrence, H, CrC4 alkyl, or cyano; R7 is H, CrC6 alkyl, C3-C6 cycloalkyi, aryl substituted with 0-3 R14; or heteroaryl substituted with 0-3 R14. R8 is H, or CrC4 alkyl; R9 is H, or CrC4 alkyl; at each occurrence, H, or CrC4 alkyl; or R10 and R4 together with the nitrogen to which R4 is attached form a nitrogen-containing ring containing 3-6 carbon atoms; RH is aryl substituted with 0-3 RI or heteroaryl substituted with 0-3 RI; Ria is, independently at each occurrence, H, CrC4 alkyl; R13 is H or Ci-C4 alkyl; Ru is, independently at each occurrence, alkyl, alkoxy, halo, CF3l OCF3, arylalkyloxy substituted with 0-3 RI, aryloxy substituted with 0-3 Ri, aryl substituted with 0-3 Ri, heteroaryl substituted with 0-3 RI, hydroxy, alkanoyloxy, nitro, cyano, alkenyl, alkynyl, alkylsulfoxide, phenylsulfoxide substituted with 0-3 R1t alkylsulfone, phenylsulfone substituted with 0-3 R1t alkylsulfonamide, phenylsulfonamide substituted with 0-3 RI, heteroaryloxy substituted with 0-3 Ri, heteroarylmethyloxy substituted with 0-3 RI, alkylamido, or arylamido substituted with 0-3 RI; or two adjacent RI also represent methylenedioxy; m is an integer from 0 to 3; n is an integer from 1 to 2; o is an integer from 0 to 3; and p is an integer from 0 to 2; wherein 1-3 carbon atoms in ring A may optionally be replaced with N. In another embodiment, the invention is directed to compounds of formula II: Re Rl° Rio -E or a pharmaceutical ly acceptable salt thereof; wherein: D and E, together with the carbon atom through which they are attached, form a carbocydic ring of 6 to 8 atoms or a heterocyclic ring of 5 to 8 atoms containing 1 td 2 h"ete'ro'at&m'"selected Trom O, S(0)p, and NRr, where any carbon ring atom may be optionally substituted with CrC4 alkyl, F or CF3; the dotted line between the two R4 groups represents an optional heterocyclic ring of 4 to 6 ring atoms that may be formed between the two R» groups, together with the nitrogen through which they are attached; G is NR7> C(Re)2, or C=O; R1 is, independently at each occurrence, alkyl, alkoxy, halo, CF3, OCFs, hydroxy, alkanoyloxy, nitro, cyano, alkenyl, alkynyl, alkylsulfoxide, alkylsulfone, alkylsulfonamide, or alkylamido; or two adjacent RI also represent methylenedioxy; R2 is aryl substituted with 0-3 R]4 or heteroary! substituted with 0-3 R14; R3 is H or d-C4 alkyl; R« is, independently at each occurrence, H, Ci-C4 alkyl, C3-C6 cycloalkyl, arylalkyl, heteroarylmethyl, cycloheptylmethyl, cyclohexylmethyl, cydopentylmethyl, or cyclobutylmethyl, or both RA groups, together with the nitrogen through which they are attached, form a heterocyclic ring of 4 to 6 ring atoms, where one carbon .may be optionally replaced with N, O, S, or SOz, and where any carbon ring atom or additional N atom may be optionally substituted with Ci-C4 alkyl, F, or CF3; Re is, independently at each occurrence, H, Ci-C4 alkyl, or cyano; R7 is H, d-C6 alkyi, C3-C6 cycloalkyl, aryl substituted with 0-3 R14; or heteroaryl substituted with 0-3 Ru. Re is H, or CrC4 alkyl; R9 is H, or Ci-C4 alkyl; R10 is, independently at each occurrence, H, or C!-C4 alkyl; or R™ and R4 together with the nitrogen to which R* is attached form a nitrogen-containing ring containing 3-6 carbon atoms; Ru is, independently at each occurrence, alkyl, alkoxy, halo, CF3, OCF3, arylalkyloxy substituted with 0-3 R1§ aryloxy substituted with 0-3 R1f aryl substituted with 0-3 RI, heteroaryl substituted with 0-3 R1f hydroxy, alkanoyloxy, nitro, cyano, alkenyl, alkynyl, alkylsulfoxide, phenylsulfoxide substituted with .0-3 R1t alkylsulfone, phenylsulfone substituted with 0-3 R1f alkylsulfonamide, phenylsulfonamide loxy substituted with 0-3 RI, heteroarylmethyloxy s'U:.stituWwith 0-3 RI, alkylamido, or arylamido substituted with 0-3 R^ or two adjacent RI also represent methylenedioxy; n is an integer from 1 to 2; p is an integer from 0 to 2; and q is an integer from 0 to 4; wherein 1-3 carbon atoms in ring A may optionally be replaced with N. In yet another embodiment, the invention is directed to compounds of formula III: or a pharmaceutically acceptable salt thereof; wherein: the dotted line between Y and Z represents an optional second bond; the dotted line between the two FU groups represents an optional heterocyclic ring of 4 to 6 ring atoms that may be formed between the two FU groups, together with the nitrogen through which they are attached; Y is N, C(R6)2, CRe, or CO; Z is O, S(0)p, N, NR7, CRs, or C(Rs)2; RI is, independently at each occurrence, alkyl, alkoxy, halo, CF3, OCF3, hydroxy, alkanoyloxy, nitro, cyano, alkenyl, alkynyl, alkylsulfoxide, alkylsulfone, alkylsulfonamide, or alkylamido; or two adjacent RI also represent methylenedioxy; R2 is aryl substituted with 0-3 R14 or heteroaryl substituted with 0-3 R14; R3 is H or CrC4 alkyl; R4 is, independently at each occurrence, H, Ci-C4 alkyl, C3-Ce cycloalkyl, arylalkyl, heteroarylmethyl, cycloheptylmethyl, cyclohexylmethy!, cyclopentylmethyl, or cyclobutylmethyl, or both R4 groups, together with the nitrogen through which they are attached, form a heterocyclic ring of 4 to 6 ring atoms, where one carbon may be optionally feplacecf'w'itK NTO", S, of SO2, and where any carbon ri'.g atom or additional N atom may be optionally substituted with CrC4 alkyl, F, or CF3; R5 is, independently at each occurrence, H, d-C4 alkyl, aryl substituted with 0-3 R14, heteroaryl substituted with 0-3 R14, or cyano; or when two R5 are present, they may form a carbocyclic ring of 3-5 carbons; Re is, independently at each occurrence, H, CrC4 alkyl, or cyano; R7 is H, Ci-C6 alkyl, C3-C6 cydoalkyl, aryl substituted with 0-3 R14. or heteroaryl substituted with 0-3 Ru; R8 is H, or Ci-C4 alkyl; R9 is H, or CrC4 alkyl; Rio is, independently at each occurrence, H, or Ci-C4 alkyl; or R10 and R4 together with the nitrogen to which R4 is attached form a nitrogen-containing ring containing 3-6 carbon atoms; Ru is, independently at each occurrence, alkyl, alkoxy, halo, CF3, OCF3l arylalkylbxy substituted with 0-3 Ri, aryloxy substituted with 0-3 Ri, aryl substituted with 0-3 RI, heteroaryl substituted with 0-3 Ri, hydroxy, alkanoyloxy, nitro, cyano, alkenyl, alkynyl, alkylsulfoxide, phenylsulfoxide substituted with 0-3 Rt, alkylsulfone, phenylsulfone substituted with 0-3 RI, alkylsulfonamide, phenylsulfonamide substituted with 0-3 RI, heteroaryloxy substituted with 0-3 R1t heteroarylmethyloxy substituted with 0-3 RI, alkylamido, or arylamido substituted with 0-3 RI; or two adjacent RI also represent methylenedioxy; n is an integer from 1 to 2; and q is an integer from 0 to 4; wherein 1-3 carbon atoms in ring A may optionally be replaced with N. In yet other embodiments, the present invention is directed to compositions, comprising: a. at least one compound of formula I, II, or III, or a pharmaceutically acceptable salt thereof; and b. at least one pharmaceutically acceptable carrier. •4>*""ln"'arl'6ther embodiment, the present invention is directed to methods for treating or preventing a condition ameliorated by monoamine reuptake in a subject in need thereof, comprising the step of: administering to said subject an effective amount of a compound of formula I, II, III, or pharmaceutically acceptable salt thereof. The conditions ameliorated by monoamine reuptake include those selected from the group consisting of vasomotor symptoms, sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof. - -: In another embodiment, the present invention is directed to methods for treating or preventing vasomotor symptoms in a subject in need thereof, comprising the step of: administering to said subject an effective amount of a compound of formula I, II, III, or pharmaceutically acceptable salt thereof. In yet another embodiment, the present invention is directed to methods for treating or preventing a depression disorder in a subject in need thereof, comprising the step of: administering to said subject an effective amount of a compound of formula I, II, III, or pharmaceutically acceptable salt thereof. In yet other embodiments, the present invention is directed to methods for treating or preventing sexual dysfunction in a subject in need thereof, comprising the step of: administering to said subject an effective amount of a compound of formula I, II, III, or pharmaceutically acceptable salt thereof. In further embodiments, the present invention is directed to methods for treating or preventing pain in a subject in need thereof, comprising the step of: 'adrnThistf i ing to said subject an effective amount of a compound of form.,la I, II, III, or pharmaceutically acceptable salt thereof. In another embodiment, the present invention is directed to methods for treating or preventing gastrointestinal or genitourinary disorder, particularly stress incontinence or urge urinary incontinence, in a subject in need thereof, comprising the step of: administering to said subject an effective amount of a compound of formula I, II, III, or pharmaceutically acceptable salt thereof. .. ^ In another embodiment, the present invention is directed to methods for treating or preventing chronic fatigue syndrome in a subject in need thereof, comprising the step of: administering to said subject an effective amount of a compound of formula I, II, III, or pharmaceutically acceptable salt thereof. i In another embodiment, the present invention is directed to methods for treating or preventing fibromylagia syndrome in a subject in need thereof, comprising the step of: administering to said subject an effective amount of a compound of formula I, II, III, or pharmaceutically acceptable salt thereof. In another embodiment, the present invention is directed to methods for treating or preventing schizophrenia in a subject in heed thereof, comprising the step of: administering to said subject an effective amount of a compound of formula I or II, or pharmaceutically acceptable salt thereof. BRIEF DESCRIPTION OF THE DRAWINGS , . \- The invention can be more fully understood from the following detailed description and the accompanying drawings that form a part of this application. "Figure 1 is an overview of estrogen action on norepinephrine/serotonin mediated thermoregulation. Figure 2 is a schematic representation of the interactions of norepinephrine and serotonin and their respective receptors (5-HT2a, ai and . In preferred embodiments of the compound of formula I, Y is C(R6)2, CR6, or C=O. In preferred embodiments of the compound of formula I, Z is CRs or C(Rs)2- In preferred embodiments of the compound of formula 1, RI is, independently at each occurrence, alkyl, alkoxy, halo, CF3, OCF3, hydroxy, alkanoyloxy, nttro, or cyano. In preferred embodiments of the compound of formula I, R2 is aryl substituted with 0-2 R-u, especially, Rz is phenyl, fluorophenyl, ordifluorophenyl. In preferred embodiments of the compound of formula I, Ra is H. In preferred embodiments of the compound of formula I, RA is H or methyl. In preferred embodiments of the compound of formula I, R5 is, independently at each occurrence, H, Ci-C4 alkyl, aryl substituted with 0-3 R14| especially H, methyl, ethyl, n-propyl, isopropyl, aryl substituted with alkoxy, aryl substituted with aryloxy or phenyl substituted with 1-2 halo. In preferreji embodiments of the compound of formula I, R6 is, independently at each occurrence, H, methyl, ethyl, n-propyl, or isopropyl. In preferred embodiments of the compound of formula I, R7 is H, CrC6 alkyl, or aryl substituted with 0-3 In preferred embodiments of the compound of formula I, R8 is H. In preferred embodiments of the compound of formula I, R9 is H. In preferred embodiments of the compound of formula I, Rio is H. In preferred embodiments of the compound of formula I, Rn is aryl substituted with 0-3 Ri, especially Rn is aryl substituted with 0-2 R1f and more especially, phenyl, or aryl substituted with 1-2 halo or alkoxy. In preferred embodiments of the compound of formula I, n is 1. In preferred embodiments of the compound of formula I, none of the carbon atoms in ring A are replaced with N. In preferred embodiments of the compound of formula I, the dotted line between Y and Z represents a second bond; Y is CRe; Z is CRs; X is -(C(R12)2)o-, -{C(R12)2)00-, or -C=C-; RI is, independently at each occurrence, alkyl, alkoxy, halo, CF3, OCF3, hydroxy or cyano; R2 is aryl substituted with 0-3 Ru or heteroaryl substituted with 0-3 R14; R3 is H; R4 is, independently at each occurrence, H or methyl; R5 is, independently at each occurrence, H, methyl or aryl substituted with 0-3 RH; ReisH; Re is H; Rio is H; Rn is aryl substituted with 0-3 RI or heteroaryl substituted with 0-3 RI; R12 is, independently at each occurrence, H or CrC4 alkyl; RM is, independently at each occurrence, alkyl. alkoxy, halo, CF3l OCF3, hydroxy or cyano; m is an integer from 0 to 2; n is 1; and o is an integer from 0 to 3; wherein none of the carbon atoms in ring A are replaced with N. <• In preferred embodiments of the compound of formula I, the bond between Y and Z is a single bond; YisC(R6)2; ZisC(R5)2; X is -{C(Ri2)2)o-, -(C(R12)2)00-, or -CsO; RI is, independently at each occurrence, alkyl, alkoxy, halo, CF3, OCF3l hydroxy or cyano; R2 is aryl substituted with 0-3 Ru or heteroaryl substituted with 0-3 Ri4; R3isH; R4 is, independently at each occurrence, H or methyl; RS is, independently at each occurrence, H, CrC4 alkyl or aryl substituted with 0-3 Ru; Re is independently at each occurrence, H or Ci-C4 alkyl; ReisH; RaisH; RIO is H; RU is aryl substituted with 0-3 RI or heteroaryl substituted with 0-3 R^; R-iz is, independently at each occurrence, H or d-C4 alkyl; R14 is, independently at each occurrence, alkyl, alkoxy, halo, CF3, OCF3, hydroxy or cyano; m is an integer from 0 to 2; n is 1; and 6"is""an integer irorrru to 3; wherein none of the carbon atoms in ring A are replaced with N. In preferred embodiments of the compound of formula I, the bond between Y and Z is a single bond; V is C=O; Z is is C(R5)2; X is -{C(Ri2)2)o-, -(C(Ri2)2)00-, or -C=C-; R-i is, independently at each occurrence, alkyl, alkoxy, halo, CF3, OCF3, hydroxy or cyano; R2 is aryl substituted with 0-3 R^ or heteroaryl substituted with 0-3 R14; R3 is H; R4 is, independently at each occurrence, H or methyl; R5 is, independently at each occurrence, H, or d-C4 alkyl; R8 is H; . R9isH; RIO is H; RH is aryl substituted with 0-3 RI or heteroaryl substituted with 0-3 R^ Ri2 is, independently at each occurrence, H or CrC4 alkyl; RU is, independently at each occurrence, alkyl, alkoxy, halo, CFa, OCF3, hydroxy or cyano; m is an integer from 0 to 2; n is 1; and o is an integer from 0 to 3; wherein none of the carbon atoms in ring A are replaced with N. In preferred embodiments of the compound of formula I, the bond between Y and Z is a single bond; Y is C=O; Z is NR7; X is -(C(R12)2)0-, - alkanoyl-(C]-C4)-alkyl, (C3-C7)-cycloalkyl, (C2-C6)-alkenyl, (CrC8)-alkyl, which can optionally be substituted by phenyl or acetyl, (C6-Q4)-aryl, (C5- Cio)-heteroaryl, trifluorornethyl, tetrahydrofuranyl or butyrolactone, R3, R4, R5, R6, R7 and R8 are identical or different and represent hydrogen or (Ci-C6)-alkyl and their salts, solvates and solvates of the salts. Likewise preferred here is the use of compounds of the general formula (I), in which - 5 - R1 represents thiophene (thienyl), in particular 2-thiophene, which can optionally be mono- or polysubstiruted by halogen, preferably chlorine or bromine, amino, aminomethyl or (Ci-C8)-alkyl, preferably methyl, where the (CrC8)-alkyl radical can for its part optionally be mono- or polysubstituted by halogen, preferably fluorine, R2 represents one of the following groups: A-, A-M-, D-M-A-, B-M-A-, B-, B-M-, B-M-B-, D-M-B-, where: the radical "A" represents (C6-Ci4)-aryl, preferably (Ct,-C10)-aryl, in particular phenyl or naphthyl, very particularly preferably phenyl; the radical "B" represents a 5- or 6-membered aromatic heterocycle, which contains up to 3 heteroatoms and/or hetero chain members, in particular up to 2 heteroatoms and/or hetero chain members, from the series S, N, NO (N-oxide) and O; the radical "D" represents a saturated or partial!)' unsaturated 4- to 7-membered heterocycle, which contains up to three heteroatoms and/or hetero chain members from the series S, SO, SO2, N, NO (N-oxide) and O; the radical "M" represents -NH-, -CH2-, -CH2CH2-, -O-, -NH-CH2-, -CH2-NH-, -OCHr, -CH2O-, -CONH-, -NHCO-, -COO-, -OOC-, -S- or a covalent bond; where the previously defined groups "A", "B" and "D" can in each case be optionally mono- or - 6 - polysubstituted by a radical from the group consisting of halogen; trifluoromethyl; oxo; cyano; nitro; carbamoyl; pyridyl; (CrC6)-alkanoyl; (C3-C7)-cycloalkanoyl; (C6-CH)- arylcarbonyl; (C5-C10)-heteroarylcarbonyl; (Ci-C6)-alkanoyloxymethyloxy; -COOR27; -S02R27; -C(NR27R28)=NR29; -CONR28R21'; -SO2NR28R29; -OR30; -NR30R31, (CrC6)-alkyl and (C3-C7)-cycloalkyl, where (C]-C6)-alkyl and (C3-C7)-cycloalkyl for their part can optionally be substituted by a radical from the group consisting of cyano; -OR27; -NR28R29; -CO(NH)V(NR27R28) and -C(NR27R28)=NR29, where: v is either 0 or 1 and R27, R28 and R29 are identical or different and independently of one another are hydrogen, (Ci-C4)-alkyl or (C3-C7)-cycloalkyl, and/or R27 and R28 or R27 and R29, together with the nitrogen atom to which they are bonded, form a saturated or partially unsaturated 5- to 7-membered heterocycle having up to three, preferably up to two identical or different heteroatoms from the group consisting of N, O and S, and R and R are identical or different and independently of one another are hydrogen, (CrC4)-alkyl, (C3-C7)-cycloalkyl, (C,-C4)-alkylsulfonyl, (C1-C4)-hydroxyalkyl, (Ci-C4)-aminoalkyl, di-(CrC4)-alkylamino-(CrC4)-alkyl, (C]-C4)-alkanoyl, (C6- C)4)-arylcarbonyl, (C5-C10)-heteroarylcarbonyl, (Ci-C4)-alkylaminocarbonyl or -CH2C(NR27R28)-NR29, R3, R4, R5, R6, R7 and R8 are identical or different and represent hydrogen or (CrC6)-alkyl and their salts, solvates and solvates of the salts. Particularly preferred here is the use of compounds of the general formula (I), in which R represents thiophene (thienyl), in particular 2-thiophene, which can optionally be mono- or polysubstituted by halogen, preferably chlorine or bromine, or (C]-C8)-alkyl, preferably - 7 - methyl, where the (CrC8)-alkyl radical can for its part optionally be mono- or polysubstituted by halogen, preferably fluorine, R2 represents one of the following groups: A-, A-M-, D-M-A-, B-M-A-, B-, B-M-, B-M-B-, D-M-B-, where: the radical "A" represents phenyl or naphthyl, in particular phenyl; the radical "B" represents a 5- or 6-membered aromatic heterocycle, which contains up to 2 heteroatoms from the series S, N, NO (N-oxide) and O; the radical "D" represents a saturated or partially unsaturated 5- or 6-membered heterocycle, which contains up to two heteroatoms and/or hetero chain members from the series S, SO, SO2, N, NO (N-oxide) and O; the radical "M" represents -NH-, -O-, -NH-CH2-, -CH2-NH-, -OCH2-, -CH2O-, -CONH-, -NHCO- or a covalent bond; where the previously defined groups "A", "B" and "D" can in each case optionally be mono- or polysubstituted by a radical from the group consisting of halogen; trifluoromethyl; oxo; cyano; pyridyl; (CrC3)-alkanoyl; (C6-C10)-arylcarbonyl; (C5-C6)-heteroary]carbonyl; (Cr C3)-alkanoyloxymethyloxy; -C(NR27R!8)=NR29; -CONR28R29; -SO2NR28R29; -OH; -NR30R31; (CrGt)-alkyl; and cyclopropyl, cyclopenryl or cyclohexyl, -8 where (CrC4)-aIkyl and cyclopropyl, cyclopentyl or cyclohexyl for their part can optionally be substituted by a radical from the group consisting of cyano; -OH; -OCH3; -NR28R29; -CO(NH)V(NR27R28) and -C(NR27R28)=NR29, where: v is either 0 or 1, preferably 0, and R27, R28 and R29 are identical or different and independently of one another are hydrogen, (CrC4)-alkyl or else cyclopropyl, cyclopentyl or cyclohexyl and/or R27 and R28 or R27 and R29, together with the nitrogen atom to which they are bonded, can form a saturated or partially unsalurated 5- to 7-membered heterocycle having up to two identical or different heteroatoms from the group consisting of N, O and S, and R ° and R3' are identical or different and independently of one another are hydrogen, (Ci-Q)-alkyl, cyclopropyl, cyclopentyl, cyclohexyl, (Ci-C4)-alkylsulfonyl, (CrC4> hydroxyalkyl, (CrC4)-aminoaIkyl, di-(CrC4)-alkylamino-(CrC4)-alkyl, (C,-C3> alkanoyl or phenylcarbonyl, R3, R4, R5, R6, R7 and R8 are identical or different and represent hydrogen or (CrC6)-alkyl and their salts, solvates and solvates of the salts. Preferred in particular here is the use of compounds of the general formula (I), in which R1 represents 2-thiophene, which can optionally be substituted in the 5-position by a radical from the group consisting of chlorine, bromine, methyl or trifluoromethyl, R2 represents one of the following groups: A-, A-M-, D-M-A-, - 9 - B-M-A-, B-, B-M-, B-M-B-, D-M-B-, where: the radical "A" represents phenyl or naphthyl, in particular phenyl; the radical "B" represents a 5- or 6-membered aromatic heterocycle, which contains up to 2 heteroatoms from the series S, N, NO (M-oxide) and O; the radical "D" represents a saturated or partially unsaturated 5- or 6-membered heterocycle, which contains a nitrogen atom and optionally a further heteroatom and/or hetero chain member from the series S, SO, SO2 and O; or up to two heteroatoms and/or hetero chain members from the series S, SO, SO2 and O; the radical "M" represents -NH-, -O-, -NH-CH2-, -CH2-NH-, -OCH2-, -CH2O-, -CONH-, -NHCO- or a covalent bond; where the previously defined groups "A", "B" and "D" can in each case optionally be mono- or polysubstituted by a radical from the group consisting of halogen; trifluoromethyl; oxo; cyano; pyridyl; (Ci-C3)-alkanoyl; (C6-C]())-arylcarbonyl; (C5-C6)-heteroarylcarbonyl; (Cr C3)-alkanoyloxymethyloxy; -CONR28R29; -SO2NR28R29; -OH; -NR30R31; (CrC4)-alkyl; and cyclopropyl, cyclopentyl or cyclohexyl, where (Ci-C4)-alkyl and cyclopropyl, cyclopentyl or cyclohexyl can for their part optionally be substituted by a radical from the group consisting of cyano; -OH; -OCH3; -NR28R29; -CO(NH)V(NR27R28) and -C(NR27R28)=NR29, where: v is either 0 or 1, preferably 0, and R , R and R" are identical or different and independently of one another are hydrogen, - 10- (Ci-C4)-alkyl or else cyclopropyl, cyclopentyl or cyclohexyl and/or R27 and R28 or R27 and R29, together with the nitrogen atom to which they are bonded, can form a saturated or partially unsaturated 5- to 7-membered heterocycle having up to two identical or different heteroatoms from the group consisting of N, O and S and R30 and R31 are identical or different and independently of one another are hydrogen, (CrC4)-alkyl, cyclopropyl, cyclopentyl, cyclohexyl, (CrC4)-alkylsulfonyl, (CrC4)- hydroxyalkyl, (Q-C^-aminoalkyl, di-(CrC4)-a[kylamino-(CrC4)-alkyl, (C,-C3)- alkanoyl or phenylcarbonyl, R3, R4, R5, R6, R7 and R8are identical or different and represent hydrogen or (CrC4)-alkyl and their salts, solvates and solvates of the salts. Very particularly preferred here is the use of compounds of the general formula (I), in which R1 represents 2-thiophene, which is substituted in the 5-position by a radical from the group consisting of chlorine, bromine., methyl or trifluoromethyl, R2 represents D-A-: where: the radical "A" represents phenylene; the radical "D" represents a saturated 5- or 6-membered heterocycle, which is linked to "A" via a nitrogen atom, which in direct vicinity to the linking nitrogen atom has a carbonyl group and in which a ring carbon member can be replaced by a heteroatom from the series S, N and 0; where the previously defined group "A" can optionally be mono- or disubstituted in the metaposition with respect to the linkage to the oxazolidinone by a radical from the group consisting of fluorine, chlorine, nitro, amiiio, trifluoromethyl, methyl or cyano, R3, R4, R5, R6, R7 and R8 represent hydrogen and their salts, solvates and solvates of the salts. Likewise very particularly preferred here is the use of the compound having the following formula and its salts, solvates and solvates of the salts. Oxazolidinones were originally described essentially only as antibiotics, sporadically also as MAO inhibitors and fibrinogen antagonists (survey: Riedl, B., Endermann, R., Exp. Opin. Ther. Patents 1999, 9 (5), 625), a small 5-[acylaminotnethyl] group (preferably 5-[acetylaminomethyl]) appearing to be essential for the antibacterial activity. Substituted aryl- and heteroarylphenyloxazolidinones, in which a mono- or polysubstituted phenyl radical can be bonded to the N atom of the oxazolidinone ring and which can contain an unsubstituted N-methyl-2-thiophenecarboxamide radical in the 5-position of the oxazoJidinone ring, and their use as antibacterially active substances are known from the U.S. patent specifications US 5 929 248, US 5 801 246, US 5 756 732, US 5 654 435, US 5 654 428 and US 5 565 571. Moreover, benzamidine-containing oxazolidinones are known as synthetic intermediates in the synthesis of factor Xa inhibitors or fibrinogen antagonists (WO 99/31092, EP 0 623 615). Compounds which can be used according to the invention, also described below as compounds according to the invention, are the compounds of the formula (I) and their salts, solvates and solvates of the salts, the compounds comprised by formula (I) of the formulae mentioned below and their salts, solvates and solvates of the salts, and the compounds comprised by formula (I), - 12- mentioned below as working examples, and their salts, solvates and solvates of the salts, inasmuch as the compounds comprised by formula (I) and mentioned below are not already salts, solvates and solvates of the salts. Depending on their structure, the compounds according to the invention can exist in stereoisomeric forms (enantiomers, diastereomers). The invention therefore comprises the use of the enantiomers or diastereomers and their respective mixtures. If the compounds according to the invention can occur in tautomeric forms, the present invention comprises the use of all tautomeric forms. Preferred salts in the context of the present invention are physiologically acceptable salts of the compounds according to the invention. Also included are salts which are not suitable themselves for pharmaceutical applications, but can be used, for example, for the isolation or purification of the compounds according to the invention. Physiologically acceptable salts of the compounds according to the invention include acid addition salts of mineral acids, carboxylic acids and sulfonic acids, e.g. salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid, acetic acid, trifluoroacetic acid, propionic acid, lactic acid, tartaric acid, malic acid, citric acid, fumaric acid, maleic acid and benzoic acid. Physiologically acceptable salts of the compounds according to the invention also include salts of customary bases, such as, by way of example and preferably, alkali metal salts (e.g. sodium and potassium salts), alkaline earth metal salts (e.g. calcium and magnesium salts) and ammonium salts, derived from ammonia or organic amines having 1 to 16 C atoms, such as, by way of example and preferably, ethylamine, diethylamuie, triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol,' procaine, dibenzylamine, N-methylmorpholine, arginine, lysine, ethylenediamine and Nmethylp iperidine. Solvates are designated within the context of the invention as those forms of the compounds according to the invention which form a complex in the solid or liquid state by coordination with solvent molecules. Hydrates are a special form of solvates, in which the coordination takes place with water. Solvates which are preferred in the context of the present invention are hydrates. Moreover, the present invention also comprises the use of prodrugs of the compounds according to the invention. The term "prodrugs" comprises compounds which can be biologically active or -13- inactive themselves, but during their residence time in the body are converted to give compounds according to the invention (for example metabolically or hydrolytically). In the context of the present invention, the substituents, if not specified otherwise, have the following meaning: Halogen represents fluorine, chlorine, bromine ant] iodine. Chlorine and fluorine are preferred. (CrCg)-Alkyl represents a straight-chain or branched alkyl radical having 1 to 8 carbon atoms. Examples which may be mentioned are: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tertbutyl, n-pentyl and n-hexyl. The corresponding alkyl groups having fewer carbon atoms such as, for example, (Ci-Ce)-alkyl and (CrC4)-alkyl are analogously derived from this definition. In general, it applies that (Ci-C4)-alkyl is preferred. The meaning of the corresponding constituent of other more complex substituents is also derived from this definition such as, for example, in the case of alkyjsulfonyl, hydroxyalkyj, hydroxyalkylcarbonyl, alkoxyalkyl alkoxycarbonylalkyl, alkanoylalkyl, aminoalkyl or alkylaminoaft (Cj-CjVCycloalkyl represents a cyclic alkyl radical having 3 to 7 carbon atoms. Examples which may be mentioned are: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl. The corresponding cycloalkyl groups having fewer carbon atoms such as, for example, (C3-C5)-cycloalkyl are analogously derived from this definition. Cyclopropyl, cyclopentyl and cyclohexyl are preferred. The meaning of the corresponding constituent of other more complex substituents such as, for example, cycloalkanoyl is also derived from this definition. (Cj-Cfi)-Alkenyl represents a straight-chain or branched alkenyl radical having 2 to 6 carbon atoms. A straight-chain or branched alkenyl radical having 2 to 4 carbon atoms is preferred. Examples which may be mentioned are: vinyl, allyl, isopropenyl and n-but-2-en-l-yi. (CI-Cs)-Alkoxy represents a straight-chain or branched alkoxy radical having 1 to 8 carbon atoms. Examples which may be mentioned are: methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, n-pentoxy, n-hexoxy, n-heptoxy and n-octoxy. The corresponding alkoxy groups having fewer carbon atoms such as, for example, (Ci-C6>alkoxy and (Ci-C4)-alkoxy are analogously derived from this definition. In general, it applies that (Ci-C^-alkoxy is preferred. The meaning of the corresponding constituent of other more complex substituents such as, for -14- example, alkoxyalkyl, ajkoxycarbonylalkyl and alkpxycarbonyl is also derived from this definition. Mono- or di-fQ-QValkylaminocarbonyl represents an amino group which is linked via a carbonyl group and which contains a straight-chain or branched or two identical or different straight-chain or branched alkyl substituents in each case having 1 to 4 carbon atoms. Examples which may be mentioned are: methylamino, ethylamino, n-propylamino, isopropylamino, t-butylamino, N,Ndimethyiamino, TV^-diethylamino, JV-ethyl-jV-methylamino, jV-methyl-JV-n-propyiamino, jV-isopropyl-,/ V-n-propylamino and ]V-t-butyl-./V-methylamino. (Ci-Cs)-Alkanoyl represents a straight-chain or branched alkyl radical having 1 to 6 carbon atoms, which carries a double-bonded oxygen atom in the 1 -position and is linked via the 1 -position. Examples which may be mentioned are: formy], acetyl, propionyl, n-buryryl, i-butyryl, pivaloyl, nhexanoyl. The corresponding alkanoyl groups having fewer carbon atoms such as, for example, (Ci-C5)-alkanoyl, (Ci-C4)-alkanoyl and (Ci-C3)-alkanoyl are analogously derived from this definition. In general, it applies that (Ci-C3)-alkanoyl is preferred. The meaning of the corresponding constituent of other more complex substituents such as, for example, cvcloalkanoyl and alkanoylalkyl is also derived from this definition. (CVCJ-Cycloalkanoyl represents a cycloalkyl radical as defined previously having 3 to 7 carbon atoms; which is linked via a carbonyl group. (CrC^)-Alkanoyloxvmethyloxy represents a straight-chain or branched alkanoyloxymethyloxy radical having 1 to 6 carbon atoms. Examples which may be mentioned are: acetoxymethyloxy, propionoxymethyloxy, n-butyroxymethyloxy, i-buryroxymethyloxy, pivaloyloxymethyloxy, nhexanoyloxymethyloxy. The corresponding alkanoyloxymethyloxy groups having fewer carbon atoms such as, for example, (Ci-C3)-alkanoyloxymethyloxy are analogously derived from this definition, hi general, it applies that (Ci-C.3)-alkarioyloxymethyloxy is preferred. jO-Aryl represents an aromatic radical having 6 to 14 carbon atoms. Examples which may be mentioned are: phenyl, naphthyl, phenanthrenyl and anthracenyl. The corresponding aryl groups having fewer carbon atoms such as, for example, (C6-Cio)-aryl are analogously derived from this definition. In general, it applies that (Q-QoJ-aryl is preferred. The meaning of the corresponding constituent of other more complex substituents such as, for example, arylcarbonyl is also derived from this definition. (Cs-CiflVHeteroaryl or a 5- to 10-membered aromatic heterocycle having up to 3 heteroatoms and/or hetero chain members from the series S, Q, N and/or NO fN-oxide) represents a mono- or -15- bicyclic heteroaromatic, which is linked via a ring carbon atom of the heteroaromatic, optionally also via a ring nitrogen atom of the heteroaromatic. Examples which may be mentioned are: pyridyl, pyridyl N-oxide, pyrimidyl, pyridazinyl, pyrazinyl, thienyl, furyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl or isoxazolyl, indolizinyl, indolyl, benzo[b]thienyl, benzofb] furyl, indazolyl, quinolyl, isoquinolyl, naphthyridinyl, quinazolinyl. The corresponding heterocycles having a smaller ring size such as, for example, 5- or 6-membered aromatic heterocycles are analogously derived from this definition. In general, it applies that 5- or 6-membered aromatic heterocycles such as, for example, pyridyl, pyridyl N-oxide, pyrimidyl, pyridazinyl, furyl and thienyl are preferred. The meaning of the corresponding constituent of other more complex substituents such as, for example, (Cj-Cjn)-heteroarylcarbonyl is also derived from this definition. A 3- to 9-membered saturated or partially unsaturated, mono- or bicyclic, optionally benzo-fused heterocycle having up to 3 heteroatoms and/or hetero chain members from the series S, SO. S02, N, NO (N-oxide) and/or O represents a heterocycle which can contain one or more double bonds, which can be mono- or bicyclic, in which a benzene ring can be fused onto two adjacent ring carbon atoms, and which is linked via a ring carbon atom or a ring nitrogen atom. Examples which may be mentioned are: tetrahydrofuryl, pyrroliditiyl, pyrrolinyL piperidinyl, 1,2-dihydropyridinyl, 1,4-dihydropyridinyl, piperazinyl, morpholinyl, rnorpholinyl N-oxide, thiomorpholinyl, azepinyl, 1,4-diazepinyl and cyclohexyl. Piperidinyl, morpholinyl and pyrrolidinyl are preferred. The corresponding cycles having a smaller ring size such as, for example, 5- to 7-membered cycles are derived analogously from this definition. The compounds of the formula (I) can be prepared by either, according to a process alternative [A], reacting compounds of the general formula (II) in which the radicals R2, R3, R4, R5, R6, R7 and R8 have the meanings indicated above, -16- with carboxylic acids of the general formula (HI) H C X . R 1 (T'l). TO in which the radical R1 has the meaning indicated above, or else with the corresponding carbonyl halides, preferably carbonyl chlorides, or else with the corresponding symmetrical or mixed carboxylic anhydrides of the previously defined carboxylic acids of the general formula (III) in inert solvents, optionally in the presence of an activating or coupling reagent and/or a base, to give compounds of the general formula (I) O R' u A N O , R R ^ . (I), Y in which the radicals R1, R2, R3, R4, R5, R*, R7 and R8 have the meanings indicated above, or else, according to a process alternative [B], converting compounds of the general formula (IV) Rs R7 N" ^R1 R5 in which the radicals R1, R3, R4, R5, R6, R7 and R8 have the meanings indicated above, - 17- using a suitable selective oxidant in an inert solvent, to the corresponding epoxide of the general formula (V) R3 R6 R7 O ±J R~ 1>V/ S/kUR 1 ™( l O^ s la R5 R8 in which the radicals R1, R3, R4, R5, R6, R7 and R8 have the meanings indicated above, and by reaction in an inert solvent, optionally in the presence of a catalyst, with an amine of the general formula (VI) R2 - NH2 (VI), in which the radical R2 has the meaning indicated above, first preparing the compounds of the general formula (VII) HOR' R £ in which the radicals R!, R2, R3, R4, R5, R6, R7 and R8 have the meanings indicated above, and subsequently, in an inert solvent in the presence of phosgene or phosgene equivalents such as. for example, carbonyldiimidazole (CDI), cyclizing them to the compounds of the general formula (I) -18- VJ A R4 ,^ (I) T in which the radicals R1, R2, R3, R4, R5, R6, R7 and R8 have the meanings indicated above, where both for process alternative [A] and for process alternative [B] for the case where R2 contains a 3- to 7-membered saturated or partially unsaturated cyclic hydrocarbon radical having one or more identical or different heteroatoms from the group consisting of N and S, an oxidation with a selective oxidant to give the corresponding sulfone, sulfoxide or Noxide can follow and/or where both for process alternative [A] and for process alternative [B] for the case where the compound prepared in this way contains a cyano group in the molecule, an amidination of this cyano group using the customary methods can follow and/or where both for process alternative [A] and for process alternative [B] for the case where the compound prepared in this way contains a BOC amino-protective group in the molecule, a cleavage of this BOC amino-protective group can follow using the customary methods and/or where both for process alternative [A] and for process alternative [B] for the case where the compound prepared in this way contains an aniline or benzylamine radical in the molecule, a reaction of this amino group with different reagents such as carboxylic acids, carboxylic anhydrides, carbonyl chlorides, isocyanates, sulfonyl chlorides or alkyl halides can follow to give the corresponding derivatives -19- and/or where both for process alternative [A] and for process alternative [B] for the case where the compound prepared in this way contains a phenyl ring in the molecule, a reaction with chlorosulfonic acid and subsequent reaction with amines to give the corresponding sulfonamides can follow. The processes can be illustrated by way of example by the following reaction schemes: [A] O o. ci "vJS * K ff— N HO. L ?• - EDCI HOBT _ (iso Pr)2EtN O NH, O Q HN O c O N [B] // Cl Cl S—/ _F!yridine / \\ O NH, O O GDI o N O HN NH, Cl The previously described oxidation step optionally carried out can be illustrated by way of example by the following reaction schemes: -20- 0. NMO/OsO4 *, Cl - Q" NalO4 O=S N Suitable solvents for the previously described processes here are organic solvents which are inert under the reaction conditions. These include halogenohydrocarbons such as dichloromethane, trichloromethane, tetrachloromethane, 1,2-dichloroethane, trichloroethane, tetrachloroethane, 1,2- dichloroethylene or trichloroethylene, ethers such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol or tert-butanol, hydrocarbons such as benzene, xylene, toluene, hexane or cyclohexane, dimethylformamide, dimethyl sulfoxide, acetonitrile, pyridine, hexamethylphosphoramide or water. It is likewise possible to employ solvent mixtures of the previously mentioned solvents. Suitable activating or coupling reagents for the previously described processes here are the reagents customarily used for this purpose, for example jV'-(3-dimethylaminopropyl)-jVethylcarbodiimide • HC1, JV,./V'-dicyclohexylcarbodiimide, 1-hydroxy-lH-benzotriazole • H2O and the like. Suitable bases are the customary inorganic or organic bases. These preferably include alkali metal hydroxides such as, for ^xample, sodium hydroxide or potassium hydroxide or alkali metal carbonates such as sodium carbonate or potassium carbonate or sodium methoxide or potassium methoxide or sodium ethoxide or potassium ethoxide or potassium tert-butoxide or amides such as sodium amide, lithium bis(trimethylsilyl)amide or lithium diisopropylamide or amines such as triethylamine, diisopropylethylamine, diisopropylamine, 4-Ar,A^-dimethylaminopyridine or pyridine. The base can be employed here in an amount from 1 to 5 mol, preferably from 1 to 2 mol, based on 1 mol of the compounds of the general formula (If). The reactions are in general carried out in a temperature range from -78°C up to reflux BHCL05J 121-Foreign countries -21 - temperature, preferably in the range from 0°C to reflux temperature. The reactions can be carried out at normal, elevated or reduced pressure (e.g. in the range from 0.5 to 5 bar). In general, they are carried out at normal pressure. Possible suitable selective oxidants both for the preparation of the epoxides and for the oxidation optionally carried out to give the sulfone, sull'oxide or N-oxide are, for example, m-chloroperbenzoic acid (MCPBA), sodium metaperiodate, N-methylmorpholine N-oxide (NMO), monoperoxyphthalic acid or osmium tetroxide. With respect to the preparation of the epoxides, the preparation conditions customary for this purpose are used. With respect to the more detailed process conditions for the oxidation optionally carried out to give the sulfone, sulfoxide or N-oxide, reference can be made to the following literature: M. R. Barbachyn et al, J. Med. Chem. 1996, 39, 680 and also WO 97/10223. In addition, reference is made to Examples 14 to 16 presented in the experimental section. The optionally carried out amidination is carried out under the customary conditions. For further details, reference can be made to Examples 31 to 35 and 140 to 147. The compounds of the formulae (II), (HI), (IV) and (VI) are known per se to the person skilled in the art or can be prepared according to customary methods. For oxazolidinones, in particular the 5- (aminomethyl)-2-oxooxazolidines needed, cf WO 98/01446; WO 93/23384; WO 97/03072; J. A. Tucker et al., J. Med. Chem. 1998, 41, 3727; S. J. Brickner et al, J. Med. Chem. 1996, 39, 673; W. A. Gregory et al., i. Med. Chem. 1989, 32, 1673. A preferred compound of the formula (I) which can be used according to the invention is 5-chloro- 7V-({(51S>2-oxo-3-[4-(3-oxo-4-morpholinyI)phenyl]-l,3-oxazolidin-5-yl}methyl)-2-thiophene* carboxamide, the compound from Example 44. The term microangiopathies in the sense of the present invention comprises occlusive syndromes, which especially result on the skin and other organs. The term microangiopathies further comprises the primary forms of thrombotic microangiopathies (TMA), such as thrombotic thrombocytopenic purpura (TTP) and the hemolytic uremic syndrome (HUS). TTP is characterized by the occurrence of intravasal clotting with formation of microthrombi in veiy small vessels, which can attack all organs. HUS is an acute syndrome, in which the aggregation of platelets, hemolysis, thrombosis in the microcirculation and consecutive -22- multiorgan failure occurs. The term TMA also comprises secondary forms, which occur, in particular, after infections, taking of medicaments (ciclosporin, mitomycin, metamizole, inter alia), endocarditis, collagenosis, malignant tumors, transplants and in pregnancy. Moreover, for example, diabetic microangiopathies (diabetic retinopathy, glomerulopathy, trophic disorders, diabetic gangrene) and also venous occlusive diseases of the liver, cerebral vasculitis, and microthromboses of the placenta, and thus the repeated miscarriages resulting therefrom, can also be treated. The present invention further relates to the use of selective factor Xa inhibitors for the production of a medicament for the treatment and/or prophylaxis of occlusive syndromes, in particular occlusive syndromes resulting on the skin and other organs, of primary forms of thrombotic microangiopathies (TMA), in particular of thrombotic thrombocytopenic purpura (TTP) and of hemolytic uremic syndrome (HUS), of secondary forms of TMA, in particular after infections, taking of medicaments, endocarditis, collagenosis, malignant tumors, transplants and secondary forms of TMA occurring in pregnancy, of diabetic microangiopathies, in particular diabetic retinopathy, glomerulopathy, trophic disorders and diabetic gangrene, of venous occlusive diseases of the liver, cerebral vasculitis and microthromboses of the placenta, and the repeated miscarriages resulting therefrom. The present invention further relates to the use of the compounds according to the invention for the production of a medicament for the treatment and/or prophylaxis of occlusive syndromes, in particular occlusive syndromes resulting on the skin and other organs, of primary forms of thrombotic microangiopathies (TMA), in particular thrombotic thrombocytopenic purpura (TTP) and of the hemolytic uremic syndrome (HUS), of secondary forms of TMA, in particular after infections, taking of medicaments, endocarditis, collagenosis, malignant tumors, transplants and secondary forms of TMA occurring in pregnancy, of diabetic microangiopathies, in particular diabetic retinopathy, glomerulopathy, trophic disorders and diabetic gangrene, of venous occlusive diseases of the liver, cerebral vasculitis and microthromboses of the placenta, and the repeated miscarriages resulting therefrom. In the case of progressive damage, especially in hypoxemic areas such as, for example, in the case of retinopathies, neovascularization (angiogenesis) and thus vitreous body hemorrhages and retinal detachments in the retina occur. The activation of blood clotting induced by tissue thromboplastin (tissue factor; TF) promotes angiogenesis. A number of proteases (factor Vila, TF-VTIa-Xa complex, factor FXa, thrombin) and their receptors, PAR1, PAR2 (protease-activatable receptors), are involved in this process. By inhibition of factor Xa, the formation of thrombin is inhibited and • -23- thus the activation of PAR1, the further generation of Vila by thrombin and thus in turn the TFVHa- mediated activation of PAR 1 and PAR2, and also the activation of PAR2 by FXa. Therefore FXa inhibitors are also suitable for reducing or preventing the harmful capillary buds resulting in the case of microangiopathies. The present invention further relates to the use of selective factor Xa inhibitors for the production of a medicament for the treatment and/or prophylaxis of harmful capillary buds resulting in the case of microangiopathies. The present invention further relates to the use of the compounds according to the invention for the production of a medicament for the treatment and/or prophylaxis of harmful capillary buds resulting in the case of microangiopathies. The present invention further relates to a procedure for the control of microangiopathies in humans and animals by administration of an efficacious amount of at least one selective factor Xa inhibitor or of a medicament comprising at least one selective factor Xa inhibitor in combination with an inert, non-toxic, pharmaceutically suitable excipient. The present invention further relates to a procedure for the control of microangiopathies in humans and animals by administration of an efficacious amount of at least one compound according to the invention or of a medicament comprising at least one compound according to the invention in combination with an inert, non-toxic, pharmaceutically suitable excipient. The present invention further relates to a procedure for the control of harmful capillary buds resulting in the case of microangiopathies in humans and animals by administration of an efficacious amount of at least one selective factor Xa inhibitor or of a medicament comprising at least one selective factor Xa inhibitor in combination with an inert, non-toxic, pharmaceutically suitable excipient. The present invention further relates to a procedure for the control of harmful capillary buds resulting in the case of microangiopathies in humans and animals by administration of an efficacious amount of at least one compound according to the invention or of a medicament comprising at least one compound according to the invention in combination with an inert, nontoxic, pharmaceutically suitable excipient. The medicaments to be prepared corresponding to the use according to the invention or to be used according to the invention contain at least one compound according to the invention, customarily together with one or more inert, non-toxic, pharmaceutically suitable excipients. -24- The compounds according to the invention can act systemically and/or locally. For this purpose, they can be administered in a suitable manner, such as, for example, orally, parenterally, pulmonarily, nasally, sublingually, lingually, buccally, rectally, dermally, transdermally, conjunctivally, otically or as an implant or stent. For these administration routes, the compounds according to the invention can be administered in suitable administration forms. For oral administration, suitable administration forms are those functioning according to the prior art, releasing the compounds according to the invention rapidly and/or in modified form, which contain the compounds according to the invention in crystalline and/or amorphized and/or dissolved form, such as, for example, tablets (noncoated or coated tablets, for example having enteric coatings or coatings dissolving with a delay or insoluble coatings, which control the release of the compound according to the invention), tablets disintegrating rapidly in the oral cavity or films/wafers, films/lyophilizates, capsules (for example hard or soft gelatin capsules), coated tablets, granules, pellets, powders, emulsions, suspensions, aerosols or solutions. Parenteral administration can be carried out circumventing an absorption step (e.g. intravenously, intraarterially, intracardially, intraspinally or intralumbarly) or with the insertion of an absorption (e.g. intramuscularly., subcutaneously, intracutaneously, percutaneously or intraperitoneally). For parenteral administration, suitable administration forms are, inter alia, injection and infusion preparations in the form of solutions, suspensions, emulsions, lyophilizates or sterile powders. For the other administration routes, for example, inhalation pharmaceutical forms are suitable (inter alia powder inhalers, nebulizers), nose drops, solutions or sprays, tablets to be administered lingually, sublingually or buccally, films/wafers or capsules, suppositories, ear or eye preparations, vaginal capsules, aqueous suspensions (lotions, shake mixtures), lipophilic suspensions, ointments, creams, transdermal therapeutic systems (e.g. patches), milk, pastes, foams, dusting powders, implants or stents. Oral and parenteral administration are preferred, in particular oral administration. The compounds according to the invention can be converted into the administration forms mentioned. This can be carried out in a manner known per se by mixing with inert, non-toxic, pharmaceutically suitable excipients. These excipients include, inter alia, vehicles (for example microcrystalline cellulose, lactose, mannitol), solvents (e.g. liquid polyethylene glycols), emulsifiers and dispersants or wetting agents (for example sodium dodecylsulfate, polyoxysorbitan oleate), binders (for example polyvinylpyrrolidone), synthetic and natural polymers (for example -25- albumin), stabilizers (e.g. antioxidants such asN for example, ascorbic acid), colorants (e.g. inorganic pigments such as, for example, iron oxides) and taste and/or odor corrigents. In general, it has proved advantageous in the case of parenteral administration to administer amounts of approximately 0.001 to 1 mg/kg, preferably approximately 0.01 to 0.5 mg/kg of body weight, to achieve efficacious results. In the case of oral administration, the dose is approximately 0.01 to 100 mg/kg, preferably approximately 0.01 to 20 mg/kg and very particularly preferably 0.1 to 10 mg/kg, of body weight. hi spite of this, it may optionally be necessary lo depart from the amounts mentioned, namely depending on body weight, route of administration, individual behavior toward the active substance, type of preparation and time or interval at which administration takes place. Thus, in some cases it may be adequate to manage with less than the abovementioned minimum amount, while in other cases the upper limit mentioned must be exceeded, hi the case of the administration of larger amounts, it may be advisable to divide these into a number of individual doses over the course of the day. The following working examples illustrate the invention. The invention is not restricted to the examples. The percentages in the following tests and examples are, if not stated otherwise, percentages by weight; parts are parts by weight. Solvent ratios, dilution ratios and concentration data of liquid/liquid solutions relate, if not stated otherwise, to the volume in each case. -26- Examples A. Assessment of the physiological activity The compounds of the formula (I) act, in particular, as selective inhibitors of blood clotting factor Xa and do not also inhibit other serine proteases such as plasmin or trypsin or only inhibit them at markedly higher concentrations. Those inhibitors of blood clotting factor Xa are designated as "selective" in which the IC50 values for the factor Xa inhibition are smaller by at least 100-fold compared to the IC5o values for the inhibition of other serine proteases, in particular plasmin and trypsin, reference being made with respect to the test methods for the selectivity to the test methods of Examples A.a.l) and A.a.2) described below. Advantageous pharmacological properties of the compounds which can be used according to the invention can be determined by the following methods. a) Test description (in vitro) a.l) Measurement of the factor Xa inhibition The enzymatic activity of human factor Xa (FXa) is measured by means of the conversion of a chromogenic substrate specific for FXa. In this, factor Xa cleaves p-nitroaniline from the chromogenic substrate. The determinations are carried out in microtiter plates as follows. The test substances are dissolved in DMSO in different concentrations and incubated at 25°C for 10 minutes with human FXa (0.5 nmol/1 dissolved in 50 mmol/1 of tris buffer [C,C,Ctris( hydroxymethyl)-aminomethane], 150 mmol/1 of NaCl, 0.1 % BSA (bovine serum albumin), pH = 8.3). Pure DMSO is used as a control. Subsequently, the chromogenic substrate (150 umol/1 of Pefachrome® FXa from Pentapharm) is added. After an incubation period of 20 minutes at 25°C, the extinction at 405 nm is determined. The extinctions of the test batches with test substance are compared with the control batches without test substance and the IC50 values are calculated therefrom. a.2) Determination of the selectivity For the detection of the selective FXa inhibition, the test substances are investigated for their inhibition of other human serine proteases such as trypsin and plasmin. For the determination of the enzymatic activity of trypsin (500 mU/ml) and plasmin (3.2 nmol/1), these enzymes are dissolved in tris buffer (100 mmol/1, 20 mmol/1 CaCl2,pH = 8.0) and incubated with test substance -27- or solvent for 10 minutes. Subsequently, the enzymatic reaction is started by addition of the corresponding specific chromogenic substrates (Chromozym Trypsin® and Chromozym Plasmin®; Roche Diagnostics) and the extinction is determined at 405 nm after 20 minutes. All determinations are carried out at 37°C. The extinctions of the test batches with test substance are compared with the control samples without test substance and the IC50 values are calculated therefrom. a.3) Determination of the anticoagulatory action The anticoagulatory action of the test substances is determined in Vitro in human and rabbit plasma. For this, blood is taken in a mixing ratio of sodium citrate/blood 1/9 using a 0.11 molar sodium citrate solution as a receiver. The blood is well mixed immediately after taking and centrifuged for 10 minutes at about 2500 g. The supernatant is pipetted off. The prothrombin time (PT, synonyms: thromboplastin time, Quick test) is determined in the presence of varying concentrations of test substance or the corresponding solvent using a commercially available test kit (Neoplastin® from Boehringer Mannheim or Hemoliance® RecombiPlastin, Fa. from Instrumentation Laboratory). The test compounds are incubated with the plasma for 3 minutes at 37°C. Subsequently, clotting is induced by addition of thromboplastin and the time of onset of clotting is determined. The concentration of test substance which causes a doubling of the prothrombin time is determined. b) Determination of the antithrombotic action (in vivo) b.l) Arteriovenous shunt model (rat) Fasting male rats (strain: HSD CPB:WU) having a weight of 200-250 g are anesthetized using a Rompun/Ketavet solution (12 mg/kg/50 mg/kg). Thrombus formation is induced in an arteriovenous shunt following the method described by Christopher N. Berry et al., Br. J. Pharmacol. (1994), 113, 1209-1214. For this, the left jugular vein and the right carotid artery are exposed. An extracorporeal shunt is arranged between the two vessels by means of a 10 cm long polyethylene tube (PE 60). This polyethylene tube was linked in the center to a further 3 cm long polyethylene tube (PE 160), which contained a nylon thread which was roughened and linked to a loop for the production of a thrombogenic surface. The extracorporeal circulation is maintained for 15 minutes. The shunt is then removed and the nylon thread with the thrombus is immediately weighed. The unloaded weight of the nylon thread had been determined before the start of the experiment. Before starting the extracorporeal circulation, test substances are administered to conscious animals either intravenously via the caudal vein or orally by means of stomach tube. Results obtained in this way are shown in Table 1: -28- Table 1: Antithrombotic action in the arteriovenous shunt model (rat) after oral or intravenous dosage Example 1 17 44 95 114 115 123 162 EDSO [mg/kg] p.o. 3 3 ED50 [mg/kg] i.v. 10 6 3 3 3 3 b.2) Arteriovenous shunt model (rabbit) Fasting male ratsrabbits (strain: HSD CPB:WUEsd: NZW) with a weight of 200-250 g are anesthetized by intramuscular dosage with a Rompun/Ketavet solution (12 5 mg/kg or 50 40 mg/kg). Thrombus formation is induced in an arteriovenous shunt following the method described by Christopher C.N. Berry et al., Br. J. Pharmacol [Semin. Thromb. Hemost. (19941996), 11322, 1209-1214 233-241]. For this, the left jugular vein and the right carotid artery are exposed. An extracorporeal shunt is arranged between the two vessels by means of a 10 cm long polyethylene tube (PE 60) venous catheter. This polyethylene lube catheter is linked in the center to a further, 3 4 cm long polyethylene tube (PE 160, Becton Dickenson), which contains a nylon thread which is roughened and arranged to give a loop for the production of a thrombogenic surface. The extracorporeal circulation is maintained for 15 minutes. The shunt is then removed and the nylon thread with the thrombus is immediately weighed. The empty weight of the nylon thread has been determined before the start of the experiment. The test substances are administered to conscious animals before applying the extra-corporeal circulation either intravenously via the caudal vein, an ear vein or orally by means of stomach tube. -29- B. Exemplary embodiments of pharmaceutical compositions The compounds according to the invention can be converted to pharmaceutical preparations in the following way: Tablet: Composition: 100 mg of the compound according to the invention, 50 mg of lactose (monohydrate), 50 mg of cornstarch (native), 10 mg of polyvinylpyrrolidone (PVP 25) (BASF, Ludwigshafen, Germany) and 2 mg of magnesium stearate. Tablet weight 212 mg. diameter 8 mm, radius of curvature 12 mm. Preparation: The mixture of compound according to the invention, lactose and starch is granulated with a 5% strength solution (m/m) of the PVP in water. The granules are mixed with the magnesium stearate for 5 minutes after drying. This mixture is compressed using a customary tablet press (for format of the tablet see above). As a standard value for the compression, a compressive force of 15 kN is used. Orally administrable suspension: Composition: 1000 mg of the compound according to the invention, 1000 mg of ethanol (96%), 400 mg of Rhodigel® (xanthan gum from FMC, Pennsylvania, USA) and 99 g of water. 10 ml of oral suspension correspond to an individual dose of 100 mg of the compound according to the invention. ( Preparation: The Rhodigel is suspended in ethanol and the compound according to the invention is added to the suspension. The addition of the water is carried out with stirring. The mixture is stirred for about 6 h up to the completion of the swelling of the Rhodigel. -30- Qrally administrable solution; Composition: 500 mg of the compound according to the invention, 2.5 g of polysorbate and 97 g of polyethylene glycol 400. 20 g of oral solution correspond to an individual dose of 100 mg of the compound according to the invention. Preparation: The compound according to the invention is suspended in the mixture of polyethylene glycol and polysorbate with stirring. The stirring process is continued up to complete dissolution of the compound according to the invention. i.v. solution: The compound according to the invention is dissolved in a concentration below the saturation solubility in a physiologically tolerable solvent (e.g. isotonic saline solution, glucose solution 5% and/or PEG 400 solution 30%). The solution is sterile filtered and filled into sterile and pyrogenfree injection containers. -31- C. Preparation examples Starting compounds The preparation of 3-morpholinone is described In US 5 349 045. The preparation of N-(2,3-epoxypropyl)phthalimide is described in J.-W. Chera et al. Tetrahedron Lett. 1998,39,8483. The substituted anilines can be obtained, for example, by reacting 4-fluoronitrobenzene, 2,4- difluoronitrobenzene or 4-chloronitrobenzene with the appropriate amines or amides in the presence of a base. This can also be done using Pd catalysts such as Pd(OAc)2/DPPF/NaOt-Bu (Tetrahedron Lett. 1999,40,2035) or copper (Renger, Synthesis 1985,856; Aebischer et al., Heterocycles 1998,45,2225). In the same manner, haloaromatics without a nitro group can first be converted to the corresponding amides, in order subsequently to nitrate them in the 4-position (US3279880). I. 4-(4-Morpholin-3-onyl)nitrobenzene H NMP, NaH 2 mol (202 g) of morpholin-3-one (E. Pfeil, U. Harder, Angew. Chem. 79,1967, 188) are dissolved in 2 1 of N-methylpyrrolidone (NMP). Over a period of 2 h, the addition of 88 g (2.2 mol) of sodium hydride (60% in paraffin) is then carried out in portions. After completion of the evolution of hydrogen, 282 g (2 mol) of 4-fluoronitrobenzcne are added dropwise in the course of 1 h with cooling at room temperature and the reaction mixture is stirred overnight. Subsequently, 1.7 1 of the volume of liquid are distilled off at 12 mbar and 76°C, the residue is poured onto 2 1 of water and this mixture is extracted twice with 1 1 each of ethyl acetate. After washing the combined organic phases with water, the mixture is dried over sodium sulfate and the solvent is distilled off in vacuo. Purification is carried out by chromatography on silica gel using hexane/ethyl acetate (1:1) and subsequent crystallization from ethyl acetate. 78 g of the product are obtained as a colorless to brownish solid in 17.6 % of theory. 'H-NMR (300MHz, CDC13): 3.86 (m, 2 H, C7f2CH2), 4.08 (m, 2 H, CH2Ctf2), 4.49 (s, 2 H, - 3 2 - C#2CO), 7.61 (d, 2 H, V=8.95 Hz, CHCH), 8.28 (d, 2 H, V=8.95 Hz, CHCft) MS (rel. int.%) = 222 (74, Nf), 193 (100), 164 (28), 150 (21), 136 (61), 117 (22), 106 (24), 90 (37), 76 (38), 63 (32), 50 (25) The following compounds were synthesized analogously: 3 -Fluoro-4-(4-morpholin-3 -onyl)nitrobenzeri e 4-(N-Piperidonyl)nitrobenzene 3-Fluoro-4-(N-piperidonyl)nitrobenzene 4-(N-pyrrolidonyl)nitrobenzene 3-Fluoro-4-(N-pyrrolidonyl)nitrobenzene II. 4-(4-Morpholin-3-onyl)aniIine H,, Pd/C *S In an autoclave, 63 g (0.275 mol) of 4-(4-morpholin-3-onyl)nitrobenzene are dissolved in 200 ml of tetrahydrofuran, treated with 3.1 g of Pd/C (5 % strength) and hydrogenated for 8 h at 70°C and a hydrogen pressure of 50 bar. After filtration of the catalyst, the solvent is distilled off in vacuo and the product is purified by crystallization from ethyl acetate. 20 g of the product are obtained as * a colorless to brownish solid in 37.6 % of theory. Purification can also be carried out by chromatography on silica gel using hexane/ethyl acetate. 'H-NMR (300MHz, CDC13): 3.67 (m, 2 H, Cy/2CH2), 3.99 (m, 2 H, CH2C#2), 4.27 (s, 2 H, C#2CO), 6.68 (d, 2 H, V=8.71 Hz, CtfCH), 7.03 (d, 2 H, V=8.71 Hz, CHCH) MS (rel. int.%) = 192 (100, M*-), 163 (48), 133 (26), 119 (76), 106 (49), 92 (38), 67 (27), 65 (45), 52 (22), 28 (22) The following compounds were synthesized analogously: - 3 3 - 3 -Fluoro-4-(4-morpholin-3 -onyl)aniline 4-(N-Piperidony l)ani 1 ine 3-Fluoro-4-(N-piperidonyl)aniline 4-(N-Pyrrolidonyl)aniline 3-Fluoro-4-(N-pyrrolidonyl)aniline General method for the preparation of 4-substituted anilines by reaction of l-fluoro-4- nitrobenzenes and l-chloro-4-nitrobenzenes with primary or secondary amines and subsequent reduction X = F, Cl Equimolar amounts of the fluoronitrobenzene or chloronitroben/ene and of the amine are dissolved in dimethyl sulfoxide or acetonitrile (0.1 M to 1 M solution) and stirred overnight at 100°C. After cooling to RT, the reaction mixture is diluted with ether and washed with water. The organic phase is dried over MgSO4, filtered and concentrated. If a precipitate is formed in the reaction mixture, this is filtered off and washed with ether or acetonitrile. If the product is also to be found in the mother liquor, this is worked up with ether and water as described. The crude products can be purified by chromatography on silica gel (dichloromethane/cyclohexane and dichloromethane/ethanol mixtures). For the subsequent reduction, the nitro compound is dissolved in methanol, ethanol or ethanol/dichloromethane mixtures (0.01 M to 0.5 M solution), treated with palladium on carbon (10%) and stirred overnight under hydrogen at normal pressure. The mixture is then filtered and concentrated. The crude product can be purified by chromatography on silica gel (dichloromethane/ethanol mixtures) or preparative reversed-phase EPLC (acetonitrile/water mixtures). Alternatively, iron powder can also be used as a reductant. For this, the nitro compound is dissolved in acetic acid (0.1 M to 0.5 M solution) and six equivalents of iron powder and water (0.3 to 0.5 times volume of acetic acid) are added in portions at 90°C in the course of 10-15 min. -34- After a further 30 min at 90°C, the mixture is filtered and the filtrate is concentrated. The residue is worked up by extraction with ethyl acetate and 2N sodium hydroxide solution. The organic phase is dried over magnesium sulfate, filtered and concentrated. The crude product can be purified by chromatography on silica gel (dichloromethane/ethanol mixtures) or preparative reversed-phase HPLC (acetonitrile/water mixtures). The following starting compounds were prepared in an analogous manner: IIL-1. Tert-butyl-l-(4-aminophenYl)-L-prolinate MS (ESI): m/z (%) = 304 (M+H+MeCN, 100), 263 (M+H, 20); HPLC (method 4): rt = 2.79 min. ni-2. l-(4-Aminophenyl)-3-piperidinecarboxarnide MS (ESI): m/z (%) = 220 (M+H, 100); HPLC (method 4): rt = 0.59 min. III-3. l-(4-Aminophenyl)-4-piperidinecarboxainide MS (ESI): m/z (%) = 220 (M+H, 100); HPLC (method 4): rt = 0.57 min. III-4. l-(4-AminophenvD-4-piperidiDone MS (ESI): m/z (%) =191 (M+H, 100); HPLC (method 4): rt = 0.64 min. DI-5. l-(4-Aminophenyl)-L-prolinamide MS (ESI): m/z (%) = 206 (M+H, 100); HPLC (method 4): rt = 0.72 min. HI-6. fl-(4-Aminophenyl)-3-piperidinYHmethanol MS (ESI): m/z (%) = 207 (M+H, 100); HPLC (method4>: rt = 0.60 min. -35- DI-7. [l-(4-Aminophenyl)-2-piperidinyllmethanol MS (ESI): m/z (%) = 207 (M+H, 100); HPLC (method 4): rt = 0.59 min. IQ-8. Ethyl-l-(4-aminophenyl)-2-piperidinecarboxylate MS (ESI): m/z (%) = 249 (M+H, 35), 175 (100); HPLC (method 4): rt = 2.43 min. HI-9. fl-(4-Aminophenvn-2-pvrrolidinvl1methanol MS (ESI): m/z (%) = 193 (M+H, 45); HPLC (method 4): rt = 0.79 min. 111-10. 4-(2-Methvlhexahvdro-5H-pvrrolof3,4-d1isoxazol-S-vnphenylamine starting from 2-metfiylhexahydro-2H-pyrrolo[3,4-d]isoxazole (Ziegler, Carl B., et al.; J. Heterocycl. Chem.; 25; 2; 1988; 719-723) MS (ESI): m/z (%) = 220 (M+H, 50), 171 (100); HPLC (method 4): rt = 0.54 min. III-ll. 4-(l-Pvrrolidinyl)-3-(trifluoromethvl)aniline MS (ESI): m/z (%) = 231 (M+H, 100); HPLC (method 7): rt = 3.40 min. ni-12. 3-Chloro-4-(l-pvrrolidinyl)apiline MS (ESI): m/z (%) = 197 (M+H, 100); HPLC (method 4): rt = 0.78 min. HI.-13. 5-Amino-2-(4-morpholinyl)benzamide MS (ESI): m/z (%) = 222 (M+H, 100); HPLC (method 4): rt = 0.77 min. -36- HI-14. 3-Methoxv-4-(4-morpholinyl)aniline MS (ESI): m/z (%) = 209 (M+H, 100); HPLC (method 4): rt = 0.67 min. HL-15. l-f5-Amino-2-(4-morpholinvr)phenvnethanone MS (ESI): m/z (%) = 221 (M+H, 100); HPLC (method 4): rt = 0.77 min. General method for the preparation 4-substituted anilines by reaction of l-fluoro-4- nitrobenzenes with amides and subsequent reduction The amide is dissolved in DMF and treated with 1.5 equivalents of potassium tert-butoxide. The mixture is stirred for Ih at RT, then 1.2 equivalents of l-fluoro-4-nitrobenzene are added in portions. The reaction mixture is stirred overnight at RT, diluted with ether or ethyl acetate and washed with satd. aq. sodium hydrogencarbonate solution. The organic phase is dried over magnesium sulfate, filtered and concentrated. The crude product can be purified by chromatography on silica gel (dichloromethane/ethanol mixtures). For the subsequent reduction, the nitro compound is dissolved in ethanol (0.01 M to 0.5 M solution), treated with palladium on carbon (10%) and stirred overnight under hydrogen at normal pressure. The mixture is then filtered and concentrated. The crude product can be purified by chromatography on silica gel (dichloromethane/ethanol mixtures) or preparative reversed-phase HPLC (acetonitrile/water mixtures). Alternatively, iron powder can also be used as a reductant. For this, the nitro compound is dissolved in acetic acid (0.1 M to 0.5 M solution) and six equivalents of iron powder and water (0.3 to 0.5 times the volume of acetic acid) are added hi portions at 90°C in the course of 10-15 min. After a further 30 min at 90°C, the mixture is filtered and the filtrate is concentrated. The - 3 7 - residue is worked up by extraction with ethyl acetate and 2N sodium hydroxide solution. The organic phase is dried over magnesium sulfate, filtered and concentrated. The crude product can be purified by chromatography on silica gel (dichloromethane/ethanol mixtures) or preparative reversed-phase HPLC (acetonitrile/water mixtures). The following starting compounds were prepared in an analogous manner: FV-1. l-f4-AmiDO-2-(trifluoromethvl)phenYl1-2-pyrrolidinone MS (ESI): m/z (%) = 245 (M+H, 100); HPLC (method 4): it = 2.98 min IV-2. 4-[4-Amino-2-(trifluoromethvr)phenvn-3 -morpholinone MS (ESI): m/z (%) = 261 (M+H, 100); HPLC (method 4): it = 2.54 min. FV-3. 4-(4-Amino-2-chlorophenyI)-3-morpholirione MS (ESI): m/z (%) = 227 (M+H, 100); HPLC (method 4): it = 1.96 min. IV-4. 4-(4-Amino-2-methvlphenyl)-3-morpholi none MS (ESI): m/z (%) = 207 (M+H, 100); HPLC (method 4): it = 0.71 min. IV-5. S-Amino-2-(3-oxo-4-morphoIinyr)benzonitrile MS (ESI): m/z (%) = 218 (M+H, 100); HPLC (method 4): it = 1.85 min. FV-6. l-(4-Amino-2-chlorophenyI)-2-pyrrolidinone MS (ESI): m/z (%) = 211 (M+H, 100); HPLC (method 4): it = 2.27 min. -38- FV-7. 4-(4-Amino-2,6-dimethvlphenyl)-3-morphoIinone starting from 2-fluoro-l,3-dimethyl-5-nitrobenzene (Bartoli et al.. J. Org. Chem. 1975, 40, 872): MS (ESI): m/z (%) = 221 (M+H, 100); HPLC (method 4): rt = 0.77 min. FV-8. 4-(2,4-DiaminophenYlV3-inorpholinone starting from l-fluoro-2,4-dinitrobenzene: MS (ESI): m/z (%) = 208 (M+H, 100); HPLC (method 4): rt = 0.60 min. FV-9. 4-(4-Amino-2-chlorophenvl)-2-methYl-3-morpholinone starting from 2-methyl-3-morpholinone (Pfeil, E.; Harder, U.; Angew. Chem. 1967, 79, 188): MS (ESI): m/z (%) = 241 (M+H, 100); HPLC (method 4): rt - 2.27 min. rV-10. 4-(4-Amino-2-chlorophenvn-6-methyl-3-morpholinone starting from 6-methyl-3-morpholinone (EP 0 350 002): MS (ESI): m/z (%) = 241 (M+H, 100); HPLC (method 4): rt = 2.43 min. -39- Synthesis examples The following examples 1 to 13, 17 to 19 and 36 to 57 relate to process variant [A]. Example 1 Preparation of S-chloro-N-{[(5S)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-l,3-oxazolidin-5- yl]methyl}-2-thiophenecarboxamide (5S)-5-(Aminomethyl)-3-(3-fluoro-4-morpholinophenyl)-l,3-oxazolidin-2-one (for preparation see S. J. Brickner et al, J. Med. Chem. 1996, 39, 673) (0.45 g, 1.52 mmol), 5-chlorothiophene-2- carboxylic acid (0.25 g, 1.52 mmol) and 1-hydroxy-lH-benzotriazole hydrate (HOBT) (0.3 g, 1.3 equivalents) are dissolved in 9.9 ml of DMF. 0.31 g (1.98 mmol, 1.3 equivalents) of N'-(3- dimethylaminopropyl)-N-ethylcarbodiimide (EDCT) are added and 0.39 g (0.53 ml, 3.05 mmol, 2 equivalents) of diisopropylethylamine (DIEA) are added dropwise at room temperature. The mixture is stirred overnight at room temperature. 2 g of silica gel are added and the batch is evaporated to dryness in vacuo. The residue is chromatographed on silica gel using a toluene-ethyl acetate-gradient. 0.412 g (61.5 % of theory) of the target compound is obtained with a melting point (m.p.) of 197°C. Rf (SiO2, toluene/ethyl acetate 1:1) = 0.29 (starting material = 0.0); i MS (DCI) 440.2 (M+H), Cl sample; 'H-NMR (d6-DMSO, 300 MHz) 2.95 (m, 4H), 3.6 (t, 2H), 3.72 (m, 4H), 3.8 (dd, IH), 4.12 (t, IH), 4.75-4.85 (m, IH), 7.05 (t, IH), 7.15-7.2 (m, 3H), 7.45 (dd, IH), 7.68 (d, IH), 8.95 (t, IH). Example 2 5-Chloro-N-{[(5S)-3-(4-morpholinophenyl)-2-oxo-l,3-oxazolidin-5-yl]methyl}-2- thiophenecarboxamide -40- is obtained analogously from benzyl 4-morpholinophenylcarbamate via the stage of (5S)-5- (aminomethyl)-3-(3-fluoro-4-morpholinophenyl)-l,3-oxazolidin-2-one (see Example 1). M.p.: 198°C; IC50 value = 43 nM; Rf (SiO2, toluene/ethyl acetate 1:1) = 0.24. Example 3 5-Chloro-N-({(5S)-3-[3-fluoro-4-(l,4-thiazinan-4-yl)phenyl]-2-oxo-l,3-oxazolidin-5- yl}methyl)-2-thiophenecarboxamide is obtained analogously from (5S)-5-(aminomethyl)-3-[3-fluoro-4-(l,4-thiazinan-4-yl)phenyl]-l,3- oxazolidin-2-one (for preparation see M. R. Barbachyn et al., J. Med. Chem. 1996, 39, 680). M.p.: 193°C; yield: 82 %; Rf (SiO2, toluene/ethyl acetate 1:1) = 0.47 (starting material = 0.0). Example 4 5-Bromo-N-({(5S)-3-[3-fluoro-4-(l,4-thiazinan-4-yI)phenyl]-2-oxo-l,3-oxazolidin-5- -41 - yl}methyl)-2-thiophenecarboxamide is obtained analogously from 5-bromothiophene-2--carboxylic acid. M.p.: 200°C. Example 5 N-({(5S)-3-[3-Fluoro-4-(l,4-thiazinan-4-yI)phenyl]-2-oxo-l,3-oxazolidin-5-yl}methyl)-5- methyl-2-thiophenecarboxamide is obtained analogously from 5-methylthiophene-2-carboxylic acid. M.p.: 167°C. -42- Example 6 5-Chloro-N-{[(5S)-3-(6-methylthieno[2,3-b]pyridin-2-yl)-2-oxo-l,3-oxazolidin-5-yl]methyl}-2- thiophenecarboxamide is obtained analogously from (5S)-5-(aminomethyl)-3-(6-methylthieno[2,3-b]pyridin-2-yl)-l,3- oxazolidin-2-one (for preparation see EP 0 785 200). M.p.: 247°C. Example 7 5-Chloro-N-{[(5S)-3-(3-methyl-2-oxo-2,3-dihydro-l,3-benzothiazol-6-yI)-2-oxo-l,3- oxazolidin-5-yl]methyl}-2-thiophenecarboxamide is obtained analogously from 6-[(5S)-5-(aminomethyl)-2-oxo-l,3-oxazolidin-3-yl]-3-methyl-l,3- benzothiazol-2(3H)-one (for preparation see EP 0 738 726). M.p.: 217°C. -43- Example 8 5-Chloro-N-[((5S)-3-{3-fluoro-4-[4-(4-pyridinyl)piperazino]phenyI}-2-oxo-l,3-oxazolidin-5- yl)methyl]-2-thiophenecarboxamide is obtained analogously from (5S)-5-(aminomethyl)-3-{3-fluoro-4-[4-(4-pyridinyl)piperazino]- phenyl}-l,3-oxazolidin-2-one (preparation analogous to J. A. Tucker et al., J. Med. Chem. 1998, 41,3727). MS (ESI) 516 (M+H), Cl sample. Example 9 5-Chloro-N-({(5S)-3-[3-fluoro-4-(4-methylpiperazino)phenyl]-2-oxo-l,3-oxazolidin-5- yI}methyl)-2-thiophenecarboxamide is obtained analogously from (5S)-5-(aminomethyl)-3-[3-fluoro-4-(4-methylpiperazino)phenyl]- 1,3-oxazolidin-2-one. -44- Example 10 5-Chloro-N-({(5S)-3-[3-fluoro-4-(4-tert-butoxycarbonylpiperazin-l-yl)phenyl]-2-oxo-l,3- oxazolidin-5-yl}methyl)-2-thiophenecarboxamide is obtained analogously from (5S)-5-(aminoniethyl)-3-[3-fluoro-4-(4-tert-butoxycarbonylpiperazinl- yl)phenyl]-l,3-oxazolidin-2-one (for preparation see already cited WO 93/23384). M.p.: 184°C; Rf (SiO2, toluene/ethyl acetate 1:1) = 0.42. Example 11 5-Chloro-N-({(5S)-3-[3-fluoro-4-(piperazin-l-yl)phenyl]-2-oxo-l,3-oxazolidin-5-yl}methyl)-2- thiophenecarboxamide is obtained by reaction of Example 12 with trifluoroacetic acid in methylene chloride. IC50 value = 140nM; 'H-NMR [d6-DMSO]: 3.01-3.25 (m, 8H), 3.5-3.65 (m, 2H), 3.7-3.9 (m, 1H), 4.05-4.2 (m, 1H), -45- 4.75-4.9 (m, 1H), 7.05-7.25 (m, 3H), 7.5 (dd, 1H), 7.7 (d, 1H), 8.4 (broad s, 1H), 9.0 (t, 1H). Example 12 5-Chloro-N-[((5S)-3-(2,4^-bipyridinyI-5-yl)-2-oxo-l,3-oxazolidin-5-yl)methyl]-2- thiophenecarboxamide O is obtained analogously from (5S)-5-aminornethyl-3-(2,4'-bipyridinyl-5-yl)-2-oxo-l,3-oxazolidin- 2-one (for preparation see EP 0 789 026). Rf (SiO2, ethyl acetate/ethanol 1:2) = 0.6; MS (ESI) 515 (M+H), Cl sample. Example 13 5-Chloro-N-{[(5S)-2-oxo-3-(4-piperidinophenyl)-l,3-oxazoIidin-5-yl]methyl}-2- thiophenecarboxamide is obtained from 5-(hydroxymethyl)-3-(4-pipericlinophenyl)-l,3-oxazolidin-2-one (for preparation see DE 2708236) by mesylation, reaction with potassium phthalimide, hydrazinolysis and reaction with 5~chlorothiophene-2-carboxylic acid. -46- Rf (SiO2, ethyl acetate/toluene 1:1) = 0.31; m.p. 205°C. Example 17 5-Chloro-N-({(5S)-2-oxo-3-[4-(2-oxo-l-pyrrolidinyl)phenyl]-l,3-oxazoIidin-5-yl}methyl)-2- thiophenecarboxamidc Starting from l-(4-arninophenyl)pyrrolidin-2-one (for preparation see Reppe et al., Justus Liebigs Ann. Chem.; 596; 1955; 209), in analogy to the known synthesis scheme (see SJ. Brickner et al., J. Med. Chem. 1996, 39, 673), by reaction with henzyloxycarbonyl chloride, subsequent reaction with ^-glycidyl butyrate, mesylation, reaction with potassium phthalimide, hydrazinolysis in methanol and reaction with 5-chlorothiophene-2-carboxylic acid, 5-chloro-N-({(5S)-2-oxo-3-[4-(2- oxo-l-pyrrolidinyl)phenyl]-l,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide is finally obtained. The 5-chloro-N-({(5S)-2-oxo-3-[4-(2-oxo-l-pyrrolidinyl)phenyl]-l,3-oxazolidin-5- yl}methyl)-2-thiophenecarboxamide obtained in this way has a value of IC50= 4 nM (test method for the IC5o value according to previously described Example A-1. a. 1) "Measurement of the factor Xa inhibition"). M.p.: 229°C; Rf value (SiO2, toluene/ethyl acetate 1:1) = 0.05 (starting material: = 0.0); MS (ESI): 442.0 (21%, M+Na, Cl sample), 420.0 (72%, M+H, Cl sample), 302.3 (12%), 215(52%), 145 (100%); 'H-NMR (d6-DMSO, 300 MHz): 2.05 (m,2H), 2.45 (m,2H), 3.6 (t,2H), 3.77-3.85 (m,3H), 4.15(t,lH), 4.75-4.85 (m,lH), 7.2 (d,lH), 7.5 (d,2H), 7.65 (d,2H), 7.69 (d,lH), 8.96 (t,lH). The individual stages of the previously described synthesis of Example 17 with the respective precursors are as follows: 4 g (22.7 mmol) of l-(4-aminophenyl)pyrrolidin-2-one and 3.6 ml (28.4 mmol) of N,N- 47- dimethylaniline are slowly treated at -20°C with 4.27 g (25.03 mmol) of benzyl chloroformate in 107 ml of tetrahydrofuran. The mixture is stirred for 30 minutes at -20°C and the whole is subsequently allowed to come to room temperature. 0.5 1 ethyl acetate is added and the organic phase is washed with 0.5 1 of saturated NaCl solution. The separated organic phase is dried using MgSO4 and the solvent is evaporated in vacuo. The residue is triturated with diethyl ether and filtered off with suction. 5.2 g (73.8 % of theory) of benzyl 4-(2-oxo-l-pyrrolidinyl)phenylcarbamate are obtained as light beige crystals having a melting point of 174°C. 1.47 g (16.66 mmol) of isoamyl alcohol in 200 ml of tetrahydrofuran under argon are treated dropwise at -10°C with 7.27 ml of a 2.5 M solution of n-butyllithium (BuLi) in hexane, a further 8 ml of the BuLi solution being necessary up to the change of the added indicator Nbenzylidenebenzylamine. The mixture is stirred for 10 minutes at -10°C, cooled to -78°C and a solution of 4.7 g (15.14 mmol) of benzyl 4-(2-oxo-l-pyrrolidinyl)phenylcarbamate is added slowly. Subsequently, up to the color change of the indicator to pink, another 4 ml of n-BuLi solution are added. The mixture is stirred for 10 minutes al -78°C and 2.62 g (18.17 mmol) of #-glycidyl butyrate are added and the mixture is stirred again for 30 minutes at -78°C. The whole is allowed to come to room temperature overnight, 200 ml water are added to the batch and the THF component is evaporated in vacuo. The aqueous residue is extracted with ethyl acetate, and the organic phase is dried using MgSO4 and evaporated in vacuo. The residue is triturated with 500 ml of diethyl ether and the crystals deposited are filtered off with suction in vacuo. 3.76 g (90 % of theory) of (5R)-5-(hydroxymethyl)-3-[4-(2-oxo-l-pyrrolidinyl)phenyl]-l,3- oxazolidin-2-one are obtained with a melting point of 148°C and an Rf value (SiO2, toluene/ethyl acetate 1:1) = 0.04 (starting material = 0.3). 3.6 g (,13.03 mmol) of (5R)-5-(hydroxymethyl)-3-[4-(2-oxo-l-pyrrolidinyl)phenyl]-l,3-oxazolidin- 2-one and 2.9 g (28.67 mmol) of triethylamine are introduced with stirring into 160 ml of dichloromethane at 0°C. 1.79 g (15.64 mmol) of methanesulfonyl chloride are added with stirring and the mixture is stirred for 1.5 hours at 0°C and for 3 h at room temperature. The reaction mixture is washed with water and the aqueous phase is extracted again with methylene chloride. The combined organic extracts are dried using MgSC>4 and evaporated. Subsequently, the residue (1.67 g) is dissolved in 70 ml of acetonitrile, treated with 2.62 g (14.16 mmol) of potassium phthalimide and stirred for 45 minutes at 180°C in a closed vessel in a microwave oven. -48- The batch is filtered off from insoluble residue, the filtrate is evaporated in vacuo, and the residue (1.9 g) is dissolved in methanol and treated with 0.47 g (9.37 mmol) of hydrazine hydrate. The mixture is boiled for 2 hours, cooled, treated with saturated sodium bicarbonate solution and extracted six times with a total of 2 1 of methylene chloride. The combined organic extracts of the crude (5S)-5-(aminomethyl)-3-[4-(2-oxo-l-pyrrolidinyl)phenyl]-l,3-oxazolidin-2-one are dried using MgSC>4 and evaporated in vacuo. The final stage, 5-chloro-N-({(5S)-2-oxo-3-[4-(2-oxo-l-pyrrolidinyl)phenyl]-l,3-oxazolidin-5- yl}methyl)-2-thiophenecarboxamide, is prepared by dissolving 0.32 g (1.16 mmol) of the (5S)-5- (aminomethyl)-3-[4-(2-oxo-l-pyrrolidinyl)phenyl]-l,3-oxazolidin-2-one prepared above, 5- chlorothiophene-2-carboxylic acid (0.19 g; 1.16 mmol) and 1-hydroxy-lH-benzotriazole hydrate (HOST) (0.23 g, 1.51 mmol) in 7.6ml of DMT. 0.29 g (1.51 mmol) of N^-(3-dimethylaminopropyl)- N-ethylcarbodiimide (EDCI) are added and 0.3 g (0.4 ml; 2.32 mmol, 2 equivalents) of diisopropylethylamine (DIEA) are added dropwise at room temperature. The mixture is stirred overnight at room temperature. The batch is evaporated to dryness in vacuo, and the residue is dissolved in 3 ml of DMSO and chromatographed on an RP-MPLC using an acetonitrile/water/0.5 % TFA gradient. The acetonitrile component is evaporated from the appropriate fractions and the precipitated compound is filtered off with suction. 0.19 g (39 % of theory) of the target compound is obtained. The following were prepared in an analogous manner: Example 18 5-Chloro-N-({(5S)-2-oxo-3-[4-(l-pyrrolidinyl)phenyI]-l,3-oxazolidin-5-yl}methyl)-2- thiophenecarboxamide Analogously to Example 17, starting from 4-pyrrolidin-l-yl-aniline (Reppe et al, Justus Liebigs Ann. Chem.; 596; 1955; 151) the compound 5-chloro-N-({(5S)-2-oxo-3-[4-(l-pyrrolidinyl)phenyl]- l,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide is obtained. IC50=40 nM; m.p.: 216°C; Rf value (SiO2, toluene/ethyl acetate 1:1) = 0.31 [starting material: = 0.0]. Example 19 -49- 5-Chloro-N-({(5S)-2-oxo-3-[4-(diethylamino)phcnyl]-l,3-oxazolidin-5-yl}methyl)-2- thiophenecarboxamide Analogously, starting from N,N-diethylphenyl-l,4-diamine (US 2 811 555; 1955), the compound 5-chloro-N-({(5S)-2-oxo-3-[4-(diethylamino)phenyl]-l,3-oxazolidin-5-yl}methyl)-2- thiophenecarboxamide is obtained. IC50=270 nM; M.p.: 181°C; Rf value (SiO2, toluene/ethyl acetate 1:1) = 0.25 [starting material: = 0.0]. Example 36 5-Chloro-Ar-({(55)-3-[2-methyl-4-(4-morpholinyl)phenyl]-2-oxo-l,3-oxazolidin-5-yl}methyl)- 2-thiophenecarboxamide starting from 2-methyl-4-(4-morpholinyl)aniline (J.E.LuValle et al. J.Am.Chem.Soc. 1948, 70, 2223): MS (ESI): m/z (%) = 436 ([M+H]+, 100), Cl sample; HPLC (method 1): rt (%) = 3.77 (98). IC50: 1.26|iM Example 37 5-Chloro-A'-{[(55r)-3-(3-chloro-4-raorpholmophenyl)-2-oxo-l,3-oxazolidin-5-yl]methyl}-2- thiophenecarboxam ide starting from 3-chloro-4-(4-morpholinyl)aniline (H.R.Snyder et al. J.Pharm.Sci. 1977, 66, 1204): MS (ESI): m7z (%) = 456 ([M+H]+, 100), C12 sample; HPLC (method 2): rt (%) = 4.31 (100). IC50: 33 nM Example 38 5-Chloro-7V-({(55)-3-[4-(4-morpholinylsulfonyl)phenyl]-2-oxo-l,3-oxazolidin-5-yl}methyl)-2- -50- thiophenecarboxamide starting from 4-(4-moirpholinylsulfonyl)aniline (Adams et al. J.Am.Chem.Soc. 1939, 61, 2342): MS (ESI): m/z (%) = 486 ([M+H]+, 100), Cl sample; HPLC (method 3): rt (%) = 4.07 (100). IC50: 2 nM Example 39 5-Chloro-Ar-({(55)-3-[4-(l-azetidinyIsulfonyl)phenyl]-2-oxo-l,3-oxazolidin-5-yl}methyl)-2- thiophenecarboxamide starting from 4-(l-azetidinylsulfonyl)aniline: MS (DCI, NH3): m/z (%) = 473 ([M+NH,]+, 100), Cl sample; HPLC (method 3): rt (%) = 4.10 (100). IC50: 0.84 nM Example 40 5-Chloro-Ar-[((51S)-3-{4-[(dimethylamino)sulfonyl]phenyl}-2-oxo-l,3-oxazolidin-5-yl)methyl]- 2-thiophenecarboxamide starting from 4-amino-AyV-dimethylbenzenesulfoiiamide (I.K.IChanna et al. J.Med.Chem. 1997, 40, 1619): MS (ESI): m/z (%) = 444 ([M+H]+, 100), Cl sample; HPLC (method 3): rt (%) = 4.22 (100). IC50: 90 nM -51 - General method for the acylation of 5-(aminomethyl)-3-[4-(2-oxo-l-pyrrolidinyl)phenyl]-l,3- oxazolidin-2-one with carbonyl chlorides. N NhL + Ck .R An about 0.1 molar solution of 5-(aminomethyl)-3-[4-(2-oxo-l-pyrrolidinyl)phenyl]-l,3- oxazolidin-2-one (from Example 45) (1.0 eq.) and absolute pyridine (about 6 eq) in absolute dichloromethane is added dropwise under argon at room temperature to the appropriate acid chloride (2.5 eq.). The mixture is stirred for about 4 h at room temperature, before about 5.5 eq of PS-trisamine (Argonaut Technologies) are added. The suspension is gently stirred for 2 h, filtered after diluting with dichloromethane/DMF (3:1) (the resin is washed with dichloromethane/DMF) and the filtrate is concentrated. The product obtained is optionally purified by preparative RPHPLC. The following was prepared in an analogous manner: Example 41 AL({2-Oxo-3-[4-(2-oxo-l-pyrrolidinyl)phenyl]-l,3-oxazoIidin-5-yl}methyl)-2-thiophenecarboxamide LC-MS (method 6): m/z (%) =i 386 (M+H, 100); LC-MS:rt(%) = 3.04(100). IC50: 1.3 uM -52- General method for the preparation of acyl derivatives starting from 5-(aminomethyI)-3-[4- (2-oxo-l-pyrrolidinyI)phenyl]-l,3-oxazolidin-2-one and carboxylic acids HCL,R YO N 0 The appropriate carboxylic acid (about 2 eq) and a mixture of absolute dichloromethane/DMF (about 9:1) are added to 2.9 eq. of resin-bound carbodiimide (PS carbodiimide, Argonaut Technologies). After gentle shaking at room temperature for about 15 min, 5-(aminomethyl)-3-[4- (2-oxo-l-pyrrolidinyl)phenyl]-l,3-oxazolidin-2-one (from Example 45) (1.0 eq.) is added and the mixture is shaken overnight, before being filtered off from the resin (washed with dichloromethane), and the filtrate is concentrated The product obtained is optionally purified by preparative RP-HPLC. The following were prepared in an analogous manner: Example 42 5-Methyl-A'-({2-oxo-3-[4-(2-oxo-l-pyrrolidinyl)phenyl]-l,3-oxazoIidin-5-yl}niethyI)-2- thiophenecarboxamide LC-MS: m/z (%) = 400 (M+H, 100); LC-MS (method 6): rt (%) = 3.23 (100). IC50: 0.16 -53- Example 43 5-Bromo-7V-({2-oxo-3-[4-(2-oio-l-pyrrolidinyl)phenyl]-l,3-oxazolidin-5-yl}methyI)-2- thiophenecarboxamide LC-MS : m/z (%) = 466 (M+H, 100); LC-MS (method 5): rt (%) = 3.48 (78). IC50: 0.014 Example 44 5-Chloro-AL({(55)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-l,3-oxazolidin-5-yl}methyl)-2- thiophenecarboxamide O - 5 4 - a) 2-((2/?)-2-Hydroxy-3-{[4-(3-oxo-4-morphoIinyI)phenyl]amino}propyl)-l/?-isoindolel, 3(2#)-dione: A suspension of 2-[(2>S>2-oxiranylmethyl]-l/:/-isoindole-l,3(2/f)-dione (A. Gutcait et al. Tetrahedron Asym. 1996, 7, 1641) (5.68 g, 27.9 mmol) and 4-(4-aminophenyl)-3-morpholinone (5.37 g, 27.9 mmol) in ethanol-water (9:1, 140 ml) is refluxed for 14 h (the precipitate goes into solution, after some time fresh formation of a precipitate). The precipitate (desired product) is filtered off, washed three times with diethyl ether and dried. The combined mother liquors are concentrated in vacuo and, after addition of a second portion of 2-[(25)-2-oxiranylmethyl]-l//- isoindole-l,3(2//)-dione (2.84 g, 14.0 mmol), suspended in ethanol-water (9:1, 70 ml) and refluxed for 13 h (the precipitate goes into solution, after some time fresh formation of a precipitate). The precipitate (desired product) is filtered off, washed three times with diethyl ether and dried. Total yield: 10.14 g, 92 % of theory. MS (ESI): m/z (%) = 418 ([M+Na]+, 84), 396 ([M HH]+, 93); HPLC (method 3): rt (%) = 3.34 (100). b) 2-({(55)-2-Oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-l,3-oxazolidin-5-yl}methyI)-l/irisoindole- l,3(2/f)-dione: AfAf'-Carbonyldiimidazole (2.94 g, 18.1 mmol) and dimethylaminopyridine (catalytic amount) are added at room temperature to a suspension of the amino alcohol (3.58 g, 9.05 mmol) in tetrahydrofuran (90 ml) under argon. The reaction suspension is stirred at 60°C for 12 h (the precipitate goes into solution, after some time fresh formation of a precipitate), treated with a second portion of A^V-carbonyldiimidazole (2.94 g, 18.1 mmol) and stirred for a further 12 h at 60°C. The precipitate (desired product) is filtered off, washed with tetrahydrofuran and dried. The filtrate is concentrated in vacuo and further product is purified by means of flash chromatography (dichloromethane-methanol mixtures). Total yield: 3.32 g, 87 % of theory. MS (ESI): m/z (%) = 422 ([M+H]+, 100); HPLC (method 4): rt (%) = 3.37 (100). c) 5-Chloro-7V-({(55')-2-oxo-3-[4-(3-oxo-4-mor])holinyl)phenyl]-l,3-oxazolidin-5-yl}methyI)-2- thiophenecarboxamide: Methylamine (40% strength in water, 10.2 ml, 0.142 mol) is added dropwise at room temperature to a suspension of the oxazolidinone (4.45 g, 10.6 mmol) in ethanol (102 ml). The reaction mixture - 5 5 - is refluxed for 1 h and concentrated in vacuo. The crude product is employed in the next reaction without further purification. 5-Chlorothiophene-2-carbonyl chloride (2.29 g, 12.7 mmol) is added dropwise under argon at 0°C to a solution of the amine in pyridine (90 ml). The ice cooling is removed and the reaction mixture is stirred for 1 h at room temperature and treated with water. After addition of dichloromethane and phase separation, the aqueous phase is extracted with dichloromethane. The combined organic phases are dried (sodium sulfate), filtered and concentrated in vacuo. The desired product is purified by means of flash chromatography (dichloromethane-methanol mixtures). Total yield: 3.92g, 86% of theory. M.p: 232-233°C; 'H NMR (DMSO-d6, 200 MHz): 9.05-8.90 (t:,J= 5.8 Hz, IH), 7.70 (d, 7= 4.1 Hz, IH), 7.56 (d, J = 9.0 Hz, 2H), 7.41 (d, J= 9.0 Hz, 2H), 7.20 (d, J= 4.1 Hz, IH), 4.93-4.75 (m, IH), 4.27-4.12 (m, 3H), 4.02-3.91 (m, 2H), 3.91-3.79 (dd, J= 6.1 Hz, 9.2 Hz, IH). 3.76-3.66 (m, 2H), 3.66-3.54 (m, 2H); MS (ESI): m/z (%) = 436 ([M+H]+, 100, Cl sample); HPLC (method 2): rt (%) = 3.60 (100); [a]21 D = -38° (c 0.2985, DMSO); ee: 99 %. IC50: 0.7 nM The following were prepared in an analogous manner: Example 45 5-Methyl-A'-({(55)-2-oxo-3-[4-(3-oxo-4-morphoIinyl)phenyI]-l,3-oxazolidin-5-yl}methyl)-2- thiophenecarboxamide MS (ESI): m/z (%) = 831 ([2M+H]+, 100), 416 ([M+H]+, 66); HPLC (method 3): rt (%) = 3.65 (100). IC50: 4.2 nM - 5 6 - Example 46 5-Bromo-Ar-({(51S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyI]-l,3-oxazolidin-5-yl}methyl)-2- thiophenecarboxamide MS (ESI): m/z (%) = 480 ([M+H]+, 100, Br sample); HPLC (method 3): rt (%) = 3.87 (100). IC50: 0.3 nM Example 47 5-Chloro-N-{[(5S)-3-(3-isopropyI-2-oxo-2,3-dihydro-l,3-benzoxazol-6-yl)-2-oxo-l,3- oxazolidin-5-yl]methyl}-2-thiophenecarboxamide hLC CIH ci- 200 mg (0.61 mmol) of 6-[(5S)-5-(aminomethyl)-2-oxo-l,3-oxazolidin-3-yl]-3-isopropyl-l,3- benzoxazol-2(3H)-one hydrochloride (EP 0 738 726) are suspended in 5 ml of tetrahydrofuran and treated with 0.26 ml (1.83 mmol) of triethylamine and 132 mg (0.73 mmol) of 5-chlorothiophene- 2-carbonyl chloride. The reaction mixture is stirred overnight at room temperature and subsequently concentrated. The product is isolated by column chromatography (silica gel, methylene chloride/ethanol = 50/1 to 20/1). 115 mg (43% of theory) of the desired compound are obtained. MS (ESI): m/z (%) = 436 (M+H, 100); HPLC (method 4): rt = 3.78 min. -57- The following compounds were prepared in an analogous manner: Example No. Structure M.p. [°C] IC50 48 n\J ClChiral 210 0 0.12 49 234 0.074 50 195 1.15 51 12 1.19 52 160 0.19 53 MS (ESI): 431([M+H]+. 100),C1 sample 0.74 -58- Example No. 54 55 56 57 255 Structure 0 Chiral / o from 5-amino-2-pyrrolidinobenzonitrile (Grell, W.,Hurnaus, R.; Griss, G.,Sauter, R,; Rupprecht, E. et al.; J.Med.Chem.1998, 41; 5219) 0 0 Chlral rv^Ci 0 from 3-(4-aminophenyl)-oxazolidin- 2-one (Artico,M. et al.; Farmaco Ed.Sci. 1969,24; 179) 0 Chiral 0 0 0 Ctmal ° 0 ° // ll \ / *^ _._y \_ / // \M.p. [°C] 221 256 218 226 228-230 ICso [uM] 0.13 0.04 0.004 0.58 The following Examples 20 to 30 and 58 to 139 relate to process variant [B], Examples 20 and 21 describing the preparation of precursors. Example 20 Preparation of ./V-alIyl-5-chloro-2-thiopheiiecar boxamide 5-Chlorothiophene-2-carbonyl chloride (7.61 g, 42 mmol) is added dropwise to an ice-cooled -59- solution of 2.63 ml (35 mmol) of allylamine in 14.2 ml of absolute pyridine and 14.2 ml of absolute THF. The ice cooling is removed and the mixture is stirred for 3 h at room temperature, before being concentrated in vacuo. The residue is treated with water and the solid is filtered off. The crude product is purified by flash chromatography on silica gel (dichloromethane). Yield: 7.20 g (99 % of theory); MS (DCI, NH4): m/z (%) = 219 (M+NH4, 100), 202 (M+H, 32); HPLC (method 1): rt (%) = 3.96 min (98.9). Example 21 Preparation of 5-chloro-7V-(2-oxiranylmethyl)-2-thiophenecarboxamide O O v, 11 c. No ^^N-NC Vci —- £>^K^\/ra H \JI O H \J/ An ice-cooled solution of 2.0 g (9.92 mmol) of A'-allyl-5-chloro-2-thiophenecarboxamide in 10 ml of dichloromethane is treated with meta-chloroperbenzoic acid (3.83 g, about 60 % strength). The mixture is stirred overnight, warming in the course of this to room temperature, and subsequently washed (three times) with 10% sodium hydrogensulfate solution. The organic phase is washed (twice) with saturated sodium hydrogencarbonate solution and with saturated sodium chloride solution, dried over magnesium sulfate and concentrated. The product is purified by means of chromatography on silica gel (cyclohexane/ethyl acetate 1:1). Yield: 837 mg (39 % of theory); MS (DCI, NH4): m/z (%) =253 (M+NH4, 100), 218 (M+H, 80); HPLC (method 1): rt (%) = 3.69 min (about 80). General method for preparation of substituted ./V-(3-amino-2-hydroxypropyI)-5-chloro-2- thiophenecarboxamide derivatives starting from 5-chloro-7V-(2-oxiranylmethyl)-2- thiophenecarboxamide 0 H " " " " -Cl 'VV"N'WCI H <|)H H U -60- 5-Chloro-AL(2-oxiranylmethyl)-2-thiophenecarboxamide (1.0 eq.) is added in portions at room temperature or at temperatures up to 80°C to a solution of primary amine or aniline derivative (1.5 to 2.5 eq.) in 1,4-dioxane, 1,4-dioxane-water mixtures or ethanol, ethanol-water mixtures (about 0.3 to 1.0 mol/1). The mixture is stirred for 2 to 6 hours, before being concentrated. The product can be isolated from the reaction mixture by chromatography on silica gel (cyclohexane-ethyl acetate mixtures, dichloromethane-methanol mixtures or dichloromethane-methanol-triethylamine mixtures). The following were prepared in an analogous manner: Example 22 7V-[3-(Benzylamino)-2-hydroxypropyl]-5-chlon)-2-thiophenecarboxamide MS (ESI): m/z (%) = 325 (M+H, 100); HPLC (method 1): rt (%) = 3.87 min (97.9). Example 23 5-Chloro-Ar-[3-(3-cyanoanilino)-2-hydroxypropyl]-2-thiophenecarboxamide MS (ESI): m/z (%) = 336 (M+H, 100); HPLC (method 2): rt (%) - 4.04 min (100). Example 24 5-Chloro-Af-[3-(4-cyanoanilino)-2-hydroxypropyl]-2-thiophenecarboxamide MS (ESI): m/z (%) = 336 (M+H, 100); HPLC (method 1): rt (%) = 4.12 min (100). Example 25 5-Chloro-N-{3-[4-(cyanomethyl)anilino]-2-hydroxypropyl}-2-thiophenecarboxamide MS (ESI): m/z (%) = 350 (M+H, 100); HPLC (method 4): rt (%) = 3.60 min (95.4). -61 - Example 26 5-Chloro-N-{3-[3-(cyanomethyl)anilino]-2-hydroxypropyl}-2-thiophenecarboxamide MS (ESI): m/z (%) = 350 (M+H, 100); HPLC (method 4): rt (%) = 3.76 min (94.2). Example 58 /erf-Butyl 4-[(3-{[(5-chloro-2-thienyl)carbonyl]amino}-2-hydroxypropyl)amino]- benzylcarbamate Starting from /er/-butyl 4-aminobenzylcarbamate (Bioorg. Med. Chem. Lett.; 1997; 1921-1926): MS (ES-pos): myz (%) = 440 (M+H, 100), (ES-neg): m/z (%) = 438 (M-H, 100); HPLC (method 1): rt (%) = 4.08 (100). Example 59 tert-Buty\ 4-[(3-{[(5-chloro-2-thienyOcarbonyl]amino}-2-hydroxypropyl)amino]phenylcarbamate Starting from //-/er/'-butyloxycarbonyl-l,4-pheny]endiamine: MS (ESI): m/z (%) = 426 (M+H, 45), 370 (100); HPLC (method 1): rt (%) = 4.06 (100). Example 60 ter^Butyl2-hydroxy-3-{[4-(2-oxo-l-pyrrolidinyI)phenyl]amino}propylcarbamate Starting from l-(4-aminophenyl)-2-pyrrolidinone (Justus Liebigs Ann. Chem.; 1955; 596; 204): MS (DCI, NH3): m/z (%) = 350 (M+H, 100); HPLC (method 1): rt (%) = 3.57 (97). -62- Example 61 5-Chloro-N-(3-{[3-fluoro-4-(3-oxo-4-morpholinyl)phenyI]amino}-2-hydroxypropyl)-2- thiophenecarboxamide 800 mg (3.8 mmol) of 4-(4-amino-2-fluorophenyl)-3-morpholinone and 700 mg (3.22 mmol) of 5- chloro-N-(2-oxiranylmethyl)-2-thiophenecarboxamide are heated under reflux in 15 ml of ethanol and 1 ml of water for 6 hours. The mixture is evaporated in vacuo, filtered off with suction from precipitated crystals after treating with ethyl acetate and, by chromatography of the mother liquor, 276 mg (17 % of theory) of the target compound are obtained. Rf (ethyl acetate): 0.25. Example 62 (7V-(3-Anilino-2-hydroxypropyl)-5-chloro-2-thiophenecarboxamide starting from aniline: MS (DCI, NH3): m/z (%) = 311 ([M+H]+, 100), Cl sample; HPLC (method 3): it (%) = 3.79 (100). Example 63 5-Chloro-Af-(2-hydroxy-3-{[4-(3-oxo-4-morpholinyl)phenyl]amino}propyl)-2- thiophenecarboxamide starting from 4-(4-aminophenyl)-3-morpholinone: MS (ESI): m/z (%) = 410 ([M+H]+,(50), Cl sample; HPLC (method 3): it (%) = 3.58 (100). Example 64 7Y-[3-({4-[Acetyl(cyclopropyl)amino]phenyl}amino)-2-hydroxypropyl]-5-chloro-2- thiophenecarboxamide starting from A/-(4-aminophenyl)-./V-cyclopropylacetamide: MS (ESI): m/z (%) = 408 ([M+H]+, 100), Cl sample; -63- HPLC (method 3): rt (%) = 3.77 (100). Example 65 N-[3-({4-[Acetyl(methyl)amino]phenyl}amino)-2-hydroxypropyl]-5-chloro-2- thiophenecarboxamide starting from N-(4-aminophenyl)-N-methylacetamide: MS (ESI): m/z (%) = 382 (M+H, 100); HPLC (method 4): rt = 3.31 min. Example 66 5-Chloro-N-(2-hydroxy-3-{[4-(lH-l,2,3-triazol-l-yl)phenyl]amino}propyl)-2- thiophenecarboxamide starting from 4-(lH-l,2,3-triazol-l-yl)aniline (Bouchet et al.; J.Chem.Soc.Perkin Trans.2; 1974; 449): MS (ESI): m/z (%) = 378 (M+H, 100); HPLC (method 4): rt = 3.55 min. Example 67 Tert-butyl l-{4-[(3-{[(5-chloro-2-thienyI)carbonyl]amino}-2-hydroxypropyl)amino]phenyl}- L-prolinate MS (ESI): m/z (%) = 480 (M+H, 100); HPLC (method 4): rt = 3.40 min. Example 68 l-{4-[(3-{[(5-Chloro~2-thienyl)carbonyl]amino}-2-hydroxypropyI)amino]phenyl}-4- piperidinecarboxamide MS (ESI): m/z (%) = 437 (M+H, 100); HPLC (method 4): rt = 2.39 min. -64- Example 69 1_{4_[(3- {[(5-Chloro-2-thienyl)carbonyl] am ino}-2-hydroxypropyl)amino] phenyl}-3- piperidinecarboxamide MS (ESI): m/z (%) = 437 (M+H, 100); HPLC (method 4): rt == 2.43 min. Example 70 5-Chloro-N-(2-hydroxy-3-{[4-(4-oxo-l-piperidinyl)phenyl]amino}propyl)-2- thiophenecarboxamide MS (ESI): m/z (%) = 408 (M+H, 100); HPLC (method 4): rt = 2.43 min. Example 71 l-{4-[(3-{[(5-Chloro-2-thienyI)carboayl]amino}-2-hydroxypropyl)amino]phenyl}-Lprolinamide MS (ESI): m/z (%) = 423 (M+H, 100); HPLC (method 4): rt = 2.51 min. Example 72 5-Chloro-N-[2-hydroxy-3-({4-[3-(hydroxymethyl)-l-piperidinyl]phenyI}amino)propyl]-2- thiophenecarboxamide MS (ESI): m/z (%) = 424 (M+H, 100); HPLC (method 4): rt = 2.43 min. Example 73 5-Chloro-N-[2-hydroxy-3-({4-[2-(hydroxymethyI)-l-piperidinyl]phenyl}amino)propyl]-2- thiophenecarboxamide MS (ESI): m/z (%) = 424 (M+H, 100); -65- HPLC (method 4): rt = 2.49 mm. Example 74 Ethyl l-{4-[(3-{[(5-chloro-2-thienyl)carbonyl]amino}-2-hydroxypropyl)amino]phenyl}-2- piperidinecarboxylate MS (ESI): m/z (%) = 466 (M+H, 100); HPLC (method 4): rt = 3.02 min. Example 75 5-Chloro-N-[2-hydroxy-3-({4-[2-(hydroxymethyl)-l-pyrrolidinyI]phenyl}amino)propyl]-2- thiophenecarboxamide MS (ESI): m/z (%) = 410 (M+H, 100); HPLC (method 4): rt = 2.48 min. Example 76 5-Chloro-N-(2-hydroxy-3-{[4-(2-methylhexahydro-5H-pyrrolo[3,4-d]isoxazol-5-yl)- phenyl] amino} propyI)-2-thiophenecarboxamid e MS (ESI): m/z (%) = 437 (M+H, 100). HPLC (method 5): rt = 1.74 min. Example 77 5-Chloro-N-(2-hydroxy-3-{[4-(l-pyrrolidinyI)-3-(trifluoromethyI)phenyI]amino}propyI)-2- thiophenecarboxamide MS (ESI): m/z (%) = 448 (M+H, 100); HPLC (method 4): rt = 3.30 min. Example 78 5-Chloro-N-(2-hydroxy-3-{[4-(2-oxo-l-pyrroIidinyl)-3-(trifluoromethyl)phenyl]- amino}propyl)-2-thiophenecarboxamide -66- MS (ESI): m/z (%) = 462 (M+H, 100); HPLC (method 4): rt = 3.50 min. Example 79 5-Chloro-N-(3-{[3-chloro-4-(3-oxo-4-morpholinyl)phenyl]amino}-2-hydroxypropyl)-2- thiophenecarboxamide MS (ESI): m/z (%) = 444 (M+H, 100); HPLC (method 4): rt = 3.26 min. Example 80 5-Chloro-N-(2-hydroxy-3-{[4-(3-oxo-4-morpholinyl)-3-(trifluoromethyl)phenyl]- amino}propyl)-2-thiophenecarboxamide MS (ESI): m/z (%) = 478 (M+H, 100); HPLC (method 4): rt = 3.37 min. Example 81 5-Chloro-N-(2-hydroxy-3-{[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]amino}propyl)-2- thiophenecarboxamide MS (ESI): m/z (%) = 424 (M+H, 100); HPLC (method 4): rt = 2.86 min. Example 82 t 5-Chloro-N-(3-{[3-cyano-4-(3-oxo-4-morpholinyl)phenyl]amino}-2-hydroxypropyl)-2- thiophenecarboxamide MS (ESI): m/z (%) = 435 (M+H, 100); HPLC (method 4): rt = 3.10 min. -67- Example 83 5-Chloro-N-(3-{[3-chloro-4-(l-pyrrolidinyl)pheayl]amino}-2-hydroxypropyl)-2- thiophenecarboxamide MS (ESI): m/z (%) = 414 (M+H, 100); HPLC (method 4): rt = 2.49 min. Example 84 5-Chloro-N-(3-{[3-chloro-4-(2-oxo-l-pyrrolidinyl)phenyl]amino}-2-hydroxypropyI)-2- thiophenecarboxamide MS (ESI): m/z (%) = 428 (M+H, 100); HPLC (method 4): rt = 3.39 min. Example 85 5-Chloro-N-(3-{[3,5-dimethyl-4-(3-oxo-4-morphoIinyl)phenyI]amino}-2-hydroxypropyl)-2- thiophenecarboxamide MS (ESI): m/z (%) = 438 (M+H, 100); HPLC (method 4): rt = 2.84 min. Example 86 N-(3-{[3-(AminocarbonyI)-4-(4-morpholinyl)plienyI]amino}-2-hydroxypropyl)-5-chloro-2- thiophenecarboxamide * MS (ESI): m/z (%) = 439 (M+H, 100); HPLC (method 4): rt = 2.32 min. Example 87 5-Chloro-N-(2-hydroxy-3-{[3-methoxy-4-(4-morpholinyl)phenyl]amino}propyl)-2- thiophenccarboxamide MS (ESI): m/z (%) = 426 (M+H, 100); -68- HPLC (method 4): it = 2.32 min. Example 88 N-(3-{[3-Acetyl-4-(4-morpholinyl)phenyl]amino}-2-hydroxypropyl)-5-chloro-2- thiophenecarboxamide MS (ESI): m/z (%) = 438 (M+H, 100); HPLC (method 4): rt = 2.46 min. Example 89 N-(3-{[3-Amino-4-(3-oxo-4-morpholinyl)phenyljamino}-2-hydroxypropyl)-5-chloro-2- thiophenecarboxamide MS (ESI): m/z (%) = 425 (M+H, 100); HPLC (method 4): rt = 2.45 min. Example 90 5-Chloro-N-(3-{[3-chloro-4-(2-methyl-3-oxo-4-roorpholinyI)phenyl]amino}-2- hydroxypropyl)-2-tfaiophenecarboxamide MS (ESI): m/z (%) = 458 (M+H, 100); HPLC (method 4): rt = 3.44 min. Example 91 5-Chloro-N-(3-{[3-chloro-4-(2-methyl-5-oxo-4-morpholinyl)phenyl]amino}-2- hydroxypropyl)-2-thiophenecarboxamide MS (ESI): m/z (%) = 458 (M+H, 100); HPLC (method 4): rt = 3.48 min. Example 91a 5-Chloro-N-[2-hydroxy-3-({4-[(3-oxo-4-morpholinyl)methyl]phenyl}amino)propyl]-2- thiophenecarboxamide -69- Starting from 4-(4-aminobenzyl)-3-morpholinone (Surrey et al.; J. Amer. Chem. Soc.; 77; 1955; 633): MS (ESI): m/z (%) = 424 (M+H, 100); HPLC (method 4): rt == 2.66 min. General method for preparation of 3-substituted 5-chloro-./V-[(2-oxo-l,3-oxazolidin-5- yl)methyI]-2-thiophenecarboxamide derivatives starting from substituted 7V-(3-amino-2- hydroxypropyI)-5-chloro-2-thiophenecarboxamide derivatives R> OH Carbodiimidazole (1.2 to 1.8 eq.) or a. comparable phosgene equivalent is added at room temperature to a solution of substituted 7V-(3-amino-2-hydroxypropyi)-5-chloro-2-thiophenecarboxamide derivative (1.0 eq.) in absolute THf (about 0.1 mo 1/1). The mixture is stirred at room temperature or optionally at elevated temperature (up to 70°C) for 2 to 18 h, before being concentrated in vacuo. The product can be purified by chromatography on silica gel (dichloromethane-methanol mixtures or cyclohexane-ethyl acetate mixtures). The following were prepared in an analogous manner: Example 27 Af-[(3-Benzyl-2-oxo-l,3-oxazolidin-5-yl)methyl|-5-chloro-2-thiophenecarboxamide MS (DCI, NR,): m/z (%) = 372 (M+Na, 100), 351 (M+H, 45); HPLC (method 1): rt (%) = 4.33 min (100). Example 28 5-Chloro-Ar-{[3-(3-cyanophenyl)-2-oxo-l,3-oxazoIidin-5-yl]methyl}-2-thiophenecarboxamide MS (DCI, NH,): m/z (%) = 362 (M+H, 42), 145 (100); HPLC (method 2): rt (%) = 4.13 min (100). -70- Example 29 5-Chloro-N-({3-[4-(cyanomethyl)phenyl]-2-oxo-l,3-oxazoIidin-5-yl}methyl)-2- thiophenecarboxamide MS (ESI): m/z (%) = 376 (M+H, 100); HPLC (method 4): it = 4.12 min Example 30 5-Chloro-N-({3-[3-(cyanomethyl)phenyI]-2-oxo-l,3-oxazolidin-5-yl}methyI)-2- thiophenecarboxamide MS (ESI): m/z (%) = 376 (M+H, 100); HPLC (method 4): it = 4.17 min Example 92 terf-Butyl 4-[5-({[(5-chloro-2-thienyl)carbonyl]amino}methyI)-2-oxo-l,3-oxazolidin-3- yl] benzy Icar hamate starting from Example 58: MS (ESI): m/z (%) = 488 (M+Na, 23), 349 (100); HPLC (method 1): rt (%) - 4.51 (98.5). Example 93 tert-Ruty\ 4-[5-({[(5-chloro-2-thienyl)carbonyl]amino}methyI)-2-oxo-l,3-oxazolidin-3- yl] phenylcarbamate starting from Example 59: MS (ESI): m/z (%) - 493 (M+Na, 70), 452 (M+H, 10), 395 (100); HPLC (method 1): rt (%) = 4.41 (100). Example 94 fert-Butyl2-oxo-3-[4-(2-oxo-l-pyrrolidinyl)phenyl]-l,3-oxazoIidin-5-yl}methylcarbamate -71 - starting from Example 60: MS (DCI, NH3): m/z (%) = 393 (M+NH4, 100); HPLC (method 3): rt (%) = 3.97 (100). Example 95 5-Chloro-N-( {3-[3-fluo ro-4-(3-oxo-4-morpholinyl)phenyI]-2-oxo-l ,3-oxazolidin-5-yl} methyl)- 2-thiophenecarboxamide 260 mg (0.608 mmol) of 5-chloro-N-(3-{[3-fluoro-4-(3-oxo-4-morpholinyl)phenyl]amino}-2- hydroxypropyl)-2-thiophenecarboxamide (from Example 61), 197 mg (1.22 mmol) of carbonylimidazole and 7 mg of dimethylaminopyridine are refluxed in 20 ml of dioxane for 5 hours. Subsequently, 20 ml of acetonitrile are added and the mixture is stirred in a closed container in a microwave oven for 30 minutes at 180°C. The solution is concentrated in a rotary evaporator and chromatographed on an RP-HPLC column. 53 mg (19% of theory) of the target compound are obtained. NMR (300 MHz, d6-DMSO): 8= 3.6-3.7 (rn,4E), 3.85 (dd,lH), 3.95 (m,2H), 4.2 (m,lH), 4.21 (s,2H), 4.85 (m,lH), 4.18 (s,2H), 7.19 (d,lH,thiophene), 7.35 (dd,lH), 7.45 (t,lH), 7.55 (dd,lH), 7.67 (d,lH,thiophene), 8.95ft, 1H,CONH). Example 96 5-Chloro-Ar-[(2-oxo-3-phenyl-l,3-oxazolidin-5-yl)methyl]-2-thiophenecarboxamide starting from Example 62: MS (ESI): m/z (%) = 359 ([M+Na]+, 71), 337 ([M+Hf, 100), Cl sample; HPLC (method 3): rt (%) = 4.39 (100). IC50: 2 -72- Example 97 5-ChIoro-7V-({2-oxo-3-[4-(3-oxo-4-morphoIinyI)phenyl]-l,3-oxazolidin-5-yl}methyl)-2- thiopheoecarboxamide starting from Example 63: MS (ESI): m/z (%) = 458 ([M+Na]+, 66), 436 ([M+H]+, 100), Cl sample; HPLC (method 3): rt (%) = 3.89 (100). IC50: 1.4nM Example 98 Af-[(3-{4-[Acetyl(cyclopropyI)amino]phenyl}-2-oxo-l,3-oxazolidin-5-yl)methyl]-5-chloro-2- thiophenecarboxamide starting from Example 64: MS (ESI): m/z (%) - 456 ([M+Na]+, 55), 434 ([M+H]+, 100), Cl sample; HPLC (method 3): rt (%) = 4.05 (100). IC50: 50 nM Example 99 N-[(3-{4-[Acetyl(methyl)amino]phenyl}-2-oxo-l,3-oxazoIidin-5-yI)methyI]-5-chloro-2- thiophenecarboxam ide MS (ESI): m/z (%) = 408 (M+H, 30), 449 (M+H+MeCN, 100); HPLC (method 4): rt = 3.66 rain. Example 100 5-Chloro-N-({2-oxo-3-[4-(lH-l,2,3-triazol-l-yl)phenyl]-13-oxazolidin-5-yI}methyl)-2- thiophenecarboxamide MS (ESI): m/z (%) = 404 (M+H, 45), 445 (M+H+MeCN, 100); HPLC (method 4): rt = 3.77 min. -73- Example 101 Tert-butyl l-{4-[5-({[(5-chIoro-2-thienyl)carbonyl]amino}methyl)-2-oxo-l,3-oxazoIidin-3- yl] phenyl}-L-prolinate MS (ESI): m/z (%) = 450 (M+H-56, 25), 506 (M+H, 100); HPLC (method 4): it = 5.13 min. Example 102 l-{4-[5-({[(5-Chloro-2-thienyI)carbonyl]amino}methyl)-2-oxo-l,3-oxazolidin-3-yl]phenyl}-4- piperidinecarboxamide MS (ESI): m/z (%) = 463 (M+H, 100); HPLC (method 4): rt = 2.51 min. Example 103 l-{4-[5-({[(S-Chloro-2-thienyl)carbonyl]amino}methyl)-2-oxo-l,3-oxazolidin-3-yl]phenyl}-3- piperidinecarboxamide MS (ESI): m/z (%) = 463 (M+H, 100); HPLC (method 4): rt = 2.67 min. Example 104 5-Chloro-N-({2-oxo-3-[4-(4-oxo-l-piperidinyl)phenyl]-l,3-oxazolidin-5-yl}methyl)-2- thiophenecarboxamide « MS (ESI): m/z (%) = 434 (M+H, 40), 452 (M+H+H2O, 100), 475 (M+H+MeCN, 60); HPLC (method 4): rt = 3.44 min. Example 105 l-{4-[5-({[(5-Chloro-2-thienyl)carbonyl]amino}methyl)-2-oxo-l,3-oxazolidin-3-yI]phenyl}-Lprolinaraide MS (ESI): m/z (%) = 449 (M+H, 100); -74- HPLC (method 4): rt = 3.54 min. Example 106 5-Chloro-N-[(3-{4-[3-(hydroxymethyl)-l-piperidinyl]phenyl}-2-oxo-l,3-oxazolidin-5- yI)methyl]-2-thiophenecarboxamide MS (ESI): m/z (%) = 450 (M+H, 100); HPLC (method 5): rt = 2.53 min. Example 107 5-Chloro-N-[(3-{4-[2-(hydroxymethyI)-l-piperidinyl]phenyl}-2-oxo-l,3-oxazolidin-5- yl)methyl]-2-thiophenecarboxamide MS (ESI): m/z (%) = 450 (M+H, 100); HPLC (method 5): rt = 2.32 min. Example 108 Ethyl l-{4-[5-({[(5-chloro-2-thienyl)carbonyl]amino}methyl)-2-oxo-l,3-oxazolidin-3- yl]phenyl}-2-piperidinecarboxylate MS (ESI): m/z (%) = 492 (M+H, 100); HPLC (method 5): rt = 4.35 min. Example 109 5-Chloro-N-[(3-{4-[2-(hydroxymethyl)-l-pyrrolidinyl]phenyl}-2-oxo-l,3-oxazolidin-5- yl)methyl]-2-thiophenecarboxamide MS (ESI): m/z (%) = 436 (M+H, 100); HPLC (method 4): rt = 2.98 min. Example 110 5-Chloro-N-({2-oxo-3-[4-(l-pyrrolidinyl)-3-(trifluoromethyl)phenyl]-l,3-oxazolidin-5- yl}methyl)-2-thiophenecarboxamide -75- MS (ESI): m/z (%) = 474 (M+H, 100); HPLC (method 4): rt = 4.63 min. Example 111 5-Chloro-N-({3-[4-(2-methylhexahydro-5H-pyrrolo[3,4-d]isoxazol-5-yl)phenyl]-2-oxo-l,3- oxazolidin-5-yl}methyl)-2-thiophenecarboxamide MS (ESI): m/z (%) = 463 (M+H, 100); HPLC (method 4): rt = 2.56 min. Example 112 5-Chloro-N-({2-oxo-3-[4-(2-oxo-l-pyrrolidinyl)-3-(trifluoromethyl)phenyl]-l,3-oxazolidin-5- yl}methyl)-2-thiophenecarboxamide MS (ESI): m/z (%) = 488 (M+H, 100); HPLC (method 4): rt = 3.64 min. Example 113 5-Chloro-N-({3-[3-chloro-4-(3-oxo-4-morpholinyl)phenyl]-2-oxo-l,3-oxazolidin-5-yl}methyl)- 2-thiophenecarboxamide MS (ESI): m/z (%) = 470 (M+H, 100); HPLC (method 4): rt = 3.41 min. Example 114 , 5-Chloro-N-({2-oxo-3-[4-(3-oxo-4-morpholinyI)-3-(trifluoromethyl)phenyl]-l,3-oxazolidin-5- yl}methyl)-2-thiophenecarboxamide MS (ESI): m/z (%) = 504 (M+H, 100); HPLC (method 4): rt = 3.55 min. Example 115 5-Chloro-N-({3-[3-methyl-4-(3-oxo-4-morpholinyl)phenyI]-2-oxo-l,3-oxazolidin-5-yl} methyl)- -76- 2-thiophenecarboxamide MS (ESI): m/z (%) = 450 (M+H, 100); HPLC (method 4): rt = 3.23 min. Example 116 5-Chloro-N-({3-[3-cyano-4-(3-oxo-4-morpholinyl)phenyl]-2-oxo-l,3-oxazolidin-5-yl}methyl)- 2-thiophenecarboxamide MS (ESI): m/z (%) = 461 (M+H, 100); HPLC (method 4): rt = 3.27 min. Example 117 5-ChIoro-N-({3-[3-chloro-4-(l-pyrrolidinyl)phenyl]-2-oxo-l,3-oxazoIidin-5-yl}methyl)-2- thiophenecarboxamide MS (ESI): m/z (%) = 440 (M+H, 100); HPLC (method 4): rt = 3.72 min. Example 118 5-Chloro-N-({3-[3-chloro-4-(2-oxo-l-pyrrolidinyl)phenyl]-2-oxo-l,3-oxazolidin-5-yI}methyl)- 2-thiophenecarboxamide MS (ESI): m/z (%) = 454 (M+H, 100); , HPLC (method 4): rt = 3.49 min. Example 119 5-Chloro-N-({3-[3,5-dimethyl-4-(3-oxo-4-morpholinyl)phenyl]-2-oxo-l,3-oxazolidin-5- yl}methyl)-2-thiophenecarboxamide MS (ESI): m/z (%) = 464 (M+H, 100); HPLC (method 4): rt = 3.39 min. -77- Example 120 N-({3-[3-(Aminocarbonyl)-4-(4-morpholinyl)phenyl]-2-oxo-l,3-oxazolidin-5-yl}methyl)-5- chloro-2-thiophenecarboxamide MS (ESI): m/z (%) = 465 (M+H, 100); HPLC (method 4): rt = 3.07 min. Example 121 5-Chloro-N-({3-[3-methoxy-4-(4-morpholinyl)phenyl]-2-oxo-l,3-oxazolidin-5-yl}methyl)-2- thiophenecarboxamide MS (ESI): m/z (%) = 452 (M+H, 100); HPLC (method 4): rt = 2.86 min. Example 122 N-({3-[3-Acetyl-4-(4-morpholinyl)phenyl]-2-oxo-l,3-oxazolidin-5-yl}methyl)-5-chloro-2- thiophenecarboxamide MS (ESI): m/z (%) = 464 (M+H, 100); HPLC (method 4): rt = 3.52 min. Example 123 N-({3- [3-Amino-4-(3-oxo-4-morpholinyl)pheny I] -2-oxo-l ,3-oxazolidin-5-yl} methyI)-5-chloro 2-thiophenecarboxamide i MS (ESI): m/z (%) = 451 (M+H, 100); HPLC (method 6): rt = 3.16 min. Example 124 5-Chloro-N-({3-[3-chloro-4-(2-methyl-3-oxo-4-morpholinyl)phenyI]-2-oxo-l,3-oxazolidin-5- yl}methyl)-2-thiophenecarboxamide MS (ESI): m/z (%) = 484 (M+H, 100); -78- HPLC (method 4): rt = 3.59 min. Example 125 5-Chloro-N-({3-[3-chIoro-4-(2-methyl-5-oxo-4-morpholinyl)phenyl]-2-oxo-l,3-oxa/olidin-5- yl}methyl)-2-thiophenecarboxamide MS (ESI): m/z (%) = 484 (M+H, 100); HPLC (method 4): rt = 3.63 min. Example 125a 5-Chloro-N-[(2-oxo-3-{4-[(3-oxo-4-morphoIinyl)methyl]phenyl}-l,3-oxazolidin-5-yl)methyl]- 2-thiophenecarboxamide MS (ESI): m/z (%) = 450 (M+H, 100); HPLC (method 4): rt = 3.25 min. The following compounds were moreover prepared via the route of the epoxide opening using an amine and subsequent cyclization to give the corresponding oxazolidinone: Example No. Structure 126 127 128 129 130 M.p. 229Z N ^ F O W S F IC50 [uM] 0.013 159 0.0007 198 196 206 0.002 0.001 0.0033 -79- Example No. Structure M.p. IC50 [uM] 130a F 0 194 o 131 195 0.85 132 206 0.12 133 F 0 217 0.062 134 207 from 1 -(4-aminopheny l)-piperidin-3 - ol (Tong,L.K.J. etal; J.Amer.Chem.Soc 1960; 82,1988). 0.48 135 202 °v 1.1 136 239 T0^0 1.2 137 219 FiF A' 0.044 138 95 0.42 - su- Example No. 139 Structure ~ C» O^- N-°i-»-»° ,rJ>-c1 o M.p. [°C] 217 IC50 [uM] 1.7 The following Examples 14 to 16 are working examples for the voluntary, i.e. optionally taking place, oxidation process step. Example 14 5-Chloro-N-({(5S)-3-[3-nuoro-4-(l-oxo-l[lambda]4,4-thiazinan-4-yl)phenyl]-2-oxo-l,3- oxazolidin-5-yI}methyI)-2-thiophenecarboxamide o=s 5-Chloro-N-({(5S)-3-[3-fluoro-4-(l,4-thiazinan-4-yl)phenyl]-2-oxo-l,3-oxazolidin-5-yl}methyl)-2- thiophenecarboxamide (0.1 g, 0.22 mmol) from Example 3 in methanol (0.77 ml) is added at 0°C to a solution of sodium periodate (0.05 g, 0.23 mmol) in water (0.54 ml) and stirred for 3 h at 0°C. Subsequently, 1 ml of DMF is added and the mixture is stirred for 8 h at RT. After addition of a further 50 mg of sodium periodate, the mixture is again stirred overnight at RT. The batch is subsequently treated with 50 ml of water and the insoluble product is filtered off with suction. After washing with water and drying, 60 mg (58 % of theory) of crystals are obtained. M.p.: 257°C; Rf (silica gel, toluene/ethyl acetate 1:1) = 0.54 (starting material = 0.46); IC50 value =1.1 uM; MS (DCI) 489 (M+NH4), Cl sample. -81 - Example 15 Preparation of 5-chloro-N-({(5S)-3-[4-(l,l-dioxo-l[lambda]6,4-thiazinan-4-yI)-3- fluorophenyl]-2-oxo-l,3-oxazolidin-5-yl}methy])-2-thiophenecarboxamide 0 5-Chloro-N-({(5S)-3-[3-fluoro-4-(l,4-thiazinan-4-yl)phenyl]-2-oxo-l,3-oxazolidin-5-yl}methyl)-2- thiophenecarboxamide from Example 3 (0.1 g, 0.22 mmol) in 3.32 ml of a mixture of 1 part of water and 3 parts of acetone is treated with 80 mg (0.66 mmol) of N-methylmorpholine N-oxide (NMO) and 0.1 ml of a 2.5 % strength solution of osmium tetroxide in 2-methyl-2-propanol. The mixture is stirred overnight at room temperature and 40 mg of NMO are added again. After a further night, the batch is added to 50 ml of water and extracted three times with ethyl acetate. From the organic phase, after drying and evaporating, 23 mg, and from the aqueous phase after filtering off the insoluble solid with suction, 19 mg (altogether 39% of theory) of the target compound are obtained. M.p.: 238°C; Rf (toluene/ethyl acetate 1:1) = 0.14 (starting material = 0.46); IC50value = 210nM; * MS (DCI): 505 (M+NH,), Cl sample. Example 16 5-Chloro-N-{[(5S)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-l,3-oxazolidin-5-yl]methyl}-2- thiophenecarboxamide N-oxide is obtained by treating 5-chloro-N-{[(5S)-3-(3-lluoro-4-morpholinophenyl)-2-oxo-l,3-oxazolidin- 5-yl]methyl}-2-thiophenecarboxamide from Example 1 with monoperoxyphthalate acid magnesium salt. MS (ESI): 456 (M+H, 21%, Cl sample), 439 (100%). The following examples 31 to 35 and 140 to 147 relate to the voluntary, i.e. optionally taking place, amidination process step. General method for the preparation of amidines and amidine derivatives starting from cyanomethylphenyl-substituted 5-cliIoro-N-[(2-oxo-l,3-oxazolidin-5-yl)methyl]-2- thiophenecarboxamide derivatives The respective cyanomethylphenyl-substituted 5-chloro-N-[(2-oxo-1,3-oxazolidin-5-yl)methyl]-2- thiophenecarboxamide derivative (1.0 eq.) is stirred in a saturated solution of hydrogen sulfide in pyridine (about 0.05 - 0.1 mol/1) for one to two days at RT together with triethylamine (8.0 eq.). The reaction mixture is diluted with ethyl acetate (EtOAc) and washed with 2 N hydrochloric acid. The organic phase is dried using MgSCU , filtered and evaporated in vacuo. The crude product is dissolved in acetone (0.01-0 1 mol/1) and treated with methyl iodide (40 eq.). The reaction mixture is stirred for 2 to 5 h at room temperature (RT) and then concentrated in vacuo. The residue is dissolved in methanol (0.01-0.1 mol/1) and, for the preparation of the unsubstituted amidines, treated with ammonium acetate (3 eq.) and ammonium chloride (2 eq.). For the preparation of the substituted amidine derivatives, primary or secondary amines (1.5 eq.) and acetic acid (2 eq.) are added to the methanolic solution. After 5-30 h, the solvent is removed in vacuo and the residue is purified by chromatography on an RP8 silica gel column (water/acetonitrile 9/1-1/1 + 0.1% trifluoroacetic acid). The following were prepared in an analogous manner: Example 31: N-({3-[4-(2-Amino-2-iminoethyl)phenyl|-2-oxo--l,3-oxazolidin-5-yl}methyl)-5-chloro-2- thiophenecarboxamide MS (ESI): m/z (%) = 393 (M+H, 100); HPLC (method 4): it = 2.63 min -83- Example 32: 5-Chloro-N-({3-[3-(4,5-dihydro-lH-imidazol-2-ylmethyl)phenyl]-2-oxo-l,3-oxazolidin-5- yl}methyl)-2-thiophenecarboxamide MS (ESI): m/z (%) = 419 (M+H, 100); HPLC (method 4): rt = 2.61 min Example 33: 5-Chloro-N-[(3-{3-[2-imino-2-(4-morphoHnyl)ethyl]phenyl}-2-oxo-l,3-oxazoIidin-5- yl)methyl]-2-thiophenecarboxamide MS (ESI): m/z (%) = 463 (M+H, 100); HPLC (method 4): rt = 2.70 min Example 34: 5-Chloro-N-[(3-{3-[2-imino-2-(l-pyrrolidinyI)ethyl]phenyI}-2-oxo-l,3-oxazoIidin-5- yl)methyl]-2-thiophenecarboxamide MS (ESI): m/z (%) = 447 (M+H, 100); HPLC (method 4): rt = 2.82 min Example 35: N-({3-[3-(2-Amino-2-iminoethyl)phenyl]-2-oxo-l,3-oxazolidin-5-yl}methyl)-5-chloro-2- thiophenecarboxamide MS (ESI): m/z (%) = 393 (M+H, 100); HPLC (method 4): rt = 2.60 min Example 140 5-Chloro-N-({3-[4-(4,5-dihydro-lH-imidazol-2-ylmethyI)phenyl]-2-oxo-l,3-oxazolidin-5- yI}methyI)-2-thiophenecarboxamide MS (ESI): m/z (%) = 419 (M+H, 100); -84- HPLC (method 4): rt = 2.65 min Example 141 5-Chloro-N-[(3-{4-[2-imino-2-(4-morpholinyl)ethyl]phenyl}-2-oxo-l,3-oxazolidin-5- yl)methyl]-2-thiophenecarboxamide MS (ESI): m/z (%) = 463 (M+H, 100); HPLC (method 4): rt == 2.65 min Example 142 5-Chloro-N-[(3-{4-[2-imino-2-(l-piperidinyl)etliyl]phenyl}-2-oxo-l,3-oxazolidin-5-yl)methyl]- 2-thiophenecarboxamide MS (ESI): m/z (%) = 461 (M+H, 100); HPLC (method 4): rt = 2.83 min Example 143 5-Chloro-N-[(3-{4-[2-imino-2-(l-pyrroIidinyl)e(hyl]phenyl}-2-oxo-l,3-oxazoIidin-5- yl)methyl]-2-thiophenecarboxamide MS (ESI): m/z (%) = 447 (M+H, 100); HPLC (method 4): rt = 2.76 min Example 144 5-Chloro-N-[(3-{4-[2-(cyclopentylamino)-2-iminoethyl]phenyl}-2-oxo-l,3-oxazolidin-5- yl)methyl]-2-thiophenecarboxamide MS (ESI): m/z (%) = 461 (M+H, 100); HPLC (method 4): rt = 2.89 min Example 145 5-Chloro-N-{[3-(4-{2-imino-2-[(2,2,2-trifluoroethyl)amino]ethyl}phenyl)-2-oxo-l,3- oxazolidin-5-yI]methyl}-2-thiophenecarboxamide -85- MS (ESI): m/z (%) = 475 (M+H, 100); HPLC (method 4): rt = 2.79 min Example 146 N-( {3- [4-(2-Anilino-2-iminoethyl)phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl)-5-chloro-2- thiophenecarboxamide MS (ESI): m/z (%) = 469 (M+H, 100); HPLC (method 4): rt == 2.83 min Example 147 5-Chloro-N-[(3-{4-[2-imino-2-(2-pyridinylamino)ethyl]phenyl}-2-oxo-l,3-oxazolidin-5- yl)methyl]-2-thiophenecarboxamide MS (ESI): m/z (%) = 470 (M+H, 100); HPLC (method 4): rt = 2.84 min The following Examples 148 to 151 relate to the cleavage of BOC amino-protective groups: General method for the cleavage of Boc protective groups (terf-buryloxycarbonyl): O I H Aqueous trifluoroacetic acid (TFA, about 90 %) is added dropwise to an ice-cooled solution of a fer?-butyloxycarbonyl- (Boc)-protected compound in chloroform or dichloromethane (about 0.1 to 0.3 mol/1). After about 15 min, the ice cooling is removed and the mixture is stirred for about 2-3 h at room temperature, before concentrating the solution and drying it in a high vacuum. The residue is taken up in dichloromethane or dichloromethane/methanol and washed with saturated sodium hydrogencarbonate or IN sodium hydroxide solution. The organic phase is washed with saturated sodium chloride solution, dried over a little magnesium sulfate and concentrated. Purification by crystallization from ether or ether/dichloromethane mixtures optionally takes place. In an analogous manner, the following were prepared from the corresponding Boc-protected precursors : - 8 6 - Example 148 AL({3-[4_(Aminomethyl)phenyl]-2-oxo-lr3-oxazolidin-5-yl}methyl)-5-chloro-2-thiophenecarboxamide starting from Example 92: MS (ESI): m/z (%) = 349 (M-NH2, 25), 305 (100); HPLC (method 1): rt (%) = 3.68 (98). IC50: 2.2 uM Example 149 A'-{[3-(4-Aminophenyl)-2-oxo-l,3-oxazolidin-5-yl]methyI}-5-chloro-2-thiophenecarboxamide starting from Example 93: MS (ESI): m/z (%) = 352 (M+H, 25); HPLC (method 1): rt (%) = 3.50 (100). IC50: 2 An enantiomerically pure alternative synthesis oi'this compound is shown in the following scheme (cf. also Delalande S.A., DE 2836305,1979; Chem.Abstr. 90, 186926): -87- LBuLi 2. R-Glvcidyl butyraje 3. NH4CI/H?0 1.) Phthalimide, DEAD/PPh3 2.) NH7NH9.H,Q in ethanol 3.) 5-Chloro-2-thiophenecarboxylicacid, EDC/HOBT \\ // O r\ ci Zn/HCI H0N Example 150 5-Chloro-7V-({3-[4-(glycylamino)phenyl]-2-oxo-l,3-oxazolidin-5-yl}methyI)-2- thiophenecarboxamide starting from Example 152: MS (ES-pos): m/z (%) = 408 (100); HPLC (method 3): rt (%) = 3.56 (97). IC50: 2 Example 151 5-(AminomethyI)-3-[4-(2-oxo-l-pyrrolidinyl)phenyl]-l,3-oxazolidin-2-one starting from Example 60: MS (ESI): m/z (%) = 276 (M+H, 100); HPLC (method 3): rt (%) = 2.99 (100). IC50: 2 The following Examples 152 to 166 relate to the amino group derivatization of aniline- or benzylamine-substituted oxazolidinones with different reagents: Example 152 5-ChIoro-Ar-({3-[4-(N-fert-butyloxycarbonylglycylamino)phenyl]-2-oxo-l,3-oxazolidin-5- yl}methyl)-2-thiophenecarboxamide 754 mg (2.1 mrnol) of jV-{[3-(4-aminophenyl)-2-oxo-l,3-oxazolidin-5-yl]methyl}-5-chloro-2- thiophenecarboxamide (from Example 149) are added at 0°C to a solution of 751 mg (4.3 mmol) of Boc-glycine, 870 mg (6.4 mmol) of HOBT (1-hydroxy-lH-benzotriazole x H2O), 1790 mg (4.7 mmol) of HBTU [o-(benzotriazol-l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate] and 1.41 ml (12.9 mmol) of A^-methylmorpholine in 15 ml of DMF/CH2C12 (1:1). The mixture is stirred overnight at room temperature, before diluting with water. The precipitated solid is filtered off and dried. Yield: 894 mg (79.7 % of theory); MS (DCI, NH3): m/z (%) = 526 (M+NH4, 100); HPLC (method 3): rt (%) = 4.17 (97). Example 153 Ar-[(3-{4-[(Acetylamino)methyl]phenyl}-2-oxo-l,3-oxazolidin-5-yI)methyl]-5-chloro-2- thiophenecarboxamide A mixture of 30 mg (0.082 mmol) of A^-({3-[4-(aminomethyl)phenyl]-2-oxo-l,3-oxazolidin-5- yl}methyl)-5-chloro-2-thiophenecarboxamide (from Example 148) in 1.5 ml of absolute THF and 1.0 ml of absolute dichloromethane, 0.02 ml of absolute pyridine is treated at 0°C with acetic anhydride (0.015 ml, 0.164 mmol). The mixture is stirred overnight at room temperature. The -89- product is obtained by addition of ether and crystallization. Yield: 30 mg (87 % of theory), MS (ESI): m/z (%) = 408 (M+H, 18), 305 (85); HPLC (method 1): rt (%) = 3.78 (97). IC50: 0.6 uM Example 154 Ar-{[3-(4-{[(Arainocarbonyl)amino]methyl}phenyl)-2-oxo-l,3-oxazolidin-5-yl]methyl}-5- chloro-2-thiophenecarboxamide O 0.19 ml (0.82 mmol) of trimethylsilyl isocyanate is added dropwise at room temperature to a mixture of 30 mg (0.082 mmol) of A^-({3-|4-(aminomethyl)phenyl]-2-oxo-l,3-oxazolidin-5- yl}methyl)-5-chloro-2-thiophenecarboxamide (from Example 148) in 1.0 ml dichloromethane. The mixture is stirred overnight, before obtaining the product by filtration after addition of ether. Yield: 21.1 mg (52 % of theory), MS (ESI): m/z (%) = 409 (M+H, 5), 305 (72); HPLC (method 1): rt (%) - 3.67 (83). IC50: 1.3 uM -90- General method for the acylation of 7V-{[3-(4-aminophenyl)-2-oxo-l,3-oxazoIidin-5- yl]methyl}-5-chloro-2-thiophenecarboxamide with carbonyl chlorides: OLV^0 + Y Under argon, an about 0.1 molar solution of ./V-fpyl] methyl}-5-chloro-2-thiophenecarboxamide (from Example 149) (1.0 eq.) in absolute dichloromethane/pyridine (19:1) is added dropwise to the appropriate acid chloride (2.5 eq.). The mixture is stirred overnight, before being treated with about 5 eq of PS-trisamine (Argonaut Technologies) and 2 ml of absolute dichloromethane. After gentle stirring for 1 h, it is filtered off and the filtrate is concentrated. A purification of the products by preparative RP-HPLC optionally takes place. The following were prepared in an analogous manner: Example 155 7V-( {3- [4-(Acety lamino)phenyl] -2-oxo-l ,3-oxazo lidin-5-yl} methyI)-5-chloro-2-thiophenecarboxamide LC-MS: m/z (%) = 394 (M+H, 100); LC-MS (method 6): rt (%) = 3.25 (100). IC50: 1.2 uM Example 156 5-Chloro-7V- [(2-oxo-3- {4- [(2-thienylcarbonyl)araino] phenyl}-1,3-oxazolidin-5-yI)methyl]-2- thiophenecarboxamide LC-MS: m/z (%) = 462 (M+H, 100); LC-MS (method 6): rt (%) = 3.87 (100). -91 - IC50: 1.3 nM Example 157 5-Chloro-A'-[(3-{4-[(methoxyacetyl)amino]phenyl}-2-oxo-l^-oxazolidin-5-yI)methyl]-2- thiophenecarboxamide LC-MS: m/z (%) = 424 (M+H, 100); LC-MS (method 6): rt (%) = 3.39 (100). IC50: 0.73 jiM Example 158 N- {4- [5-( {[(5-Chloro-2-thieny l)carbonyl] arnino} methyl)-2-oxo-l,3-oxazolidin-3-yl] phenyl} - 3,5-dimethyl-4-isoxazolecarboxamide LC-MS: m/z (%) = 475 (M+H, 100). IC50: 0.46 jiM Example 159 5-Chloro-7V-{[3-(4-{[(3-chloropropyl)sulfonyI]amino}phenyl)-2-oxo-l,3-oxazolidin-5- yI]methyI}-2-thiophenecarboxamide 35 mg (0.1 mmol) of A^-{[3-(4-aminophenyl)-2-oxo-l,3-oxazolidin-5-yl]methyl}-5-chloro-2- thiophenecarboxamide (from Example 149) are added to an ice-cooled solution of 26.4 mg (0.15 mmol) of 3-chloro-l-propanesulfonyl chloride and 0.03 ml (0.2 mmol) of triethylamine in 3.5 ml of absolute dichloromethane. After 30 min, the ice cooling is removed and the mixture is stirred overnight at room temperature, before adding 150 mg (about 5.5 eq) of PS-trisamine (Argonaut Technologies) and 0.5 ml of dichloromethane. The suspension is gently stirred for 2 h, filtered (the resin is washed with dichloromethane/methanol) and the filtrate is concentrated. The product is purified by preparative RP-HPLC. Yield: 19.6 mg (40 % of theory), LC-MS: m/z (%) = 492 (M+H, 100); LC-MS (method 5): rt (%) = 3.82 (91). IC50: 1.7 uM Example 160 5-ChIoro-Ar-({3-[4-(l,l-dioxido-2-isothiazoIidinyl)phenyl]-2-oxo-l,3-oxazolidin-5-yl}methyl)- 2-thiophenecarboxamide A mixture of 13.5 mg (0.02.7 mmol) of 5-chloro-N-{[3-(4-{[(3-chloropropyl) sulfonyl]amino}phenyl)-2-oxo-1,3-oxazoli din-5 -yl]methy 1} -2-thiophenecarboxamide (from Example 159) and 7.6 mg (0.055 mmol) of potassium carbonate in 0.2 ml of DMF is heated for 2 h at 100°C. After cooling, it is diluted with dichloromethane and washed with water. The organic phase is dried and concentrated. The residue is purified by preparative thin layer chromatography (silica gel, dichloromethane/methanol, 95:5). Yield: 1.8 mg (14.4 % of theory), MS (ESI): m/z (%) = 456 (M+H, 15), 412 (100); LC-MS (method 4): rt (%) = 3.81 (90). IC50:0.14uM Example 161 * 5-Chloro-N- [((5S)-3- {4- [(S-chloropentanoyl)aniino] phenyl} -2-oxo-1,3-oxazoIidin-5- yI)methyl]-2-thiophenecarboxamide o 0.5 g (1.29 mmol) of N-{[(5S)-3-(4-amiriophen\l)-2-oxo-l,3-oxazolidin-5-yl]methyl}-5-chloro-2- -93- thiophenecarboxamide (from Example 149) are dissolved in 27 ml of tetrahydrofuran and treated with 0.2 g (1.29 mmol) of 5-chlorovaleryl chloride and also 0.395 ml (2.83 mmol) of triethylamine. The batch is evaporated in vacuo and chroma tographed on silica gel using a toluene/ethyl acetate=l:l -> ethyl acetate gradient. 315 mg (52% of theory) of a solid are obtained. M.p.:21PC. Example 162 5-Chloro-N-({(5S)-2-oxo-3-[4-(2-oxo-l-piperidinyl)phenyl]-l,3-oxazoIidin-5-yl}methyI)-2- thiophenecarboxamide 30 mg of 60 per cent NaH in liquid paraffin are added under inert conditions to 5 ml of DMSO and the mixture is heated for 30 min to 75°C until completion of the evolution of gas. Subsequently, a solution of 290 mg (0.617 mmol) of 5-chloro-N-[((5S)-3-{4-[(5~chloropentanoyl)amino]phenyl}-2- oxo-l,3-oxazolidin-5-yl)methyl]-2-thiophenecarboxamide (from Example 161) in 5 ml of methylene chloride is added and the mixture is stirred overnight at room temperature. The reaction is terminated and the mixture is added to 100 ml of water and extracted with ethyl acetate. The evaporated organic phase is chromatographed on an RP-8 column and eluted with acetonitrile/water. 20 mg (7.5% of theory) of the target compound are obtained. M.p.: 205°C; NMR (300 MHz, d6-DMSO): 8= 1.85 (rn,4H), 2.35 (m,2H), 3.58 (m,4H), 3.85 (m,lH), 4.2 (t,lH), 4.82 (m,lH), 7.18 (d,lH,thiophene), 7.26 (d,2H), 7.5 (d,2H), 2.68 (d,lH,thiophene), 9.0 (t,lH,CONH). IC50: 2.8 nM -94- Example 163 5-Chloro-N-[((5S)-3-{4-[(3-bromopropionyl)amino]phenyl}-2-oxo-l,3-oxazolidin-5- yI)methyl]-2-thiophenecarboxamide O ^ /^ is obtained in an analogous manner from Example 149. Example 164 5-Chloro-N-({(5S)-2-oxo-3-[4-(2-oxo-l-azetidinyl)pheny!]-l,3-oxazolidin-5-yl}methyl)-2- thiophenecarboxamide is obtained in an analogous manner by cyclization of the open-chain bromopropionyl compound from Example 163 by means of NaH/DMSO. MS (ESI): m/z (%) = 406 ([M+H]+, 100), Cl sample. IC50:380nM Example 165 tert-Eutyl 4-{4-[5-({[(5-chloro-2-thienyl)carbonyl]amino}methyl)-2-oxo-l,3-oxazolidin-3- yl]phenyl}-3,5-dioxo-l-piperazinecarboxylate rvci s O o -95- 300 mg (0.85 mmol) of Af-{[3-(4-aminophenyl)-2-oxo-l,3-oxazolidin-5-yl]methyl}-5-chloro-2- thiophenecarboxamide in 6 ml of a mixture of DMF and dichloromethane (1:1) are added to a solution of 199 mg (0.85 mmol) of Boc-iminodiacetic acid, 300 mg (2.2 mmol) of HOST, 0.66 ml (6 mmol) of 7V-methylmorpholine and 647 mg (1.7 mmol) of HBTU. The mixture is stirred overnight, before, after diluting with dichloromethane, being washed with water, saturated ammonium chloride solution, saturated sodium hydrogencarbonate solution, water and saturated sodium chloride solution. The organic phase is dried over magnesium sulfate and concentrated. The crude product is purified by chromatography on silica gel (dichloromethane/methanol 98:2). Yield: 134 mg (29 % of theory); MS (ESI): m/z (%) = 571 (M+Na, 82), 493 (100); HPLC (method 3): rt (%) = 4.39 (90). IC50: 2 uM Example 166 N-[((5S)-3-{4-[(3R)-3-Amino-2-oxo-l-pyrrolidiriyl]phenyI}-2-oxo-l,3-oxazolidin-5-yl)methyl]- 5-chloro-2-thiophenecarboxamide trifluoroacetate BOCNH^COOH s HOBT S-CH EDC, DIEA Me3SI, K2C03 -96- N2-(tert-Butoxycarbonyl)-Nl-{4-[(5S)-5-({[(5-chIoro-2-thienyl)carbonyl]amino}methyl)-2- oxo-l,3-oxazolidin-3-yl]phenyl}-D-methioninamide 429 mg (1.72 mmol) of N-BOC-D-methionine, 605 mg (1.72 mmol) of N-{[(5S)-3-(4- aminophenyl)-2-oxo-l,3-oxazolidin-5-yl]methyl}-5-chloro-2-thiophenecarboxamide, and 527 mg (3.44 mmol) of HOBT hydrate are dissolved in 35 ml of DMF, and treated with 660 mg (3.441 mmol) of EDC1 hydrochloride and subsequently dropwise with 689 mg (5.334 mmol) of N-ethyldiisopropylamine. The mixture is stirred at room temperature for two days. The suspension obtained is filtered off with suction and the residue is washed with DMF. The combined filtrates are treated with some silica gel, evaporated in vacuo and chromatographed on silica gel using a toluene -> T10EE7 gradient. 170 mg (17% of theory) of the target compound having a melting point of 183°C are obtained. Rf (SiO2, toluene/ethyl acetate=l:l):0.2. 'H-NMR (300 MHz, d6-DMSO): <5=1.4 (s,lH,BOC), 1.88-1.95 (m,2H), 2.08 (s,3H,SMe), 2.4-2.5 (m,2H, partially masked by DMSO), 3.6 (m,2H), 3.8 (m,lH), 4.15 (m,2H), 4.8 (m,lH), 7.2 (1H, thiophene), 7.42 (d, part of an AB system, 2H), 7.6 (d, part of an AB system, 2H), 7.7 (d, 1H, thiophene), 8.95 (t,lH, CH2NHCO), 9.93 (bs,lH,NH). tert-Butyl (3R)-l-{4-[(5S)-5-({[(5-chloro-2-thienyI)carbonyl]amino}methyl)-2-oxo-l,3- oxazolidin-3-yl]phenyl}-2-oxo-3-pyrrolidinylcarbamate 170 mg (0.292 mmol) of N2-(tert-butoxycarbonyl)-Nl-{4-[(5S)-5-({[(5-chloro-2- thienyl)carbony 1] amino} methyl)-2 -oxo-1,3 -oxazo 1 idin-3 -y l]pheny 1} -D-methioninamide are dissolved in 2 ml of DMSO and treated with 178.5 mg (0.875 mmol) of trimethylsulfonium iodide and also 60.4 mg (0.437 mmol) of potassium carbonate and stirred for 3.5 hours at 80°C. Subsequently, the mixture is evaporated in a high vacuum and the residue is washed with ethanol. 99 mg of the target compound remain. -97- 'H-NMR (300 MHz, d6-DMSO): 8 =1.4 (s,m,BOC), 1.88-2.05 (m,lH), 2.3-2.4 (m,lH), 3.7-3.8 (m,3H), 3.8-3.9 (m,lH), 4.1-4.25 (m,lH), 4.25-4.45 (m,lH), 4.75-4.95 (m,lH), 7.15 (IH, thiophene), 7.25 (d,lH), 7.52 (d, part of an AB system, 2H), 7.65 (d, part of an AB system, 2H), 7.65 (d, IH, thiophene), 9.0 (broad s,lH). N-[((5S)-3-{4-[(3R)-3-Amino-2-oxo-l-pyrrolidinyl]phenyI}-2-oxo-l,3-oxazolidin-5-yl)methyl]- 5-chloro-2-thiophenecarboxamide trifluoroacetate 97 mg (0.181 mmol) of tert-butyl (3R)-l-{4-[(5S)-5-({[(5-chloro-2- thienyl)carbonyl]amino}methyl)-2-oxo-l,3-oxazolidin-3-yl]phenyl}-2-oxo-3-pyrrolidinylcarbamate are suspended in 4 ml of methylene chloride, 1.5 ml of trifluoroacetic acid are added and the mixture is stirred for 1 hour at room temperature. Subsequently, it is evaporated in vacuo and purified on an RP-HPLC (acetonitrile/wal:er/0.1%TFA gradient). After evaporating the fraction concerned, 29 mg (37% of theory) of the target compound having a melting point of 24 l°C(des.) are obtained. Rf (SiO2,EtOH/TEA=17:l) 0.19. 'H-NMR (300 MHz, d6-DMSO): S =1.92-2.2 (m,lH), 2.4-2.55 (m,lH, partially masked by DMSO peak), 3.55-3.65 (m,2H), 3.75-3.95 (m,3H), 4.1-4.3 (m,2H), 4.75-4.9 (m,lH), 7.2 (IH, thiophene), 7.58 (d, part of an AB system, 2H), 7.7 (d, part of an AB system, 2H), 7.68 (d, IH, thiophene), 8.4 (broad s,3H, NH3), 8.9 (t,lH,NHCO). The following Examples 167 to 170 relate to the introduction of sulfonamide groups into phenylsubstituted oxazolidinones: General method for the preparation of substituted sulfonamides starting from 5-chloro-Ar- [(2-oxo-3-phenyl-l,3-oxazolidin-5-yI)methyl]-2-thiophenecarboxamide -98- 5-Chloro-7V-[(2-oxo-3-phenyl-l,3-oxazolidin-5-yl)methyl]-2-thiophenecarboxamide (from Example 96) is added under argon at 5°C to chlorosulfonic acid (12 eq.). The reaction mixture is stirred at room temperature for 2 h and subsequently added to ice water. The precipitate deposited is filtered, washed with water and dried. Subsequently, it is dissolved in tetrahydrofuran (0.1 mol/1) under argon at room temperature and treated with the corresponding amine (3 eq.), tricthylamine (1.1 eq.) and dimethylaminopyridine (0.1 eq.). The reaction mixture is stirred for 1-2 h and subsequently concentrated in vacuo. The desired product is purified by means of flash chromatography (dichloromethane-methanol mixtures). The following were prepared in an analogous manner: Example 167 5-Chloro-Ar-({2-oxo-3-[4-(l-pyrrolidinylsulfonyl)phenyll-l,3-oxazolidin-5-yl}methyl)-2- thiophenecarboxamide MS (ESI): m/z (%) = 492 ([M+Na]+, 100), 470 ([M+H]+, 68), Cl sample; HPLC (method 3): rt (%) = 4.34 (100). IC50: 0.5 uM Example 168 5-Chloro-A^-[(3-{4-[(4-methyl-l-piperazinyI)sulfonyI]phenyI}-2-oxo-l,3-oxazolidin-5- yl)methyI]-2-thiophenecarboxamide MS (ESI): m/z (%) = 499 ([M+H]+, 100), Cl sample; > HPLC (method 2): rt (%) = 3.3 (100). Example 169 5-Chloro-7V-({2-oxo-3-[4-(l-piperidinylsuIfonyl)phenyl]-l,3-oxazolidin-5-yl}methyl)-2- thiophenecarboxamide MS (ESI): m/z (%) = 484 ([M+H]+, 100), Cl sample; HPLC (method 2): rt (%) = 4.4 (100). -99- Example 170 5-Chloro-7V-[(3-{4-[(4-hydroxy-l-piperidinyl)sulfonyl]phenyl}-2-oxo-l,3-oxazoIidin-5- yl)methyl]-2-thiophenecarboxamide MS (ESI): m/z (%) = 500 ([M+H]+, 100), Cl sample; HPLC (method 3): rt (%) = 3.9 (100). Example 171 5-ChIoro-N-({2-oxo-3-[4-(l-pyrroIidinyl)phenyl|-l,3-oxazolidin-5-yl}methyl)-2- thiophenecarboxaraide 780 mg (1.54 mmol) of tert-butyl-l-{4-[5-({[(5-chloro-2-thienyl)carbonyl]amino}methyl)-2-oxol, 3-oxazolidin-3-yl]phenyl}prolinate are dissolved in 6 ml of dichloromethane and 9 ml of trifluoroacetic acid and the mixture is stirred for two days at 40°C. The reaction mixture is then concentrated and stirred with ether and 2 N sodium hydroxide solution. The aqueous phase is concentrated and stirred with ether and 2 N hydrochloric acid. The organic phase from this extraction is dried over MgSO4, filtered and concentrated. The crude product is chromatographed on silica gel (CH2Cl2/EtOH/conc. aq. NH3 soln. = 100/1/0.1 to 20/1/0.1). < 280 mg (40 % of theory) of the product are obtained. MS (ESI): m/z (%) = 406 (M+H, 100); HPLC (method 4): rt = 3.81 min. HPLC parameters and LC-MS parameters of the HPLC and LC-MS data indicated in the preceding examples (the unit of the retention time (it) is minutes): [1] Column: Kromasil C18, L-R temperature: 30°C, flow = 0.75 mlrmV, eluent: A = 0.01 M -100 - HC104, B = CH3CN, gradient: -> 0.5 min 98%A -> 4.5 min 10%A ->6.5 min 10%A [2] Column: Kromasil CIS 60*2, L-R temperature: 30°C, flow = 0.75 mlmin"1, eluent: A = 0.01 M H3PO4, B = CH3CN, gradient: -> 0.5 min 90%A -> 4.5 min 10%A ->6.5 min 10%A [3] Column: Kromasil CIS 60*2, L-R temperature: 30°C, flow - 0.75 mlmin"1, eluent: A = 0.005 M HC1O4, B = CH3CN, gradient: -> 0.5 min 98%A -> 4.5 min 10%A ->6.5 min 10%A [4] Column: Symmetry CIS 2.1x150 mm, column oven: 50°C, flow = 0.6 mlmin"1, eluent: A = 0.6 g of 30% strength HC1/1 water, B = CH3CN, gradient: 0.0 min 90%A -> 4.0 min 10%A ->9 min 10%A [5] MHZ-2Q, Instrument Micromass Quattro LCZ Column Symmetry CIS, 50 mm x 2.1 mm, 3.5 urn, temperature: 40°C, flow = 0.5 ml min"1, eluent A = CH3CN + 0.1% formic acid, eluent B = water + 0.1% formic acid, gradient: 0.0 min 10% A -> 4 min 90% A -> 6 min 90% A [6] MHZ-2P, Instrument Micromass Platform LCZ Column Symmetry CIS, 50 mm x 2.1 mm, 3.5 um, temperature: 40°C, flow = 0.5 mlmin"1, eluent A = CH3CN + 0.1% formic acid, eluent B = water + 0.1% formic acid, gradient: 0.0 min 10% A -> 4 min 90% A -> 6 min 90% A [7] MHZ-7Q, Instrument Micromass Quattro LCZ Column Symmetry CIS, 50 mm x 2.1 mm, 3.5 urn, temperature: 40°C, flow = 0.5 mlmin"1, eluent A = CH3CN + 0.1% formic acid, eluent B = water + 0.1% formic acid, gradient: 0.0 min 5% A -> 1 min 5% A -> 5 min 90% A -> 6 min 90% A i General method for preparation of oxazolidinones of the general formula B by solid phaseassisted synthesis Reactions with different resin-bound products took place in a set of separate reaction vessels. 5-(Bromomethyl)-3-(4-fluoro-3-nitrophenyl)-l,3-oxazolidin-2-one A (prepared from epibromohydrin and 4-fluorine-3-nitrophenyl isocyanate using LiBr/Bu3PO in xylene analogously to US 4128654, Ex.2) (1.20 g, 3.75 mmol) and ethyldiisopropylamine (DEEA, 1.91 ml, 4.13 mmol) were dissolved in DMSO (70 ml), treated with a secondary amine (1.1 eq, amine component 1) and reacted for 5 h at 55°C. TentaGel SAM resin (5.00 g, 0.25 mmol/g) was added to this solution and -101 - reacted for 48 h at 75°C. The resin was filtered and repeatedly washed with methanol (MeOH), dimethylformamide (DMF), MeOH, dichloromethane (DCM) and diethyl ether and dried. The resin (5.00 g) was suspended in dichloromethane (80ml), treated with DIEA (10 eq) and 5- chlorothiophene-2-carbonyl chloride [prepared by reaction of 5-chlorothiophene-2-carboxylic acid (5 eq) and l-chloro-l-dimethylamino-2-methylpropene (5 eq) in DCM (20 ml) at room temperature for 15 minutes] and reacted for 5 h at room temperature. The resin obtained was filtered and repeatedly washed with MeOH, DCM and diethyl ether and dried. Subsequently, the resin was suspended in DMF/water (v/v 9:2, 80 ml), treated with SnCl2*2H2O (5 eq) and reacted for 18 h at room temperature. The resin was in turn repeatedly washed with MeOH, DMF, water, MeOH, DCM and diethyl ether and dried. This resin was suspended in DCM, treated with DEEA (10 eq) and at 0°C with an acid chloride (5 eq of acid derivative 1) and reacted at room temperature overnight. Carboxylic acids were converted into the corresponding acid chlorides before the reaction by reaction with l-dimethylamino-l-chloro-2-methylpropene (1 eq, based on the carboxylic acid) in DCM at room temperature for 15 min. The resin was repeatedly washed with DMF, water, DMF, MeOH, DCM and diethyl ether and dried. In the case of the use of Fmocprotected amino acids as acid derivative 1, the Fmoc protective group was cleaved at room temperature for 15 minutes in the last reaction step by reaction with piperidine/DMF (v/v, 1/4) and the resin was washed with DMF, MeOH, E>CM and diethyl ether and dried. The products were subsequently cleaved from the solid phase using trifluoroacetic acid (TFA)/DCM (v/v, 1/1), the resin was filtered off and the reaction solutions were evaporated. The crude products were filtered through silica gel (DCM/MeOH, 9:1) and evaporated in order to obtain a set of products B. TentaGelSAM" 2 R TentaGelSAM - 102 - Cl 5Eq TGSAM TFA/DCM, 1/1 Compounds prepared by solid phase-assisted synthesis: Example 172 N-( {3- [3-Amino-4-(l -py rrolidinyl)phenyl] -2 -oxo-1,3-oxazoIidin-5-y 1} methyl)-5-chloro- 2-thiophenecarboxamide Analogously to the general working procedure for the preparation of the derivatives B, 5 g (1.25 mmol) of TentaGel SAM resin were reacted with pyrrolidine as amine derivative 1. The aniline obtained after the reaction with SnCl2*2H2O was cleaved from the solid phase without a further acylation step and evaporated. The crude product was partitioned between ethyl acetate and - 103 - NaHCO3 solution, the organic phase was salted out using NaCl, decanted and evaporated to dryness. This crude product was purified by vacuum flash chromatography on silica gel (dichloromethane/ethyl acetate, 3:1 - 1:2). 'H-NMR (300 MHz, CDC13): 1.95 - 2.08, br, 4 H; 3.15-3.30, br, 4 H; 3.65-3.81, m, 2 H; 3.89, ddd, IH; 4.05, dd, 1 H; 4.81, dddd, 1 H; 6.46, dd, 1 H; 6.72, dd, 1 H; 6.90, dd, 1 H; 6.99, dd, 1 H; 7.03, dd, 1 H; 7.29, d, 1 H. Example 173 N-[(3-{3-(B-Alanylamino)-4-[(3-hydroxypropyl)amino]phenyl}-2-oxo-l,3-oxazolidin-5- yl)methyl]-5-chloro-2-thiophenecarboxamide Analogously to the general working procedure for the preparation of the derivatives B, 5 g (1.25 mmol) of TentaGel SAM resin were reacted with azetidine as amine derivative 1 and Fmocli- alanine as acid derivative 1. The crude product obtained after the cleavage was stirred for 48 h in methanol at room temperature and evaporated to dryness. This crude product was purified by reversed phase HPLC using a water/TFA/acetonitrile gradient. 'H-NMR (400 MHz, CD3OD): 2.31, tt, 2 H; 3.36, t, 2 H; 3.54, t, 2 H; 3.62, t, 2 H; 3.72, dd, 1 H; 3.79, dd, 1 H; 4.01, dd, 1 H; 4.29, dd, 2 H; 4.43, t, 2 H; 4.85-4.95, m, 1 H; 7.01, d, 1 H; 4.48 - 7.55, m,,2 H; 7.61, d, 1 H; 7.84, d, 1 H. Example 174 N-({3-[4-(3-Amino-l-pyrrolidinyl)-3-nitrophenyl]-2-oxo-l,3-oxazolidin-5-yl}methyl)-5- chloro-2-thiophenecarboxamide - 104 - NO Analogously to the general general working procedure for the preparation of the derivatives B, 130 mg (32.5 umol) of TentaGel SAM resin were reacted with /erf-butyl 3-pyrrolidinylcarbamate as amine derivative 1. The nitrobenzene derivative obtained after the acylation with 5- chlorothiophenecarboxylic acid was cleaved from the solid phase and evaporated. This crude product was purified by reversed phase HPLC using a water/TFA/acetonitrile gradient. 'H-NMR (400 MHz, CD3OH): 2.07-2.17, m, 1 H; 2.39-2.49, m, 1 H; 3.21-3.40, m, 2 H; 3.45, dd, 1 H; 3.50-3.60, m, 1 H; 3.67, dd, 1 H; 3.76, dd, 1 H; 3.88-4.00, m, 2 H; 4.14 - 4.21, t, 1 H; 4.85 - 4.95, m, 1 H; 7.01, d, 1 H; 7.11, d, 1 H; 7.52, d, 1 H; 7.66, dd, 1 H; 7.93, d, 1 H. Example 175 N-({3-[3-Amino-4-(l-piperidinyl)phenyl|-2-oxo-l,3-oxazolidin-5-yl}methyl)-5-chloro-2- thiophenecarboxamide V_7 \= Analogously to the general working procedure for the preparation of the derivatives B, 130mg (32.5 umol) of TentaGel SAM resin were reacted with piperidine as amine derivative 1. The aniline obtained after the reduction was cleaved from the solid phase without a further acylation step and evaporated. This crude product was purified by reversed phase HPLC using a water/TFA/acetonitrile gradient. (400 MHz, CD3OH): 1.65-1.75, m, 2 H; 1.84-1.95, m, 4 H; 3.20-3.28, m, 4 H; 3.68, dd, 1 H; 3.73, dd, IH; 3.90, dd, 1 H; 4.17, dd, 1 H; 4.80-4.90, m, 1 H; 7.00, d, 1 H; 7.05, dd, 1 H; 7.30- 7.38, m, 2H; 7.50, d, 1 H. Example 176 N-({3-[3-(Acetylamino)-4-(l-pyrrolidinyl)phenyl]-2-oxo-l,3-oxazolidin-5-yl}methyl)-5- chloro-2-thiophenecarboxamide - 105 - Analogously to the general working procedure for the preparation of the derivatives B, 130mg (32.5 umol) of TentaGel SAM resin were reacted with pyrrolidine as amine derivative 1 and acetyl chloride as acid derivative 1. The crude product was partitioned between ethyl acetate and NaHCO3 solution, the organic phase was salted out using NaCl, decanted and evaporated to dryness. This crude product was purified by vacuum flash chromatography on silica gel (dichloromethane/ethyl acetate, 1:1-0:1). 'H-NMR (400 MHz, CD3OH): 1.93 - 2.03; br, 4 H; 2.16, s, 3 H; 3.20-3.30, br, 4 H; 3.70, d, 2 H; 3.86, dd, 1H; 4.10, dd, 1 H; 4.14, dd, 1 H; 4.80-4.90, m, 1 H; 7.00, d, 1 H; 7.07, d, 1 H; 7.31, dd, 1 H; 7.51, d , l H ; 7.60, d, 1 H. The following compounds were prepared analogously to the general working procedure. - 106- Example Structure Ret. time HPLC 177 N N NA- =AN o 2.62 79.7 178 cCil 2.49 33.7 179 180 181 182 N N o = v o 4.63 46.7 3.37 44.8 2.16 83 2.31 93.3 - 107 - Example Structure 183 N Ret. time HPLC 2.7 100 184 O 3.91 51 185 o 2.72 75.2 186 0 N o 3.17 46 187 o O 4.61 50.2 188 3.89 56.6 - 108- Example Structure Ret. time HPLC 89 190 3.37 52.9 N 3.6 63.9 o o N O 191 192 193 2.52 70.1 0 ° N N 0 N 3.52 46.6 o-f° 2.87 50.1 N -109- Example Structure Ret. time HPLC 194 3.25 71.1 195 196 N N 2.66 67 2.4 52.1 197 PN 3.13 48.9 198 r N 2.67 75.5 -110- Example Structure Ret. time HPLC 199 o ^r~ o N VN 2.72 N N- 65.7 200 2.71 O Cl N NN 57.3 201 O O 2.22 s tj N N 0 100 202 N 3.89 N N 75.7 203 O 0 N 3.19 O N N 49.6 204 O N \-N 2.55 N NN -111 - Example Structure Ret. time HPLC 205 N 2.44 68.6 206 N 2.86 71.8 207 /- C,A,SY) N N 2.8 63.6 208 o 0 N O 2.41 77 209 o N 2.56 67.9 O N Example Structure -112- Ret. time HPLC 210 ^ o I/\-N YNo 3.67 78.4 211 0 o 2.54 69.8 212 3.84 59.2 213 214 N o N 2.41 67.8 2.41 75.4 215 4.01 81.3 -113- Example Structure Ret. time HPLC 216 O N 3.46 49.5 217 0 V-Q N N-^aCl 4.4 60.2 218 O Cl N \ If N 0- N-(' V-N O 3.79 70.9 219 O 4.57 51.5 220 O N N 2.68 100 -114- Example Structure Ret. time HPLC 221 o 4.53 63.5 222 o N 2.66 89.2 223 4.76 69.3 •224 o 3.45 .4 225 226 o N iA> 0 3.97 63.2 3.94 61.4 -115- Example Structure Ret. time HPLC 227 228 4.15 66.3 4.41 55.1 229 o N N N o 2.83 41.1 230 o N 2.7 83 231 o 4.39 64.2 232 4.85 74.9 -116- Example Structure Ret. time HPLC 233 o 4.17 41 234 o =< N N o 4.21 61.8 235 c, N 2.75 100 236 o 3.94 50 237 4.65 75.8 - 1 1 7 - Example Structure Ret. time HPLC 238 o 0 4.4 75.3 239 4.24 62.2 240 4.76 75.1 241 242 243 S o 4.17 72.5 4.6 74.8 4.12 51.6 o 0 -118- Example Structure Ret. time HPLC 244 245 4.71 66.2 4.86 62 246 o 5.23 58.3 247 4.17 72.4 248 3.35 59.6 N 0=^ -119- Example Structure Ret. time HPLC 249 N 2.41 60.3 250 N 3.31 65.2 251 2.86 36.5 252 V-N S-/ C.-O O N 2.69 89.8 253 N N 2.81 67.4 -120 - Example Structure Ret. time HPLC 254 2.19 75.4 All products of the solid phase-assisted synthesis were characterized by means of LC-MS. For this, the following separation system was used as standard: HP 1100 with UV detector (208 - 400 nm), 40°C oven temperature, Waters Symmetry CIS column (50mm x 2.1 mm, 3.5 um), eluent A: 99.9 % acetonitrile/0.1 % formic acid, eluent B: 99.9 % water/0.1 % formic acid; gradient: Time 0.00 4.00 6.00 6. 10 7.50 A:% 10.0 90.0 90.0 10.0 10.0 B:% 90.0 10.0 10.0 90.0 90.0 Flow 0. 50 0.50 0.50 1.00 0. 50 The detection of the substances was carried out by means of a Micromass Quattro LCZ MS, ionization: ESI positive/negative. In the structures mentioned above which contain the or the radicals NT or -O, an TH 'NH2 or -OH function is always meant. or a pharmaceutically acceptable salt thereof; wherein: the dotted line between Y and Z represents an optional second bond; the dotted line between the two R4 groups represents an optional heterocyclic ring of 4 to 6 ring atoms that may be formed between the two RA groups, together with the nitrogen through which they are attached; Y is N, C(R6)2, CR6, or C=O; ', CR5) or C(R5)2; RI is, independently at each occurrence, alkyl, alkoxy, halo, CF3, OCF3, hydroxy, alkanoyloxy, nitro, cyano, alkenyl, alkynyl, alkylsulfoxide, alkylsulfone, alkylsulfonamide, or alkylamido; or two adjacent RI also represent methylenedioxy; R2 is aryl substituted with 0-3 RU or heteroaryl substituted with 0-3 R-|4; R3 is H or CrC4 alkyl; R4 is, independently at each occurrence, H, Ci-C4 alkyl, C3-Ce cycloalkyl, arylalkyl, heteroarylmethyl, cycloheptylmethyl, cyclohexylmethyl, cyclopentylmethyl, or cyclobutylmethyl, or both R4 groups, together with the nitrogen through which they are attached, form a heterocyclic ring of 4 to 6 ring atoms, where one carbon may be optionally replaced with N, O, S, or SO2, and where any carbon ring atom or additional N atom may be optionally substituted with Ci-C4 alkyl, F, or CF3; R5 is, independently at each occurrence, H, Ci-C4 alkyl, aryl substituted with' 0-3 Ri4, heteroaryl substituted with 0-3 Ri4> or cyano; or when two RS are present, they may form a carbocyclic ring of 3-5 carbons; Re is, independently at each occurrence, H, CrC4 alkyl, or cyano; R7 is H, Ci-C6 alkyl, C3-C6 cycloalkyl, aryl substituted with 0-3 R14, or heteroaryl substituted with 0-3 Ri4; Re is H, or CrC4 alkyl; Rg is H, or Ci-C4 alkyl; Rio is, independently at each occurrence, H, or Ci-C4 alkyl; or Rio and R4 together with the nitrogen to which R4 is attached form a nitrogen-containing ring containing 3-6 carbon atoms; RM is, independently at each occurrence, alkyl, alkoxy, halo, CF3, OCF3, arylalkyloxy substituted with 0-3 RI, aryloxy substituted with 0-3 RI, aryl substituted with 0-3 RI; heteroaryl substituted with 0-3 RI, hydroxy, alkanoyloxy, nitro, cyano, alkenyl, alkynyl, alkylsulfoxide, phenylsulfoxide substituted with 0-3 RL alkylsulfone, phenylsulfone substituted with 0-3 RI, alkylsulfonamide, phenylsulfonamide substituted with 0-3 RI, heteroaryloxy substituted with 0-3 RI, heteroarylmethyloxy substituted with 0-3 RI, alkylamido, or arylamido substituted with 0-3 RI; or two adjacent RI also represent methylenedioxy; n is an integer from 1 to 2; and qls'arfihtegef trorn'O to 4; wherein 1-3 carbon atoms in ring A may optionally be replaced with N. In preferred embodiments of the compound of formula III, the dotted line between Y and Z represents a second bond. Y is CRS; and Z is CR5. In preferred embodiments of the compound of formula III, the bond between Y and Z is a single bond; Y is C(R6)2; and Z is C(R5)2. in preferred embodiments of the compound of formula III, the bond between Y and Z is a single bond; Y is C=O; Z is C(R5)2. • ,-• In preferred embodiments of the compound of formula HI, the bond between Y and Z is a single bond; Y is C=O; ZisNR?. In preferred embodiments of the compound of formula III, Y is C(Re)2, or C=O. In preferred embodiments of the compound of formula III, Z is CR5 or C(R5)2. In preferred embodiments of the compound of formula III, Ri is, independently at each occurrence, alkyl, alkoxy, halo, CF3, OCFa, hydroxy, alkanoyloxy, nitro, or cyano. ;v'" I'h" preferred' embodiments of the compound of formula III, Ra is aryl substituted with 0-2 Ri4. In preferred embodiments of the compound of formula III, R2 is phenyl, fluorophenyl, or difluorophenyl. In preferred embodiments of the compound of formula III, R3 is H. In preferred embodiments of the compound of formula III, R4 is H or methyl. In preferred embodiments of the compound of formula III, R5 is, independently at each occurrence, H, Ci-C4 alkyl, aryl substituted with 0-3 Ri4. In preferred embodiments of the compound of formula III, R5 is, independently at each occurrence, H, methyl, ethyl, n-propyl, isopropyl, aryl substituted with alkoxy, aryl substituted with aryloxy or phenyl substituted with 1-2 halo. , In preferred embodiments of the compound of formula III, Re is, independently at each occurrence, H, methyl, ethyl, n-propyl, or isopropyl. In preferred embodiments of the compound of formula III, R7 is H, Ci-C6 alkyl, or aryl substituted with 0-3 Ri4. In preferred embodiments of the compound of formula III, R& is H. In preferred embodiments of the compound of formula III, R9 is H. In preferred embodiments of the compound of formula III, Rio is H. In preferred embodiments of the compound of formula III, n is 1. ' In preferred embodiments of the compound of formula III; q is an integer from 0 to 2. In preferred embodiments of the compound of formula III, none of the carbon atoms in ring A are replaced with N. In preferred embodiments of the compound of formula III, the dotted line between Y and 2 represents a second bond; Y is CR6; Z is CR5; RI is, independently at each occurrence, alkyl, alkoxy, halo, CF3, OCF3, hydroxy or cyano; Ra is aryl substituted with 0-3 R14 or heteroaryl substituted with 0-3 R14; R3 is H; R< is, independently at each occurrence, H or methyl; Rs is, independently at each occurrence, H, methyl or aryl substituted with 0-3 ReisH; RaisH; R9 is H; Rio is H; RU is, independently at each occurrences, alkyl, alkoxy, halo, CF3, OCF3, hydroxy or cyano; nis1;and q is an integer from 0 to 3; wherein none of the carbon atoms in ring A are replaced with N. In preferred embodiments of the compound of formula III, the bond between Y and Z is a single bond; YisC(R6)2; ZisC(R6)2; Ri is, independently at each occurrence, alkyl, alkoxy, halo, CF3, OCF3| hydroxy or cyano; R2' 'is "aryl substitutecl with 0-3 Ru or heteroaryl substituted with 0-3 Ri4; R3 is H; R4 is, independently at each occurrence, H or methyl; R5 is, independently at each occurrence, H, CrC4 alkyl or aryl substituted with 0-3 R14; Re is independently at each occurrence, H or CrC4 alkyl; Re«sH; Rg is H; Rio is H; Ri4 is, independently at each occurrence, alky!, alkoxy, halo, CF3| OCFa, hydroxy or cyano; n is 1; and q is an integer from 0 to 3; wherein none of the carbon atoms in ring A are replaced with N. In preferred embodiments of the compound of formula III, the bond between Y and Z is a single bond; Y is C=O; Z is is C(R5)2; RI is, independently at each occurrence, alkyl, alkoxy, halo, CF3, OCF3l hydroxy or cyano; R2 is aryl substituted with 0-3 R14 or heteroaryl substituted with 0-3 Ri4; Ra is H; R4 is, independently at each occurrence, H or methyl; R$ is, independently at each occurrence, H, or CrC4 alkyl; RaisH; R9 is H; RIO is H; Ri4 is, independently at each occurrence, alkyl, alkoxy, halo, CF3, OCF3, hydroxy or cyano; n is 1; and q is an integer from 0 to 3; wherein none of the carbon atoms in ring A are replaced with N. In preferred embodiments of the compound of formula III, the bond between Y and Z is a single bond; Y is C=O; Z is NR7; R! is, independently at each occurrence, alkyl, alkoxy, halo, CF3| OCF3, hydroxy or cyano; R2 is aryl substituted with 0-3 R14 or heteroaryl substituted with 0-3 R14; R3 is H; R4 is, independently at each occurrence, H or methyl; R7 is CrC6 alkyl, Cs-C6 cycloalkyi, aryl substituted with 0-3 Ri4or heteroaryl substituted with 0-3 R14; R8 is H; R9 is H; RIO is H; .R-I4 is, independently at each occurrence, alkyl, alkoxy, halo, CF3, OCF3, hydroxy or cyano; n is 1; and q is an integer from 0 to 3; wherein none of the carbon atoms in ring A are replaced with N. Preferred compounds of the invention include, but are not limited to: 1 -[5-(benzyloxy)-1 H-indoM -yl]-3-(methy lamino)-1 -phenylpropan-2-ol; 1 -[4-(benzyloxy)-1 H-indoM -yl]-3-(methy lamino)-1 -phenylpropan-2-ol; 1 -[6-(benzyloxy)-1 H-indol-1 -yl]-3-(rnethylamino)-1 -phenylpropan-2-ol; 1 -[7-(benzyloxy)-1 H-indol-1 -yl]-3-(methylamino)-1 -phenylpropan-2-ol; 1 -{5-[(2-methoxybenzyl)oxy]-1 H-indol-1 -yl}-3-(methylamino)-1 -phenylpropan-2-ol; 1 -{5-[(3-methoxybenzyl)oxy]-1 H-indol-1 -yl}-3-(methylamino)-1-phenylpropan-2-ol; 1 -{5-[(4-methoxybenzyl)oxy]-1 H-indol-1 -yl}-3-(methylamino)-1 -phenylpropan-2-ol; T^5-l(2-chlorobenzyl)oxy]-1 H-indol-1-yl}-3-(methylamino)-1-phenylprcipan-2-ol; 1 -{5-[(3-chlorobenzyl)oxy]-1 H-indol-1 -yl}-3-(methylamino)-1 -phenylpropan-2-ol; 1 -{5-[(4-chlorobenzyl)oxy]-1 H-indol-1-yl}-3-(methylamino)-1 -phenylpropan-2-ol; 1 -{5-[(2-fluorobenzyl)oxy]-1 H-indol-1 -yl}-3-(methylamino)-1 -phenylpropan-2- 0|: 1 -{5-[(3-fluorobenzyl)oxy]-1 H-indol-1 -yl}-3-(methylamino)-1 -phenylpropan-2- ol; 1 -{5-[(4-fluorobenzyl)oxy]-1 H-indol-1 -yl}-3-(methylamino)-1 -phenylpropan-2-ol; 3-(methylamino)-1 -{5-[(2-methylbenzyl)oxy]-1 H-indol-1 -yl}-1 -phenylpropan-2-ol; 3-(methylamino)-1 -{5-[(3-methylbenzyl)oxy]-1 H-indol-1 -yl}~1 -phenylpropan-2-ol; 3-(methylamino)-1-{5-t(4-methylbenzyl)oxy]-1 H-indol-1 -yl}-1 -phenylpropan-2-ol; 3-(methylamino)-1-phenyl-1-[5-(1-phenylethoxy)-1H-indol-1-yl]propan-2-ol; 3-(methyiamino)-1-phenyl-1-[5-(2-phenylethoxy)-1 H-indol-1 -yl]propan-2-ol; 3-(methylamino)-1 -(5-phenoxy-1 H-indol-1 -yl)-1 -phenylpropan-2-ol; 3-(methylamino)-1 -(4-phenoxy-1 H-indol-1 -yl)-1 -phenylpropan-2-ol; 3-(methylamino)-1-phenyl-1-(4-phenyl-1 H-indol-1-yl)propan-2-ol; 3-(methylamino)-1 -phenyl-1 -(6-phenyl-1 H-indol-1 -yl)propan-2-ol; 3-(methylamino)-1 -phenyl-1 -(7-phenyl-1 H-indol-1 -yl)prapan-2-ol; 1 -[5-(ben2yloxy)-1 H-indol-1 -yl]-1 -(3-fluorophenyl)-3-(methylamino)propan-2-ol; 1-[5-(ben2yloxy)-2,3-dihydro-1H-indol-1-yl]-1-(3-fluonDphenyl)-3-(methylamino)propan-2-ol; 1 -[5-(benzyloxy)-2,3-dihydro-1 H-indol-1 -yl]-3-(methyiamino}-1 -phenylpropan-2-ol; 5'-chloro-1'-[2-hydroxy-3-(methylamino)-1-phenylpropyl]spiro[cyclohexane- |orb-T-l(2-hyclifoxy-3-(methylamino)-1-phenylpropyl]spiro[cyclohexane--indol]-2'(1'H)-one; 6'-fluoro-1l-[2-hydroxy-3-(methylamino)-1-phenylpropyl]spiro[cyclohexane-l.a'-indolK'CTHJ-one; 5'-fIuoro-1'--[2-hydroxy-3-(methylamino)-1-phenylpropylJspiro[cyclohexane-1,3'-indolj-2'(1'H)-one; T'-chloro-l'-p-hydroxy-S^methylamino^l-phenylpropylJspiroIcyclohexane-1,3'-indol]-2'(1'H)-one; 6'-fluoro-1 '-[1 -(3-fluorophenyl)-2-hydroxy-3-(methylamino) propyl]spiro[cyc!ohexane-1,3'-indol]-2X1 'H)-one; 3-(methylamino)-1-phenyl-1-spiro[cyclohexane-1,3'-indolJ-1'(2'H)-ylpropan-2-ol; 1-(3-fluorophenyl)-3-(methylamino)-1-{3-[2-(trifluoromethoxy)phenyl]-1H-indol-1-yl}propan-2-ol; 1-(3-fluorophenyl)-1-{3-(2-isopropoxyphenyl)-1H-indol-1-yl]-3-(methylamino)propan«2-ol; 1-(3-fluorophenyl)-1-[3-(4-fluorophenyl)-1 H-indol-1-yl]-3-(methylamino)propan-2-ol; 1-(3-fluorophenyl)-3-(methylamino)-1-[3-(2-phenoxyphenyl)-1H-indol-1-yl]propan-2-ol; 1 -[3-(2,4-difluorophenyl)-1 H-indol-1 -yl]-1 -(3-fluorophenyl)-3-(methylamino)propan-2-ol; H3-(2,5-difluorophenyl)-1 H-indol-1-ylJ-1 -(3-fluorophenyl)-3-(methylamino)propan-2-ol; 1-{3-(2,3-dimethoxyphenyl)-1H-indol-1-yl]-1-(3-fluofX)phenyl)-3-(methylamino)propan-2-ol; 1-[3-(2,4-dichlorophenyl)-1 H-indol-1-yl]-1 -(3-fluoropheny()-3-(methylamino)propan~2-ol; 1 -[3-(2-ethoxyphenyl)-1 H-indol-1 -yl]-1 -(3-fluorophenyl)-3-(methylamino)propan--2-o!; 1-(7-chloro-5-methoxy-1H-pyrrolo[2,3-c]pyridin-1-yl)-1-(3-fluorophenyl)-3-(methylamino)propan»2-ol; 'i^rcHlbro-S-methyT-l H-pyrrolo[2,3- -c]pyridin-1 -yl)-3-(methylamino)-1 -phenylpropan-2-ol; 1-(5-methoxy-1 H-pyrrolo[2,3-c]pyridin-1-yl)-3-(methylamino)-1-phenylpropan-2-ol; ^(S-fluorophenyO-I^S-methoxy-IH-pyrrolo^.S-cjpyridin-l-yO-S- (methylamino)propan-2-ol; 3-(methylamino)-1-(5-methyl-1H-pyrrolo[2,3-c]pyridin-1-yl)-1-phenylpropan-2- ol; 1 -(3-fluorophenyl)-3-(methylamino)-1 -(5-methyl-1 H-pyrrolo[2,3-c]pyridin-1 -yl)propgn-2-ol; 3-(rnethylamino)-1-(7-methyl-1H-pyrrolo[2,3-c]pyridin-1-yl)-1-phenylpropan-2- ol; 1-(3-fluorophenyl)-3-(methylamino)-1-(7-methyl-1H-pyrrolo[2,3-c]pyridin-1-yl)propan-2-ol; 1-(3,3~dJethyl-2,3-dihydro-1 H-indol-1-yl)-1-(3-fluorophenyl)-3-(methylamino)propan-2-ol; 1-(6-fluoro-3,3-dimethyl-2,3-dihydro-1H-indol-1-yl)-1-(3-fluorophenyl)-3-(methylamino)propan-2-ol; 1 -(4-benzyl-3,4-dihydroquinoxalin-1 (2H)-yl)-1 -(3-fluorophenyl)-3-(methylamino)propan--2-ol; 1-(5-fluoro-3,3-dimethyl-2,3-dihydro-1H-indol-1-yl)-1-(3-fluorophenyl)-3-(methylamino)propan-2-ol; 1 -(3-fluorophenyl)-3-(methylamino)-1 -[(3S)-3-methyl-2,3-dihydro-1 H-indol-1 -yl]propan-2-ol; 1 -(3-fluorophenyl)-3-(methylamino)-1 -[(3R)-3-methyl-2,3-dihydro-1 H-indol-1 -yl]propan-2-ol; 1-(3-fluorophenyl)-1-(3-isopropyl-2,3-dihydro-1 H-indol-1-yl)-3-(methylamino)propan--2-ol; H3-ethyl-2,3-dihydro-1 H-indol-1-yl)-1-(3-fluorophenyl)-3-(melhy!am!no)propan-2-ol; 1 -(3-ethyl-2,3-dihydro-1 H-indol-1 -yl)-3-(methylamino)-1 -phenylpropan-2-ol; 1 -(3-isopropyl-2,3-dihydro-1 H-indol-1 -yl)-3-(methylamino)-1 -phenylpropan-2-ol; 3-ammo-i-(a,b-ai!uorophenyl)-1-(3,3-dimethyl-2,3-dihydro-1H-indol-1- yl)propan-2-ol; 1-[1-(3,5-difluorophenyl)-2-hydroxy-3-(methylamino)propyl]-7-fluoro-3,3- dimethyl-1,3-dihydro-2H-indol-2-one; 5,7-difluoro-1-[1-(3-fluorophenyl)-2-hydroxy-3-(methylamino)propyl]-3,3-dimethyl-1,3-dihydro-2H-indol-2-one, 1 -[1 -(3,5-difluorophenyl)-2-hydroxy-3-(methylamino)propyl]-3,3-dimethyl-1,3-dihydro-2H-indol-2-one; 1 -[2-hydroxy-3-(methylamino)-1 -phenylpropyl]-1 H-indol-5-ol; 1 _[i -(3-f|uoropheny!)-?-hydroxy-3-(methylamino)propyl]-1 H-indol-5-ol: 5'-(benzyloxy)-1'-[2-hydroxy-3-(methylamino)-1-phenylpropyl]spiro [cyclohexane-1,3'-indol]-2'(1 'H)-one; 5-(benzyloxy)-1 -[2-hydroxy-3-(methylamino)-1 -phenylpropyl]-3,3-dimethyl-1,3-dihydro-2H-indol-2-one; 1-[1-(3-chlorophenyl)-2-hydroxy-3-(methylamino)propyl]-7-fluoro-3,3-dimethyl-1,3-dihydro-2/-/-indol-2-one; 1 -(3-chloro-5-fluorophenyl)-1 -(1 H-indol-1 -yl)-3-(methylamino)propan-2-ol; 3-chloro-N-{1 -[2-hydroxy-3-(methylamino)-1 -phenylpropyl]-1 H-indol-5-yl}-4-methylbenzamide; 3-chloro-N-{1 -[2-hydroxy-3-(methylamino)-1 -phenylpropyl]-2,3-dihydro-1 H-indol-5-yl}benzamide; 3-chloro-N-{1 -[2-hydroxy-3-(methylamino)-1 -phenylpropyl]-1 H-indol-5-yljbenzamide; N-{1 -l2-hydrox;y-3-(nnethylamino)-1 -phenylpropyl]-2,3-dihydro-1 H-indol-5-yl}benzamide; N-{1 -[2-hydrox/-3-(methylamino)-1 -phenylpropyl]-1 H-indol-5-yl}benzamide; N-{1-[2-hydroxy-3-(methylamino)-1-phenylpropyl]-2,3-dihydro-1H-indol-5-yljcyclohexanecarboxamide; N-{1-[2-hydroxy-3-(methylamino)-1-phenylpropyl)-1H-indol-5-y IJcyclohexanecarboxam ide; N-(3-chlorophenyl)-1-[2-hydroxy-3-(methylamino)-1-phenylpropyl]indoline-5-carboxamide; 5-carboxamide; 3-(methylamino)-1 -(6-phenoxy-1 H-indol-1 -yl)-1 -phenylpropan-2-ol; 3-(methylamino)-1-(7-phenoxy-1H-indol-1-yl)-1-pheny1propan-2-ol; 3-amino-1-[5-(benzyloxy)-1 H-indol-1 -yl]-1-pheny!propan-2-ol; 1 -{5-(benzyloxyj- 1 H-indoi- 1 -yl]-3-(ethy larnino)- \ -phenylpropan-2-ol; 1 -[5-(benzyloxy)-1 H-indol-1 -yl]-1 -phenyl- 3-(propylamino)propan-2-ol; 1-{5-(benzyloxy)-1H-indol-1-yl]-3-(isopropylamino)-1-phenylpropan-2-ol; 1-[5-(benzyloxy)-1 H-indol-1 -yl]-3-(dimethylamino)-1 -phenylpropan-2-ol; 1 -[5-(ben7/loxy)-1 H-indol-1 -yl]-3-[ethyl(rnethyl)arnino]-1 -phenylpropan-2-ol; 1-[5-(benzyloxy)-1 H-indol-1 -yl]-3-(diethylamino)-1 -phenylpropan-2-ol; 1 -[5-(benzyloxy)-1 H-indol-1 -yl]-1 -phenyl -3-pyrrolidin-1 -ylpropan-2-ol; 1-[5-(benzyloxy)-1 H-indol-1 -yl]-1-phenyl-3-piperidin-1-ylpropan-2-ol; 1 -[5-(benzyloxy)-1 H-indol-1 -yl]-3-(4-methylpiperazin-1 -yl)-1 -phenylpropan-2-ol hydrochloride 3-(methylamino)-1-phenyl-1-[5-(pyridin-2-ylmethoxy)-1 H-indol-1 -yl]propan-2-ol; 3-(methylamino)-1 -phenyl-1 -[5-(phenylethynyl)-1 H-indol-1 -yl]propan-2-ol; 3-(methylamino)-1-phenyl-1-[5-(2-phenylethyl)-1 H-indol-1 -yl]propan-2-ol; 1 '-l3-amino-2-hydroxy-1 -phenylpropyl]-6'-fiuorospiro[cyclohexane-1 ,3l-indol]-2'(1'H)-one; 1 '-l3-(ethylamino)-2-hydroxy-1 -phenylpropyl]-6'-fluorospiro[cyclohexane-1 ,3'-indol]-2'(1'H)-one; 6'-fluoro-1'-[2-hydroxy-3-(is6propylamino)-1-phenylpropyl]spiroi_cyclohexane- 6'-fluoro-1 '-[2-hydroxy-1 -phenyl-3-(propylamino)propyl]spiro[cyclohexane-1 ,3'-indol]-2'(1'H)-one; 1 '-[3-amino-2-hydroxy-1 -phenylpropyl]-5'-fluorospiro[cyclohexane-1 ,3'-indolJ-2'(1'H)-one; 1'-[3-(ethyIamino)-2-hydroxy-1-phenylpropyl]-5'-fluorospiro[cyclohexane-1,3'-indol]-2'(1'H)-one; S'-fluoro- 1 '-[2-hydroxy-3-(isopropylamino)- 1 -phenylpropyl]spiro[cyclohexane- '' 5v-fllJ'b"r'6-r:-[2-HyW6xy-1 -phenyl-3-(propylamino)propyl]spirolcyclohexane-1 ,3-ndol]-2'(1'H)-one; I'-lS^dimethylaminoJ^-hydroxy-l-phenyipropylJ-S'-fluorospirotcyclohexane- S'-fluoro-l'-^-hydroxy-S-morpholin^-yl-l-phenylpropyllspirotcyclohexane-t,3'-indol]-2'(1'H)-one; 1'-[2-hydroxy-3-(methylamino)-1-phenylpropyl]-5'-methoxyspiro[cyclohexane-1,3'-indol]-2'(1'H)-one; 1'-[2-hydroxy-3-(methylamino)-1-phenylpropyl]-6'-methoxyspiro[cyclohexane-1,3'-indol]-2'(rH)-one; 1 '-[2-hydroxy-3-(methylamino)-1-phenylpropyl]-2'-oxo-1 ',2'-dihydrospiro[cyclohexane-1,3'-indole]-5'-carbonitrile; 1 '-[2-hydroxy-3-(methylamino)-1-phenylpropyl]-2'-oxo-1 ',2-dihydrospiro[cyc!ohexane-1,3'-indole]-6'-carbonitrile; ^.S'-difluoro-l'-p-hydroxy-S^methylaminoJ-l-phenylpropyllspirofcyclohexane-1,3f-indol]-2'(1'H)-one; 7'-fluoro-1'-[1-(3-fluorophenyl)-2-hydroxy-3-(methylamino)propyl] spiro[cyclohexane-1 ,3'-indol]-2'(1'H)-one; 1 '-[1 -(3-chlorophenyl)-2-hydroxy-3-(methylamino)propyll-6'-fluorospiro[cyclohexane-1 ,3'-indo!]-2'(1 'H)-one; 1-[1-(3-chloro-£>-fluorophenyl)-2-hydroxy-3-(methyIamrno)propyl]-7-fluoro-3,3-dimethyl-1,3-dihydro-2H-indol-2-one; 1 -(3-chloro-5-fluorophenyl)-1 -(2,3-dihydro-1 H-indoU -yl)-3-(methylamino)prbpan-2-ol; 1 -(3-chloro-5-fluorophenyl)-1 -<7-fluoro-3, 3-dimethyl-2,3-dihydro-1 H-indol-1 -yl)-3-(methylamino)propan-2-ol; 1-(3-chloro-5-fluorophenyl)-1-(3,3-dimethyl-2,3-dihydro-1H-indol-1-yl)-3-(methylamino)propan-2-ol; 7'-fluoro-1 '-[1 -(3-fluoropheny!)-2-hydroxy-3-(methylaminoJpropyOspirotcyclobutane-I.S'-indolJ^'CI'HJ-one; 7-fluoro- 1 '-[1 -(3-fluorophenyl)-2-hydroxy - 3-(methylamino)propyl]spiro[cyclopentane-1 ,3'-indol]-2'(1 'H)-one; S-fruord-T-lT-Ca-lluorophenyO-Z-hvdroxy-SKmethylaminoipropyll-S.S-dimethyl- 1,3-dihydro-2H-indol-2one; 1-(7-fluoro-2,3-dihydro-1H-indol-1-yl)-3-(methylamino)-1-phenylpropan-2-ol; 4-f luoro-3-[1 -(3-fluorophenyl)-2-hydroxy-3 -(methylamino)propyl]-1 -phenyl-1,3- dihydro-2H-benzimidazol-2-one; 4-fluoro-1-(3-fiuorophenyl)-3-{1-(3-f!uorophenyl)-2-hydroxy-3- (methylamino)propyl]-1,3-dihydro-2H-benzimidazol-2-one; l-lS-amino-HS.S-difluorophenyO^-hydroxypropylH-fluoro-S.S-dimethyl-I.S-dihydro-2H-indol-2-one; and pharmacsutically acceptable salts thereof, especially hydrochloride salt. i Especially preferred compounds of the invention include, but are not limited to: (1 S,2R)-1 -[5-(benzyloxy)-1 H-indol-1 -yl]-3 ~(methylamino)-1 -phenylpropan-2-ol; (1 S,2R)-1 -[4-(benzyloxy)-1 H-indol-1 -yl]-3~(methylamino)-1 -phenylpropan-2-ol; (1 S,2R)-1 -[6-(benzyloxy)-1 H-indol-1 -yl]-3-(methylamino)-1 -phenylpropan-2-ol; (1 S,2R)-1 -[7-(benzyloxy)-1 H-indol-1 -yl]-3~(methylamino)-1 -phenylpropan-2-ol; (1S,2R)-1-{5-[(2-methoxyben2yl)oxy]-1H-indol-1-yl}-3-(methylamino)-1-phenylpropan-2-ol; (1 S,2R)-1 -{5-l(:i-methoxybenzyl)oxy]-1 H-indol-1 -yl}-3-(methylamino)-1 -phenylpropan-2-ol; tlS,2R)-H5-[(4-methoxybenzyl)oxy]-1H-indol-1-yl)-3-(methylamino)-1-phenylpropan-2-ol; (1 S,2R)-1 -{54(2-chlorobenzyl)oxy]-1 H-indol-1 -yl)-3-(methylamino)-1 -phenylpropan-2-ol; (1 S,2R)-1 -{5-t(:J-chlorobenzyl)oxy]-1 H-indol-1-yl}-3-(methylamino)-1-phenylpropan-2-ol; (1 S,2R)-1 -{5-[(^chlorobenzy))oxy]-1 H-indol-1 -yl}-3-(methylamino)-1 -phenylpropan-2-ol; (1 S,2R)-1 -{5-[(2-fluorobenzyl)oxy]~ 1 H-indol-1 'ylJ-3-(methylamino)-1 -phenylpropan-2-ol; (1 S,2R)-1 -{5-[(3-fluorobenzyl)oxy]-1 H-indol-1 -yl}-3-(methylamino)-1 -phenylpropan-2-ol; V '(TS';'2R)-1-{5-[{4-fluorobenzyl)oxy]-1H-indol-1-yl}-3-(methylamino)-1-phenylpropan-2-ol; (1S,2R)-3-(methylamino)-1-{5-[(2-methylben2yl)oxy]-1H-indol-1-yl}-1-phenylpropan-2-ol; (1S,2R)-3-(methyIamino)-1-{5-[(3-methylbenzyl)oxy]-1H-indol-1-ylh1-phenylpropan-2-ol, (1 S,2R)-3-(methylamino)-1 -{5-[(4-methylbenzyl)oxy]-1 H-indol-1 -yl}-1 -phenylpropan-2-ol; (1S,2R)-3-(methylamino)-1-phenyl-1-[5-(1-phenylethoxy)-1 H-indol-1- yl]propan-2-ol; (1S,2R)-3-(methylamino)-1-phenyl-1-[5-(2-phenylethoxy)-1 H-indol-1-yl]propan-2-ol; (1S,2R)-3-(meihylamino)-1-(5-phenoxy-1 H-indol-1-yl)-1-phenylpropan-2-ol; (1S,2R)-3-(methylamino)-1-(4-phenoxy-1 H-indol-1 -yl)-1 -phenylpropan-2-ol; (1S,2R)-3-(methylamino)-1-phenyl-1-(4-phenyl-1H-indol-1-yl)propan-2-ol; (1S,2R)-3-(methylamino)-1-phenyl-1-(6-phenyl-1H-indol-1-yl)propan-2-ol; (1S,2R)-3-(methylamino)-1-phenyl-1-(7-phenyl-1 H-indol-1-yl)propan-2-ol; (1 S,2R)-1 -[5-(benzyloxy)-1 H-indol-1 -yl]-1 -(3-fluorophenyl)-3-(methylamino)propan-2-ol; (1S,2R)-1-[5-(benzyloxy)-2,3-dihydro-1H-indol-1-yl]-1-(3-fluorophenyl)-3-(methylamino)propan-2-ol; (IS^RJ-HS-ftienzyloxy^.S-dihydro-l H-indol-1 -yl]-3-(methylamino)-1-phenylpropan-2-ol; 5'-chloro-1'-[(1S(2R)-2-hydrbxy-3-(methylamino)-1-phenylpropyl]spiro [cyclohexane-1,3'-indol]-2'(1 'H)-one; 6'-chloro-1 '-[(1 S,2R)-2-hydroxy-3-(methylamino)-1 -phenylpropyl]spiro [cyclohexane-1,3'-indol]-2'(1 'H)-one; e'-fluoro-l'-^IS^RJ^-hydroxy-S^methylaminoJ-l-phenylpropy^spiro [cyclohexane-1,3'-indol)-2'(1 'H)-one; 5'-fIuoro-1'-[(1S,2R)-2-hydroxy-3-(methylamino)-1-phenylpropyl]spiro [cyclohexane-1,3'-indol]-2'(1 'H)-one; 7'-chloro-1 '-[(1 S,2R)-2-hydroxy-3-(methylamino)-1 -phenylpropyl]spiro [cyclohexane-1,3'-indol]-2'(1 'H)-one; B^fdord-1-l(TS',2R)-1-(3-fluorophenyl)-2-hydroxy-3-(methylamino) propyl]spiro[cyclohexane-1,3'-indol]-2'(1 'H)-one; (IS^Ri-S-Cmethylamino^l-phenyl-l-spirotcyclohexane-I.S'-indolJ-l^'H)-ylpropan-2-ol; (1 S,2R)-1 -(3-fluorophenyl)-3-(methylamino)-1 -{3-[2-(trifluoromethoxy) phenyl]-I H-indol-1-yl}propan-2-ol; (1S,2R)-1-(3-fluorophenyl)-1-[3-(2-isopropoxyphenyl)-1 H-indol-1-yl]-3-(methylamino)propan-2-ol; (1S,2R)-1-(3-fluorophenyl)-1-[3-(4-fluorophenyl)-1 H-indol-1 -yl]-3-(methylamino)propan-2-ol; (1S,2R)-1-(3-fluorophenyl)-3-(methylamino)-1-[3-(2-phenoxyphenyl)-1H-indol-1-yl]propan-2-ol; (1S,2R)-1-[3-(2,4-difluorophenyl)-1 H-indol-1-yl]-1-(3-fluorophenyl)-3-(methylamino)propan-2-ol; (1 S,2R)-1 -[3-(2,5-difluorophenyl)-1 H-indol-1 -yl]-1 -(3-fluorophenyl)-3-(methylamino)propan-2-ol; (1S,2R)-1-[3-(2,,3-dimethoxyphenyl)-1H-indol-1-yl]-1-(3-fluorophenyl)-3-(methylamino)propan-2-ol; (1 S,2R)-1 -[3-(2,,4-dichlorophenyl)-1 H-indol-1 -yl]-1 -(3-fluorophenyl)-3-(methylamino)propan-2-ol; (1S,2R)-1-[3-(2-ethoxyphenyl)-1H-indol-1-yl]-1-(3-fluorophenyl)-3-(methylamino)propan-2-ol; (1 S,2R)-1 -<7-chloro-5-methoxy-1 H-pyrrolo[2,3-c]pyridin-1 -yl)-1 -(3-fluorophenyl)-3-(methylamino)propan-2-ol; (1 S,2R)-1 -<7-chloro-5-methyl-1 H-pyrrolo[2,3-c]pyridin-1 -yl)-3-(methylamino)-1 -phenylpropan-2-ol; (1 S,2R)-1 -(5-methoxy-1 H-pyrrolo[2,3-c]pyridin-1 -yl)-3-(methylamino)-1 -phenylpropan-2-ol; (1S,2R)-1-(3-fluorophenyl)-1-(5-methoxy-1H-pyrrolot2,3-c]pyridin-1-yl)-3-(methylamino)propan-2-ol; (1S,2R)-3-(methylamino)-1-(5-methyl-1H-pyrrolo[2,3-c]pyridin-1-yl)-1-phenylpropan-2-ol; ;'2R)-1 -(3-fluorophenyl)-3-(methylamino)-1 -;'5-methyl-1 H-pyrrolo[2,3-c]pyridin-1 -yl)propan-2-ol; (1S,2R)-3-(methylamino)-1-(7-methyl-1H--pyrrolo[2,3--c)pyridin-1-yl)-1-phenylpropan-2-ol; cjpyridin-1 -yl)propan-2-ol; (1S,2R)-1-(3,3-diethyl-2,3-dihydro-1H-indol-1-yl)-1-(3-fluorophenyl)-3-(methylamino)propan-2-ol; (1S,2R)-1-(6-fIuoro-3,3-dimethyl-2r3-dihydro-1H-indol-1-yl)-1-(3-fluorophenyl)-3-(methylamino)propan -2-ol; (1S,2R)-1-(4-benzyl-3,4-dihydroquinoxalin-1(2H)-yl)-1-(3-fluorophenyl)-3-(methylamino)propan -2-ol; (1S,2R)-1-(5-fluoro-3,3-dimethyl-2,3-dihydro-1H-indol-1-yl)-1-(3-fluorophenyl)-3-(methylamino)propan-2-ol; (1S,2R)-1-(3-fluorophenyl)-3-(methylamino)-1-[(3S)-3-methyl-2,3-dihydro-1H-indol-1 -yl]propan-2-ol; (1S,2R)-1-(3-fluorophenyl)-3-(methylamino)-1-[(3R)-3-methyl-2,3-dihydro-1H-indol-1 -yllpropan-2-ol; (1S,2R)-1-(3-fluorophenyl)-1-(3-isopropyl-2,3-dihydro-1H-indol-1-yl)-3-(methylamino)propan-2-ol; (1 S,2R)-1-(3-ethyl-2,3-dihydro-1 H-indol-1 -yl)-1 -{3-fluorophenyl)-3-(methylamino)propan-2-ol; (1 S,2R)-1-(3-ethyl-2,3-dihydro-1 H-indol- 1 -yl)-3-(methylamino)-1 - phenylpropan-2-ol; • (1 S,2R)-1 -(3-isopropyl-2,3-dihydro-1 H-indol-1 -yl)-3-(methylamino)-1 -phenylpropan-2-ol; (1S,2R)-3-amino-1-(3,5-difluorophenyl)-1-(3,3-dimethyl-2,3-dihydro-1H-indol-1-yl)propan-2-ol; 1-t(1S,2R)-1-(3,5-difluorophenyl)-2-hydroxy-3-(methyiamino)propyl]-7-fluoro-3,3-dimethy!-1,3-dihydro-2H-indo!-2-one; 5,7-difluoro-1-[(1S,2R)-1-(3-fluorophenyl)-2-hydroxy-3-(methylamino)propyl]-S.S-dimethyl-I.S-dihydro^H-indol^-one; 1-t(fS';2R)-T-(3,5-aifluorophenyl)-2-hydroxy-3-(methylamino)propyl]-3,3-dimethyl-1,3-dihydro-2H-indol-2-one; 1 -[(1 S,2R)-2-hydroxy-3-(methylamino)-1 -phenylpropyl]-1 H-indol-5-ol; 1 -[(1 S,2R)-1 -(3-fluorophenyl)-2-hydroxy-3-(methylamino)propyl]-1 H-indol-5-ol: 5'-(benzyloxy)-r-[(1 S,2R)-2-hydroxy-3-(methylamino)-1 -phenylpropyljspiro{cyclohexane-1,3'-indolJ-2'( I 'H)-one; S^benzyloxyy-l-KIS^RJ^-hydroxy-S^methylaminoJ-l-phenylpropyll-S.S-dimethyl-1,3-dihydro-2H-indol-2-one; 1 -[(1 S,2R)-1 -(S-chlorophenyl^-hydroxy-S-^methylaminoJpropyll-T-fluoro-S.S-dimethyl-1,3-dihydro-2H-indo!-2~one; . (1 S,2f?)-1 -(3-chloro-5-fluorophenyl)-1 -(1 H-indol-1-yl)-3-(methylamino)propan-2~ol; 3-chloro-N-{1 -[(1 S,2R)-2-hydroxy-3-(methylamino)-1-phenylpropyl]-1 H-indol-5-yl}-4-methylbenzamide; 3-chloro-N-{1-[(1S,2R)-2-hydroxy-3-(methylamino)-1-phenylpropyl]-2,3-dihydro-1 H-indol-5-yl}benzamide; 3-chloro-N-{1 -[(1 S,2R)-2-hydroxy-3-(methylamino)-1-phenylpropyl]-1 H-indol-5-yl}benzamide; N-{1 -[(1 S,2R)-2-hydroxy-3-(methylamino)-1 -phenylpropyl]-2,3-dihydro-1 H-indol-5-yl}benzamide; N-{1 -[(1 S,2R)-2-hydroxy-3-(methylamino)-1 -phenylpropyl]-1 H-indol-5-yljbenzamide; N-{1 -1(1 S,2R)-2-hydroxy-3-(methylamino)-1-phenylpropyl>2,3-dihydro-1 H-indol-5-yl}cyclohexahecarboxamide; N-{1 -{(1 S,2R;>-2-hydroxy-3-(methylamirio)-1 -phenylpropyl]-1 H-indol-5-yi}cyclohexanecarboxamide; N-(3-chlorophenyl)-1 -[(1 S,2R)-2-hydroxy-3-(methylamino)-1 -phenylpropyl]indoline-5-carboxamide; N-(3-chlorophenyl)-1-l(1S,2R)-2-hydroxy-3-(methylamino)-1-phenylpropyl]-1 H-indo?e-5-carboxamide; (1S,2R)-3-(methylamino)-1-(6-phenoxy-1H-indol-1-yl)-1-phenylpropan-2-ol; (1 S,2R)-3-(methylamino)-1 -(7-phenoxy-1 H-indol-1 -yl)-1 -phenylpropan-2-ol, (1S,2R)-3-amino-1-[5-(benzyloxy)-1H-indol-1-yl]-1-phenylpropan-2-ol; (1S,2R)-1-[5-(benzyloxy)-1H-indol-1-yl]r1-phenyl-3-(propylamino)propan-2-oI; (1 S,2R)-1 -[5-(benzyloxy)-1 H-indol-1 -yl]-3-(isopropylamino)-1 -phenylpropan-2- ol; (1S,2R)-1-[5-(benzyloxy)-1H-indol-1-yl]-3-(dimethylamino)-1-phenylpropan-2- ol; (1 S,2R)-1 -[5-(benzy1oxy)-1 H-indol-1 -yi]-3-[ethyl(methyl)amino]-1 - phenylpropan-2-ol; (1S,2R)-1-[5-(benzyloxy)-1 H-indol-1-yl]-3-(diethylamino)-1-phenylpropan-2-ol; (1S,2R)-1-[5-(benzyloxy)-1 H-indol-1-yl]-1-phenyl-3-pyrrolidin-1-ylpropan-2-ol; (1 S,2R)-1-[5-(benzyloxy)-1 H-indol-1-yl]-1-phenyl-3-piperidin-1-ylpropan-2-ol; (1 S,2R)-1 -[5-(benzyloxy)-1 H-indol-1 -yl]-3-(4-methylpiperazin-1 -yl)-1 -phenylpropan-2-ol hydrochloride (1 S,2R)-3-(methylamino)-1 -phenyl-1 -[5-(pyridin-2-ylmethoxy)-1 H-indol-1-yl]propan-2-ol; (1 S,2R)-3-(methylamino)-1 -phenyl-1 -[5-(phenylethynyl)-1 H-indol-1 -yljpropan-2-ol; (1S,2R)-3-(methylamino)-1 -phenyl-1 ~[5-(2-phenylethyl)-1 H-indol-1 -yl]propan-2-ol; 1'-t(1S,2R)-3-amino-2-hydroxy-1-phenylpropyl]-6'-fluorospiro[cyclohexane-1,3'-indol]-2'(1'H)-one; 1 '-[(1 S,2R)-3-(ethylamino)-2-hydroxy-1 -phenylpropyl]-6'-fluorospiro[cydohexane-1,3-mdolj-2'(1 *H)-one; ' 6'-fiuoro-1 '-[(1 S,2R)-2-hydroxy-3-(isopropylamino)-1-' phenylpropyl]spiro[cyclohexane-1,3'-indol3-2'(1 'H)-one; e'-fluoro-r-KIS^R^-hydroxy-l-phenyl-S-(propylamino)propyl]spiro[cyclohexane-1,3'-indol]-2l(1'H)-one; 1 '-[(1 S,2R)-3-amino-2-hydroxy-1 -phenylpropyl]-5'-fluorospiro[cyclohexane-1,3'-indol]-2'(1'H)-one; 1 '-[(1 S,2R)-3-(ethylamino)-2-hydroxy-1 -phenylpropyl]-5'-fluorospiro[cyclohexane-1,3'-indol]-2'(1 'H)-one; 5'-fluoro-1 '-[(18,2R)-2-hydroxy-3-Osopropylamino)-1 -phenylpropyl]spiro[cyclohexane-1,3'-indol]-2'(1 'H)-one; 'S'-flubro-iq'(Ts;2'R:)-2-hydroxy-1-Phenyl-3-(propylaminoJpropyllspirolcyclohexane-I.S'-indolJ^XI'HJ-one; 1 '-[(1 S,2R)-3-(dimethylamino)-2-hydroxy-1 -phenylpropyl]-5'-fluorospiro[cyclohexane-1,3'-indol]-2'(1 'H)-one; 5'-fluoro-1 '-[(1 S,2R)-2-hydroxy-3-morpholin-4-yl-1 -phenylpropyljspiro[cyclohexane-1,3'-indolJ-2'(1 'H)-one; 1 '-[(1 S,2R)-2-hydroxy-3-(methylamino)-1 • phenylpropyl]-5'-methoxyspiro[cyclohexane-1 ,3'-indol]-2'(1 'H)-one; 1 '-[(1 S,2R)-2-hydroxy-3-(methylamino)-1 ~phenylpropyl]-6'-methoxyspiro[cyclohexane-1,3'-indol]-2'(1 'H)-one; 1 '-[(1 S,2R)-2-hydroxy-3-(methylamino)-1 -phenylpropyrj-2'-oxo-1 ',2'-dihydrospiro[cyclohexane-1,3'-indole]-5'-carbonitrile; 14(1 S,2R)-2-hydroxy-3-(methy!amino)-1 -phenylpropy^'-oxo-l', 2'-dihydrospiro[cyclohexane-1,3'-indole]-6'-carbonitrile; 4',5'-difluoro-14(1 S,2R)-2-hydroxy-3-(methylamino)-1-phenylpropyl]spiro[cyclohexane-1,3'-indol]-2'(1 'H)-one; 7'-fluoro-1 '-[(1 S,2R)-1 -(3-fluorophenyl)-2-hydroxy-3-(methylamino)propyl]spiro[cyclohexane-1,3'-indol]-2'(1 'H)-one; 14(1 S,2R)-1 -(3-chlorophenyl)-2-hydroxy-3-(methylamino)propyl]-6'-fluorospiro[cyclohexane-1,3'-indol]-2'(1'H)-one; 1 -[(1 S,2R)-1 -(3-chloro-5-fluorophenyl)-2-hydroxy-3-(methylamino)propyl]-7-fluoro-3,3-dimethyl-1,3-dihydro-2H-indol-2-one; (1S,2R)-1-<3-chloro-5-fluorophenyl)-1-(2,3-dihydro-1H-indol-1-yl)-3-(methylamino)propan-2-ol; (1S,2R)-1-(3-chloro-5-fluorophenyl)-1-(7-fIuoro-3,3-dimethyl-2,3-dihydro-1H-indol-1-yl)-3-(methylamino)propan-2-ol; (1S,2R)-1-(3-chloro-5-fluorophenyl)-1-(3,3-dimethyl-2,3-dihydro-1H-indol-1-yl)-3-(methylamino)propan-2-ol; 7'-fluoro-14(1 S,2R)-1 -(3-fluorophenyl)-2-hydroxy-3-(methylaminoJpropyl^piroJcyclobutane-I.S'-indoO^'CI'HJ-one; 7'-fluoro-14(1 S ,2R)-1 -(3-fluorophenyl)-2- hydroxy-3-(methylamino)propyl]spiro[cyclopentane-1 .S'-indolJ^XI 'H)-one; B-'l-lffS,2R5-T-(3-fluorophenyl)-2-hydroxy--3-(methylamino)propyl]-3,3-dimethyl-1,3-dihydro-2H-indol-2-one; (1S,2R)-1-(7-fluoro-2,3-dihydro-1H-indol-1-yl)-3-(methylamino)-1- phenylpropan-2-ol; 4-fluoro-3-[(1S,2R)-1-(3-fluorophenyl)-2-hydroxy-3-(methylamino)propyl]-1-phenyl-1,3-dihydro-2H-benzimidazol-2-one; 4-fluoro-1 -(3-fluorophenyl)-3-[(1 S,2R)-1 -(3-fluorophenyl)-2-hydroxy-3-(methylamino)propyl]-1,3-dihydro-2H-benzimidazol-2-one; 1-[(1S,2R)-3-arnino-1-(3,5-difluorophenyl)-2-hydroxypropyl]-7-fluoro-3,3-dimethyl-1,3-dihydro-2H-indoI-2-one; and pharmaceutically acceptable salts thereof, especially hydro-chloride salt. Some of the compounds of the present invention may contain chiral centers and such compounds may exist in the form of stereoisomers (;.e. enantiomers). The present invention includes all such stereoisomers and any mixtures thereof including •racemic mixtures. Racemic mixtures of the stereoisomers as well as the substantially pure stereoisomers are within the scope of the invention. The term "substantially pure," as used herein, refers to at least about 90 mole %, more preferably at least about 95 mole %, and most preferably at least about 98 mole % of the desired stereoisomer is present relative to other possible stereoisomers. Preferred enantiomers may be isolated from racemic mixtures by any method known to those skilled in the art, including high performance liquid chromatography (HPLC) and the formation and crystallization of chiral salts or prepared by methods described herein. Sese, for example, Jacques, et a/., Enantiomers, Racemat/9S and Resolutions (Wiley Interscience, New York, 1981); Wilen, S.H., et a/., Tetrahedron, 33:2725 (1977); Eliel, E.L. Stereochemistry of Carbon Compounds, (McGraw-Hill, NY, 1962); Wilen, S.H. Tables of Resolving Agents and Optical Resolutions, p. 268 (E.L. Eliel, Ed., University of Notre Dame Press, Notre Dame, IN 1972). i 'v;-j The present invention includes prodrugs of the compounds of formula I, II, or III. "Prodrug," as used herein, means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis) to a compound of formula I, II, or III. Various forms of prodrugs are known in the art, for example, as discussed in Bundgaard, (ea.), Design or nvarugs, Eisevier (1985); Widder, et al. (ed.), Methods in Enzymology, vol. 4, Academic Press (1985); Krogsgaard-Larsen, et al., (ed). "Design and Application of Prodrugs," Textbook of Drug Design and Development, Chapter 5, 113-191 (1991), Bundgaard, et al., Journal of Drug Deliver Reviews, 1992, 8:1-38, Bundgaard, J. of Pharmaceutical Sciences, 1988, 77:285 et seq.; and Higuchi and Stella (eds.) Prodrugs as Novel Drug Delivery Systems, American Chemical Society (1975). oi4«> Further, the compounds of formula I, II, or III may exist in unsolvated as well as in solvated forms with pharmaceutical/ acceptable solvents such as water, ethanoi, anc ihe like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purpose of the present invention. In certain embodiments, the compounds of formula I, II, or III specifically exclude the following compounds: 1-(1H-indol-1-yl)-3-(4-methylpiperazin-1--yl)-1-phenylpropan-2-ol; 1-(5-fluoro-1H-indol-1-yl)-3-(4-methylpiperazin-1-yl)-1-phenylpropan-2-ol; 1-(1H-indol-1-yl)-3-morpholin-4-yl-1-phenylpropan-2-ol; 3-(dimethylamino)-1-(1H-indol-1-yl)-1-phenylpropan-2-ol; 3-(ethylamino)-1-(1H-indol-1-yl)-1-phenylpropan-2-ol; 1 -(1 H-indol-1 -yl)-3-(isopropylamino)-1 -phenylpropan-2-ol; 3-(benzylamino)-1-(1H-indol-1-yl)-1-phenylpropan-2-ol; 3-[(cyclohexylrnethyl)amino]-1-(1H-indol-1-yl)-1-phenylpropan-2-ol; 3-[(cyclohexylrnethyl)amino]-1-(3-methyl-1H-indol-1i-yl)-1-phenylpropan-2-ol; 3-(isopropylamino)-1-(3-methyl-1 H-indol-1-yl)-1-phenylpropan-2-ol; 1 -(1 H-indol-1 -y!)-3-(methylamino)-1 -phenylpropan-2-ol; 3-(ethylamino)-1-(3-methyl-1 H-indol-1-yl)-1-phenylpropan-2-ol; 1-(1 H-indol-1 -yl)-1-phenyl-3-piperazin-1-ylpropan-2-ol di; 1-(1 H-indol-1-yl)-1-phenyl-3-[(pyridin-4-ylmethyl) amino]propan-2-ol; 1 -(5-chloro-1 H-indol-1 -yl)-1 -phenyl-3-piperidin-1 -ylpropan-2-ol; 1 -(1 H-indol-1 -yl)-3-(methylamino)-1 -phenylpropan-2-d; 3-amino-1 -(1 H-indol-1 -yl)-1 -phenylpropan-2-ol; 3-(ethylamino)»1 -(5-fluoro-1 H-indol-1 -yl)-1 -phenylpropan-2-ol; "'3-amlMb-1 -(5-fluorb-l H-indol-1 -yl)-1 -phenylpropan-2-ol; 1-(5-fluoro-1H-indol-1-yl)-3-(methylamino)-1-phenylpropan-2-ol; 3-(methylamino)-1-(3-methyl-1H-indol-1-yl)-1-phenylpropan-2-ol; 1-(1 H-indol-1 -yl)-3-(methylamino)-1 -phenylpropan-2-ol; 1 -(1 H-indol-1 -yl)-3-(methylamino)-1 -phenylpropan-2-ol; 3-amino-1 -(3-methyl-1 H-indol-1 -yl)-1 -phenylpropan-2-ol; 3-[ethyl(methyl)amino]-1-(1 H-indol-1 -yl)-1 -phenylpropan-2-ol; 1-(5-chloro-1H-indol-1-yl)-3-(methylamino)-1 -phenylpropan-2-ol; 1-(5-chloro-1H-indol-1-yl)-3-(methylamino)-1-phenylpropan-1-ol; 1 -[2-hydroxy-3-(methylamino)-1 -phenylpropyl]-1 H-indole-3-carbonitri!e; 1-(1 H-indol-1 -yl)-3-(methylamino)-1-phenyipropan-2-ol; 1 -(1 H-indol-1 ~yl)-3-(methylamino)-1 -phenylpropan-2-ol; 3-(methylamino)-1-(3-methyl-1H-indol-1-yl)-1-phenylpropan-2-ol; 1 -(3-chlorophenyl)-1 -(1 H-indol-1 -yl)-3-(methylamino)propan-2-ol; 1-(4-chlorophenyl)-1-(1 H-indol-1-yl)-3-(methylamino)propan-2-ol; 1-(1 H-indol-1-yl)-3-(methylamino)-1-[3-(trifluoromethoxy)phenyl]propan-2-ol; 1-(1H-indol-1-yl)-3-(methylamino)-1-[2-(trifluoromethoxy)phenyl]propan-2-ol; 1 -(1 H-indol-1 ~yl)-3-(methylamino)-1 -[2-(trifluoromethoxy)phenyl]propan-2-ol; 1-(2-chlorophenyl)-1-(1H-indol-1-yl)-3-(methylamino)propan-2-ol; 1 -(1 H-indol-1 -yl)-3-(methylamino)~1 -[4-(trifluoromethoxy)phenyl]propan-2-ol; 1-(1H-indol-1-yl)-3-(methylamino)-1-[4-(trifluoromethoxy)phenyl]propan-2-ol; 1 -(1 H-indol-1 -yl)-3-(methylamino)-1 -[4-(trifluoromethoxy)phenyl]propan-2-ol; 4-amino-1-(3-chlorophenyl)-1-(1H-indol-1-yl)butan-2-ol 1-(3-bromophenyl)-1-(1H-indol-1ryl)-3-(methylamino)propan-2-ol; 3-{2-hydroxy-1 -(1 H-indol-1 -yl)-3-(methylamino)propyl]benzonitrile 1-(3-fluorophenyl)-1-(1H-indol-1-yl)-3-(methylamino)propan-2-ol; 1 -{3-fluorophenyl)-3-(methylamino)-1 -[3-(3-methylphenyl)-1 H-indol-1 -yl]propan-2-ol; 1-(4-fluorophenyl)-3-(methylamino)-1-(3-methyl-1 H-indol-1-yl)propan-2-ol; 1-(2-fluorophenyl)-1-(1H-indol-1-yl)-3-(methylamino)propan-2-ol; 1-(4-fluorophenyl)-1-(1H-indol-1-yl)-3-(methylamino)propan-2-ol; 1 -{1 H-indol-1 -yl)-3-(methyIamino)-1 -(3-methylphenyl)propan-2-ol; 1-(1H-indol-1-yl)-3-(methylamino)-1-(2-methylphenyl)propan-2-ol; ^W-ind6l-T-y[)-3-Tmethylamino)-1-(2-methylpheRyl)propan-2-ol; 3-(ethylamino)-1-(3-fluorophenyl)-1-(1H-indol-1-yl)propan-2-ol; 1 -(3-fluorophenyl)-1 -(1 H-indol-1 -yl)-3-morpholin-4-ylpropan-2-ol; 1 -(3-fluorophenyl)-1 -(1 H-indol-1 -yl)-3-(propylamino)propan-2-ol; 1 -(3-fluorophenyl)-1 -(1 H-indol-1 -yl)-3-(4-methylpiperazin-1 -yl)propan-2-ol; 1 -(1 H-indol-1 -yl)-3-(methylamino)-1 -(4-methylphenyl)propan-2-ol, 1-(2,3-dihydro-1 H-indol-1 -yl)-1-(3-fluorophenyl)-3-(methylamino)propan-2-ol; 1 -(2,3-dihydro-1 H-indol-1 -yl)-3-{methyIamino)-1 -phenylpropan-2-ol; 1 -(3-fluorophenyl)-3-(methylamino)-1 -[3-(2-methylphenyl)-1 H-indol-1 -yl]propan-2-ol; 1-(3-fluorophenyl)-3-(methylamino)-1-(2-methyl-2,3-dihydro-1H-indol-1-yl)propan-2-ol; H7-fluoro-3,3"dimethyl-2,3-dihydro-1 H-indol-1-yl)-1-(3-fluorophenyl)-3-(methylamino)propan-2-ol; 1-(T-fluoro-S.S-dimethyl^.S-dihydro-l H-indol-1-yl)-3-(methylamino)-1-phenylpropan-2-ol; 3-{methylamino)-1-(7-methyl-2,3-dihydro-1 H-indol-1 -yl)-1 -phenylpropan-2-ol; 1-(3-fluorophenyl)-3-(methylamino)-1-(7-methyl-2,3-dihydro-1H-indol-1-yl)propan-2-ol; 1 -(3-fluorophenyl)-3-(methylamino)-1 -(5-methyl-2,3-dihydro-1 H-indol-1-yl)propan-2-ol; 1 -(1 H-indol-1 -yl)-1 -(3-methoxyphenyl)-3-(methylamino)propan-2-ol; 1 -(1 H-indol-1 -yl)-1 -(4-methoxyphenyl)-3-(methylamino)propan-2-ol; 3-(methylamino)-1 -(2-methyl-1 H-indol-1 -yl)-1 -phenylpropan-2-ol; 1-(1H-benzimidazol-1-yl)-3-{methylamino)-1-phenylpropan-2-ol; 3-(methylamino)-1-(2-methyl-1H-ben2imida2ol-1-yl)-1-phenylpropan-2-ol; 1 -(4-methoxy-1 H-indol-1 -yl)-3-(methylamino)-1 -phenylpropan-2-ol; 1 -(5-fluoro-1 H-indol-1 -yl)-3-(methylamino)-1 -phenylpropan-2-ol; 1-(5-methoxy-1H-indol-1-yl)-3-(methylamino)-1-phenylpropan-2-ol; 1-(7-methoxy-1 H-indol-1 -yl)-3-(methylamino)-1-phenylpropan-2-ol; 1-(4-methoxy-1H-indol-1-yl)-3-(methylamino)-1-phenylpropan-2-ol; 1 -(6-methoxy-1 H-indol-1 -yl)-3-(methylamino)-1 -phenylpropan-2-ol; 1 -(5-methoxy-1 H-indol-1 -yl)-3-(methylamino)-1 -phenylpropan-2-ol; i;l-^tl'6ropHeny(}-r-(6-methoxy-1 H-indol-1 -yl)-3-(methylamino)propan-2-ol; 3-(methylamino)-1-phenyl-1-(1H-pyrrolo[2,3-b]pyridin-1-yl)propan-2-ol; 1 -(5-chloro-2,3-dihydro-1 H-indol-1 -yl)-1 -(3-fluorophenyl)-3-(methylamino)propan-2-ol; 3-(methylamino)-1-phenyl-1-(1H-pyrrolo[2,3-c]pyridin-1-yl)propan-2-ol; I -(5-fiuoro-1 H-indol-1 -yl)-1 -(3-fluorophenyl)-3-(methyldmino)propan-2-oi, 3-(methylamino)-1-(3-fluorophenyl)-1-(1H-pyrrolo[2,3-c]pyridin-1-yl)propan-2- ol; 1-(5-chloro-2,3-dihydro-1 H-indol-1-yl)-3-(methylamino)-1-phenylpropan-2-ol; 3-(methylamino)-1-(6-methyl-1H-indot-1-yl)-1-phenylpropan-2-ol; 3-(methylamino)-1-(7-methyl-1H-indol-1-yl)-1-phenylpropan-2-ol; 1 -(3-fluorophenyl)-3-(methylamino)-1 -(5-methyl-1 H-indol-1 -yl)propan-2-ol; 1-(3-fluorophenyl)-3-(methylamino)-1-(7-methyl-1 H-indol-1-yl)propan-2-ol; 3-(methylamino)-1 -(4-methyl-1 H-indol-1 -yl)-1 -phenylpropan-2-ol; 3-(methylamino)-1-(5-methyl-1 H-indol-1-yl)-1-phenylpropan-2-ol; 1 -(3-fluorophenyl)-3-(methylamino)-1 -(4-methyl-1 H-indol-1 -yl)propan-2-ol; 1 -(3-ethyl-1 H-indol-1 -yl)-1 -(3-fluorophenyl)-3-(methylamino)propan-2-ol; 1 -(3-fluorophenyl)-3-(methylamino)-1 -(3-phenyl-1 H-indol-1 -yl)propan-2-ol; 7-fluoro-1 -[2hydroxy-3-(methylamino)-1 -phenylpropyl]-3,3-dimethyM,3-dihydro-2H-indol-2-one; 1 -[2hydroxy-3-(methylamino)-1 -phenylpropyl]-3,3-dimethyl-1,3-dihydro- 2H-indol-2-one; 7-fluoro-1 -{1 -(3-fluorophenyl)-2-hydroxy-3-{methylamino)propyl]-3,3- dimethyl-1,3-dihydro-2H-indol-2-one; 1 -(1 H-indol-1 -yl)-3-(methylamino)-1 -(2-thienyl)propan-2-ol; 1 (1 H-indol-1 -yl)-3-(methylamino)-1 -(2-thieny!)propan-2-ol; 1'-[2-hydroxy-3-(methylamino)-1-phenylpropylJspiro[cyclohexane-1,3'-indol]-2'(1'H)-one; 2-(3-fluorophenyl)-2-(1 H-indol-1 -yl)-1-[(2S)-pyrrolidin-2-yl]ethanol; 2-(3-fluorophenyl)-2-(1 H-indol-1 -yl)-1 -[pyrrolidin-2-yl]ethanol; 1 '-[2hydroxy-3-(methylamino)-1 -phenylpropyl]spiro[cyclobutane-1,3-indol]-2'(1'H)-one; 1 '-"[2riy'dfoxy-3-(m8tllylamino)-1 -phenylpropyl]spiro[cyciopentane-1 ,3'-indol]- 2'(1'H)-one; 1 '-[2hydroxy-3-(methylamino)-1 -phenylpropyl]spiro[cyciopropane-1 ,3'-indol]- 2'(1'H)-one; 5-fluoro-1 -[2hydroxy-3-(methylamino)-1 -phenylpropy)]-3,3-dimethyl-1 ,3-dihydro-2H-indol-2-one, 3-(cyclopropylamino)-1 -{3-fluorophenyl)-1 -(1 H-indol-1 -yl)propan-2-ol; T'-fluoro-l'-phydroxy-S-CmethylaminoJ-l-phenylpropyllspirofcyclohexane-l.a1- 5'-bromo-1t-[2hydroxy-3-3-dihydro-4H-1,4-benzoxazin-4-yl)-3-(methy!amino)-1-phenylpropan-2-ol; 1 -(6-chloro-2,3-dihydro-4H-1,4-benzoxazin-4-yl)-1 -(3-fluorophenyl)-3~ (methylamino)propan-2-ol; T-'(2,'2-ciimethyl-2,3-dihydro-4H-1(4-benzoxazin-4-yl)-1-(3-fluorophenyl)-3-(methylamino)propan-2-ol; 1 -(2,2-dimethyl-2,3-dihydro-4H-1,4-benzoxazin-4-yl)-3-(methylamino)-1 -phenylpropan-2-ol; 1 -(2,3-dihydro-4H-1,4-benzothiazin-4-yl)-1 -(3-fluorophenyl)-3-(methylamino)propan--2-ol, 1 -(3-fluoropheriyl)-3-(methylamino)-1 -(2-phenyl-2,3-dihydro-4H-1,4-benzoxazin-4-yl)propan-2-ol; 1-(3-fluorophenyl)-3-(methylamino)-1-[2-phenyl-2,3-dihydro-4H-1,4-benzoxazin-4-yl]propan-2-ol; 1 -(3-fluorophenyl)-3-(methylamino)-1 -[2-phenyl-2,3-dihydro-4H-1,4-benzoxazin-4-yl]propan-2-ol; and pharmaceutically acceptable salts thereof. The compounds of the present invention may be prepared in a number of ways well known to those skilled in the art. The compounds can be synthesized, for example, by the methods described below, or variations thereon as appreciated by the skilled artisan. All processes disclosed in association with the present invention are contemplated to be practiced on any scale, including milligram, gram, multigram, kilogram, multikilogram or commercial industrial scale. As will be readily understood, functional groups present may contain protecting groups during the course of synthesis. Protecting groups are known per se as chemical funcbonal groups that can be selectively appended to and removed from functionalities, such as hydroxyl groups and carboxyl groups. These groups are present in a chemical compound to render such functionality inert to chemical reaction conditions to which the compound is exposed. Any of a variety of protecting groups may be employed with the present invention. Protecting groups that may be employed in accordance with the present invention may be described in Greene, T.W. and Wuts, P.G.M., Protective Groups in Organic Synthesis 2d. Ed., Wiley & Sons, 1991. "-•""'"Co'rn'pouncts 6'fffie present invention are suitably prepared in accordance with the following general description and specific examples. Variables used are as defined for formula I, unless otherwise noted. The reagents used in the preparation of the compounds of this invention can be either commercially obtained or can be prepared by standard procedures described in the literature. -> The compounds of this invention contain chiral centers, providing various stereoisomeric forms such as enantiomeric mixtures as well as optical isomers. The individual optical isomers can be prepared directly through asymmetric and/or stereospecific synthesis or by conventional chiral separation of optical isomers from the enantiomeric mixture. The compounds of the present invention may be prepared in a number of ways well known to those skilled in the art. The compounds can be synthesized, for example, by the methods described below, or variations thereon as appreciated by the skilled artisan. All processes disclosed in association with the present invention are contemplated to be practiced on any scale, including milligram, gram, multigram, kilogram, multikilogram or commercial industrial scale. Compounds of the present invention are suitably prepared in accordance with the following general description and specific examples. Variables used are as defined for formula I, unless otherwise noted. The reagents used in the preparation of the compounds of this invention can be either commercially obtained or can be prepared by standard procedures described in the literature. The compounds of this invention contain chiral centers, providing various stereoisomeric forms such as enantiomeric mixtures as well as optical isomers. The individual optical isomers can be prepared directly through asymmetric and/or stereospecific synthesis or by conventional chiral separation of optical isomers from the enantiomeric mixture. As will be readily understood, functional groups present may contain protecting groups during the course of synthesis. Protecting groups are known per se as chemical functional groups that can be selectively appended to and removed frt>rft1fuKcWo1ial1SeCsOcK''as'hydroxyl groups and carboxyl groups. These groups are present in a chemical compound to render such functionality inert to chemical reaction conditions to which the compound is exposed. Any of a variety of protecting groups may be employed with the present invention. Protecting groups that may be employed in accordance with the present invention may be described in Greene, T.W. and Wuts, P.G.M., Protective Groups in Organic Synthesis 2d. Ed., Wiley & Sons, 1991. i In accordance with this invention, compounds of formula \ are produced by the following reaction schemes (Schemes /to /V) Depending on the desired diastereomer, the compounds can be prepared via two different synthetic routes (A and B, Schemes / and II). If it is desired to synthesize compounds of formula l-a. they can be prepared from compounds of formula 1 by selectively converting the primary alcohol into a leaving group and displacing it with a desired amine. (Route A, Scheme /) Any conventional method for the selective conversion of a primary alcohol into a leaving group, and any conventional method for displacing a primary leaving group with an amine can be utilized for this conversion. In accordance with the preferred embodiment of this invention, the diol of formula 1. is treated with para-toluenesulfonyl chloride in pyridine to form the tosylate of formula 2, which is converted to the compound of formula jki through treatment with an excess of alcoholic amine solution, either at room temperature or heated to about 40°C to about 80°C in a sealed tube. Compounds of formula Ua can be converted to a pharmaceutically acceptable salt using any conventional method. Scheme I (Scheme Removed) Where: A, X, Y, Z, RI, m, R2, R4, Re, Rg, Rio, Rn are as previously described. R3 = Ci-C-4 lower alkyl, P = protecting group; preferably trimethylsilyl, tert-butyldimethylsilyl, pa/a-nitrobenzoyl; and OTs = para-toluenesulfonylate or any conventional leaving group If it is desired to form compounds of formula l-aa. they can be prepared from compounds of formula 1 via selective protection of the primary alcohol, followed by alkylation of the secondary alcohol, and deprotection of the primary alcohol. Any conventional alcohol protecting groups can be utilized for this conversion and any method for the selective protection of a primary alcohol can be employed. According to the preferred embodiment of this invention, the reaction is carried out at low temperature in dichloromethane with trimethylsilyl chloride and triethylamine as base to form compounds of formula 3. Alkylation of the secondary alcohol can be iccomplished via any conventional method of alkylating a secondary alcohol found i the literature. According to the preferred embodiment of this invention, >mpounds of formula 3 are reacted with an alkyl halide using sodium hydride as se to form compounds of formula 4, which can be deprotected to form compounds formula 5 via any conventional method for deprotection of a primary alcohol. ording to the preferred embodiment of this invention, compounds of formula 4 treated with dilute aqueous hydrochloric acid or trifluorbacetic acid in archlbrSmetrfahe to torm compounds of formula 5. Conversion of the primary alcohol in compounds of formula 5 to complete the synthesis of compounds of formula l-aa can be performed as previously described for the synthesis of compounds of formula Isa. Compounds of formula l-aa can be converted to a pharmaceutically acceptable salt using any conventional method. u . v.s Alternatively, compounds of formula 6 can be prepared directly from compounds of formula 2. Any method of alkylating a hydroxyl group in the presence of a tosyl group can be employed for this conversion. In accordance with the preferred embodiment of this invention, compounds of formula 2 are treated with an alkyl trifluoromethanesulfonate, e.g. methyl trifluoromethanesulfonate, in the presence of a hindered base, e.g. 2,6-di-terf-buty!-4-methylpyridine. The reaction can be performed either at room temperature or heated to about 40°C to about 80°C. Compounds of formula 6 can be converted to compounds of formula l-aa as previously described for the synthesis of compounds of formula l-a. Compounds of formula l-aa can be converted to a pharmaceutically acceptable salt using any conventional method. j If it is desired to form compounds of l-b, they can also be prepared from compounds of formula 1 via Route B (Scheme //). This route involves the selective protection of the primary alcohol followed by conversion of the secondary alcohol to a leaving group. Any conventional method for the selective protection of a primary alcohol, and any conventional method for converting of a secondary alcohol into a leaving group can be utilized for this conversion. In accordance with the preferred embodiment of this invention, compounds of formula ± are treated with para- nrtrobenzoyl chloride in pyridine at low temperature (preferably below about 0°C) to form compounds of formula 7. Compounds of formula 7 can be converted to a secondary mesylate of formula 8 via reaction with methanesulfonyl chloride in dichloromethane using triethylamine as base. The reaction is preferably carried out at temperatures between about -15°C and about 10°C. Deprotection of the primary alcohol in compounds of formula 8 allows for the formation of a primary epoxide through an Ss2 reaction resulting in an inversion of the stereocenter. Any conventional method for deprotection of a primary alcohol, and any conventional m6thoa'>f6Yl'"ep"&5{ide'15rf^tTdn onto an alpha leaving group can be employed for this diversion. In accordance with the preferred embodiment of this invention, compounds of formula 8 are treated with an aqueous solution of a suitable base in organic solvent, preferably, aqueous sodium hydroxide in dioxane. The resulting epoxide of formula 9 can be ring-opened regioselectively with an amine to produce the dssirsd aminoalcohol of formula !-b. Any conventional method for the regioselective ring opening of a primary epoxide can be employed for this conversion. In accordance with the preferred embodiment of this invention, compounds of formula 9 are treated with an excess of an alcoholic amine solution in a sealed flask, either at room temperature or heated to about 40°C to about 90°C. Compounds of formula l-b can be converted into a pharmaceutically acceptable salt using conventional methods. Scheme // (Scheme Removed) Where: A, X, Y. Z, Ri, m, R2, and R4, Re, RIO, Rn are as previously described RsisH PNB = para-nitrobenzoyl or any conventional protecting group; and OMs = methanesulfonate or any conventional leaving group If it is desired to form compounds of formula l-bb. they can be made from compounds of formula Ub via protection of the amine, alkylation of the secondary alcohol and deprotection of the amine (Scheme III). Any conventional method for protection of an amine, alkylation of a secondary alcohol, and deprotection of an amine can be utilized for this conversion. In accordance with the preferred embodiment of this invention, compounds of formula I4> are treated with boc anhydride, where boc = tert-butoxycarbonyl, to form compounds of formula 10 whicr can be alkylated with an alkyl halide using sodium hydride as base to forrr compounds of formula 1M.. Deprotection is accomplished using an acid, preferably trifluoroacetic acid in dichlorornethane to form compounds of formula l-bb that car be converted into a pharmaceutically acceptable salt using conventional methods. Scheme /// (Scheme Removed) Where: A, X, Y, Z, Ri, m, R2, and R4, RS, Rio, Rn are as previously described R9isH R3 = Ci-C3 lower alkyl, P = protecting group, preferably tert-butoxycarbonyl Compounds of formula ± are formed via a regio- and stereo-selective ring opening of an appropriately substituted epoxide of formula 13 (formed via an epoxidation of an appropriately substituted allylic alcohol 14) with an appropriately substituted compound of formula 12 (Scheme IV). Any conventional method for the regio- and stereo-selective ring opening of an epoxide can be employed for this conversion. In accordance with the preferred embodiment of this invention, compounds of formula ,12 are treated with a base, e.g. sodium hydride, sodium tert-butoxide, potassium hydroxide, potassium tert-butoxide or potassium hydroxide, then treated with the epoxide of formula 13. The epoxide of formula 13_ can be pre-treated with a Lewis acid, e.g. titanium /so-propoxide, boron-trifluoride, etc., to ensure regio-selective ring-opening. The reaction occurs at room temperature over a duration of about 2 hours to about 72 hours. Alternatively, compounds of formula 12 that are suitably nucleophilic, e.g. indoline, can be heated with the epoxide of formula 13 at temperatures from about 50°C to about 170°C to form compounds of formula 1. Epoxidation of traris-allylic alcohols .14 can be performed either racemically or asymmetrically using methods described in the literature. In accordance with the 'p^eterreH'emBbdiment oHHis invention, racemic epoxidation is conducted with either peracetic acid or mefa-chloroperbenzoic acid. If it is desired to produce a single enantiomer of compounds of formula I, asymmetric epoxidation of an allylic alcohol can be performed with terf-butylhydroperoxide or cumene hydroperoxide in the presence of the appropriate tartrate ester, titanium (IV) isopropoxide, and molecular sieves. This method is well established in the literature (e.g. K. B. Sharpless, et. a/., J. Org. Chem. 1986, 51, 3710). Compounds of formula 12 and the starting allylic alcohols 14 are either available from commercial sources or are accessible through methods well established in the literature. Scheme IV(Scheme Removed) -OH RIO Rio Where: A, X, Y, Z, RI, m, R2, Ra, Rg, RIO and RH are as previously described. In accordance with this invention, compounds of formula II are produced by the following reaction schemes (Schemes V to VIII). Depending on the desired diastereomer, the compounds can be prepared via two different synthetic routes (A and B, Schemes Vand VI). If it is desired to synthesize compounds of formula tl-a. they can be prepared from compounds of formula 15 by selectively converting the primary alcohol into a leaving group and displacing it with a desired amine. (Route A, Scheme V) Any conventional method for the selective conversion of a primary alcohol into a leaving group, and any conventional method for displacing a primary leaving group with an amine can be utilized for this conversion. In accordance with the preferred embodiment of this invention, the diol of formula 15 is treated with para-toluenesulfonyl chloride in pyridine to form the tosylate of formula 16, which is converted to the compound of formula ll-a through treatment with an excess of alcoholic arriine sclution, either at room temperature or heated to about 40°C co about 80°C in a sealed tube. Compounds of formula j)-a can be converted to a pharmaceutically acceptable salt using any conventional method. (Scheme Removed) '. If it is desired to form compounds of formula ll-aa, they can be prepared from compounds of formula 15 via selective protection of the primary alcohol, followed by alkylation of the secondary alcohol, and deprotection of the primary alcohol. Any conventional alcohol protecting groups can be utilized for this conversion and any method for the selective protection of a primary alcohol can be employed. According to the preferred embodiment of this invention, the reaction is carried out at low temperature in dichloromethane with trimethylsilyl chloride and triethylamine as base to form compounds of formula 1£. Alkylation of the secondary alcohol can be accomplished via any conventional method of alkylating a secondary alcohol found in the literature. According to the preferred embodiment of this invention", "eorhpounds of formula 1? are reacted with an alkyl halide using sodium hydride as base to form compounds of formula 18, which can be deprotected to form compounds of formula 19 via any conventional method for deprotection of a primary alcohol. According to the preferred embodiment of this invention, compounds of formula 18 are treated with dilute aqueous hydrochloric acid or trifluoroacetic acid in clichloromethane to form compounds or" formula |9. Conversion of the primary alcohol in compounds of formula 19 to complete the synthesis of compounds of formula ll-aa can be performed as previously described for the synthesis of compounds of formula II^i. Compounds of formula ll-aa can be converted to a pharmaceutically acceptable salt using any conventional method. Alternatively, compounds of formula 20 can be prepared directly from compounds of formula 1.6. Any method of alkylating a hydroxyl group in the presence of a tosyl group can be employed for this conversion. In accordance with the preferred embodiment of this invention, compounds of formula 1j> are treated with an alkyl trifluoromethanesulfonate, e.g. methyl trifluoromethanesulfonate, in the presence of a hindered base, e.g. 2,6-di-terf-butyl-4-methylpyridine. The reaction can be performed either at room temperature or heated to about 40°C to about 80°C. Compounds of formula 20 can be converted to compounds of formula ll-aa as previously described for the synthesis of compounds of formula Ilia. Compounds of formula ll-aa can be converted to a pharmaceutically acceptable salt using any conventional method. f .o. If it is desired to form compounds of ll-b, they can also be prepared from compounds of formula 15 via Route B (Scheme \fl). This route involves the selective protection of the primary alcohol followed by conversion of the secondary alcohol to a leaving group. Any conventional method for the selective protection of a primary alcohol, and any conventional method for converting of a secondary alcohol into a leaving group can be utilized for this conversion. In accordance with the preferred embodiment of this invention, compounds of formula 15 are treated with para-nitrobenzoyl chloride in pyridine at low temperature (preferably below about 0°C) to form compounds of formula 21. Compounds of formula 2J. can be converted to a secondary mesylate of formula 22 via reaction with methanesulfonyl chloride in "dichldfomethahe using"tfMhylamine as base. The reaction is preferably carried out at temperatures between about -15°C and about 10°C. Deprotection of the primary alcohol in compounds of formula 22 allows for the formation of a primary epoxide through an SN2 reaction resulting in an inversion of the stereocenter. Any conventional method for deprotection of a primary alcohol, and any conventional method for epoxide formation onto an alpha leaving group can be employed for this conversion. In accordance with the preferred embodiment of this invention, compounds of formula 22 are treated with an aqueous solution of a suitable base in organic solvent, preferably, aqueous sodium hydroxide in dioxane. The resulting epoxide of formula 23 can be ring-opened regioselectively with an amine to produce the desired aminoalcohol of formula ll-b. Any conventional method for the regioselective ring opening of a primary epoxide can be employed for this conversion. In accordance with the preferred embodiment of this invention, compounds of formula 23 are treated with an excess of an alcoholic amine solution in a sealed flask, either at room temperature or heated to about 40°C to about 90°C. Compounds of formula ll-b can be converted into a pharmaceutically acceptable salt using conventional methods. Scheme 1/7 (Scheme Removed) Where: A, D, E, G, q, R2, and R4, F^, R10, and R14 are as previously described; Rs isH PNB = para-nitrobenzoyl or any conventional protecting group; and OMs = methanesulfonate or any conventional leaving group * If Ifis"desired to tofrrfcornpounds of formula U-bb. they can be made from compounds of formula ]Mo via protection of the amine, alkylation of the secondary alcohol and deprotection of the amine (Scheme VII). Any conventional method for protection of an amine, alkylation of a secondary alcohol, and deprotection of an amine can be utilized for this conversion. In accordance with the preferred embodiment of this invention, compounds or formula 1U> are treated with boc anhydride, where boc = tert-butoxycarbonyl, to form compounds of formula 24 which can be alkylated with an alkyl halide using sodium hydride as base to form compounds of formula 25. Deprotection is accomplished using an acid, preferably trifluoroacetic acid in dichlnromethane to form compounds of formula ll-bb that can be converted into a pharmaceutically acceptable salt using conventional methods. Scheme VII (Scheme Removed) Where: A, D, E, G, q, Fk, and RA, Re, Rio, and Ru are as previously described; R9 is H Rz = CrC3 lower alkyl, P = protecting group, preferably tert-butoxycarbonyl Compounds of formula 15 are formed via a regio- and stereo-selective ring opening of an appropriately substituted epoxide of formula 13 (formed via an epoxidation of an appropriately substituted allylic alcohol 14) with an appropriately substituted compound of formula 26 (Scheme IV). Any conventional method for the regio- and stereo-selective ring opening of an epoxide can be employed for this conversion. In accordance with the preferred embodiment of this invention, compounds of formula 26 are treated with a base, e.g. sodium hydride, sodium tert- ' Potassium terf-butoxide or potassium hydroxide, then treated with the epoxide of formula 13. The epoxide of formula .13 can be pre-treated with a Lewis acid, e.g. titanium /so-propoxide, boron-trifluoride, etc. to ensure regio-selective ring-opening. The reaction occurs at room temperature over a duration of about 2 hours to about 72 hours. Alternatively, compounds of formula 26 that are suitably nucleophilic, e.g. indoline, can be heated with the epoxide of formula 13 at temperatures from about 50°C to about 170°C to form compounds of formula 15. Epoxidation of trans-allylic alcohols 14 can be performed either racemically or asymmetrically using methods described in the literature. In accordance with the preferred embodiment of this invention, racemic epoxidation is conducted with either peracetic acid or mefa-chloroperbenzoic acid. If it is desired to produce a single enantiomer of compounds of formula H, asymmetric epoxidation of an allylic alcohol can be performed with te/f-butylhydroperoxide or cumene hydroperoxide in the presence of the appropriate tartrate ester, titanium (IV) isopropoxide, and molecular sieves. This method is well established in the literature (e.g. K. B. Sharpless, et a/., J. Org. Chem. 1986, 51, 3710). Compounds of formula 26 and the starting allylic alcohols ,13_ are either available from commercial sources or are accessible through methods well established in the literature. Scheme VIII(Scheme Removed) Pftere/ u&A!BrBra'ri""SN2'"fe"aClti'd'rf""resulting in an inversion of the stereocenter. Any conventional method for deprotection of a primary alcohol, and any conventional method for epoxide formation onto an alpha leaving group can be employed for this conversion. In accordance with the preferred embodiment of this invention, compounds of formula 34 are treated with an aqueous solution of a suitable base in organic solvent, preferably, aqueous sodium hydroxide in dioxane. The resulting epoxide of formula 35 can be ring-opened regioselectively with an amine to produce the desired aminoalcohol of formula Ul-b. Any conventional method for the regioselective ring opening of a primary epoxide can be employed for this conversion. In accordance with the preferred embodiment of this invention, compounds of formula 35 are treated with an excess of an alcoholic amine solution in a sealed flask, either at room temperature or heated to about 40°C to about 90°C. Compounds of formula lil-b can be converted into a pharmaceutically acceptable salt using conventional methods. Scheme X(Scheme Removed) Where: A, Y, Z, R-i, q, R2> and R4, Re, and R10 are as previously described. RgisH PNB = para-nitrobenzoyl or any conventional protecting group; and OMs = methanesulfonate or any conventional leaving group , .If it is desired to form compounds of formula Ill-bb. they can be made from compounds of formula H>-b via protection of the amine, alkylation of the secondary alcohol and deprotection of the amine (Scheme XI). Any conventional method for protection of an amine, alkylation of a secondary alcohol, and deprotection of an '"dt!tfze"d"" fo'r this conversion. In accordance with the preferred embodiment of this invention, compounds of formula Ill-b are treated with boc anhydride, where boc = tert-butoxycarbonyl, to form compounds of formula 36 which can be alkylated with an alkyl halide using sodium hydride as base to form compounds of formula 37. Deprotection is accomplished using an acid, preferably trirluoroacetic acid in dichloromethane to form compounds of formula iil-bb that can be converted into a pharmaceutically acceptable salt using conventional methods. Scheme XI(Scheme Removed) Where: A, Y, Z, Ri, q, R2, RA, Ra, and Rio are as previously described Rgis H Ra = Ci-C3 lower alkyl, P = protecting group, preferably tert-butoxycarbonyl Compounds of formula 27 are formed via a regie- and stereo-selective ring opening of an appropriately substituted epoxide of formula 13> (formed via an epoxidation of an appropriately substituted allylic alcohol 14) with an appropriately substituted compound of formula 38 (Scheme Xlf). Any conventional method for the regio- and stereo-selective ring opening of .an epoxide can be employed for this conversion. In accordance with the preferred embodiment of this invention, compounds of formula 38 are treated with a base, e.g. sodium hydride, sodium tert-butoxide, potassium hydroxide, potassium tert butoxide or potassium hydroxide, then treated with the epoxide of formula 13. The epoxide of formula 13 can be pre-treated with a Lewis acid, e.g. titanium /so-propoxide, boron-trifluoride, etc. to ensure fe'gi6-si!lfetitiVe'"rlr1fg-'6f5"erii-tg. The reaction occurs at room temperature over a duration of about 2 hours to about 72 hours. Alternatively, compounds of formula 38 that are suitably nucleophilic, e.g. indoline, can be heated with the epoxide of formula 13 at temperatures from about 50°C to about 170°C to form compounds of formula 27. Epoxidation of trans-allylic alcohols 14 can be performed either racemically or asymmetrically using methods described in the literature. In accordance with the preferred embodiment of this invention, racemic epoxidation is conducted with either psracatic acid or msfa-chloroperbenzoic acid. If it is desired to produce a single enantiomer of compounds of formula I, asymmetric epoxidation of an allylic alcohol can be performed with terf-butylhydroperoxide or cumene hydroperoxide in the presence of the appropriate tartrate ester, titanium (IV) isopropoxide, and molecular sieves. This method is well established in the literature (e.g. K. B. Sharpless, ef. a/., J. Org. Chem. 1986, 51, 3710). Compounds of formula 38 and the starting allylic alcohols 44 are either available from commercial sources or are accessible through methods well established in the literature. Scheme XII (Scheme Removed) Where: A, Y, Z, R1( q, R2l R8, Rg, and RIO are as previously described. In other embodiments, the invention is directed to pharmaceutical compositions, comprising: a. at least compound of formula I, II, or III, or pharmaceutically acceptable salt Hie'reof; and b. at least one pharmaceutically acceptable carrier. Generally, the compound of formula I, II, or III, or a pharmaceutically acceptable salt thereof, will be present: at a level of from about 0.1%, by weight, to about 90% by weight, based on the total weight of the pharmaceutical composition, based on the total weight or the pharmaceutical composition. Preferably, £ne compound oi formula I, II, or III, or a pharmaceutically acceptable salt thereof, will be present at a level of at least about 1%, by weight, based on the total weight of the pharmaceutical composition. More preferably, the compound of formula I, II, or III, or a pharmaceutically acceptable salt thereof, will be present at a level of at least about 5%, by weight, based on the total weight of the pharmaceutical composition. Even more preferably, the norepinephrine reuptake inhibitor or a pharmaceutically acceptable salt thereof will be present at a level of at least about 10%, by weight, based on the total weight of the pharmaceutical composition. Yet even more preferably, the compound of formula I, II, or III, or a pharmaceutically acceptable salt thereof, will be present at a level of at least about 25%, by weight, based on the total weight of the pharmaceutical composition. Such compositions are prepared in accordance with acceptable pharmaceutical procedures, such as described in Remington's Pharmaceutical Sciences, 17th edition, ed. Alfonoso R. Gennaro, Mack Publishing Company, Easton, PA (1985). Pharmaceutically acceptable carriers are those that are compatible with the other ingredients in the formulation and biologically acceptable. The compounds of this invention may be administered orally or parenterally, neat or in combination with conventional pharmaceutical carriers. Applicable solid carriers can include one or more substances that may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents or an encapsulating material. In powders, the carrier is a finely divided solid that is in admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shaipe and size desired. The powders and tablets preferably jinb' 99% of ""the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins. Liquid carriers may be used in preparing solutions, suspensions, emulsions, syrups, and elixirs. The active ingredient of this invention can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fat. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers, or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (particularly containing additives as above, e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydiric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration, the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration. Liquid pharmaceutical compositions, which are sterile solutions or suspensions, can be administered by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. Oral administration may be either liquid or solid composition form. i"l Preferably the pharmaceutical composition is in unit dosage form, e.g. as tablets, capsules, powders, solutions, suspensions, emulsions, granules, or suppositories. In such form, the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient; the unit dosage forms can be packaged compositions, for example packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids. The unit dosage form can be, for example, a t, ont can be the appropriate number of any such compositions in package form. In another embodiment of the present invention, the compounds useful in the present invention may be administered to a mammal with one or more other pharmaceutical active agents such as those agents being used to treat any other medical condition present in the mammal. Examples of such pharmaceutical active agents include pain relieving agents, anti-angiogenic agents, anti-neoplastic agents, anti-diabetic agents, anti-infective agents, or gastrointestinal agents, or combinations thereof. jM¥preMfficl:*i§fti'bodirnent of the present invention the compounds useful in the present invention are administered in mammals to treat chronic pain such as neuropathic pain associated for example with damage to or pathological changes in the peripheral or central nervous systems; cancer pain; visceral pain associated with for example the abdominal, pelvic, and/or perineal regions or pancreatitis; musculoskeletal pain associated with for example the lower or upper back, spine, fibromylagia, temporomandibular joint, or myofascial pain syndrome; bony pain associated with for example bone or joint degenerating disorders such as osteoarthritis, rheumatoid arthritis, or spinal stenosis; headaches such migraine or tension headaches; or pain associated with infections such as HIV, sickle cell anemia, autoimmune disorders, multiple sclerosis, or inflammation such as osteoarthritis or rheumatoid arthritis. In a more preferred embodiment, the compounds useful in this invention are used to treat chronic pain that is neuropathic pain, visceral pain, musculoskeletal pain, bony pain, cancer pain or inflammatory pain or combinations thereof, in accordance with the methods described herein. Inflammatory pain can be associated with a variety of medical conditions such as osteoarthritis, rheumatoid arthritis, surgery, or injury. Neuropathic pain may be associated with for example diabetic neuropathy, peripheral neuropathy, post-herpetic neuralgia, trigeminal neuralgia, lumbar or cervical radiculopathies, fibromyalgia, glossopharyngeal neuralgia, reflex sympathetic dystrophy, casualgia, thalamic syndrome, nerve root avulsion, or nerve damage cause by injury resulting in peripheral and/or central sensitization such as phantom limb pain, reflex sympathetic dystrophy or postthoracotomy pain, cancer, chemical injury, toxins, nutritional deficiencies, or viral or bacterial infections such as shingles or HIV, or combinations thereof. The methods of use for compounds of this invention further include treatments in which the neuropathic pain is a condition secondary to metastatic infiltration, adiposis dolorosa, burns, or central pain conditions related to thalamic conditions. As mentioned previously, the methods of the present invention may be used to treat pain that is somatic and/or visceral in nature. For example, somatic pain that can be treated in accordance with the methods of the present invention include pains associated with structural or soft tissue injury experienced during surgery, dental procedures, burns, or traumatic body injuries. Examples of visceral pain that can be treated in accordance with the methods of the present invention include those types of pain associated with or resulting from maladies of the internal organs such as ulcerative colitis, irritable bowel syndrome, irritable bladder, Crohn's disease, rheumatologic (arthralgias), tumors, gastritis, pancreatitis, infections of the organs, or biliary tract disorders, or combinations thereof. One skilled in the art will also recognize that the pain treated according to the methods of the present invention may also be related to conditions of hyperalgesia, allodynia, or both. Additionally, the chronic pain may be with or without peripheral or centra! sensitization. The compounds useful in this invention may also be used to treat acute and/or chronic pains associated with female conditions, which may also be referred to as female-specific pain. Such groups of pain include those that are encountered solely or predominately by females, including pain associated with menstruation, ovulation, pregnancy or childbirth, miscarriage, ectopic pregnancy, retrograde menstruation, rupture of a follicular or corpus luteum cyst, irritation of the pelvic viscera, uterine fibroids, adenomyosis, endometriosis, infection and inflammation, pelvic organ ischemia, obstruction, intra-abdominal adhesions, anatomic distortion of the pelvic viscera, ovarian abscess, loss of pelvic support, tumors, pelvic congestion or referred pain from non-gynecological causes. The compounds of formula I, II, or a pharmaceutically acceptable salt thereof, are useful in treating and preventing schizophrenia in a subject in need thereof. j The present invention is further defined in the following Examples, in which all parts and percentages are by weight and degrees are Celsius, unless otherwise stated. It should be understood that these examples, while indicating preferred embodiments of tries invention, are given by way of illustration only. From the above discussion and these examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can maKe various changes and modifications of the invention to adapt it to various usages and conditions. EXAMPLES Ji^^ phenvlpropan-2-ol hvdrochloride Step 1: A mixture of diisopropyl D-tartrate (d 1.119, 6.0 ml, 29 mmol), 4 A powdered molecular sieves (28 g, dried overnight at 200°C) and dry dichloromethane (800 mL) was cooled to -20°C. Titanium (IV) isopropoxide (dO.97, 5.9 ml, 20 mmol) was added and the mixture was stirred for 15 minutes. Anhydrous te/t-butyl hydroperoxide (ca. 5.5 M in decane, 90 mL, ca. 500 mmol), further dried for 15 minutes over 4 A molecular sieve pellets (dried overnight at 200°C), was added slowly and the mixture was stirred for 45 minutes at -20°C. A solution of cinnamyl alcohol (27 g, 200 mmol) in dry dichloromethane (200 mL) was added during 1 hour at -20°C. After a further 2 hours at -20°C, the reaction mixture was quenched with a cooled (-20°C) mixture of 30 % aqueous sodium hydroxide-saturated aqueous sodium chloride solution (35 mL). Diethyl ether (100 mL) was added and the mixture was vigorously stirred at 6°C for 1.5 hours. Magnesium sulfate (75 g) was added, the mixture was stirred for 20 minutes, then filtered through silica gel (100 g) and washed with diethyl ether (250 mL). The filtrate was concentrated under vacuum and excess te/t-butyl hydroperoxide was azeotroped off with several portions of toluene to provide a cloudy yellow oil. Flash column chromatography (silica 500 g, 25 %, 50 % ethyl acetate/hexanes) provided a white crystalline solid (27 g). Recrystallization from hot 20 % ethyl acetate-hexanes provided [(2R3R)-3- pheny!dx7rah-.^yl]methanol (21 g, 70 %) as white needles. MS (ES) m/z 133 ([M+H- ! Step 2: A suspension of 5-benzyloxyindole (8.9 g, 40 mmol) in glacial acetic acid (40 ml) was treated with sodium cyanoborohydride (5.0 g, 80 mmol) portionwise at 0JC. After 2 hours at O'C, the reaction mixture was diluted with water (80 ml) and made alkaline with 40 % aqueous sodium hydroxide at 0°C. The aqueous phase was extracted with dichloromethane (3 x 75 ml) and the combined extracts were washed with saturated brine (100 mL), and dried (sodium sulfate). Filtration through silica ge! (50 g) washing with dichloromethane provided 5-(benzyloxy)indoline (7.8 g, 87 %) as a clear, yellow oil. MS (ES) m/z 226 ([M+H]+). ,0227) Step 3: A mixture of [(2R,3F?)-3-phenyloxiran-2-yl]methanol (10.0 g, 66.6 mmol, from step 1) and 5-(benzyloxy)indoline (15.0 g, 66.6 mmol) was heated at 1 35°C for 1 .5 hours. The mixture was dissolved in dichloromethane (40 mL) and pre-adsorbed on silica gel (40 g). Flash column chromatography (silica 600 g, 30 %, 40 %, 50 %, 80 % ethyl acetate/hexanes) provided (2S,3S)-3-[5-(benzyloxy)-2,3-dihydro-1H-indol-1-yl]-3-phenylpropane-1 ,2-diol (22.0 g, 88 %) as an amber oil. MS (ES) m/z 376 ([M+Hf). Step 4: A solution of (2S,3S)-3-[5-(benzyloxy)-2,3-dihydro-1H-indol-1-yl]-3-phenylpropane-1 ,2-diol (1 1 .0 g, 29.3 mmol) in dry toluene (1 50 mL) was treated with a solution of 2,3-dichloro-5,6-dicyano-1 ,4-benzoquinone (6.65 g, 29.3 mmol) in dry toluene (150 mL) at 0°C. After 1.5 hours, the thick mixture was quenched with 5 % aqueous sodium carbonate (370 mL) and stirred vigorously for 5-10 minutes. The mixture was partitioned between ethyl acetate (1.1 L) and 5 % aqueous sodium carbonate (1.1 L). The organic phase was separated, washed with 5 % aqueous sodium carbonate (4 x 1.1 L) and saturated brine (1.1 L), dried over magnesium sulfate, filtered and concentrated under reduced pressure to give a crude brown solid (10.4 g). Flash column chromatography (silica 150 g, 40 %, 50 %, 60 %, 80 %, 100 % ethyl acetate/hexanes) provided (2S,3S)-3-[5-(benzyloxy)-1H-indol-1-yl]-3-phenylpropane-1 ,2-diol (9.2 g, 84 %) as a tan solid. MS (ES) m/z 374 'Step 5: A solution of (2S,3S)-3-[5-(b2nzyloxy)-1W-indol-1-yl]-3-phenylpropane-1,2-diol (7.5 g, 20 mmol) in dry pyridine (55 mL) was treated with p-toluenesulfonyl chloride (3.9 g, 20 mmol) at 23°C. After 21 hours, the reaction mixture was diluted with ethyl acetate (1 L) and the organic phase was washed with 1.0 M aqueous sodium hydroxide (1 L), water (1 L), 1.0 M aqueous hydrochloric acid (1 L) and saturated brine (I L), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a dark oil (11 g) that was dissolved in dichloromethane and pre-adsorbed on silica gel (15 g). Flash column chromatography (silica 165 g, 20 %, 40 %, 60 % ethyl acetate/hexanes) provided (2S, 3S)-toluene-4-sulfonic acid 3-(5-bentyloxy-indol-1-yl)-2-hydroxy-3-pheny!-propyl ester (8.3 g, 78 %) as an orange foam. MS (ES) m/z 528 ([M+H]+). i Step 6: (2S,3S)-Toluene-4-sulfonic acid 3-(5-benzyloxy-indoM-yl)-2-hydroxy-3-phenyl-propyl ester (4.1 g, 7.8 mmol) was treated with a solution of methylamine (2.0 M in methanol, 40 mL, 80 mmol) and the solution was stirred at 23°C for 24 hours. At this time, the solution was concentrated under reduced pressure and the residue was partitioned between diethyl ether (500 mL) and 1 .0 M aqueous sodium hydroxide (500 mL). The organic phase was separated, washed with water (500 mL.) and saturated brine (500 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to provide a tan foam (3.0 g). Flash column chromatography (silica 125 g, 2.5 %, 5 % ammonia-saturated methanol/dichloromethane) provided (1 S,2f?)-1 -[5-(benzyloxy)-1 /-/-indol-1 -yl]-3-(methylamino)-1-phenylpropan-2-ol (2.3 g, 77 %) as a pale yellow solid. The solid (0.28 g) was dissolved in warm methanol (2-3 mL) and treated with a solution of hydrogen chloride (4.0 M in 1,4-dioxane, 0.18 mL, 0.72 mmol). The precipitated solid was stirred vigorously with diethyl ether (25 mL) for ca. 1 minute. Vacuum filtration provided (1 S.2/?M-r5-(benzvloxv)-1 /7-indol-1-vl1-3-{rnethvlamino)-1 -phenvlpropan-2-ol hvdrochloride (0.30 g, 97 % recovery) as a white solid. MS (ES) m/z 387 , Example 2: f 1 S.2fl)-1 -f4-(benzvloxvM H-indoM-vl1-3-fmethvlamino>-1-DhenvlDropan-2-ol hvdrochloride (Scheme Removed) In an analogous manner to Example 1, step 2, 4-(benzyloxy)indoline was prepared from 4-benzyloxyindole. MS (ES) m/z 226 In an analogous manner to Example 1, step 3, (2S,3S)-3-[4-(benzyloxy)-2,3-dihydro-1H-indo!-1-yl]-3-phenylpropane-1,2-diol was prepared from 4-(benzyloxy)indoline and [(2R,3R)-3-phenyloxiran-2-yl]methanol. MS (ES) m/z 376 In an analogous manner to Example 1, step 4, (2S,3S)-3-[4-(benzyloxy)-1/V-indol-1-yl]-3-phenylpropane-1,2-diol was prepared from (2S,3S)-3-[4-(benzyloxy)-2,3-dihydro-1H-indol-1-yl]-3-phenylpropane-1.2-diol. MS (ES) m/z 374 In an analogous manner to Example 1 , step 5, (2S,3S)-toluene-4-sulfonic acid 3-(4-benzyloxy-indol-1-yl)-2-hydroxy-3-phenyl-propyl ester was prepared from ((2S,3S)-3-[4-(benz>'loxy)-1H-indol-1-yl]-3-phenylpropane-1 ,2-diol. MS (ES) m/z 528 ([M+HD- In an analogous manner to Example 1, step 6, (1 S.2iR)-1-f4-(benzvloxvV-1 H-indol-1 -yll-3-f methylamino)-1 -phenvlpropan-2-ol hvdrochloride was prepared from (2S,3S)-toluene-4-sulfonic acid 3-(4-benzyloxy-indol-1-yl)-2-hydroxy-3-phenyl-propyl ester. MS (ES) m/z 387 ([M+H]*). Example 3: nS.2ffl-1-f6-(ben2vloxv)-1H-indol-1-vn-3-(methvlamino)-1-phenvlpropan-2-ol hydrochloride WAY-318969-A-1 L31 883-1 35-B In an analogous manner to Example 1, step 2, 6-(benzyloxy)indoline was prepared from 6-benzyloxyindole. MS (ES) m/z 226 ([M+H]+). In an analogous manner to Example 1 , step 3, (2S,3S)-3-[6-(benzyloxy)-2,3-dihydro-1W-indol-1-yl]-3-phenylpropane-1,2-diol was prepared from 6-(benzyloxy)indoline and [(2/?,3R)-3-phenyloxiran-2-yl]methanol. A/IS (ES) m/z 376 In an analogous manner to Example 1, step 4, (2S,3S)-3-[6-(benzyloxy)-1H-indol-1-yl]-3-phenylpropane-1,2-diol was prepared from (2S,3S)-3-[6-(ben2yloxy)-2,3-dihydro-1H-indol-1-yl]-3-phenylpropane-1,2-diol. MS (ES) m/z 374 ([M+Hf). In an analogous manner to Example 1 , step 5, (2S,3S)-toluene-4-sulfonic acid 3-(6-benzyloxy-indol-1-yl)-2-hydroxy-3-phenyl-propyl ester was prepared from ((2S,3S)-3-[6--3- (methvlamino)-l -prienvlpropan-2-ol hvdrochloride ..,,,. Step 1: A solution of (1S,2R)-1-[5-(benzyloxy)-1H-indol-1-yl]-3-(methylamino)-1-phenylpropan-2-ol (1.7 g, 4,4 mmol, from Example 1, step 6) in dichloromethane (30 ml) was treated with triethylamine (d 0.726, 1.23 mL, 8.8 mmol) and di-terf-butyl dicarbonate (1.2 g, 5.5 mmol) at 23°C. After 16 hours, the reaction mixture was washed with 1 .0 M aqueous potassium hydrogen sulfate (3 x 15 ml), saturated aqueous sodium bicarbonate (15 mL), 10 % (wA/) aqueous citric acid (15 rnL) and saturated brine (15 mL), dried over magnesium sulfate, filtered and concentrated under reduced pressure to give an orange foam (2.3 g). Flash column chromatography (silica 40 g, 40 % ethyl acetate/hexanes) provided terf-butyl {(2R,3S)-3-[5-(ben^loxy)-1H-indol-1-yl]-2-hydroxy-3-phenylpropyl}methylcarbamate (2.1 g, 100 %) as a pale yellow foam. MS (ES) m/z 487 "" ~ Step 2: A solution of tert-butyl {(2/?,3S)-3-[5-(benzyloxy)-1H-indol-1-yl]-2-hydroxy-3-phenylpropyl}methylcarbamate (5.3 g, 11 mmol) in 1:1 v/v ethyl acetate-ethanol (100 mL) was hydrogenated over 10 % palladium-on-carbon (1.7 g) at 50 psi. After 16 hours, the catalyst was filtered (Celite) and washed with hot ethanol (3 x 100 mL). Concentration of the filtrate gave a tan solid (4.3 g) which was triturated overnight with ethyl acetate (30 mL) to provide terf-butyl [(2f?,3S)-2-hydroxy-3-(5-hydroxy-1H-indol-1-yl)-3-phenylpropyl]methylcarbamate (3.8 g, 88 %) as a white solid. MS (ES) m/z 397 Step 3: A solution of terf-butyl [(2R,3S)-2-hydroxy-3-(5-hydroxy-1 H-indol-1 -yl)-3-phenylpropyl]methylcarbamate (300 mg, 0.757 mmol) in dry acetonitrile (5 mL) was treated with 2-methoxybenzyl chloride (d 1.125, 105 uL, 0.754 mmol) followed by cesium carbonate (247 mg, 0.758 mmol) and the mixture was heated at 70°C. After 12 hours, the cooled mixture was filtered (Celite), washed with acetonitrile (2 x 5 mL), and concentrated under reduced pressure. Pre-adsorbtion on silica (1 g in dichloromethane) and purification via ISCO CombiFlash Companion chromatography (12 g RediSep silica, 30 mL/min, 0-40% ethyl acetate/hexane) p'rovide'd fert-butyl ((2R,3S)-2-hydroxy-3-{5-[(2-methoxybenzyl)oxy]-1 H-indol-1 -yl}-3-phenylpropyl)methylcarbamate (131 mg, 46 %) as a white foam. MS (ES) m/z 517 ([M+Hf). Step 4: Tert-butyl ((2R,3S)-2-hydroxy-3-{5-[(2-methoxybenzyl)oxy]-1H-indo!-1-yl}-3-phenylpropyl)methylcarbamate (1 76 mg, 0.341 mmol) was heated at 200°C with vigorous stirring for 8 minutes. Flash column chromatography (silica 8 g, 1.25 %, 2.5 %, 5 % ammonia-saturated methanol/dichloromethane) provided (1S,2f?)-1-{5-[(2-methoxybenzyl)oxy]-1 H-indol-1 -yl}-3-(methylamino)-1 -phsnylpropan-2-o! (34 mg, 24 %) ss a whits foam. The foam was dissolved in diethyl ether (3 mL), filtered and methanol (5 drops) was added. The solution was treated with a solution of hydrogen chloride (4.0 M in 1,4-doxane, 0.02 ml, 0.08 mmol) and vigorously stirred for ca. 1 minute. Vacuum filtration provided (1S.2R)-1-(5-f(2-methoxvbenzvhoxv]-1 H-indol-1 -yl}-3-(methvlamino)-1-phenvlpropan-2-ol hvdrochloride (27 mg, 18 %) as an off-white solid. MS (ES) m/z 417 Example 6: (1 S.2R)-1-f5-ff 3-methoxvbenzvl)oxv1-1 H-indol-1 -v!V3-( methvlaminoVI -phenvlpropan-2-ol hvdrochloride W'J.., In an analogous manner to Example 5, step 3, te/f-butyl ((2R,3S)-2- hydroxy-3-{5-[(3-m6}thoxybenzyl)oxy]-1 H-indol-1 -yl}-3- phenylpropyl)methylcarbamate was prepared from terf-butyl [(2R,3S)-2-hydroxy-3-(5-hydroxy-1 H-indol-1 -yl)-3-phenylpropyl]methylcarbamate, substituting 3-methoxybenzyl bromide in place of 2-methoxybenzyl chloride. MS (ES) m/z 517 ........ • ...... in an analogous manner to Example 5, step 4, (1S.2ftVU5-f(3- methoxybenzvl)oxv1-1 H-indol-1 -y|>-3-(methylamino)-1 -phenvlpropan-2-ol hvdrochloride was prepared from terf-butyl ((2f?,3S)-2-hydroxy-3-{5-[(3-methoxybenzyl)ox:y]-1H-indol-1-yl}-3-phenylpropyl)methylcarbamate. MS (ES) m/z 417 Example 7: HS.2R)- 1 -(5-K4-methoxvbenzvnoxv1-1 H-indol-1 -vlV3-(methylamino)-l -phenvlpropan-2-ol hvdrochloride (Scheme Removed) In an analogous manner to Example 5, step 3, terf-butyl ((2R,3S)-2-hydroxy-3-{5-[(4-methoxybenzyl)oxy]-1 H-indol-1 -yl}-3- pheny!propyl)methy(carbamate was prepared from tert-butyl [(2R,3S)-2-hydroxy-3-(5-hydroxy-1 H-indol-1 -yl)-3-phenylpropyl]methylcarbamate, substituting 4-methoxybenzyl chloride in place of 2-methoxybenzyl chloride. MS (ES) m/z 517 OM+HT). In an analogous manner to Example 5, step 4, (1S.2RV-1-{5-((4-methoxvbenzyl)o>cv]-1 ff-indol-1 -vl}-3-(methylamino)-1 -phenylpropan-2-ot hvdrochloride vras prepared from terf-butyl ((2R3S)-2-hydroxy-3-{5-[(4-methoxybenzyl)o>cy]-1/-A-indol-1-yl}-3-phenylpropyl)methylcarbamate. MS (ES) m/z * [Example 8: ( 1S.2ffl-1-{5-rf2-chlorobenzvl)oxv1-1 H-indol-1 -vlV3- ( methvlaminoM -phenvlpropan-2-ol hvdrochloride (Scheme Removed) In an analogous manner to Example 5, step 3, fert-butyl ((2R,3S)-3-{5-[(2-chlorobenzyl)oxy]-1 H-indol-1 -yl}-2-hydroxy-3-phenylpropyl)methylcarbamate was prepared from tert-butyl [(2R3S)-2-hydroxy-3-(5-hydroxy-1 H-indol-1 -yl)-3-phenylpropyl]methylcarbamate, substituting 2-chlorobenzyl bromide in place of 2-methoxybenzyl chloride. MS (ES) m/z 521 ([M+H]*). In an analogous manner to Example 5, step 4, (1S.2f?)-1-{5-{(2-chlorobenzyltoxvl-1 H-indol-1 -vl>-3-(methvlamino)-1 -phenvlpropan-2-ol hvdrochloride was prepared from tert-butyl ((2R,3S)-3-{5-[(2-chlorobenzyl)oxy]-1 H-indol-1 -yl}-2- hydroxy -3-ph8nylpropyl)m3thylcarbamata. MS (ES) m/z 42 1 ([M >-H]+). f Example 9: HS.2RM-{5-f(3-chlorobenzvl)oxvH H-indol-1 -vlV-3- (methvlamino)-1-phenvlpropan-2-ol hvdrochloride (Scheme Removed)OH In an analogous manner to Example 5, step 3, tort-butyl ((2f?,3S)-3-{5-|;(3-chlorobenzyl)oxy]-1 H-indol-1 -yl}-2-hydroxy-3-phenylpropyl)methylcarbamate was prepared from tert-butyl [(2R3S)-2~hydroxy-3-(5-hydroxy-1 H-indol-1 -yl)-3-phenylpropynmethylcarbamate, substituting 3-chlorobenzyl bromide in place of 2-methoxybenzyl chloride. MS (ES) m/z 521 in an analogous manner to Example 5, step 4, (1S,2/?)-1-{5-[(3-chlorobenzyl)oxy]-1 H-indol-1 -ylJ-S^methylamino)-!-phenylpropan-2-ol hydrochloride was prepared from terf-butyl ((2R,3S)-3-{5-[(3-chlorobenzyl)oxyM H-indol-1-yl}-2-hydroxy-3-phenylpropyl)methylcarbamate. MS (ES) m/z 421 ([M+H]*). Example 10: M S.2R)-1 -|5-r(4-c'nloroben zvl )oxv I -1 r/-indoi -1 -yl h3 -(methylaminoVI -phenylpropan-2-ol hydrochloride. (Scheme Removed) ru c-' ; In an analogous manner to Example 5, step 3, te/f-butyl ((2f?,3S)-3-{5-[(4-chlorobenzyl)oxy]-1 H-indol-1 -yl}-2-hydroxy-3--phenylpropyl)methy!carbamate was prepared from terf-butyl [(2R,3S)-2-hydroxy-3-(5-hydroxy-1 H-indol-1-yl)-3-phenylpropyl]methylcarbamate, substituting 4-chlorobenzyl bromide in place of 2-methoxybenzyl chloride. MS (ES) m/z 521 ([M+H]*). In an analogous manner to Example 5, step 4, (1S.2/?)-1-{5-IY4-chlorobenzyl)oxv1-1 H-indol-1 -vlV-3-(methvlamino)-1 -phenvlpropan-2-ol hvdrochloride was prepared from terf-butyl ((2R,3S)-3-{vt)-[(4-chlorobenzyl)oxy]-1 H-indol-1-yl}-2-hydroxy-3-phenylpropyl)methylcarbamate. MS (ES) m/z 421 ([M+H]+). Example 11: f 1 S.2RV-1-(5-f f2-fluorobenzvnoxv1-1 H-indol-1 -vlV3-(methvlamino)-l -phenylpropan-2-ol hvdrochloride In an analogous manner to Example 5, step 3, te/f-butyl ((2/?,3S)-3-{5-[(2-fluorobenzyl)oxy]-1 ft-indol-1 -yl}-2-hydroxy-3-phenylpropyl)methylcarbamate was prepared from terf-butyl [(2f?,3S)-2-hydroxy-3-(5-hydroxy-1H-indol-1-yl)-3-phenylpropyl]methylcarbamate, substituting 2-fluorobenzyl bromide in place of 2-methoxybenzyl chloride. MS (ES) m/z 505 ([M+H]*). In an analogous manner to Example 5, step 4, (1S.2f?)-1-f5-f(2-fluorobenzvl)oxvl-1 H-indol-1 -vl>-3-(methvlamino)-1 -phenylpropan-2-ol hydrochloride was prepared from te/f-butyl ((2R,3S)-3-{5-[(2-fluorobenzyl)oxy]-1/^-indol-1-yl}-2- hydroxy-3-phenyipropyl)methylcarbamate. MS (ES) m/z 405 Example 12: nS.2ffl-M5-r(3-fluorobenzvl)oxv1-1H-indol-1-vl>-3-(methvlamino)-l -phenvlpropan-2-ol hvdrochloride In an analogous manner to Example 5, step 3, te/t-butyl ((2R,3S)-3-{5-[(3-fluorobenzyl)oxy]-1 W-indol-1 -yl}-2-hydr6xy-3-phenylpropyl)methylcarbamate was prepared from terf-butyl K2/:;?,3S)-2-hydroxy-3-(5-hydroxy-1f/-indoH-yl)-3-phenylpropyl]methylccirbamate, substituting 3-fluorobenzyl bromide in place of 2-methoxybenzyl chloride. MS (ES) m/z 505 ([M+H]+). "Iff an ""anardgous manner to Example 5, step 4, dS.2ffl-1-(5-r(3-fluQrobenzvl)oxv1-1H-indol-1-vll-3-(methvlamino)-1-Dhenvlpiopan-2-ol hvdrochloride was prepared from tert-butyl ((2R3S)-3-{5-[(3-fluorobenzyl)oxy]-1H-indol-1-yl}-2-hydroxy-3-phenylpropyl)methylcarbamate. MS (ES) m/z 405 ([M+H]*). Exarngte.. 1 3: (1 S.2ff)-1 -f5-r(4-fluorpbenzvl)oxv1-1 H-JndoM .y|V3 -( methylaminoM -phenvlpropan-2-ol hvdrochloride WAY-318373-A-1 L31 883-71 -B In an analogous manner to Example 5, step 3, terf-butyl ((2R,3S)-3-{5-[(4-fluorobenzyl)oxy]-1H-indol-1-yl}-2-hydroxy-3-pheny!propyl)methylcarbamate v/as prepared from tort-butyl [(2R,3S)-2-hydroxy-3-(5-hydroxy-1H-indol-1-yl)-3-phenylpropyljmethylcarbamate, substituting 4-fluorobenzyl bromide in place of 2-methoxybenzyl chloride. MS (ES) m/z 505 ([M+Hf). In an analogous manner to Example 5. step 4, (1 S.2/?M-l5-r(4-fluorobenzvnoxv1-1 H-indol-1 -vlV-3-fmethvlamino)-1 -phenvlpropan-2-ol hvdrochloride was prepared from te/t-butyl ((2/?,3S}-3-{5-[(4-fluorobenzyl)oxy]-1 f/-indol-1-yl}-2-hydroxy-3-phenylpropyl)methylcarbamate. MS (ES) m/z 405 ([M+H]*)- Example 14: nS.2ffl-3-fmethvlaminoV-1-f5-f(2-methvlbenzvnoxvl-1f^indol-1 -vl)-1 -phenylpropan-2-ol hvdrochloride OH 'WM"7rt'-"an""aMI6g5us manner to Example 5, step 3, terf-butyl ((2/?,3S)-2-hydroxy-3-{5-[(2-methylbenzyl)oxy]-1H-indol-1-yl}-3-phenylpropyl)methylcarbamate was prepared from terf-butyl [(2R,3S)-2-hydroxy-3-(5-hydroxy-1H-indol-1-yl)-3-phenylpropyljmethylcarbamate, substituting 2-methylbenzyl bromide in place of 2-methoxybenzyl chloride. MS (ES) m/z 501 ([M+H]*). In an analogous manner to Example 5, step 4, (1 S^ffl-S-fmethvlaminoM-f5-f(2-methvlbenzvl)oxv1-1H-indol-1-vl>-1-phenvlpropan-2-ol hvdrochloride was prepared from te/f-butyl ((2f?,3S)-2-hydroxy-3-{5-[(2-methylben2yl)oxy]-1H-indol-1-yl}-3-phenylpropy!)methylcarbamate. MS (ES) m/z 401 (F.M+HJ1"). Example 15: (1S.2f?)-3-(methvlamino)-1-(5-f(3-methylbenzvl)oxv1-1/V-indol-1 -vlV-1-phenvlpropan-2-oi hvdrochloride In an analogous manner to Example 5, step 3, tert-butyl ((2R,3S)-2-hydroxy-3-{5-[(3-me1hylbenzyl)oxy]-1W-indol-1-yl}-3-phenylpropyl)methylcarbamate was prepared from tert-butyl [(2R,3S>-2-hydroxy-3-(5-hydroxy-1H-indol-1-yl)-3-phenylpropyl}methylrarbamate, substituting 3-methylbenzyl bromide in place of 2-methoxybenzyl chloride. MS (ES) m/z 501 In an analogous manner to Example 5, step 4, n£.2R)-3-(methvlamino)-1-f5-f(3-methvlbenzvl)oxv1-1 /^-indol-1 -vl}-1 -phenvlpropan-2-ol hvdrochloride was prepared from terf-butyl ((2R,3S)-2-hydroxy-3-{5-[(3-methylbenzyl)oxy]-1H-indol-1-yl}-3-phenylpropyl)methylcarbamate. MS (ES) m/z 401 TOmpfe tfr. ff5:'^R)-3-(methvlamino)-1-(5-f(4-methvlbenzvn.jxvl-1 H-indol: 1 -vlV1 -phenylpropan-2-ol hvdrochloride Step 1: In an analogous manner toExample 5, step 3, tert-butyl ((2R.3S)-2-hydroxy-3-{5-[(4-rnethylben2yl)oxy]-1 H-indol-1 -yl}-3- phenylpropyl)methylcarbamate was prepared from tert-butyl [(2R,3S)-2-hydroxy-3-(5-hydroxy-1 H-indol-1 -yl)-3-pheny lpropyl]methylcarbamate, substituting 4-methylbenzyl bromide in place of 2-methoxybenzyl chloride. MS (ES) m/z 501 Step 2: A solution of tert-butyl ((2R,3S)-2-hydroxy-3-{5-[(4- methylbenzyl)oxyl-1H-indoH-yl3-3-phenylpropyl)methylcarbamate (288 mg, 0.575 mmol) in diethyl ether (3 mL) was treated with a solution of hydrogen chloride (4.0 M in 1,4-dioxane, 0.17 mL, 0.68 mmol). After 16 hours, additional hydrogen chloride solution (4.0 M in 1,4-dioxane, 0.17 mL, 0.68 mmol) was added. After 5 days, the precipitated solid was vacuum filtered and washed with diethyl ether to provide a light pink solid (216 mg) that was partitioned between dichloromethane (20 mL) and saturated aqueous sodium bicarbonate (20 mL). The organic phase was separated, washed with saturated brine (20 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to provide a light orange foam (183 mg). Flash column chromatography (silica 13 g, 1 %, 2 %, 4 % ammonia-saturated methanol/dichloromethane) provided (1S,2R>-3-(methylamino)-1-{5-[(4- methylbenzyl)oxy]-1H-indol-1-yl}-1-phenylpropan-2-ol (55 mg, 24 %) as a white solid. The solid was dissolved in diethyl ether (3 mL), filtered and treated with a solution of hydrogen chloride (4.0 M in 1,4-dioxane, 0.04 mL, 0.16 mmol) and " ' * — " ninute. Vacuum filtration provided (1S.2R)-3- fmethylamlnoVI -< 5-1 (4-mftthylbfin7vl)Qxy1-1 H-indol-1 -yl)-1 -phenvlpropan-2-ol hvdrochloride (54 mg, 22 %) as a light pink solid. MS (ES) m/z 401 ([M+Hf). Example 17: (1S.2ffl-3-(methvlamino)-1-phenvl-1-r5-(1RSV(1-phenylethoxvVIH-indol-1 -ynpropan-2-ol hvdrochloride OH In an analogous manner to Example 5, step 3, tert-butyl {(2R,3S)-2-hydroxy-3-phenyl-3-[5-(1/?SH1-phenylethoxy)-1H-indol-1-yl]propyl}methylcarbamate was prepared from ferf-butyl [(2R,3S)-2-hydroxy-3-(5-hydroxy-1 H-indol-1 -yl)-3-phenylpropyl]methylcarbamate, substituting (1-bromoethyl)-ben2ene in place of 2-methoxybenzyl chloride. MS (ES) mfi 501 «M+H]+). In an analogous manner to Example 5, step 4, (1 S.2R)-3-(methvlarninoV-1 -phenvl-1 -f5-(1 /?S)-(1 -phenylethoxvH H-jndol-1 -vnpropan-2-ol hvdrochloride was prepared from terf-butyl {(2R,3S)-2-hydroxy-3-phenyl-3-t5-(1RS)-(1-phenylethoxy)-1W-indol-1-yl]propyl}methylcarbamate. MS(ES)m£401 ' Example 18: nS.2ffV3-(methvlamino)-1-Dhenvl-1-f5-r2-DhenvlethoxvV1H-indol-1-vllpropan-2-ol hvdrochloride OH W'ari'ana'ldgous marner to Example 5, step 3, te/f-butyl {(2R,3S)-2-hydroxy-3-phenyl-3-[5-(2-phenylethoxy)-1 H-indol-1 -yl]propyl}methylcarbamate was prepared from ferf-butyl [(2R,3S)-24iydroxy-3-(5-hydroxy-1H-indol-1-yl)-3-phenylpropyljmethylcarbamate, substituting (2-bromoethyl)-benzene in place of 2-methoxybenzyl chloride. MS (ES) m/z 501 ([M+Kf). In an analogous manner to Example 5, step 4, (1S.2R)-3-fmethvlamino)-i-phenvl-H5-f2-pherwlethow)-1H-indoM-vllpropan-2-ol hvdrochloride was prepared from terf-butyl {(2f?,3S)-2-hydroxy-3-phenyl-3-[5-(2-phenylethoxy)-1 H-indol-1 - yljpropyljmethylcarbamate. MS (ES) m/z 401 ([M+H]*). Example 19: (1 S.2R)-3-(methylamino)-1 -FS-fphen oxv)-1 H-indol-1 -vll-1 -phenvlpropan-2-ol hvdrochloride (Scheme Removed) • Step 1: Potassium hydroxide (3.0 g, 53 mmol) was added to molten phenol (15 g, 160 mmol) at 110°C with stirring. After all the potassium hydroxide had dissolved, the solution was cooled to 23°C and 5-fluoro-2-nitrotoluene (7.75 g, 50.0 mmol) was added. The mixture was heated at 130°C for 2 hours. At this time, additional hot potassium phenoxide (5 g phenol, 1 g potassium hydroxide) solution was added. After 3.5 hours (total), the mixture was heated at 150°C. After 5 hours (total), the cooled mixture was poured into 10 % aqueous sodium hydroxide (200 ml) and extracted with diethyl ether (2 x 100 ml_). The combined extracts were washed with 10 % aqueous sodium hydroxide (2 x 100 ml) and water (2 x 100 ml_), dried over sodium sulfate, filtered and concentrated under reduced pressure to yield a brown oil (11.6 g) that was taken up in diethyl ether and pre-adsorbed on silica gel (15 g). Purification by flash column chromatography (silica 135 g, 5 % ethyl acetate/hexanes) provided 2-methyM-nitro-4-phenoxybenzene (11.4 g, 99 %) as a clear, light yellow oil. MS (ES) m/z 230 ([M+H]*). "Step" "'2 " Absolution of 2-methyl-1-nitro-4-phenoxybenzene (4.6 g, 20 rr.mol) and N.W-dimethylformamide diethyl acetal (d 0.859, 4.0 ml, 23 mmol) in dry N,N~ dimethylformamide (12.5 ml) was heated at 150°C. The light yellow solution turned dark reddish-brown. After 22 hours, the cooled mixture was taken up in diethyl ether (500 mL), washed with water (3 x 250 ml) and saturated brine (250 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to provide crude dimethyl-[2-(2-nitro-5-phenoxy-phenyl)-vinyl]-amine (5.5 g, 96 %) as a dark red oil. Step 3: A solution of dimethyl-[2-(2-nitro-5-phenoxy-phenyl)-vinyl]-amine (5.5 g, 19 mmol) in ethyl acetate (60 ml) was hydrogenated over 10 % palladium-on-carbon (0.55 g) at 50 psi. After 2 hours, the catalyst was filtered (Celite) and washed with ethyl acetate (2 x 30 mL) and the filtrate was concentrated ' under reduced pressure to yield a brown oil (4.4 g). Purification by flash column chromatography (silica 160 g, 35 % dichloromethane/hexanes) provided 5-phenoxy-1H-indole (2.7 g, 68 %) as white needles. MS (ES) m/z 210 ([M+H]*). Step 4: In an analogous manner to Example 1, step 2, 5-phenoxyindoline was prepared from 5-phenoxy-1H-indole. MS (ES) m/z 212 ([M+-Hf ). Step 5; In an analogous manner to Example 1, step 3, (2S,3S)-3-[5-(phenoxy^.S-dihydi-o-IH-indol-l-ylJ-S-phenylpropane-l^-diol was prepared from 5-phenoxyindoline. MS (ES) m/z 362 Step 6: In an analogous manner to Example 1, step 4, (2S,3S)-3-[5-(phenoxy)-1H-indol-1-ylJ-3-phenylpropane-1,2-diol was prepared from (2S,3S)-3-[5-(phenoxy)-2,3-dihydro-1H-indol-1-yl]-3-phenylpropane-1,2-diol. MS (ES) m/z 360 ([M+H]*). Step 7: In an analogous manner to Example 1, step 5, (2S,3S)-toluene-4-sulfonic acid 2-hydroxy-3-(5-phenoxy-indol-1-yl)-3-phenyl-propyl ester was prepared from (2S,3S)-3-[5-(phenoxy)-1W-indoH-yl]-3-phenylpropane-1,2-diol. MS (ES) m/z 514 "" S'tep'""8':"" In an analogous manner to Example 1, step 6, (1S.2f?)-3- rmethylamino)-1-r5-(phenoxv)-1/-/-indol-1-vn-1-phenYlproDan-2-ol hvdrochloride was prepared from (2S,3S)-toluene-4-sulfonic acid 2-hydroxy-3-(5~phenoxy-indol-1-yl)-3-phenyl-propyl ester. MS (ES) m/z 372.9 ([IVH-H]+). Exampl'e 20: (1S.2/?)-3-(meth.vlamlno)-1-r4-(ghanoxv)-1H-indol-1 -yll-1 • phenylpropan-2-ol hvdrochloride (Scheme Removed) Step 1: 2-Methyl-3-nitrophenol (4.6 g, 30 mmol), phenylboronic acid (7.3 g, 60 mmol), copper (II) acetate (5.5 g, 30 mmol) and 4 A powdered molecular sieves (30 g, dried at 200°C) were combined in dry dichloromethane (300 ml_) at 23°C. Triethylamine (d 0.726, 21 ml, 150 mmol) was added and the mixture was stirred vigorously at 23°C. After 24 hours, additional phenylboronic acid (7.3 g, 60 mmol) was added. After 28 hours (total), additional copper (II) acetate (2.3 g, 13 mmol) was added. After 48 hours, the mixture was filtered (Celite) and washed with dichloromethane. The filtrate was washed with saturated aqueous EDTA (disodium satt) solution (4 x 300 ml) and brine (300 ml), dried over sodium sulfate, filtered and concentrated under reduced pressure to yield a tacky brown solid (6.9 g) that was dissolved in dichloromethane and pre-adsorbed on silica gel (15 g). Purification by flash column chromatography (silica 135 g, 1 %, 2 %, 5 %, 10 %, 20 %, 40 % ethyl acetate/hexanes) provided 2-methyl-1-nitro-3-phenoxybenzene (2.9 g, 91 % based on recovered 2-methyl-3-nitrophenol) as a clear, light yellow oil. MS (El) m/z 229 [M+). Step 2: In an analogous manner to Example 19, step 2, dimethyl-[2-(2-nitro-6-phenoxy-phenyl)-vinyl]-amine was prepared from 2-methyl-1-nitro-3-phenoxybenzene. ........ Step 3: ..... In ah" analogous manner to Example 19, step 3, 4-phenoxy-1f/- indole was prepared from dimethyl-[2-(2-nitro-6-phenoxy-phenyl)-vinyl]-amine. MS (ES)/r7/z210([M+Hf). .Step 4: In an analogous manner to Example 1, step 2, 4-phenoxyindoline was prepared from 4-phenoxy- IH-indoie. MS (ES) m/z2\2 ([iVI t-Hf). Step 5: In an analogous manner to Example 1, step 3, (2S,3S)-3-[4-(phenoxy)-2,3-dihydro-1H-indol-1-yl]-3-phenylpropane-1,2-diol was prepared from 4-phenoxyindoline. MS (ES) mh 362 ([M+Hf). Step 6: In an analogous manner to Example 1, step 4, (2S,3S)-3-[4-(pnenoxy)-1H-indol-1-yl]-3-phenylpropane-1,2-diol was prepared from (2S,3S)-3-[4-(phenoxy)-2,3-dihydro-1H-indol-1-yl]-3-phenylpropane-1,2-diol. MS (ES) m/z 360 Step 7: In an analogous manner to Example 1, step 5, (2S,3S)-toluene-4-sulfonic acid 2-hydroxy-3-(4-phenoxy-indol-1-yl)-3-phenyl-propyl ester was prepared from (2S,3S)-3-[4-(phenoxy)-1H-indol-1-yl]-3-phenylpropane-1,2-diol. MS (ES) m/z 514 Step 8: In an analogous manner to Example 1, step 6, (1 S.2f?)-3-f methvlaminoM -f4-{phenoxv)-1 H-indol-1 -vll-1 -ohenylpropan-2-ol hvdrochloride was prepared from (2S,3S)-toluene-4-sulfonic acid 2-hydroxy-3-(4-phenoxy-indoM-yl)-3-phenyl-propyl ester. MS (ES) m/z 372.9 Example 21 : (1 S.2/?)-3-(methvlamino)-1-Dhenvl-1-(4-phenvl-1H-indol-1-vl)propan-2-ol hvdrochloride Step 1: A mixture of 4-bromo-1H-indoIe (1.57 g, 8.0 mmol), phenylboronic acid (1.17 g, 9.6 mmol) and potassium carbonate (3.32 g, 24 mmol) in 3:1 v/v dioxane:water (40 ml) was purged with a bubbling stream of nitrogen for 15 minutes. rAB/?s-dichlorobis(tri-o-tolylphosphine)palladium(ll) (0.314 g, 0.4 mmol) was then added and the reaction mixture stirred at ambient temperature overnight. The mixture was then concentrated under reduced pressure and the residue partitioned between 2.0 N sodium hydroxide solution and ethyl acetate. The layers were separated and the aqueous layer extracted 3 times with ethyl acetate. The combined organic layers were washed once with brine, dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography (silica gel 5 % ethyl acetate in hexane) to give 1.45 g (94 %) of 4-p_henyl-1H-indole as cream-colored solid. HRMS: calculated for C-uHuN + H*. 194.09642; found (ESI, [M+H]*), 194.0967). Step 2: In an analogous manner to Example 1, Step 2, 4-phenylindoline was prepared from 4-phenyl-1H-indole. HRMS: calculated for C14Hi3N -f H*, 196.11207; found (ESI, [M+HD, 196.1129. Step 3: In an analogous manner to Example 1, Step 3, (2S,3S)-3-phenyl-3~ (4-phenyl-2,3-dihydro-1H-indol-1-yl)propane-1,2-diol was prepared from 4-phenylindoline. HRMS: calculated for CaHaNOa + H+, 346.18016; found (ESI, [M+H]+), 346.1807. Step 4: In an analogous manner to Example 1, Step 4, (2S,3S)-3-phenyl-3-(4-phenyM/-/-indol-1-yl)propane-1,2-diol was prepared from (2S,3S)-3-phenyl-3-(4-phenyl-2,3-dihydro-1H-indol-1-yl)propane-1,2-diol. HRMS: calculated for + H+, 344.16451; found (ESI, [M+Hf), 344.164. ' "Step"B: fnan analogous manner to Example 1, Step 5, (2S,3o)-toluene-4- sulfonic acid 3-(4-phenyl-indol-1-yl)-2-hydroxy-3-phenyl-propyl ester was prepared from (2S,3S)-3-phenyl-3-(4-phenyl-1H-indol-1-yl)propane-1,2-diol. MS (ESI) m/z 498,2 ([M+H]*). Step 6: In an analogous manner to Example 1, Step 6, _CL-S.2R)-3-rmethvlamino)-1-phenvl-1-(4-phenvl-1 /-/-indol- !-vl)propan-2-ol hvdrochloride was prepared from (2S,3S)-toluene-4-sulfonic acid 3-(4-phenyl-indol-1-yl)-2-hydroxy-3-phenyl-propyl ester. HRMS: calculated for C24H24N2O + H+, 357.19614; found (ESI, [M+Hf), 357.1962. Example 22: (1 S.2ffl-3-(methvlamino)-1-phenvl-1-(6-phenvl-1f/-indol-1-vl)propan-2-ol hvdrochloride (Formula Removed) In an analogous manner to Example 21, Step 1, 6-phenyl-1H-indole was prepared from 6-brorno-1H-indole: HRMS: calculated for Ci4HiiN, 193.08915; found (El, NT), 193.0891). In an analogous manner to Example 1, Step 2, 6-phenylindoline was prepared from 6-phenyMfA-indole. HRMS: calculated for C14Hi3N, 195.10480; found (El ,M+), 195.1034. In an analogous manner to Example 1, Step 3, (2S,3S)-3-phenyl-3-(6-phenyl-2,3-dihydro-1W-indol-1-yl)propane-1,2-diol was prepared from 6-phenylindoline. HRMS: calculated for C^HzaNO;, + H", 346.18016; found (ESI, [M+H]*), 346.1787. rri"""a"n "analogous manner to Example 1, Step 4, (2S,3S)-3-phenyl-3-(6- phenyl-1/-/-indol-1-yl)propane-1,2-diol was prepared from (2S,3S)-3-phenyl-3-(6-phenyl-2,3-dihydro-1H-indol-1-yl)propane-1,2-diol. HRMS: calculated for C23H2iNO2 + H+, 344.16451; found (ESI, [M+HD, 344.1633. In an analogous manner to Example 1, Step 5, (2vS,3S)-toluene-4-sulfonic acid 3-(6-phenyl-indol-1-yl)-2-hydroxy-3-phenyl-propyl ester was prepared from (2S,3S)-3-phenyl-3-(6-phenyl-1H-indol-1-yl)propane-1,2-diol. MS (ESI) m/z 498.2 ([M+Hf). In an analogous manner to Example 1, Step 6, (1 S.2/?KHmethvlamino)-1-phenvM-(6-phenyl-1 f/-indol-1-yl)propan-2-ol hvdrochloride was prepared from (2S,3S)-toluene-4-sulfonic acid 3-(6-phenyl-indol-1 -yl)-2-hydroxy-3-phenyl-propyl ester. HRMS: calculated for C24H24N2O i- H", 357.19614; found (ESI, [M+HJ*), 357.1958. Example 23: (1 S.2ffl-3-(methvlamino)-1-phenvl-1-(t7-Dhenvl-1H-indol-1-vl)propan-2-ol hvdrochloride (Formula Removed) In an analogous manner to Example 21, Step 1, 7-phenyMH-indo!e was prepared from 7-bromo-1H-indole. HRMS: calculated for CuHuN, 193.08915; found (El, M+), 193.0878. In an analogous manner to Example 1, Step 2, 7-phenylindoline was prepared from 7-phenyl-1H-indole. MS (ESI) m/z 196.2 ([M+Hf). Id" an analogous manner to Example 1, Step 3, (2S,3S)-3-phenyl-3-(7- phenyl-2,3-dihydro-1H-indol-1-yl)propane-1,2-diol was prepared from 7-phenylindoline. HRMS: calculated for C23H23NO2 + H+, 346.18016; found (ESI, [M+HD.346.1816. In an analogous manner to Example I, Step 4, (23,33)~3~phany!-3-(7-phenyMH-indol-l-yOpropane-l^-diol was prepared from (2S,3S)-3-phenyl-3~(7-phenyl-2,3-dihydro-1H-indol-1-yl)propane-1,2-diol. HRMS: calculated forC23H2iNO2 + H+, 344.16451; found (ESI, [M+Hf), 344.1626. In an analogous manner to Example 1, Step 5, (2S,3S)-to!uene-4-sulfonic acid 3-(7-phenyl-indol-1-yl)-2-hydroxy-3-phenyl-propyl ester was prepared from (2S,3S)-3-phenyl-3-(7-phenyl-1H-indol-1-yl)propane-1,2-diol. MS (ESI) m/z 498.2 ([M+Hf). "/-. * In an analogous manner to Example 1, Step 6, (1S,2R)-3-fmethvlamino)-1-phenvl-1-(7-Dhenvl-1 H-indol-1-yl)propan-2-ol hvdrochloride was prepared from (2S,3S)-toluene-4-sulfonic acid 3-(7-pheny l-indol-1 -yl)-2-hydroxy-3-phenyl-propyl ester. HRMS: calculated for C24H24N2O + H*, 357.19614; found (ESI, [M+H]*), 357.1971. Example 24: (1S.2ffl-1-f5-(benzvloxv)-1^indo{-1-vn-1-f3-fluorophenvlV3-fmethvlamino)propan-2-ol hvdrochloride (Formula Removed) Step 1: An oven-dried, three-neck, 2-L round bottomed flask fitted with two oven-dried addition tunnels and a rubber septum was charged with diisopropyl D-tartrate (11.55 g, 49.3 mmol, 0.30 equiv.), 4 A powdered, activated molecular sieves (40 g) and anhydrous dichloromethane (800 ml) under nitrogen. After being cooled to -25 °C, to the reaction mixture was added titanium isopropoxide (9.6 ml_, 33 mmol, 0.20 equiv.) slowly via a hypodermic syringe. After stirring for 10 minutes, annyd'rotlS't-bUtyrnydroperoxide (5.5 M in decane, 75.0 ml, 413 mmol, 2.5 equiv.) was added at a moderate rate via an addition funnel. The resulting mixture was stirred at -25 °C for 30 minutes. frans-3-Ruorocinnamy! alcohol (25.0 g, 164 mmol) in anhydrous dichloromethane (50 ml) was added dropwise via an addition funnel while maintaining the temperature at -25 °C. After the addition, the reaction mixture was stirred at -25 JC for i hour and at -20 "C for additional 3 hours. After the reaction was complete, cooled aqueous sodium hydroxide solution (30%, 20 mL) saturated with sodium chloride was added slowly at -20°C. After diethyl ether (150 mL) was added, the cold bath was removed and the mixture was warmed to ~ 5 °C and stirred for 1 hour. Anhydrous magnesium sulfate (50 g) was added and the mixture was stirred for 20 minutes, then filtered through a pad of silica gel, and washed with diethyl ether (300 mL). The filtrate was concentrated and toluene was used to azeotropically remove excess t-butyl hydroperoxide. The residual oil was purified on silica gel (0 - 30% ethyl acetate/hexane) to give 24.80 g (90%) of [(2R,3R)-3-(3-fluorophenyl)oxiran-2-yl]methanol as a viscous colorless oil. Percent ee: >96.5%. MS (ESI) m/z 169.1 !( Step 2: A mixture of sodium hydride (60% in mineral oil, 0.40 g, 10 mmol) and te/f-butanol (5 mL) was stirred for 15 minutes under nitrogen at room temperature. 5-Benzyloxyindole (2.23 g, 10 mmol) in methylene chloride (2 mL) was then added and the mixture was stirred for an additional 30 minutes at room temperature. A pre-mixed solution of titanium isopropoxide (3.55 mL, 12 mmol) and [(2f?,3R)-3-(3-fluorophenyl)oxiran-2-yl]methanol (68 g, 10 mmol) in methylene chloride (2 mL) was added, and the reaction mixture was stirred at room temperature for 15 hours until no epoxide remained as determined by tic. The mixture was filtered through a Celite pad, and the filtrate was then treated with a 2N aqueous solution of hydrochloric acid (50 mL) with stirring over 30 minutes. The organic layer was separated and the aqueous layer was extracted with methylene chloride several times. The combined extracts were washed with water, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified via Biotage Horizon (FlasH 40 M, silica, gradient from 10% ethyl acetate/hexane to 65% ethyl acetate/hexane) to yield (2S,3S)-3-(5- as an oil. MS (ESI) m/z 392 ' In an analogous manner to Example 1, step 5 (2S,3S)-toluene-4-sulfonic acid 3-(5-benzyloxy-indol-1-yl)-2-hydroxy-3-(3-fluorophenyl)-propyl ester was prepared from (2S,3S)-3-(5-benzy!oxy-1H-i'^'!ol-1-y!)-^-(3-f!uoroph3ny!)-propan9-1,2-diolasanoil. MS (ESI) m/z 546 In an analogous manner to Example 1, step6, (1S.2f?)-1-(5-benzvloxv-1/-/-indol-1-vl)-1-(3-fluorophenvl)-3-(methvlamino)propan-2-ol hvdrochloride was prepared from (28,3S)-toluene-4-sulfonic acid 3-(5-benzyloxy-indol-1-yl)-2-hydroxy-3-(3-fluorophenyl>propyl ester and methylamine solution (2.0 M in methanol) as an off-white solid. MS (ES) m/z 405.2; HRMS: calculated for C25H25FN2O2 + H+, 405.19728; found (ESI, [M+H]*), 405.1989. Example 25: (1 S.2RV-1-r5-(benzyloxv)-2.3-dihvdro-1 H-indol-1-vn-1-r3-fluorophenvn-3-(methvlamino)propan-2-ol hvdrochloride (Formula Removed) Step 1: To a mixture of frans-3-fluorocinnamic acid (50 g, 300 mmol) and iodomethane (300 mL) in acetone (1 L) was added portionwise cesium carbonate (147 g, 450 mmol, 1.5 equiv.), and the mixture was heated at 65 °C for 1.5 hours in a sealed reaction vessel. Upon cooling to room temperature, the reaction mixture was diluted with ethyl acetate (1 L), filtered through a pad of silica gel, and concentrated under reduced pressure to give 47.33 g (87%) of frans-3-fluorocinnamic acid methyl ester as a colorless oil. MS (ES) m/z 180.0 (M+). Step 2: To a solution of trans-3-fluorocinnamic acid methyl ester (69.61 g, 386 mmol) in dry dichloromethane (1 L) at -78 °C under nitrogen was added dropwise diisobutylaluminum hydride (neat, 172 mL, 965 mmol, 2.5 equiv.) via an addition funnel. After the addition was complete, the reaction mixture was allowed to \warrntd""-30""C a'lnCJ stifre'o: for an additional 1 hour, then quenched with methanol (150 mL). Upon warming to room temperature, the reaction mixture was treated with saturated aqueous of sodium/potassium tartrate solution (300 mL) and stirred for 30 minutes. The organic layer was washed sequentially with 1 N aqueous hydrochloric acid solution, saturated aqueous sodium bicarbonate solution and brine, dried over sodium suli'ate, filtered and concentrated ender reduced pressure. The crude oil was purified by silica gel chromatography (0-50% ethyl acetate:hexane) to give 53.07 g (90%) of fAa/?s-3-fluorocinnamyl alcohol as a colorless oil. MS (ES) m/z 152.1 (M*). Step 3: M oven-dried, 3-neck, 2-L. round bottom flask fitted with two oven-dried addition funnels and a rubber septum was charged with diisopropyl D-tartrate (11.55 g, 49.3 mmol, 0.30 equiv.), 4 A powdered, activated molecular sieves (40 g) and dry dichloromethane (800 mL) under nitrogen. After being cooled to -25 °C, to the reaction mixture was added titanium isopropoxide (9.6 mL, 33 mmol, 0.20 equiv.) slowly via a hypodermic syringe. After stirring for 10 minutes, anhydrous £-butyl hydroperoxide solution (5.5 M in decane, 75.0 mL, 413 mmol, 2.5 equiv.) was added at a moderate rate via an addition funnel. The resulting mixture was stirred at -25 °C for 30 min. 96.5%. MS (ESI) m£ 169.1 ([M+H]*). "••Step 4"."""ln"'a''rr*analogous manner to Example 1, step 3, (2S,3S)-3-[5- (benzyloxy)-2,3-dihydro-1 H-indol-1-yl]-3-(3-fluorophenyl)propane-1,2-diol was prepared from 5-(benzyloxy)indoline (Example 1, step 2) and [(2/?,3f?)-3-(3-fluorophenyl)oxiran-2-yl]methanol as an amber colored oil. MS (ESI) m/z 394.2 ([M+Hf); HRMS: calculated for CjwHwFNOa + H*. 394.1813; found (ESI, [M+Hf), 394.1808. Step 5: To a solution of (2S,3S)-3-[5-(benzyloxy)-2,3-dihydro-1H-indol-1- yl]-3-(3-fluorophenyl)propane-1,2-diol (348 mg, 0.884 mmol) in dichloromethane (3 ml) under nitrogen was added triathylamins (0.62 ml, 4.43 mmo!, 5 aquiv.). The mixture was cooled to 0 °C, and para-toluenesulfonyl chloride (219 mg, 1.15 mmol) was added portionwise. The reaction mixture was stirred at 0 °C for 6 hours and methylamine solution (33% in absolute ethanol, 5 mL) was added and the reaction mixture was sealed, and stirred overnight while warming to room temperature. All volatiles were removed under reduced pressure. The oily residue was dissolved in dichloromethane (20 mL), washed with aqueous potassium carbonate (5 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by Biotage chromatography (FlasH12i, silica, 0-15% MeOH/dichloromethane/0.5% triethylamine) gave 282 mg (78%) (1S,2f?)-1-[5-(ben2yloxy)-2,3-dihydro-1H-indol-1- yl]-1-(3-fluorophenyl)-3-(methylamino)propan-2-ol, which was dissolved dichloromethane (5 mL) and treated with hydrogen chloride solution (1.0 M in diethyl ether, 0.80 mL, 0.80 mmol). To the resulting solution was added hexane until white powder formed, which was collected, washed with hexane, and dried in vacuo to yield (1S.2/RV1-f5-(benzvtoxv)-2.3-dihvdro-1Wndot-1-vn-1-f3-fluoroDhenvn-3- fmethylamino)Dropan-2-ol hvdrochloride as a white powder. MS (ES) m/z 407.0 ([M+HD; HRMS: calculated for C25Hz7FN2O2 + H*. 407.2129; found (ESI, [M+Hf), 407.2131. Example 26: (1S.2/?)-1-f5-(benzvloxv)-2.3-dihvdro-1H-indol-1-vn-3-(methvlaminoV-1 -phenvlpropan-2-ol hvdrochloride (Formula Removed) In an analogous manner to Example 25, step 5, (1 S.2R)-1 -f 5-(benzvloxy)-2,3-dihydro-1 H-indol-1-vl|-3-(methylamino)-1 -phenvlpropan-2-ol hvdrochloride was prjp-ared from (2S,3S):3-[5-(b9n?/bxy)-2,?J-Jihydr3-lr/-inJol-i-ylj-3-pi-idnyIpropdncs-1,2-diol (Example 1, step 3) as a white powder. MS (ES) m/z 389.2 ([M+H]+); HRMS: calculated for CssHaa^Oa + H+, 389.2224; found (ESI, [M+H]*), 389.2220. Example 27: 5'-chloro-1'-rf1S.2R)-2-hvdroxv-3-(methvlamino)-1-phenvlpropvllspirofcvclohexane-l .3'-indoll-2'(1 'HV-one hvdrochloride (Formula Removed) Step 1: 5-Chlorooxindole (1 g, 6.0 mmol) and lithium chloride (0.63 g, 14.8 mmol) were suspended in tetrahydrofuran (50 mL) and the mixture cooled to 0 °C. n-Butylithium (6.2 mL, 12.6 mmol) was added slowly and the mixture was stirred for 20 minutes, then dibromopentane (0.82 mL, 6.0 mmol) was added. The mixture was warmed to 25 °C and stirred for 16 hours. The reaction was quenched with saturated aqueous ammonium chloride and diluted with diethyl ether. The organics were washed with water and saturated brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. Purification by flash chromatography (0-20% hexane/ethyl acetate) afforded 700 mg (50%) of 5'-chlorospiro[cyclohexane- as a white solid. MS (ESI) m/z 236 ([M+Hf ). » Step 2: S'-chlorospirotcyclohexane-I.S'-indoll-^l'Hy-one (700 mg, 3.0 mmoD was dissolved in A/.AMimethylformamide (10 mL) and sodium hydride (244 mg, 6.1 mmol, 60% wt suspension in mineral oil) was added in portions over 15 minutes and the mixture stirred for an additional 30 minutes. In a separate flask, [(2K,3R)-3-phenyloxiran-2-yl]methanol (0.8 g, 5.3 mmol, from Example 1 Step 1) (10 ml) and titanium isopropoxide (1.6 mL, 5.3 mmol) was added and the mixture stirred 30 minutes. The titanium isopropoxide/epoxide solution was then added to the solution of oxindole sodium salt dropwise and the mixture stirred at room temperature for 16 hours. The mixture was then carefully quenched with 2.0 N aqueous hydrochloric acid and diluted with 200 mL of 2.0 N aqueous hydrochloric acid, me mixture was extracted with ethyl acetate and then the organic layers were combined, washed with water, and saturated brine, dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The crude product was purified via Isco chromatography (Redisep, silica, gradient ?0% to 100% athyl restate in hex-ans) to afford 0.5 g (43%) of 5'-chloro-14(1 S,2S)-2,3-dihydroxy-1 -phenylpropyl]splro[cydohexane-1,3'-indol]-2'(1'H)-one as a foaming solid. MS (ES) mJz 335.9 ([M>H]+). Step 3: 5'-chloro-1'-{(1Sp2S)-2,3-dihydroxy-1- phenylpropyllspirofq/clohexane-I.S'-indo^Xl'HJ-one (0.5 g, 1.3 mmol) was dissolved in pyridine (4 ml), p-toluenesufonyl chloride (310 mg, 1.6 mmol) added and the mixture stirred for 4 hours. The reaction mixture was then diluted with diethyl ether and washed with water, 2.0 N aqueous hydrochloric acid, saturated copper sulfate, 2.0 N hydrochloric acid, and saturated brine. The organic layer was separated, dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The crude product was immediately dissolved in a solution of methylamine (8.0 M in ethanol, 10 mL, 80 mmol) and stirred for 16 hours. The mixture was then concentrated under reduced pressure and purified via flash chromatography (0% to 10% methanol in dichloromethane) to give 5'-chloro-1'-[(1 S^R^-hydroxy-^Hmethylarnino)-! -phenylpropyl]spiro[cyclohexane-1,3'-indoll-2'(1'H)-one as a colorless oil. The freebase was dissolved in diethyl ether (10 mL) and treated with a solution of hydrogen chloride (2.0 M in diethyl ether, 1.1 equivalent). The white precipitate was collected and dried under vacuum to give 180 mg (32% over three steps) of 5'-chloro-1 '-f(1 S.2R)-2-hvdroxv-3-(methvlamino)-1 -phenvlPropvnsDirofcvclohexane-1.3'-indon-2'f 1 'H)-onQ hydrochloride. HRMS: calculated for CjaHayCINzOa + H+, 399.18338; found (ESI, [M+Hf), 399.1822. :;::RIUM> " "Exa'mDTe""2!8: 6'-Chloro-1'-rMS.2m-2-hvdroxv-3-(methvlamino)-1 phenvlpropyllspirofcvclohexane-I.S'-indon^'d'HVonehvdrochloride (Formula Removed) In an analogous manner to Example 27, Step 1, 6'-chlorospiro[cyclohexane-1,3'-indoll-2'(1'H)-one was prepared from 6-chlorooxindole. MS (ES) m/z 236.0 ([M+Hf ). In an analogous manner to Example 27, Step 2, 6'-chloro-1'-[(1S,2S)-2,3-dihydroxy-1-phenylpropyl]spiro[cyclohexane-1 .S'-indolJ-ZO'l-O-one was prepared from 6'-chlorospiro[cyclohexane-1,3'-indol]-2'(rH)-one.MS (ES) m/z 385.8 ([M+Hf). In an analogous manner to Example 27, Step 3, 6'-chloro-1 '-f(1 S.2R)-2-hvdroxv-3-(methvliarnino)-1-phenvlpropvnspirorcvclohexane-1.3'-indon-2'(1'H)-one hydrochloride was prepared from e'-chlorospirofcydohexane-I.S'-indol^'O'Hy-one. HRMS: calculated for CzjH^CINzOa + H*. 399.18338; found (ESI, [M+Hf), 399.182. Example 29: 6'-fluoro-1 '-f(1 S.2RV2-hvdroxv-3-(methvlaminoV-1 -phenvlpropvnspiro[cvclohexane-1 .3'-indoll-2'(1 'H)-one hvdrochloride • step' 1: In an analogous manner to Example 27, Step 1, 6'-fluorospirofcyclohexane-I.S'-indori^'O'l-O-one was prepared from 6-fluorooxindole. MS(ES)m/z219.9([M-mf). Step 2: In an analogous manner to Example 27, Step 2, 1'-[(1S,2S)-2r3-dinydroxy- !~pnenyipropylj-6'-f!uorospiro|;cyc!ohexane-1,3 -mdol|-2'( I 'H)-one was prepared from 6'-fluorospiro[cyclohexane-1,3'-indol]-2'(1 'H)-one. \ Step 3: In an analogous manner to Example 27, Step 3, 6'-fluoro-1'- f(1S!2R)-2-hvdrox'/-3-(methvlamino)-1-ph9nvlproDvnspirorcvc!oh3xan9-1,3'-indol')-2Y1'H)-one hvdrochloride was prepared from 1'-[(1S,2S)-2,3-dihydroxy-1-ph2nylpropyl]-5'-fluorospiro[cydohexane-1,3'-indolj-2'( 1 'H)-one. HRMS: calculated for C23H27FN2O2 + H+, 383.21293; found (ESI, [M+H]*), 383.2139. Example 30: 5'-fluoro-1'-rnS.2R)-2-hvdroxv-3-fmethvlaminoV-1- phenylpropynspiroFcyclohexane-l .3'-indolI-2'(1 'H)-one hvdrochloride (Formula Removed) Step 1: In an analogous manner to Example 27, Step 1, 5'-fluorospirofcydohexane-I.S'-indolj-ZO'HJ-one was prepared form 5-fluorooxiindole. MS (ES) m/z 219.9 ([M+Hf). Step 2: In an analogous manner to Example 27, Step 2, 1'-[(1S,2S)-2,3-dihydroxy-1 -phenylpropyl]-5'-fluorospiro[cyclohexane-1,3'-indol]-2'(1 'H)-one was prepared from 5'-flLiorospiro[cydohexane-1,3'-indol]-2'(rH)-one. MS (ES) m/z 369.8 (IM+HD. Step 3: In an analogous manner to Example 27, Step 3, 5'-fluoro-1'-f(1S.2R)-2-hvdroxv-3-(methvlamino)-1-phenv(propvnspirorcvclohexane-1.3'-indon- 2'(1"' Hf ahla! ....... hva"r56l i!6Tide was prepared from 1'-[(1S,2S)-2,3-dihydroxy-1- phenylpropyl]-5'-fluorospiro[cyclohexane-1 ,3'-indol]-2'(1'H)-one. HRMS: calculated for C23H27FN202 + H+, 383.21293; found (ESI, [M-H-if ), 383.2125. Example 31: 7M3hloro-1MnS.2R)-2-hvdroxv-3-(methvlamino)-1- - 1 ,3'-ina JJ1-2Y ) 'H)-ona hydrochloride (Formula Removed) In an analogous manner to Example 27, Step 1, 7'-chlorospirofcyclohexane-I.S'-indolJ^'CI'HJ-one was synthesized from 7-chlorooxindole. MS (ES) m/z 236.0 In an analogous manner to Example 27, Step 2, 7'-chloro-1'-[(1S,2S)-2,3-dihydroxy-1-phenylpropyl]spiro[cyclohexane-1 ,3'-indol]-2'(1 'H)-one was prepared from r-chlorospiroIcydohexane-I.S'-indol^XI'HJ-one.MS (ES) m/z 385.8 ([M+Hf). In an analogous manner to Example 27, Step 3, 7'-chloro-1 '-f(1 S.2R)-2-hydroxv-3-(methvlamino>-1-phenylpropyt1spirorcvclphexane-1.3'-indon-2'(1'H)-one hvdrochloride was prepared from 7>-chlorospiro[cydohexane-1F3'-indol]-2l(1'H)-one. HRMS: calculated for CaHzrCINaOa + H+, 399.18338; found (ESI, [M+Hf), 399.1837. Example 32: 6'-fluoro-1'-f(1S,2R)-1-(3-fluoroDlianvl)-2-hvdroxy-3-(methvlamino)propvl]spirofcvclohexane-1,3'-indon-2'(1'H)-one hvdrochloride (Formula Removed) In an analogous manner to Example 27, Step 2, 1'-[(1S,2S)-2,3-dihydroxy-I^S-fluorophenyO-propylJ-S'-fluorospiroJcyclohexane-I.S'-indol^XI'HJ-one was prepared from 6'-fluorospirofcyclohexane-1,3*-indon-2l(1'H)-one (from Example 29 Step 1) and [(2R,3R)-3-(3-fluorophenyl)oxiran-2-yl]methanol. ,u In an analogous manner to Example 27, Step 3, 6'-f|uoro-1 '-K1 S.2R)-1 -(3- fluorophenvlV2-hvdroxy-3-(methylaminQ)propvnspirofcvclohexane-1,3'-indon-2Y1'H)- one hvdrochloride was prepared from 1'-[(1S,2S)-2,3-dihydroxy-l-(3- fluorophenyl)propyl]-6'-fluorospiro[cyclohexane-1,3'-indol]-2'(1 'H)-one. HRMS: calculated for 6231^2^02 + H+, 401.20351; found (ESI, [M+Hf), 401.2005. "gx'am0tef'"33: n"S,2ffl-3-(methvlarT;no)-1-Phenvl-1-sDirofcvclohexane-1.3'- indoll-1 '(2'HVvlpropan-2-ol hvdrochloride (Formula Removed) In an analogous manner to Example 1, step 3, (2S,3S)-3-phenyl-3-spiro[cyclohexane-lr3'-indol]-1'(2'H)-ylpropane-1,2-diol was prepared from spirofcycloheyane-1 S'-indoline]1 ^nd [(^R.^-S-phenyloxiran-^-ynmethanol (from Example 1, step 1) as a white solid. MS (ESI) m/z 338.2 ([M+Hf); HRMS: calculated for C22H2fMO2 t- H", 333.2115; found (ESI, [M+HJ+), 338.2115. In an analogous manner to Example 25, step 5, f 1 S.2/?)-3-fmethvlamino)-1 -phenvl-1-spirofcvcilohexane-1.3'-indon-1 Y 2'H)-vlpropan-2-oi hvdrochloride was prepared from (2S,3S)-3-phenyi-3-spiro[cyclohexane-1,3'-indol]-1 '(2'H)-ylpropane-1,2-diol as a white powder. MS (ES) m/z 351.2 ([M+H]"); HRMS: calculated for C23H3oN2O + H+, 351.2431; found (ESI, [M+H]"). 351.2421. Example 34: (1S.2ffl-1-(3-fluorophenvlV-3-(methvlamino)-1-f3-f2-(trifluoromethoxv)phenvn-l ff-indol-1 -vlk)ropan-2-ol hvdrochloride (Formula Removed) Step 1: A mixture of indoline (1.42 g, 11.89 mmol) and [(2R,3R)-3-(3-fluorophenyl)oxiran-2~yl]methanol (2.0 g, 11.89 mmol, from Example 25, Step 3) was heated at 125 °C for 5 hours in a sealed reaction vial. Upon cooling, the crude product was dissolved in ethyl acetate, absorbed on Fluorocil, and purified by '. Kucerovy, A.; Hathaway, J. S.; Mattner, P. G.; Repic, O. Synth, Commun. 1992,22,729-733. BidtaW'*cWmat6gtaph'y (FlasH40i, silica 0-55% EtOAc/hexane) to give 2.55 g (75%) of (2S)3S)-3-(2,3-dihydro-1H-indol-1-yl)-3-(3-fluorophenyl)propane-1,2-diol as a colorless oil. MS (ESI) m/z 288.1 ([M+Hf). Step 2: A mixture of (2S,3S)-3-(2,3-dihydro-1H-indol-1-yl)-3-(3-fiuorophenyl)propane-1,2-diol (2.00 g, 6.96 mrnol) and activated manganese dioxide (20.0 g, 230 mmol) in dichloromethane (30 ml.) was stirred at 20 °C for 3 hours. The mixture was diluted with ethyl acetate (15 ml), filtered through a pad of silica gel, and concentrated under reduced pressure. The crude product was purified by Biotags chromatography (FlasH-IOi, silica, 0-70% EtOAc/fmans) to giva 1.40 g (71%) of (2S,3S)-3-(3-fluorophenyl)-3-(1H-indol-1-yl)propane-1,2-diol as a colorless oil. MS (ESI) m/z 236.0 ({M+HJ+). HRMS: calculated for C17H18FNO2 + Hf, 286.1238; found (ESI, [M+Hf),.286.1239. Step 3: To a solution of (2S,3S)-3-{3-fluorophenyl)-3-(1H-indol-1-yl)propane-1,2-diol (1.34 g, 4.56 mmot} in /V,/V-dimethylformamide (20 mL) was added pulverized solid potassium hydroxide (0.76 g, 13.68 mmol). The mixture was stirred for 15 minutes under nitrogen at room temperature, whereupon iodine (1.21 g, 4.72 mmol) was added in one portion. The mixture was stirred for 30 minutes at room temperature and then poured into 5% aqueous sodium thiosulfate solution (100 mL). The solution was extracted 3 times with ethyl acetate and the combined extracts were washed 3 times with water. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified via Biotage chromatography (FlasH40i, silica, 40 % ethyl acetate/hexane) to yield 0.91 g (48%) of (2S,3S)-3-(3-fluorophenyl)-3-(3-iodo-1H-indol-1-yl)propane-1,,2-diol as a dark brown oil. MS (ES) m/z 411.9 ([M+H]*). Step 4: A mixture of (2S,3S)-3-(3-fkiorophenyl)-3-(3-iodo-1H-indol-1-yl)propane-1,2-diol (0.51 g, 1.24 mmol), 2-(triftuoromethoxy)phenylboronic acid (0.38 g, 1.85 mmol), and potassium phosphate (0.78 g, 3.72 mmol) in N,N-dimethylformamide (10 mL) was degassed with nitrogen for 5 minutes then a catalytic amount (0.02 g) of [1,4-bis-(diphenylphosphine)butane]palladium (II) dichloride was added. The solution was heated to 90°C for 3 hours then cooled and ifito' 'Water (TOO TnL). The aqueous mixture was extracted 3 times wi'ji ethyl acetate and the combined extracts were then washed 2 times with water. The ethyl acetate phase was dried by filtration through a plug of silica gel then concentrated under reduced pressure. The residue was purified by Biotage chromatography (FlasH40i, silica, 40% ethyl acetate/hexane) to yield 0.17 g of (2S,3S)-3-(3-;iuarQphenyi)-3-{3-i2-(tYii:luo/omdihoxy)phanyij- l/'-/-inclol- l-yl/propdne- i,2-cliol as an oil, which was used in the next step without further purification. •i Step 5: In an analogous manner to Example 27, step 3, vllpropan-2-ol hvdrochloride was prepared from (2S,3S)-3-(3-fluorophenyl)-3-{3-[2- (trif1uoromethoxy)ph9ny!]-1H-indo!-1-y!}prop3ne-1,2-diol. MS (ES) m/z 459.1 ([M+Hf); HRMS: calculated for 6351^4^02 + H+, 459.16902; found (ESI, [M+Hf), 459.1706. Example 35: (1 S.2ffl-1 -D-fluorophenvl)-3-(methvlaminoV-1-f3-f2-fisopropoxv)phenvH-1 H- indol-1-vl)propan-2-ol hvdrochloride (Formula Removed) In an analogous manner to Example 34, step 4, (2S,3S)-3-(3-fluorophenyl)-3-{3-[2-(isopropoxy)phenyl]-1H-indol-1-yl}propane-1,2-diol was prepared from (2S,3S)-3-(3-fluorophenyl)-3-(3-iodo-1/^-indol-1-yl)propane-1,2-diol (from Example 34, step 3) and 2-(isopropoxyphenyl)boronic acid. In an analogous manner to Example 27, step 3, (1 S.2R)-1-(3-fluorophenYJ>-3-(methvlamino)-143-f2-(i80Dropoxv)phenvn-1H-indol-1-vl)propan-2-ol hvdrochloride was prepared from (2S,3S)-3-(3-fluorophenyl)-3-{3-[2-(isopropoxy)phenyl]-1H-indol-1-yl}propane-1,2-diol. MS (ES) m/z 433.2 ([M+H]*); HRMS: calculated for C27H29FN2O2 + H*, 433.22858; found (ESI, [M+Hf), 433.2221. Example 36: nS.2ffl-1-(3-fluorophenvl)-1-f3-(4-fluorophenvl)-1H-indol-1-vn-3-fmethvlamino)Dropan-2-olhvdrochloride (Formula Removed) In an analogous manner to Example 34, step 4, (2S,3S)-3-(3-fluorophenyl)-3-{3-[4-fluorophenyl]-1H-indol-1-yl}propane-1,'>-diol was prepared from (2S,3S)-3-(3-fluorophenyl)-3-(3-iodo-1H-indol-1-yl)propane-1,2-diol (from Example 34, step 3) and 4-(fluorophenyl)boronic acid. In an analogous manner to Example 27, step 3, (1 S,2/?)-1-(3-fluorophenvl)-1-f3-(4-fluorophenyl)-IH-indol-1-vll-3-(methvlamino)prQpan-2-ol hydrochloride was prepared from (2S,3S)-3-(3-fluorophenyl)-3-{3-[4-fluorophenyl]-1 H-indol-1 -yl}propane-1,2-diol. MS (ES) m/z 393.2 ([M+Hf); HRMS: calculated for C24H22F2N2O + H*. 393.17729; found (ESI, [M+Hf), 393.1767. Example 37: (1 S.2ffl-1 -f3-fluoroDhenvn-3-fmethvlamino)-1 -f3-(2-phenoxyphenvl)-1 H-indol-1 -vnpropan-2-ol hvdrochloride (Formula Removed) In an analogous manner to Example 34, step 4, (2S,3S)-3-(3-fluorophenyl)-3-{3-[2-phenoxyphenyl]-1H-indol-1-yl}propane-1,2-diol was prepared from (2S,3S)-3-(3-fluorophenyl)-3-(3-iodo-1H-indol-1-yl)propane-1,2-diol (from Example 34, step 3) and 2-(phenoxyphenyl)boronic acid. In an analogous manner to Example 27, step 3, (1 S.2R)-1 -(3-fluorophenvl V 1 -[3-(2-phenoxvDhenvl)-1 H-indoM -vn-3-fmethvlamino)propan-2-ol hvdrochloride was prepared from (2S,3S)-3-(3-fluorophenyl)-3-{3-[2-phenoxyphenyl]-1H-indol-1-yl}propane-1,2-diol. MS (ES) m/z 467.2 ([M+Hf); HRMS: calculated for H", 467.2 1 293; round (£3i, iii/i-i-Hf), 467.2 i3 I. Example 38: ' M S.2ffl-1 -r3-f2.4-difluorophenvl)-1 H-indol-1 -vll-1 -(3-fluorophenvlV3-(methvlannino')propan-2-ol hvdrochloride (Formula Removed) In an analogous manner to Example 34, step 4, (2S,3S)-3-(3-(2,4-difluorophenyl)-1 H-indol-1 -yl)-3-(3-fluorophenyl)propane-1,2-diol was prepared from (2S,3S)-3-(3-fluorophenyl)-3-(3-iodo-1H-indol-1-yl)propane-1 ,2-diol (from Example 34, step 3) and 2,4-(difluorophenyl)boronic acid. In an analogous manner to Example 27, step 3, (1S.2ffl-1-r3-f2.4-difluorophenvl)-1 H-indol-1 -vll-1 -(3-fluorophenviV3-(methylamino)propan-2-ol hvdrochloride was prepared from (2S,3S)-3-(3-(2,4-difluorophenyl)-1 H-indol-1 -yl)-3-(3-fluorophenyl)propane-1 ,2-diol. MS (ES) m/z 411.2 ([M+Hf); HRMS: calculated for C24H2iF3N20 + H+, 411.16787; found (ESI, [M+Hf), 41 1.167 Example 39: f 1 S.2ft)-1 -r3-(2.5-difluorophenvl)-1 H-indol-1 -vl]-1 -f3-fluorophenvn-3-(methvlamino)propan-2-ol hvdrochloride (Formula Removed) In an analogous manner to Example 34, step 4, (2S,36>3-(3-(2,5-difluorophenyl)-1H-indol-1-yl)-3-(3-fluorophenyl)propane-1,2-diol was prepared from (2S,3S)-3-(3-fluorophenyl)-3-(3-iodo-1H-indol-1-yl)propane-1,2-diol (from Example 34, step 3) and 2,5-(difluorophenyl)boronic acid. In an analogous manner to Example 27 step 3, (1S.2f?)-1-f3-f2.5-difluorophenyl)-lH-indol-l-vl]-j-(3-fluoroQhenvl)-3-(methylamino)propan-2-oj hydrochioride was prepared from (2S,3S)-3-(3-(2,5-difluorophenyl)-1H-indol-1-yl)-3-(3-fluorophenyl)propane-1,2-diol. MS (ES) m/z411.2 ([M+H]*); HRMS: calculated for C24H2iF3N2O + H*. 411.16787; found (ESI, [M+Hf), 411.1663. Example 40: (1 S.2K)-1 -r3-(2.3-dimethoxvphenvl)-1 H-indol-1 -vll-1 -(3-fluorophenvO-3-(methvlamino)propan-2-ol hvdrochioride (Formula Removed) In an analogous manner to Example 34, step 4, (2S,3S)-3-(3-(2,3-:limethoxyphenyl)-1 H-indol-1 -yl)-3-(3-fluorophenyl)propane-1,2-diol was prepared from (2S,3S)-3-(3-fluorophenyl)-3-(3-iodo-1 H-indol-1-yl)propane-1,2-diol (from Example 34, step 3) and 2,3-(dimethoxyphenyl)boronic acid. In an analogous manner to Example 27, step 3, (1S.2R)-1-F3-(2.3-dimethoxyphenvIM H-indol-1 -vll-1 -(3-fluoroDhenvlV-3-(methvlaminobroDan-2-oi hvdrochioride was prepared from (2S,3S)-3-(3-(2,3-dimethoxyphenyl)-1 H-indol-1 -yl)- J-: l(i6^f!t'rie'hVI)pr5pari"e-T;2-diol. MS (ES) m/z 435.1 ([M+H]*); URMS: calculated for C26H27FN2O3 + H*. 435.20785; found (ESI, [M+H]*), 435.2067. Example 41: M S.2RW3-(2.4-dichlorophenvl)-1 H-indol-1-vll-1-(3-fluorophenylV3-(methvlamino)propan-2-ol hvdrochloride (Formula Removed) In an analogous manner to Example 34, step 4, (2S,3S)-3-(3-(2,4-dichlorophenyl)-1H-indol-1-yl)-3-(3-fluorophenyl)propane-1,2-diol was prepared from (2S,3S)-3-(3-fluorophenyl)-3-(3-iodo-1 H-indol-1 -yl)propane-1,2-diol (from Example 34, step 3) and 2,4-(dichlorophenyl)boronic acid MS (ES) m/z 429.6 ([M+Hf). In an analogous manner to Example 27, step 3, (1S.2ffl-1-r3-(2.4-dichlorophenyl)-1 H-indol-1 -yf|-1 -(3-fluorophenvl)-3-(methylamino)propan-2-ol hvdrochloride was prepared from (2S,3S)-3-(3-(2,4-dichlorophenyl)-1 H-indol-1 -yl)-3-(3-fluorophenyl)propane-1,2-diol. MS (ES) m/z 442.7 ([M+Hf); HRMS: calculated for C24H2iCI2FN2O + H+, 443.10877; found (ESI, [M+Hf), 443.1086. Example 42: nS.2ffl-1-f3-(2-ethoxvphenvl)-1 H-indol-1 -v!1-1-r3-fluorophenvl)-3-(methvlamino)propan-2-ol hvdrochloride (Formula Removed) In an analogous manner to Example 34, step 4, (2S,3S)-3-(3-fluorophenyl)-3-{3-[2-(ethoxy)phenyl]-1 H-indol-1 -yl}propane-1,2-diol was prepared from (2S,3S)-3- (from Example 34, step 3) and 2-(Ethoxyphenyl)boronic acid. In an analogous manner to Example 27, step 3, (1S.2/:?)-1-f3-(2- ethoxvphenvn-1H-indol-1-vn-1-(3-fluorophenvn-3-fmethvlamino^proDan-2-ol hydrQChloride was prepared rrorn (2^,36>3-(3-fluorophenyl)-3-{3-[2- (ethoxy)phenyl]-1H-indol-1-yl}propane-1,2-diol. MS (ES) m/z 419.0 ([M+H]4); HRMS: calculated for C26H27FN2O2 + H+, 419.21293; found (ESI, [M+H]*), 419.2132. Example 43: f1 S.2RV1 -f7-chloro-5-m<3thoxv-1 H-pvrrolor2.3-c1pyridin-1 -vIV 1 -(3-fluorophenvO-3-(methvlamino)propan-2-ol hvdrochloride (Formula Removed) Step 1: 2-Chloro-6-methoxy-3-nitropyridine (5 g, 0.027 mol) was dissolved in anhydrous tetrahydrofuran (200 ml) under nitrogen and the solution was cooled to -78 °C. Excess of vinylmagnesium bromide (1.0 M in tetrahydrofuran, 100 mL, 100 mmol) was added and the reaction mixture was stirred at -20 °C for 8 hours and then the reaction mixture1 was quenched with 20% aqueous ammonium chloride (150 mL). The aqueous layer was extracted with ethyl acetate and the combined extracts were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified via Biotage Horizon (FlasH 40 M, silica, gradient from 20% ethyl acetate/hexane to 60% ethyl acetate/hexane) to yield 7-chloro-5-methoxy--1W-pyrrolo[2,3-c]pyridine:! as a yellow solid. MS (ESI) m/z 183 (IM+HT). Step 2: In an analogous manner to Example 24, step 2 (2S,3S)-3-(7-chioro-5-methoxy-1H-pyrrolo[2,3-c]pyridin-1-yl)-3-(3-fluorophenyl)propane-1,2-diol was prepared from 7-chloro-5-methoxy-1H-pyrrolo[2,3-c]pyridine and [(2R,3R)-3-(3- 2 Zhang, Z., et al., J. Org. Chem. 2002,612345-2347 fldofo'|3Mriyi)&5- 1 -(3-fluorophenyl)-3-(methylamino)propan-2-ol as a white solid. HRMS: calculated for C18H2oFN30 + H+, 314.16632; found (ESI, [M+Hf), 314.1628. 3-diethvl-2.3-dihydro-1H-indol-1-vn-1-f3- fluorophenvl)-3-(miethvlamino)proDan-2-ol hvdrochloride (Formula Removed) In an analogous manner to Example 1, step 3, (2S,3S)-3-(3,3-diethyl-2,3-dihydro-1H-indol-1-yl)-3-(3-fluorophenyl)propane-1,2-diol was prepared from 3,3-diethylindoline1 and [(2/?,3/?)-3-(3-fluorophenyl)oxiran-2-yl]methanol (Example 25, step 3) as an amber colored oil. MS (ESI) m/z 344.2 ([M+Hf); HRMS: calculated for C21H26FNO2 + H+, 344.2026; found (ESI, [M+Hfi, 344.2048. In an analogous manner to Example 25, step 5, (1 S.2/?H-(3.3-diethvl-2.3-dihydro-1 H-indol-1 - vl)-1 -(3-fluorophenvl)-3-(rnethvlamino)propan-2-ol hvdrochloride was prepared from (2S,3S)-3-(3,3-diethyl-2,3-dihydro-1H-indol-1-yl)-3-(3-fluorophenyl)propane-1 ,2-diol as a white powder. MS (ES) m/z 357.3 ([M+H]*); HRMS: calculated for Cz^F^O + H*, 357.2337; found (ESI, [M+H]+), 357.2340. Example 52: (1 S.2R)-1-(6-fluoro-3.3-dimethvt-2.3-dihvdro-1H-indol-1-vl)-1-(3-fluorophenvl)-3-(methvlamino)propan-2-ol hvdrochloride ,F (Formula Removed) ' 'Step T: In an analogous manner to Example 27, step 1, 6-fluoro-3,3- dimethyloxindole was prepared from 6-fluorooxindole and iodomethane (2 equiv.) as a yellowish solid. MS (El) m/z 179.1 ([M]**); HRMS: calculated for C10Hi0FNO, 179.0746; found (El, (Mf), 179.0742. Step 2: A mixture or t>-riuoro-3,3-dimeihyloxindoie (LOG g, 5.56 mmoi; in toluene (10 mL) under nitrogen was heated at 80 °C. Vitride (65 wt% in toluene, 2.7 ml, 8.9 mmol) was added dropwise via an addition funnel. The resulting solution was stirred at 80 °C for an additional 1.5 hours, then cooled in an ice bath. Aqueous oodium hydroxide solution (1N, 15 mL) wa5 added slowly to qusnch tha raaction. Water (15 mL) was added and the reaction mixture was extracted with ethyl acetate (20 mL). The organic layer was washed with brine, dried over sodium sulfate, filtered through a pad of silica gel, and concentrated under reduced pressure to yield 728 mg (79%) of 6-fluoro-3,3-dimethylindoline as an amber colored oil. MS (ES) m/z 166.2([M+H]+). Step 3: In an analogous manner to Example 1, step 3, (2S,3S)-3-(6-fluoro- 3,3-dimethyl-2,3-dihydro-1 /-Mndol-1 -yl)-3-(3-fluorophenyl)propane-1,2-diol was prepared from 6-fluoro-3,3-dimethylindoline and [(2R,3R)-3-(3-fluoropnenyl)oxiran-2~ yljmethanol (from Example 25, step 3) as a brown solid. MS (ESI) m/z 334.2 ([M+HD; HRMS: calculated for Ci9H2iF2NO2 + H+, 334.1613; found (ESI, [M+Hf), 334.1597. Step 4: In an analogous manner to Example 25, step 5, nS.2RV1-(6-fluoro-3.3-dimethyl-2.3-dihvdro-1>/-indol-1-vl)-1-(3-fluorophenvl)-3-(methvlamino)propan-2-ol hvdrochloride was prepared from (2S,3S)-3-(6-fluoro-3,3-dimethyl-2,3-dihydro-1H-indol-1-yl)-3-(3-fluorophenyl)propane-1,2-diol as a white powder. HRMS: calculated for C2oH24F2N2O + H+, 347.1929; found (ESI, [M+Hf), 347.1914. - Example M: (1 S.2ffl-1-(4-benzv • 3.4-dihvdroguinoxalin-1 (2K)-vD-1 -(3- fluorophenvl)-3-(methvlamino)propan-2-ol hydrochloride (Formula Removed) In an analogous manner to Example 1, step 3, (2S,3S)-3-(4-benzyl-3,4-dihydroquinoxalin-1(2H)-yl)-3-(3-fluorophenyl)propane-1,2-diol was prepared from 1-benzyl-1,2,3,4-tetrahydroquinoxaline3 and [(2R,3f?)-3-(3-fluorophenyt)oxiran-2-yijmethanol (from Example 25, ^cep 3) a-s a viscous, brown oil. A/IS (E3i) m/z 393.2 ([M+HD; HRMS: <^lculated for C24H25FN2O2 + H*. 393.1973; found (ESI, [M+H]+), 393.1967. In an analogous manner to Example 25, step 5, (1 S^ffl-l^-benzvl-S^-dihvdroquinoxalin-1(2HV-vO-1-(3-fluorophenvlV-3-(methvlamino)propan-2-oi hydrochloride was prepared from (2S,3S)-3-(4-benzyl-3,4-dihydroquinoxalin-1(2H)-yl)-3-(3-fluorophenyl)propane-1,2-diol as a white powder. MS (ES) m/z 406.2 (IM+Hf). Example 54: (1S.2ffl-1-r5-fluoro-3.3-dimethvl-2.3-dihvdro-1H-indol-1-yn-1-(3-fluorophenvl)-3-{methvlamino^propan-2-olhvdrochloride (Formula Removed) In an analogous manner to Example 27, step 1, 5-fluoro-3,3-dimethyloxindole v/as prepared from 5-fluorooxindole and iodomethane (2 equiv.) as a white crystals. HRMS: calculated for C10Hi0FNO •*• H*, 180.0825; found (ESI, [M+Hf), 180.0832. 3. Smith, R. F.; Rebel, W. J.; Beach, T. N. J. Org. Cham. 19S9,24,205-207. in an analogous manner to Example 52, step 2, 5-fluoro-3,3-dimethylindoline was prepared from 5~fluoro-3,3-dimethyloxindole as an amber colored oil. MS (ES) m/z 166.2 ([M+Hf); HRMS: calculated for Ci0Hi2FN + H+, 166.1027; found (EESI, [M+Hft, 166.1024. In an analogous rndnnar to Exampla 1, stap 3, (23,3S)-3-(5-auoro-3,3-dimethyl-2,3-dihydro-1H-indol-1-yl)-3-(3-fluorophenyl)propane-1 ,2-diol was prepared from 5-fluoro-3,3-dimethylindoline and [(2R,3R)-3-(3-fluorophenyl)oxiran-2-yl]methanol (from Example 25, step 3) as a viscous, colorless oil. MS (ESI) m/z 334.2 ([M+Hf); HRMS: calculated for CigH?1F?NO? + H*. 334.1613; found (ESI, D, 334.1606. In an analogous manner to Example 25, step 5, (1S.2f?)-1-(5-fluoro-3.3-dimethyl-2.3-dihvdro-1H-indolTl-vl)-1-f3-fluorophenvl)-3-(methvlamino)propan-2-ol hvdrochloride was prepared from (2S,3S)-3-(5-fluoro-3,3-dimethyl-2,3-dihydro-1H-indol-1-yI)-3-(3-fluorophenyl)propane-1,2-dio! as a white powder. MS (ESI) m/z 347.3 ([M+Hf); HRMS: calculated for C2oH24F2N2O + H*. 347.1929; found (ESI, [M+Hf), 347.1940.. Example 55: (1 S.2RV-1 -(3-fluorophenvn-3-(methvlaminoM -f(3SV-3-methvl-2.3-dihvdro-1 H-indoM -vllpropan-2-ol hvdrochloride (Formula Removed) Step 1: In an analogous manner to Example 1, step 3, (2S,3S)-3-(3-fluorophenyl)-3-(3-methyl-2,3-dihydro-1/-/-indol-1-yl)propane-1,2-diol was prepared from 3-methylindoline4 and [(2R,3R)-3-(3-fluorophenyl)oxiran-2-yl]methanol (from Example 25, step 3) as a viscous, yellowish liquid. MS (ES) m/z 301.8 ([M+H]+); HRMS: calculated for Ci8H2oFNO2 + H+, 302.1551; found (ESI, [M+Hf), 302.1539. |0452]' -"Sfe'p;"2: 1ft an"analogous manner to Example 25, step 5, (1S,2R)-1-(3- fluorophenyl)-3-(methylamino)-1-(3-methyl-2,3-dihydro-1W-indol-1-yl)propan-2-ol was prepared from (2S,3S)-3-(3-fluorophenyl)-3-(3-methyl-2,3-dihydro-1H-indol-1-yl)propane-1,2-diol as a viscous, colorless liquid. [0453] Step 3: The diastereomefic mixture of (IS,2f?)-1-{3-fIuorophenyl)-3- (methylamino)-1--(3-methyl-2,3-dihydro-1H-indol-1-yl)propan-2-ol was dissolved in methanol. The* resulting solution was injected onto the Supercritical Fluid Chromatography instrument. The baseline resolved diastereomers, using the conditions described below, were collected SFC Instrument: Berger MultiGram Prep SFC (Berger Instruments, Inc. Newark, DE 19702. Column: Chiralpak AD-H; 250mm L x 20mm ID . Column temperature: 35°C SFC Modifier 10 % MeOH, 90 % CO2, with 0.2 % diethylamine .Flow rate: 50 mL/minute Outlet Pressure: 100 bar Detector. UVat254nm [0454] Step 4: (1S,2R)-1-(3-fluorophenyl)-3-(methylamino)-1-[(3S)-3-methyl-2,3-dihydro-1H-indol-1-yl]propan-2-ol, isolated as peak 1, was subjected to hydrochloride salt formation in an analogous manner to Example 25, step 5 to give (1 S.2fft-1 -(3-fluorophenvh-3-( methvlaminoM -f(3S)-3-methvl-2.3-dihvdro-1 H-indo(-1 -vnpropan-2-ol hydrochloride as a white powder. The stereochemistry at the C3 of the indoline ring is arbitrarily assigned. MS (ES) m/z 315.2 ([M+KT); HRMS: calculated for Ci9H23FN2O + H+. 315.1873; found (ESI, [M+H]*), 315.1885. [0455] Example 56: (1 S.2RV1 -(3-fluorophenvl)-3-(methvlamino)-1 -f(3ffV3-methvl-2.3-dihvdro-1 H-indoM-vnDropan-2-ol hvdrochloride (Formula Removed) In an analogous manner to Example 55, step 4, f 1 S.2RV1-(3-fluorophenylV hvdrochloride was prepared as a white powder from (methylamino)-1-[(3/?)-3-methyl-2I3-dihydro-1/-/-indol-1-yl]propan-2-olI which was isolated as peak 2 of the diastereomeric separation (Example 55, step 3). The stereochemistry at the C3 of the indoline ring is arbitrarily assigned. MS (ES) m/z 314.9 ([M+H]+); HRMS: calculated for C19H23FN2O + H*. 315.1873; found (ESI, [M+Hf), 315.1880. Example 57: (1S.2R)-1-(3-fluorophenvl)-1^3-isoproPvl-2.3-dihvdro-1H-indol-1 -vl)-3-(methvlamino)propan-2-ol hvdrochloride (Formula Removed) Step 1: In an analogous manner to Example 1, step 2, 3-isopropylindoline was prepared from 3-isopropylihdole5 as a colorless oil. MS (ESI) m/z 162.2 ([M+Hf). Step 2: In an analogous manner to Example 1, step 3, (2S,3S)-3-(3- fluorophenyl)-3-(3-isopropyl-2,3-dihydro-1 H-indol-1 -yl)propane-1 ,2-diol was prepared from 3-isopropylindoline and [(2f?,3/?)-3-(3-fluorophenyl)oxiran-2-yl]methanol (Example 25, step 3) as a colorless oil. MS (ESI) m/z 330.3 ([M+H]+); HRMS: calculated for CaoH^FNOz + H*. 330.1864; found (ESI, [M+Hf), 330.1855. Step 3: In an analogous manner to Example 25, step 5, (1S.2ffl-1-f3-fluorophenvn-1-(3-isopropvl-2.3-dihydro-1H-indol-1-vlV3-(methvlamino>propan-2-ol was prepared from (2S,3S)-3-(3-f!uorophenyl)-3-(3-isopropyl-2,3-dihydro-1H-indol-1~yl)propane-1,2-diol as a white powder. MS (ESj) m/z 343.0 ([M+H]*); HRMS: calculated for C21H27FN.O + H+, 343.2180; found (ESI, [M+Hf), 343.2191. Example 58: MS.2ff)-1-(3-ethvl-2.3-dihvdro-1Wndol-1-vn-1-(3-fluorophenvlV3-(methvlamino)propan-2-ol hvdrochloride (Formula Removed) Step 1: In an analogous manner to Example 1 , step 2, 3-ethylindoline was prepared from 3-ethylindole5 as a colorless oil. MS (El) m/z 147.0 ([Mf); HRMS: calculated for Ci0H13N, 147.1048; found (El, [M]*"), 147.1043. Step 2: In an analogous manner to Example 1 , step 3, (2S,3S)-3-(3-ethyl-2,3-dihydro-1Wnclol-1-yl)-3-(3-fluorophenyl)propane-1,2-diol was prepared from 3-ethylindoline and [(2f?,3R)-3-(3-fluorophenyl)oxiran-2-yl]methanol (from Example 25, step 3) as a colorless oil. MS (ESI) m/z 316.2 ([M+HH; HRMS: calculated for C19H22FNO2 + H+, 316.1707; found (ESI, [M+Hf), 316.1699. Step 3: In an analogous manner to Example 25, step 5, (1S.2ffV-1-(3-ethvl-2.3-dihvdro-1 H-indoM -vl)-1 -(3-fluorophenvn-3-(rnethvlamino)propan-2-ol hvdrochloride was prepared from (2S,3S)-:i-(3-ethyl-2,3-dihydro-1HHndol-1-yl)-3-(3-fluorophenyl)prop5=ine-1 ,2-diol as a white powder. MS (ESI) m/z 329.0 ([M+H]*); HRMS: calculated for C^oHreF^O + H+, 329.2024; found (ESI, [M+Hf), 329.2023. : Example 59: (1S.2RV1-(3-ethvl-2.3-dihvdro-1H-indoH-vlV3- (methvlamino)-l -phenvlpropan-2-ol hvdrochloride (Formula Removed) In an analogous manner to Example 1, step 3, (2S,3S)-3-(3-ethyl-2,3-dihydro-1H--indol-1-ylV3-pneny1propane-1 2-diol was prepared from 3-ethylindoline (from Example 58, step 1) and [(2R3R)-3-phenyloxiran-2-yl]methanol (Example 1, step 1) as a while solid. MS (ESI) m/z 297.8 ([M+Hf); HRMS: calculated for Ci9H23NO2 + H+, 298.1802; found (ESI, [M+H]+), 298.1816. In an analogous manner to Example 25, step 5, (1 S.2RV-1-(3-ethvl-2.3-dihvdro-1 H-indol-1 -yl)-3-(methvlamino)-1 -phenv(propan-2-ol hydrochloride was prepared from (2S,3S)-3-(3-ethyl-2,3-dihydro-1 H-indoM-yl)-3-phenylpropane-1,2-diol as a tan powder. MS (ESI) m/z 311.0 ([M+Hf). Example 60: (1S.2ffl-1-(3-isopropyl-2.3-dihvdro-1Wndol-1-vl)-3-(methvlamino)-l -phenvlpropan-2-ol hvdrochloride (Formula Removed) In an analogous manner to Example 1, step 3, (2S,3S)-3-{3-isopropyl-2,3-dihydro-1 H-indol-1-yl)-3-phenylpropane-1,2~diol was prepared from 3-isopropylindoline (from Example 57, step 1) and [(2R3R)-3-phenyloxiran-2-yl]methanol (from Example 1, step 1) as a colorless oil. MS (ESI) m/z 312.0 ([M+Hf); HRMS: calculated for C2oH25NO2 + H+, 312.1964; found (ESI, [M+H]*), 312.1981. In an analogous manner to Example 25, step 5, (1 S.2f?)-1 -(3-isopropvl-2.3-dihvdro-1 H-indol-1 -vn-3-(methvlaminoV1 -phenvipropan-2-ol hvdrochloride was prepared from (2S,3S)-3-(3-isopropyl-2,3-dihydro-1H-indol-1-yl)-3-phenylpropane-1,2--2-hvdroxv-3-(methvlamino)procivn-3.3-dimethvl-1.3-dihYdro-2H-indol-2-one hvdrochloride (Formula Removed) -"'..'Step* ^. "3;7_0ff|uorooxindo:difluorophenyl)-2,3indon2'(1IH)-one as a clear oil. The oil was dissolved in ethanol (2-3 mL) and treated with hydrogen chloride solution (1.0 M in diethyl ether, 1.1 equivalents). The ethanol was removed to give 5'-benzvloxv-1 '-K1 S. __ 2/?)-2-hvdroxv-3-(methvlamino)-1- phenvlpropvllspirofcyclohexane-1 .3'indon2'(1 'HV-one hvdrochloride as an amorphous solid. MS(ES)m£471 Example 68: 5-benzvloxv-1-fnS.2ffl-2-hvdroxv-3-(methvlamino)-1-phenvlpropvn-3.3-3-(3-chIoro-5-fluorophenyI)-3-(lff-indol-l-yl)propaiie-1^2-diol and methylamine. MS (ES) m/z 333 Example 71: phenylpropyl]-LH-iindol-5-yl}-4-methylbenzamidehydrochloride (Formula Removed) Step 1: A mixture of 5-aminoindole (1.32 g, 10 mmol), 1-hydroxybenzotriazole (1.49 g, 11 mmol), and 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride (2.11 g, 11 mmol) was dissolved in A/,/V-dimethylformamide (30 ml_). To this was added 3-chloro-4-methylbenzoic acid (1.71 g, 10 mmol) and the reaction mixture was stirred for 2 hours until the reaction was complete. The mixture was then partitioned between water and dichloromethane solution. The organic layer was separated and the aqueous layer was extracted with dichloromethane several times. The combined extracts were washed with water and brine, dried over anhydrous sodium sulfate, "filtered, a'fftf ?;'6'h"c'ei1tfated"tlKaer reduced pressure. The crude product was purified via Biotage Horizon (FlasH 40 M, silica, gradient from 0% ethyl acetate/hexane to 70% ethyl acetate/hexane) to give 3-chloro-N-(1H-indol-5-yl)-4-methylbenzamide as a light tan solid. MS (ESI) m/z 284.9 ([M+Hf). In an analogous manner to Example I, Step 2, 3-chloro-i\l-(indolin-5-yl)-4-methylbenzamide was prepared from 3-chloro-N-(1H-indol-5-yl)-4-methyl benzamide as a light tan solid. MS (ESI) m/z 286.9 ([M+Hf). In gn analogous manner to Example 1, Step 3, 3-chloro-N-{1-K1S,2S)-2,3- dihydroxy-1-phenylpropyl]indolin-5-yl}-4-metny|benzamide was prepared from 3-chloro-N-(indolin-5-yl)-4-methylbenzamide as a white fluffy solid, MS (ESI) m/z 437 In an analogous manner to Example 1, Step 4, 3-chloro-N-{1-[(1S,2S)-2,3-dihydroxy-1-phenylpropyl]-1f/-indol-5-yl}-4-methylbenzamide was prepared from 3-chloro-N-}1 -[(1 S,2S)-2,3-dihydroxy-1 -benzamide as an oil. MS (ESI) m/z 435.1 In an analogous manner to Example 1 , Step 5, (2S,3S)-3-[5-(3-chloro-4- methylbenzamido)-1H-indol-1-yl]-2-hydroxy-3-phenylpropyl 4-methylbenzene sulfonate was prepared from 3-chloro-N-{1-[(1S,2S)-2,3-dihydroxy-1-phenylpropyl]-1H-indol-5-yl}-4-methylbenzamide as an oil. MS (ESI) m/z 589 ([M+Hf). In an analogous manner to Example 1 , Step 6, 3-chloro-AH1 -f(1 S.2RV-2-hvdroxv-3-(methvlamino)-1-phenvlpropvn-1H-indol-5-vl>-4-methvlbenzamide hvdrochloride was prepared from (2S,3S)-3-[5-(3-chloro-4-methylbenzamido)-1H-indoM -yl]-2-hydroxy-3-phenylpropyl 4-methylbenzenesulfonate and methylamine (2N solution in methanol) as a tan solid. MS (ESI) m/z 448 ([M+H]+); HPLC purity 100% at 210-370 nm, 8.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for 10min, hold 4min. HRMS: calculated for CzeHaeCINaOa + H+, 448.17863; found (ESI, [M+H]*), 448.1692. Example 72: 3-Chloro-Ar-{l-l(15,2jf?)-2-hydroxy-3-(methylamino)-l-phenylpropyll-l^dihydro-ljy-indol-S-ylJbenzamidehydrochloride(Formula Removed) Step 1: In an analogous manner to Example 71, Step 1, 3-chloro-N-(1 H-indol-5-yl)benzamide was prepared from 5-aminoindole and 3-chlorobenzoic acid as a dark tan solid. MS (ESI) m/z 270.9 ([M+Hf)- Step 2: In an analogous manner to Example 1, Step 2, 3-chloro-N-(indolinT 5-yl) benzamlde was prepared from 3-chloro-N-(1H-indol-5-yl)benzamide as a light tan solid. MS (ESI) m/z 272.9 ([M+Hft. Step 3: In an analogous manner to Example 1, Step 3, 3-ch!oro-N-{1-[(IS^S^.S-dihyclroxy-l-phenylpropylJindolin-S-yllbenzamide was prepared from 3-chloro-N-(indolin-5-yl)benzamide as a pale yellow solid. MS (ESI) m/z 423 Step 4: In an analogous manner to Example 1 , Step 5, (2S,3S)-3-[5-(3-chlorobenz-amido)indolin-1 -yl]-2-hydroxy-3-phenylpropyl 4-methylbenzene sulfonate was prepared from 3-chloro-N-{1-[(1S,2benzamide hvdrochloride (Formula Removed) In an analogous manner to Example 1, Step 4, 3-chloro-N-{1-[(1S,2S)-2,3-dihydroxy-1-phenylpropyl]-1Wndol-5-yl}ben;z:amide was prepared from 3-chloro-N-{1-[(1S,2S)-2,3-dihydroxy-1-phenylpropyl]indolin-5-yl}benzamide (from Example 72, Step 3) as an oil. MS (ES) m/z 421 .1 In an analogous manner to Example 1 , Step 5, (2S.3S)-3-f5-(3-chlorobenz-amidoVI H-indol-1 - vl1-2-hvdroxv-3-phenvlpropvl 4-methvlbenzenesulfonate was prepared from 3-ch!oro-N-{1-[(1 S,2S)-2,3-dihydroxy-1-phenylpropyl]-1 W-indol-5-yljbenzamide as an oil. MS (ESI) m/z 576 In an analogous manner to Example 1, Step 6, 3-chloro-A/-(1-[f 1 S.2R)-2-hvdroxv-3-f methvlamino)-1 -phenvl&ropvl]-1 Ay-indol-5-yl}benzannide hvdrochloride was prepared from (2S,3S)-3-[5-(3-chlorobenzamido)-1W-indol-1-yl]-2-hydroxy-3-phenylpropyl 4-methylbenzenesulfonate and methylamine (2N solution in methanol) as a white solid. MS (ES) m/z 434.1 ([M+Hf); HPLC purity 100% at 210-370 nm, 8.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for 10min, hold 4min. HRMS: calculated for C25H24CIN3O2 + Hh, 434.16298; found (ESI, [M+Hf), 434.1617. Example 74: ^V-{l-[(LS^K>2-Hydroxy-3-(methylamino)-l-phenylpropyl]-2^-dihydro-l/f-indol-f5-yl}benzamide hydrochloride (Formula Removed) Step V. in an analogous manner to Example 71, Step 1, N-(1/-/-lndol-5-yl)benzamide was prepared from 5-aminoindole and benzoic acid as a light tan solid. MS (ESI) m/z 237 ([M+Hf). Step 2: In an analogous manner to Example 1, Step 2, N-(indolin-5-yl) benzamide was prepared from N-( IH-indoi-S-yObenzamide as a light tan solid. MS (ESI) m/z 239.0 ([M+Hf). Step 3: In an analogous manner to Example 1, Step 3, N-{1-[(1S,2S)-2,3-dihydroxy-1-phenylpropyl1indolin-5-yl}ben^amide was prepared from N-(indolin-5-yl) benzamide as a pale yellow solid. MS (ESI) m/z 389.1([M+Hf). Step 4: In an analogous manner to Example 1, Step 5, (2S.3SKH5-benzarnidoindolin-1-vlV2-hvdroxv-3-DhenvlprQpvl 4-methvlbenzenesuifonate was prepared from N-{1-[(1S,2S)-2,3-dihydroxy-1-phenylpropyl]indolin-5-yl}benzamide as an oil. MS (ESI) m/z 543 ([M+Hf). Step 5: In an analogous manner to Example 1, Step 6, AH1-f(1S.2ffl-2-hvdroxv-3-f methvlaminoH -phenvlpropvn-2.3-dihvdro-1 /-/-indol-5-yl}benzamide hydrochloride was prepared from (2S,3S)-3-(5-benzamidoindolin-1-yl)-2-hydroxy-3-phenylpropyl 4-methylbenzenesulfonate and methylamine (2N solution in methanol) as a light tan solid. MS (ES) m/z 402.1 ([M+H]+); HPLC purity 96.8% at 210-370 nm, 7.3 min.; Xterra RFJ18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for 10min, hold 4min. HRMS: calculated for C25H27N3O2 + H*. 402.21760; found (ESI, [M+Hf), 402.212. Example 75: A/-(1-f(1S.2f?)-2-Hvdroxv-3-(methvlaminoV1-phenvlDroDvl1-1 B-indol-5-vl>benzamide hydrochloride (Formula Removed) In an analogous manner to Example 1, Step 4, N-{1-[(1S,2S)-2,3-dihydroxy-1-phenylpropyl]-1H-indol-5-yl}benzamide was prepared from N-{1-[(1S,2S)-2,3-dihydroxy-1-phenylpropyl]indolin-5-yl}benzamide (from Example 74, step 3) as an oil. MS (ES) m/z 387.1 ([M+H]+). In an analogous manner to Example I, Step 5, (2S,3S)-3-(5-benzamido-1H-indol-1-yl)-2-hydroxy-3-phenylpropyl 4-methylbenzenesulfonate was prepared from N-{1-[(1S,2S)-2,3-dihydroxy-1-phenylpropyl]-1H-indol-5-yl}benzamide as an oil. MS (ESI) m/z 541 ([M+HD. In an analogous manner to Example 1, Step 6, AM 1 -f(1 S.2R)-2-hvdroxv-3- (methvlamino)-l -phenvlpropyll-1 /-^indol-5-yl}benzamide hvdrochloride was prepared from (2S,3S)-3-(5-(benzamido-1 H-indoM -yl)-2-hydroxy-3-phenylpropyl 4- methylbenzenesulfonate and methylamine (2N solution in methanol) as an off- white solid. MS (ES) m/z 400.1 ([M+H]+); HPLC purity 100% at 210-370 nm, 7.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for 10min, hold 4min. HRMS: calculated for C2^25^O2 + H+, 400.20195; found (ESI, [M+H]*), 400.2034. Example 76: JV-{l-[(15^/I)-2-Hydroxy-3-(methylamino>l-ph«ByIpropyl]-2v3-dihydro-l£f-indol-3-yl}cydohexanecarboxamide hydrochloride (Formula Removed) Step 1: In an analogous manner to Example 71, Step 1, N-(1H-indol-5-yl)cydohexanecarboxamide was prepared from 5-aminoindole and cyclohexanecarboxylic acid as an oil. MS (ESI) m/z 243.0 ([M+Hf). Step 2: In an analogous manner to Example 1, Step 2, N-(indolin-5-yl)cyclohexanecarboxamide was prepared from N-(1H-indol-5-yl)cyclohexanecarboxamide as an oil. MS (ESI) m/z 245 ([M+H]*). ' 3: "TrTah analogous manner to Example 1, Step 3, N-{1-[(1S,2S)-2,3-lihydroxy-1-phenylpropyl]indolin-5-yl}cyclohexanecarboxamide was prepared from 4-(indolin-5-yl)cyclohexanecarboxamide as a white solid. MS (ESI) m/z 395.1 Step 4: In an analogous manner to Example I, Step 5, (2S,33)-3-{5- cyclohexanecarboxamido)indolin-1-yl]-2-hydroxy-3-phenylpropyl 4- nethylbenzenesulfonate was prepared from N-{1-[(1S,2S)-2,3-dihydroxy-1-)henylpropyl]indolin-5-yl}cyclohexanecarboxamide as an oil. MS (ESI) m/z 547 [M+Hf). Step 5: In an analogous manner to Exampls 1, Sisp 3, A/-f1-F(13.2ffl-2- ivdroxv-3-(methvlarnino)-1-phenvlpropyl1-2.3-dihvdro-1/-/-indol-5-vl}cvclohexane arboxamide hvdrochloride was prepared from (2S,3S)-3-[5- cyclohexanecarboxamido)indolin-1 -yl]-2-hydroxy-3-phenylpropyl 4- nethylbenzenesulfonate and methylamine (2N solution in methanol) as an off-white ;olid. MS (ES) m/z 408.2 ([M+Hf); HPLC purity 100% at 210-370 nm, 7.9 min.; -2,3-dihydroxy-l-[>henyIpropyl]-Lff-indol-5-yl}cyclohexanecarboxamide was prepared from N-{1-[(l^iy^l.S-dihydroxy-l-phenylpropyljindolin-S-ylJcycIohexanecarboxamide (from Example 76, Step 3) as an oil MS (ES) m/z 393.1 ([M+H]+). "IrFari a7ialbg&eisjfmanner to Example 1, Step 5, (2S,3S)~3-[5-(cyclohexane carboxamido)-1W-indol-1-yl]-2-hydroxy-3-phenylpropyl 4-methylbenzene sulfonate was prepared from N-{1-[(1S,2S)-2,3-dihydroxy-1-phenylpropyl]-1/V-indol-5-yljcyclohexanecarboxamide as an oil. MS (ESI) m/z 547 ([M+Hf). In an analogous manner co Example I, Step 6, AHI-f(IS.ZRj-Z-hvdroxv-S-(methvlaminoV1-pihenvlpropvO-1H-indol-5-vl}cvclohexanecarboxamide hvdrochloride was prepared from (2S,3S)-3-[5-(cyclohexanecarboxamido)-1H-indol-1-yl]-2-hydroxy-3-phenylpropyl-4-methylbenzenesulfonate and methylamine (2N solution in methanol) as an off-white solid MS (ES) mfz 406.1 (fM+Hf): HPLC purity 100% at 210-370 nm, 8.0 min.; Xterra RP 18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MsOH) for 10min, hold 4min. HRMS: calculated for C25H3iN3O2 + H*. 406.24890; found (ESI, [M+HD, 406.2492. Example 78: A^-(3-ChIorophenyI)-l-[(l^/f)-2-hydroxy-3-(methylaniino)-l- phenylpropyljiudolifle-5-carboxamidehydrochloride (Formula Removed) Step 1: In an analogous manner to Example 71, Step 1, N-(3-chlorophenyl)-1H-indole-5-carboxamide was prepared from 1B-indote-5-carboxylic acid and 3-chloroaniline as a oily tan solid. MS (ESI) m/z 270.9 ([M+H]*). Step 2: In an analogous manner to Example 1, Step 2, N-(3-chlorophenyl)indoline-5-carboxamide was prepared from N-(3-chIorophenyl)-1/-/-indole-5-carboxarnide as a light tan solid. MS (ESI) m/z 272.9 ([M+H]"1"). Step 3: In an analogous manner to Example 1, Step 3, N-(3-chlorophenyl)-l-KIS^S^.S-dihydroxy-l-phenylpropyllindoline-S-carboxamide was prepared from N-(3-chlorophenyl)indoline-5-carboxamide as a white solid. MS (ESI) m/z 423 Step 4: irr'aTt analogous manner to Example 1, Step 5, (2S,3S)-3-[5-(3- chlorophenyl carbamoyl)indolin-1-yl]-2-hydroxy-3-phenylpropyl 4-methylbenzene sulfonate was prepared from N-(3-chlorophenyl)-1-[(1S,2S)-2,3-dihydroxy-1-phenylpropyl] indolline-5-carboxamide as an oil. MS (ESI) m/z 577 ([M+H]+). 'M, Step 5; In an analogous manner to Example I, Step 6, /V-(3-chlorophenvl)-1-r(1S.2R)-2-hvdroxy-3-(methvlaminoV1-phenvlpropvnindoline-5-carboxamide hvdrochloride was prepared from (2S,3S)-3-[5-(3-chlorophenylcarbamoyl)indolin-1-yl]-2-hydroxy-3-phenylpropyl 4-methylbenzene sulfonate and methylamine (2N solution in methanol) as a pale yellow solid. MS (ES) m/7 436 1 ([M+Hf); HPLC purity 100% at 210-370 nm, 8.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff.. Ph=3.5/ACN+MeOH) for 10min, hold'4 minutes. HRMS: calculated for C25H26CIN3O2 + H*, 436.17863; found (ESI, [M+HD, 436.1802. Example 79: A/-(3-Chlorophenyl)-1 -[(1 S,2R)-2-hydroxy-3-(methylamino)-1 -phanylpropyl]-1 f/-indo!e-5-carboxamide hydrochloride (Formula Removed) In an analogous manner to Example 1, Step 4, N-{3-chlorophenyl)-1-[(1S,2S)-2,3-dihydroxy-1-phenylpropyl]-1H-indole-5-carboxamide was prepared from N-(3-chlorophenyl)-1 -[(1 S,2S)-2,3-dihydroxy-1 -phenylpropyl]indoline-5-carboxamide (from Example 78, Step 3) as an oil. MS (ESI) m/z 421.1. In an analogous manner to Example 1, Step 5, (2S,3S)-3-[5-(3-chlorophenyl carbamoyl)-1 H-indol-1 -yl]-2-hydroxy-3-phenylpropyl 4-methylbenzenesulfonate was prepared from N-(3-chlorophenyl)-1-[(1 S,2S)-2,3-dihydroxy-1 -phenylpropy]-1 H-indole-5-carboxamide as an oil. MS (ESI) m/z 575 ([M+KT). In an analogous manner to Example 1, Step 6, A/-(3-chlorophenyl)-1-[(1 S,2R)-2-hydroxy-3-(methylamino)-1 -phenylpropyl]-1 H-indole-5-carboxamide hydfo'fcrtloflidelfwasrrp'r6p'a"re'd from (2S,3S)-3-[5-(3-chlorophenylcarbamoyl)-1H-indol-1-yl]-2-hydroxy-3-phenylpropyl 4-methylbenzenesulfonate and methylamine (2N solution in methanol) as a white solid. MS (ES) m/z 434.1 ([M+Hf); HPLC purity 100% at 210-370 nm, 8.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for 10min, hold 4min. HRMS: calculated for CzsH^CINaOa + H", 434.16298; found (ESI, [MtH]*), 434.1634. Example 80: (1S,2R)-3-(methylamino)-1-(6-phenoxy-1H-indol-1-yl)-1-phenylpropan-2-ol hydrochloride (Formula Removed) \=J OH In an analogous manner to Example 20, Step 1, 2-methyl-1-nitro-5-phenoxybenzsne was prepared from 4-methyl-3-nitrophenol. 1H NMR (400 MHz, (CD3)2SO) 5 2.48 (s, 3H), 7.10 (d, 2H), 7.23 (t, 1H), 7.31 (dd, 1H), 7.45 (t, 2H), 7.52 (d, 1H), and 7.55 (rn, 1H). In an analogous manner to Example 19, Step 2, dimethyl-[2-(2-nitro-4-phenoxy-phenyl)-vinyl]-amine was prepared from 2-methyl-1-nitro-5-phenoxybenzene. *H NMR (400 MHz, (CD3)2SO) 5 2.88 (s, 6H), 5.66 (d, 1H), 7.05 (d, 2H), 7.15-7.20 (m, 2H), 7.32 (d, 1H), 7.39-7.43 (m, 3H), 7.71 (d, 1H). In an analogous manner to Example 19, Step 3, 6-phenoxy-1H-indole was prepared from dimethyl-[2-(2-nitro-4-phenoxy-phenyl)-vinyl]-amine. MS (ES) m/z 210([M+Hf). In an analogous manner to Example 1, Step 2, 6-phenoxyindoline was prepared from 6-phenoxy-1H-indole. MS (ES) m/z 212 ([M+Hf). In an analogous manner to Example 1, Step 3, (2S,3S)-3-(6-phenoxy-2,3- was prepared from 6-phenoxyindoline. MS (ES) m/z 362 ([M+Hf). In an analogous manner to Example 1, Step 4, (2S,3S)-3-(6-phenoxy-1H-indol-1-y!)-3-phenylpropane-1,2-diol was prepared from (2S,3S)-3-(6-phenoxy-2,3- dihydro-IH-indol-l-yO-n-phenylpropan--?-!? die! MS (ES) n?A 360 {[M+H]*). In an analogous manner to Example 25, Step 5, (1 S.2RK?-(methvlamino)-1 -(6-phenoxv-1 H-indol-1 -vl)-1 -phenvlpropan-2-ol hvdrochloride was prepared from (2S,3S)-3~(6-phenoxy-1H-indol-1-yl)-3-phenylpropane-1,2-diol. MS (ES) m/z 373 ((M+H\r); HRMS: calculated for C24^24^2O2 + H', 373.19I05, round (£31, [iVI+Hj1"), 373.1916. Example 81: (1S.2R)-3-(methvlamino)-1-(7-phenoxv-1H-indol-1-vl>-1-phenvlpropan-2-ol hvdrochloride (Formula Removed) In an analogous manner to Example 20, Step 1, 2-methyl-1-nitro-6-phenoxybenzene was prepared from 3-methyl-2-nitrophenol. 1H NMR (400 MHz, (CD3)2SO) 6 2.34 (s, 3H), 6.93 (d. 1H), 7.07 (d, 2H), 7.22 (t, 2H), and 7.41-7.49 (m, 3H). In an analogous manner to Example 19, Step 2, dimethyl-[2-(2-nitro-3-phenoxy-phenyl)-vinyl]-amine was prepared from 2-methyl-1-nitro-6-phenoxybenzene. 1H NMR (400 MHz, (CD3)2SO) 5 2.83 (s, 6H). 4.66 (d, 1H), 6.48 (d, 1H), 7.04 (d, 2H), 7.19 (t, 1H), 7.25 (t, 1H), and 7.32-7.43 (m, 4H). In an analogous manner to Example 19, Step 3, 7-phenoxy-1H-indole was prepared from dimethyl-[2-(2-nitro-3-phenoxy-phenyl)-vinyl]-amine. MS (ES) m/z 210([M+Hf)."" ...... In an analogous manner to Example 1, Step 2, 7-phenox/irdoline was prepared from 7-phenoxy-1H-indole. MS (ES) m/z 212 ([M+Hf). In an analogous manner to Example 1 , Step 3, (2S,3S)-3-(7-phenoxy-2,3-dihydro-1H-indol-1-yl)-3-phenylpropane-1,2~diol was prepared from 7-phenoxyindoline. A/I3 (£Sj m/z362 In an analogous manner to Example 1, Step 4, (2S,3S)-3-(7-phenoxy-1H-indol-1-yl)-3-phenylpropane-1,2-diol was prepared from (2S,3S)-3-(7-phenoxy-2,3-dihydro-1 H-indol-1-yl)-3-phenylpropane-1 ,2-diol MS (CS1! mfi 360 In an analogous manner to Example 25, Step 5, ( I S.2f?)-3-fmethvlamino')-1-(7-phenoxv-1 H-indol-1-ylV-1-phen.vlpropan-2-ol hvdrochloride was prepared from (2S,3S)-3-(7-phenoxy-1H-indol-1-yl)-3-phenylpropane-1 ,2-diol. MS (ES) m/z 373 ([M+Hf); HRMS: (calculated for C24H24N2O2 + H+, 373.19105; found (ESI, [M+H]*), 373.1912. Example 82: (1 S.2ffl-3-amino-1 -fS-fbenzvloxvVI H-indol-1 -vll-1 -phenvlpropan-2-ol hvdrochloride (Formula Removed) step i: in an analogous manner to Exsmple 1, Step 4, (2S,3S)-3-[5-(benzyloxy)-1H-indol-1-yl]-3-phenylpropane-1,2-diol was prepared from (2S,3S)-3-[5-(benzyloxy)-2,3-dihydro-1H-indol-1-yl]-3-phenylpropane-1,2-diol. MS (ES) m/z 374 Step 2: In an analogous manner to Example I, Step 5, (2S,3S)-3-(5-(benzyloxy)-l H-indol-1 -yl)-2-hydroxy-3-phenylpropyl 4-methylbenzenesulfonate was prepared from (2S,3S)-3-[5-(benzyloxy)-1H-indol-1-yl]-3-phenylpropane-1,2-diol. MS (ES) m/z 528 [(M+H)+]. Step 3: In an analogous manner to Example 1, Step 6, (1S,2fl)-3-amino-1- [5-(benzyloxy)-l/4-indol-l-yl]-1-ph3nylpropan-2-ol hydrochloride was prepared r'rom (2S,3S)-3-(5-(benzyloxy)-1H-indol-1-yl)-2-hydroxy-3-phenylpropyl-4- methylbenzenesulfonate, substituting ammonia in methanol solution in place of methylamine in methanol solution. MS (ES) m/z 373 [(M+H)*]. Example 83: (1 S,2R)-1 -[5-(benzyloxy)-1 H-indol-1-yl]-3-(ethylamino)-1-phenylpropan-2-ol hydrochloride (Formula Removed) In an analogous manner to Example 1, Step 6, (1 S,2R)-1-r5-(benzvloxvV- 1 Wndol-1 -vn-3-(ethvlamino)-1 -phenylpropan-2-ol hvdrochloride was prepared from (2S,3S)-3-(5-(ben:zyloxy)-1f/-indol-1-yl)-2-hydroxy-3-phenylpropyl 4- methylbenzenesulfonate (from Example 82, Step 2), substituting ethylamine in place of methylamine. MS (ES) m/z 401 [(M+H)*]. Example 84: nS.2ffl-1-f5-(benzvloxv)-1H-indol-1-vn-1-phenvl-3- (bfotMaWriWDr'5pan-2-b[ hvdrochloride (Formula Removed) In an analogous manner to Example 1, Step 6, (1 S.2/?)-1-r5-fbenzvloxv)- 1 H-indol-1 -yll-1 -phenvl-3-(propvlamino)propan-2-ol hvdrochloride was prepared from (2S,3S)-3-(5-(benzyloxy)-1 H-indol-1 -yl)-2-hydroxy-3-phenylpropyl 4- methylbenzenesulfonate (from Example 82, Step 2), substituting propylamine in place of methylamine. MS (ES) m/z 415 [(M+H)*]. Example 85: (1 S.2KV1-r5-(benzvloxvV1H-indoM-vl1-3-nsoproDvlamino)-1 -phenylpropan-2-ol hvdrochloride (Formula Removed) In an analogous manner to Example 1, Step 6, (1S,2/?)-1-[5-(benzyloxy)- 1/-/-indol-1-yl]-3-(isopropylamino)-1 -phenylpropan-2-ol hydrochloride was prepared from (2S,3S)-3-(5-(ben2yloxy)-1f/-indot-1-yl)-2-hydroxy-3-phenylpropyl 4- methylbenzenesulfonate (from Example 82, Step 2), substituting isopropylamine in place of methylamine. MS (ES) m/z 415 Example 86: (1S.2ffl-1-f5-(benzvloxv)-1H-indol-1-vll-3-(dimethvlamino^1-Dhenvlpropan-2-ol hvdrochloride (Formula Removed) In an analogous manner to Example 1, Step 6, (1S,2f?)-1-[5-(benzyloxy)- 1f/-indol-1-yl]-3-(dirnethylamino)-1-phenylpropan-2-ol hydrochloride was prepared from (2S,3S)-3-(5-(benzyloxy)-1 H-indol-1 -yl)-2-hydroxy-3-phenylpropyl 4- methylbenzenesulfonate (from Example 82, Step 2), substituting A/,/V-dimethylamine . in place of methylamine. MS (ES) m/z 401 f(M+H)*]. Example 87: (1S,2R)-1-[5-(benzyloxy)-1 H-indol-1-yl]-3- [ethyl(methyl)amino]-1 -phenylpropan-2-ol hydrochloride (Formula Removed) ' In an analogous manner to Example 1, step 6, (1S,2R)-1-[5-(benzyloxy)- 1 H-indol-1 -yl]-3-[ethyl(methyl)amino]-1 -phenylpropan-2-ol hydrochloride was prepared from (2S,3S)-3-(5-(benzyloxy)-1 H-indol-1 -yl)-2-hydroxy-3-phenylpropyl 4- methylbenzenesulfonate (from Example 82, Step 2), substituting A/-ethylmethylamine in place of methylamine. MS (ES) m/z 415 [(M+H)+]. Example 88: (1 S,2R)-1-[5-(benzy)oxy)-1 H-indol-1 -yl]-3-(diethylamino)-1-phenylpropan-2-ol hydrochloride (Formula Removed) o In an analogous manner to Example 1, Step 6, (1S,2R)-1-[5-(benzyloxy)- 1 Hrindol-1-yl]-3-(diethylamino)-1 -phenylpropan-2-ol hydrochloride was prepared from (2S,3S)-3-(5-(benzyloxy)-1 H-indol-1 -yl)-2-hydroxy-3-phenylpropyl 4- methylbenzenesulfonate (from Example 82, Step 2), substituting diethylamine in place of methylamine. MS (ES) m/z 429 [(M+H)*} Example 89: (1 S.2R)-1-F5-(benzvloxv)-1 H-indol-1 -vll-1 -Dhenvl-3-Dvrrolidin-1-vlpropan-2-ol hvdrochloride (Formula Removed) In an analogous manner to Example 1, Step 6, (1S,2f?)-1-[5-(benzyloxy)-1 H-indol-1-yl]-1-phenyl-3-pyrrolidin-1-ylpropan-2-ol hydrochloride was prepared from (2S,3S)-3-(5-(benzyloxy)-1 H-indol-1 -yl)-2-hydroxy-3-phenylpropyl 4-methylbenzene s'Ulfo'rt'aWffi'om Example'B'2, Step 2), substituting pyrrolidine in place of methylamine. MS (ES) m/z 427 [(M+H)1 Example 90: f 1 S.2f?)-1-f5-(benzvloxvM H-indol-1-vn-1-phenvl-3-piperidin-1-vlpropan-2-ol hvdrochloride (Formula Removed) In an analogous manner to Example 1, Step 6, (1S,2f?)-1-[5-(benzyloxy)-1H-indol-1-yl]-1-phenyl-3-piperidin-1-ylpropan-2-ol hydrochloride was prepared from (2S,3S)-3-(5-(benzylo>y)-1 H-indol-1 -yl)-2-hydroxy-3-phenylpropyl 4-methylbenzene sulfonate (from Example 82, Step 2), substituting piperidine in place of methylamine. MS (ES) m/z 441 f(M+H)l Example 91: (1 S.2ffl-1-f5-(benzvloxv)-1 H-indol-1-vll-3-(4-methvlDiperazin-1 -vl)-1 -phenylpropan-2-ol hvdrochloride (Formula Removed) Irf an analogous manner to Example 1, Step 6, (1S,2R)-1-[5-(benzyloxy)- 1H-indol-1-yl]-3-(4-methylpiperazin-1-yl)-1-phenylpropan-2-ol hydrochloride was prepared from (2S,3S)-3-(5-(benzyloxy)-1H-indol-1-yl)-2-hydroxy-3-phenylpropyl 4-methylbenzenesulfonate (from Example 82, Step 2), substituting 1-methylpiperazine in place of methylamine. MS (ES) m/z 456 [(M+H)*]. Example 92: (1 S.2ffl-3-(methYlamino)-1-phenvl-1-f5-(Dvridin-2-vlmethoxv)-1 H-indol-1 -vnpropan-2-ol hvdrochloride (Formula Removed) In an analogous manner to Example 5, Step 3, te/f-butyl {(2R3S)-2-hydroxy-3-phenyl-3-[5-(pyridin-2-ylmethoxy)-1/-/-indol-1-yl]propyl}methylcarbamate was prepared from te/f-butyl [(2f?,3S)-2-hydroxy-3-(5-hydroxy-1 H-indol-1 -yl)-3-phenylpropyl]methylcarbamate (from Example 5, step 2), substituting 2-(bromomethyl)pyridine hydrobromide in place of 2-methoxybenzyl chloride. MS (ES) m/z 488 [(M+H)*]. In an analogous manner to Example 5, step 4, (1S,2f?)-3-(methylamino)-1-phenyl-1 -[5-(pyridin-2-ylmethoxy)-1 W-indol-1 -yl]propan-2-ol hydrochloride was prepared from te/f-butyl {(2R,3S)-2-hydroxy-3-phenyl-3-[5-(pyridin-2-ylmethoxy)-1H-indol-1-yl]propyl}methylcarbamate. MS (ES) m/z 388 [(M+H)*]. Example 93: (1S.2ffl-3-(methvlamino)-1-phenvl-1-f5-(Dhenvlethvnvn-1H-indol-1 -vnpropan-2-ol hvdrochloride (Formula Removed) In an analogous manner to Example 1, Step 2, 5-bromoindoline was prepared from 5-bromoindole. MS (ES) m/z 198 [(M+H)+]. In an analogous manner to Example 1, Step 3, (2S,3S)-3-(5-bromo-2,3-dihydro-1H-indol-1-yl)-3-phenylpropane-1,2-diol was prepared from [(2R3R)-3-phenyloxiran-2-yl]methanol (from Example 1, step 1), substituting 5-bromoindoline in place of 5-(benzyloxy)indoline. MS (ES) m/z 348 t(M+H)+]. In an analogous manner to Example 1, Step 4, (2S,3S)-3-(5-bromo-1H-indol-1-yl)-3-phenylpropane-1,2-diol was prepared from (2S,3S)-3-(5-bromo-2)3-dihydro-1H-indol-1-yl)-3-phenylpropane-1,2-diol. MS (ESI) m/z 346 A mixture of (2S,3S)-3-(5-bromo-1H-indol-1-yl)-3-phenylpropane-1,2-diol (500 mg, 1.44 mmol), phenylacetylene (d 0.930, 0.32 ml_, 2.9 mmol), copper (I) iodide (27 mg, 0.14 mmol), potassium carbonate (398 mg, 2.9 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (II) (57 mg, 0.007 mmol) in N,N-dimethyiformamide (10 mL) was purged with nitrogen for 30 minutes and then heated at 100°C. After 15 hours, the cooled mixture was filtered through Celite and washed with ethyl acetate (30 mL). The filtrate was diluted with ethyl acetate (120 ml), washed with water (5 x 100 mL) and saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The resulting dark oil was dissolved in dichloromethane and pre-adsorbed on silica gel (2.5 g). (SCO CombiFlash Companion chrornatography (40 g RediSep silica, 40 mL/min, 30-50% ethyl acetate/hexane) provided (2S,3S)-3-phenyl-3-[5-(phenylethynyl)-1H-indol-1-yl]propane-1,2-diol (452 mg, 85 %) as a tan solid. MS (ES) m/z 368 [(M+H)4]. In an analogous manner to Example 1, Step 5, (2S,3S)-2-hydroxy-3-phenyl-3-[5-(phenylethynyl)-1H-indol-1-yl]propyl 4-methylbenzenesulfonate was prepared from (2S,3S)-3-phenyl-3-[5-(phenylethynyl)-1H-indol-1-yl]propane-1,2-diol. MS (ES) m/z 522 [(M+H)*]. In an analogous manner to Example 1 , step 6, (IS^ffl-S-fmethvlaminoV-l-phenyl-1 -f5-(phenvlethvnvlV1 H-indol-1-ynpropan-2-ol hvdrochloride was prepared from (2S,3S)-2-hydroxy-3-phenyl-3-[5-(phenyl6thynyl)-1 H-indol-1 -yljpropyl 4-methylbenzenesulfonate. MS (ES) m/z 381 Example 94: (1 S.2ff)-3-(methvlamino)-1 -phenvl-1 -f 5-(2-phenvlethvlV1 H-indol-1-vnpropan-2-ol hvdrochloride (Formula Removed) A solution of (2S,3S)-3-phenyl-3-[5-(phenytethynyl)-1H-indol-1-yl]propane-1,2-diol, Example 93, Step 4, (1.2 g. 3.3 mmol) in ethyl acetate (40 ml_) was hydrogenated over 10 % palladium-on-carbon (0.24 g) at 50 psi. After 24 hours, the reaction mixture was filtered through Celrte and washed with ethyl acetate. The filtrate was concentrated under reduced pressure and the residue was dissolved in warm ethyl acetate (< 5 ml) and pre-adsorbed on silica gel (3 g). ISCO CombiFlash Companion chromatography (80 g RediSep silica, 60 mUmin, 30-100% ethyl acetate/hexane) provided (2S,3S)-3-phenyl-3-[5-(2-phenylethyl)-1H-indol-1-yl]propane-1,2-diol (0.96 g, 80 %) as a light yellow solid. MS (ES) m/z 372 In an analogous manner to Example 1, Step 5, (2S,3S)-2-hydroxy-3-phenyl-3-[5-(2-phenylethyl)-1/Y-indol-1 -yljpropyl 4-methylbenzenesulfonate was prepared 2^3S)-3-p!Ke'ny'l-3-[5-(2-phenylethyl)-1H-indol-1-yl]propane 1,2-diol. MS (ES) >6 In an analogous manner to Example 1 , Step 6, (1 S.2R)-3-(methvlaminoV-1 -1-1 -f 5-(2-phenvlethvlV1 H-indol-1 -vnpropan-2-ol hvdrochloride was prepared (2S,3S)-2-hydroxy-3-phenyl-3-[5-(2-phenylethyl)-1 H-indol-1 -yl]propyl 4-Ibenzenesulfonate. MS (ES) m/z 385 [(M+H)+J. Example 95: 1'-r(1S.2R)-3-amino-2-hvdroxv-1-phenvlpropvl1-6'-spjrofcvclohexarie-l .3'-indon-2'(1 'HVone hydrochlpride (Formula Removed) In an analogous manner to Example 27, Step 3, 1'-f(1 S.2R)-3-amino-2-xv-1 -phenvlpropyll-6'-fluorospirofcvclohexane-1.3'-indon-2'(1 'HVone chloride was prepared from 14(1S,2S)-2,3-dihydroxy-1-phenylpropyl]-6'-spirofcyclohexane-I.S'-indol^'tl'HJ-one (from Example 29, Step 2), substituting ammonium hydroxide in place of methylamine in ethanol solution. MS (ES) m/z 369.1 ([M+Hf); HRMS: calculated for C&HzsFNaOa + H+, 369.19728; found (ESI, [M+H]*), 369.1977. Example 96: 1 '-f(1 S.2ffl-3-(ethvlamino)-2-hvdroxv-1 -phenvlpropvll-e1-fluorospirofcvclohexane-1.3'-indon-2'(1'H)-one hvdrochloride (Formula Removed) In an analogousmanner to Example 27, Step 3, j'-fd S.2ffl-3-(ethvlamino)-2-hvdroxv-1 -phenvlpropvn-6'-fluorospirorcvclohexane-1.3'-indol]-2'(1'/-A-one hvdrochloride was prepared from r-[(1S,2S)-2,3-dihydroxy-1-phenylpropyl]-6'-fluorospiro[cyclohexane-1,3'-indol]-2'(r/-0-one (from Example 29, Step 2), substituting ethylamine in place of methylamine in ethanol solution. MS (ES) m/z 397.2 ([M+H]*); HRMS: calculated for C24H29FN202 + H*. 397.22858; found (ESI, [M+H]*), 397.2275. Example 97: 6'-fluoro-1'-[(1S.2ffl-2-hvdroxv-3-(isopropvlamino)-1- (Formula Removed) In an analogous manner to Example 27, Step 3, 6'-fluoro-1 '-f(1 S.2R)-2-hvdroxy-3-(isopropylarnino)-1-phenvlpropyl1spirorcyclohexane-1.3'-indol]-2'(1'H)-gne hvdrochloride was prepared from 1'-[(1S,2S)-2,3-dihydroxy-1-phenylpropyl]-6'-fluorospiro[cyclohexane-1,3'-indol]-2'(1'H)-one (from Example 29, Step 2), substituting isopropyl amine in place of methylamine in ethanol solution. MS (ES) m/z 411.2 <[M+H]+); HRMS: calculated for C25H3iFN2O2 + H*. 411.24423; found (ESI, [M+HD.411.2413. Example 98: 6'-fluQro-1'-f(1S.2f?)-2-hvdroxv-1-phenyl-3- (propylamino)propvnspirofcvclohexane-l .3'-indon-2'(1 V-fl-one hvdrochloride (Formula Removed) In an analogous manner to Example 27, Step 3, 6'-fluoro-1'-f(1S.2ffl-2-hvdroxv-1-Dhenvl-3-(proDvlamino)propvnspirorcvclohexane-1.3'-indon-2'(1'H)-one hvdrochloride was prepared from I'-KIS^S^.S-dihydroxy-l-phenylpropyll-e1-fluorospiro[cyclohexane-1,3'-indol]-2'(1'H)-one (from Example 29, Step 2), substituting propylamine in place of methylamine in ethanol solution. MS (ES) m/z 411.2 ([M-HHf); HRMS: calculated for C25H3iFN2O2 + H+, 411.24423; found (ESI, [M+H]+),411.2413. Example 99: 1'-fnS.2R)-3-amino-2-hvdroxv-1-phenvlDroDvn-5'- Q;g^ (Formula Removed) In an analogous manner to Example 27, Step 3, 1'-f(1 S.2/?)-3-amino-2-hvdroxv-1 -phenvlpropvl1-5'-fluorospirorcvclohexane-1.3'-indol]-2'I1 'H)-one hvdrochloride was prepared from 1'-[(1S,2S)-2,3-dihydroxy-1-phenylpropyl]-5'-fluorospiro[cyclohexane-1,3'-indol]-2l(.1'H)-one (from Example 30, Step 2), substituting ammonium hydroxide in place of methylamine in ethanol solution, MS (ES) m/z 369.1 ([M+HT); HRMS: calculated for C22H25FN2O2 + H+, 369.19728; found (ESI, [M+HD, 369.1982. :7i Example 100: 1 '-[(1 S.2ffl-3-(ethvlamino)-2-hvdroxv-1 -Dhenvlpropvll-S'-fluorospirofcvclohexane-1.3'-indon-2'(1 'H)-one hvdrochloride (Formula Removed) '"' Tn an analogous manner to Example 27, Step 3, 1'-f(1 S.2R)-3-(ethvlamino)-2-hvdroxv-1-phenvlpropvll-5'-fluorospirorcYclohexane-1.3'-indon-2'(1'H^-one hvdrochloride was prepared from 14(1S,2.S)-2,3-dihydroxy-1-phenylpropyl]-5'-fluorospirotcyclohexane-I.S'-indoll-^l'HJ-one (from Example 30, Step 2), substituting ethylamine in place of methylamine in ethanol solution. MS (ES) m/z 397.2 ([M+HD; HRMS: calculated for C24H29FtM2O2 -<• hT, 397.22858; found (ESI, IM+Hf), 397.229. Example 101: 5'-fluoro-1'-f(1S,2ffl-2-hvdroxv-3-(isopropylamino)-1-phenvlpropvnspirQfcycjohexane-l,3>iridon-2X1'HVQnehvdrpchlQride (Formula Removed) In an analogous manner to Example 27, Step 3, 5'-fiuoro-1'-ff1 S.2RV2 hydroxy-3-(isopropvlamino)-1-phenvlpropynspirofcvclohexane-1.3'-indoll-2'(1'H)~one hydrochloride was prepared from 14(1S,2S)-2,3-dihydroxy-1-phenylpropyl]-5'-fluorospirofcyclohexane-I.S'-indol^XI'HJ-one (from Example 30, Step 2), substituting isopropylamine in place of methylamine in ethanol solution. MS (ES) m/z 411.2 ([M+HD: HRMS: calculated for CjsHaiFNaOa + H+, 411.24423; found (ESI, [M-t-Hf), 411.2433. Example 102: 5'-fluoro-1'-f(1S.2f?V2-hvdroxv-1-phenvl-3-(propvlamino)propvnspi'rofcvclohexane-1.3'-indon-2'(1'/V)-ojie hvdrochloride (Formula Removed) "In""an'"anal6g6"us manner to Example 27, Step 3, 5'-fluoro-1'-r(1S.2R)-2- hvdroxv-1-phenvl-3-(propvlamino)proDvnspirorcvclohexane-1.3'-indol1-2'(1'H)-one hvdrochloride was prepared from 1'-[(1S,2S)-2,3-dihydroxy-1-phenylpropyl]-5'-fluorospiro[cyclohexane-1,3'-indol]-2'(1'H)-one (from Example 30, Step 2), substituting propylamine in place of methylamine in ethanol solution. MS (ES) mfc 411.2; HRMS: calculated for C25H3iFN2O2 + Hv, 411.24423; found (ESI, [M+H]+), 411.2438. Example 103: 1 '-f (1 S.2ffl-3-(dimethvlamino)-2-hvdroxv-1 -phenvlpropvll-S'-fluorospirorcvclohexane-1.3'-indol1-2'(1 'HV-one hydrochloride (Formula Removed) In an analogous manner to Example 27, Step 3, l'-r(1S.2/?)-3-(dimethvlamino)-2-hvdroxv-1-phenvlpropvn-5'-fluorospirorcyclohexane-1.3'-indon-2'(1'H)-one hvdrochloride was prepared from 1'-[(1S,2S)-2,3-dihydroxy-1-phenylpropyl]-5'-fluorospiro[cyclohexane-1,3'-indol]-2'(1'H)-one (from Example 30, Step 2), substituting dimethylamine in place of methylamine in ethanol solution. MS (ES) m/z 397.2 ([M+H]*); HRMS: calculated for Cs-tHagFNaOz + H*. 397.22858; found (ESI, [M+Hf), 397.2283. Example 104: 5'-fluoro-1'-f(1S.2R)-2-hvdroxv-3-morpholin-4-vl-1-phenvlpropvnspirofcvclohexane-1.3'-indon-2'n 'H>-one hvdrochloride (Formula Removed) in an analogous manner to Example^?, Step 3, 5'-fluoro-1 '-K1 S.2ffl-2-hvdroxy-3-morpholin-4-vl-1-phenvlpropvllspirofcyclohexane-1.3'-indon-2'(1'H)-one hvdrochloride was prepared from r-[(1S,2S)-2,3-dihydroxy-1-phenylpropyl]-5'-fluorospirotcyclohexane-I.S'-indoll^'O'HJ-one (from Example 30, Step 2), substituting morpholine in place of methylamine in ethanol solution. MS (ES) m/z 439.1 ([M+H]*); HRMS: calculated for CaeHaiFNaCb + H*. 439.23915; found (ESI, [M+Hf), 439.2392., Example 105: 1'-r(1S.2R)-2-hvdroxv-3-(methvlamino)-1-phenvtpropvn-5'-methoxvsDirofcvclohexane-1.3'-indoll-?'(1 'H]-one hvdrochloride (Formula Removed) In an analogous manner to Example 27, Step 1, 5'-methoxyspiro[cycIohexane-1,3'-indol]-2'(1'H)HDne was prepared from 5-methoxyoxindole. In an analogous manner to Example 27, Step 2, 1'-[(1S,2S)-2,3-dihydroxy-1-phenylpropyl]-5'-methoxyspiro[cyclohexane-1 .S'-indolj^XI'H^ne was prepared from S'-methoxyspirolcydohexane-l ,3'-indol]-2'(1 'H)-one. In an analogous manner to Example 27, Step 3, 1 '-IY1 S.2f?)-2-hvdroxv-3-(methvlamino)-1-phenvlpropvn-5'-methoxvsDirofcvclohexane-1.3'-indot1-2'n'Hy-one hvdrochloride was prepared from 1'-[(1S,2S)-2,3-dihydroxy-1-phenylpropyl]-5'-methoxyspiroIcyclohexane-I.S'-indoll^XI'^-one. MS (ES) m/z 395.2 ([M+H]+); HRMS: calculated for Ca^ao^Oa + H+, 395.23292; found (ESI, [M+Hf), 395.2313. Example 106: 1'-rMS.2ffl-2-hvdroxv-3-(methvlamino)-1-Phenvlpropvn-6'' methoxvspirorcvclohexane-1.3'-indon-2'(1 'H)-one hvdrochloride (Formula Removed) In an analogous manner to Example 27, Step 1, 6'- methoxyopiro[cyclohexane-i,3'-indol]-2'(1'H)-one was prepared from 6-methoxyoxindole. In an analogous manner to Example 27, Step 2, 1'-[(1 S.2S)-2,3-dihydroxy-1-phenylpropyl]-6'-methoxyspiro[cyclohexane-1,3'-indol]-2'(1'H)-one was prepared from 6'-methoxyspiro[cyclohexane-1,3'-indol]-2'(1 '/-/)-one. In an analogous manner to Example 27, Step 3, 1 '-[(1 S.2f?V-2-hvdroxv-3-(methylaminoM -pherivlpropvn-6'-methoxvspirorcvclohexane-1.3'-indon-2'(1 'H)-one hydrochloride was prepared from 1'-[(1S,2S)-2,3-dihydroxy-1-phenylpropyl]-6'-methoxyspiro[cyclohexane-1,3'-indol]-2'(1'H)-one. MS (ES) m/z 395.1 ([M+H]*); HRMS: calculated for C^M^Oa + H+, 395.23292; found (ESI, [M+H]*), 395.2317. Example 107: 1 '-K1 S.2KV-2-hvdroxv-3-(methvlaminoV-1 H3henvlpropvn-2'-oxo-1 '.2'-dihydrospirorcyclohexane-1,3'-indole1-5'-carbonitrile hvdrochloride (Formula Removed) in an analogous manner to Example 27, Step 1, 2'-oxo-1',2'-dihydrospiro[cyclohexane-1,3'-indole]-5'-carbonitrile was prepared from 5-cyano-oxindole. MS (ES) m/z 225.0 {[M-H]'). In an analogous manner to Example 27, Step 2, 1 -phenylpropyO^'-oxo-V^'-dihydrospirolcyclohexane-l ,3'-indole]-5'-carbonitrile was prepared from 2'-oxo-1l,2l-dihydrospiro[cyclohexane-1,3'-indole]-5'-carbonitrile. MS (ES) m/z 377.1 In an analogous manner to Example 27, Step 3, 1 '-f (1 S,2R)-2-hvdroxv-3-(methvlamino)-1-phenvlpropvn-2'-oxo-1'.2'-dihvdrospirofcvclohexane-1.3'-indole1-5'-carbonitrile hvdrochloride was prepared from 1'-[(1S,2S)-2,3-dihydroxy-1-phenylpropyI]-2'-oxo- 1 ',2'-dihydrospiro[cyclohexane-1 .S'-indoleJ-S'-carbonitrile. MS (ES) m/z 390.1 ([M+H]+); HRMS: calculated for CuUzjMiOi + H*. 390.21760; found (ESI, [M+H]*), 390.2184. Example 1 08: 1 '-f ( 1 S.2/?)-2-hvdroxv-3-(meth ylamino)-1 -phenylpropvn-2'-oxo-1'.2'-dihvdrospirorcvclohexane-1.3'-indole1-6'-carbonitrile hvdrochloride (Formula Removed) In an analogous manner to Example 27, Step 1, 2'-oxo-1',21-dihydrospiro[cyclohexane-1,3'-indole]-6'-carbonitrile was prepared from 6-cyano-oxindole. MS (ES) m/z 225.0 ([M-H]'). In an analogous manner to Example 27, Step 2, I'-1 -phenylpropyl]-2'-oxo-1 ',2'-dihydrospiro(cyclohexane-1 ,3'-indoleJ-6'-carbonitrile was prepared from 2'-oxo-1',2'-dihydrospiro[cyclohexane-1,3l-indole]-6'-carbonitrile. MS (ES) m/z 377.1 ([M+H]*). In an analogous manner to Example 27, Step 3, 1'-f(1 S.2f?V2-hydroxv-3-(methylaminoH -phenvlpropvn-2'-oxo-1 '.2'-djhvdrospirofcvclohexane-1 .3'-indole1-6'-carbonitrile hydroc:hloride was prepared from 1'-[(1S)2S)-2,3-dihydroxy-1-phenylpropyl]-2'-oxo--1 ',2'-dihydrospiro[cyclohexane-1 ,3'-indole]-6'-carbonitrile. MS (ES) m/z 390.2 ([M+Hf); HRMS: calculated for C24H27N3O2 + H+, 390.21760; found (ESI, [M+Hfj, 390.2186. Example 1 09: 4',5'-difluoro-1 -[(1 S,2R)-2-hydroxy-3-(methylamino)-1 -phenylpropyl]spiro[cyclohexane-1 ,3'-indol]-2'(1 'H)-one hydrochloride (Formula Removed) in an analogous manner to Example 27, Step 1, 4',5'-difluorospiro[cyclohexane-1,3l-indol]-2'(1'H)-one was prepared from 4,5-difluoro-oxindole. MS (ES) mlz 238.1 ([M-v-Hf). In an analogous manner to Example 27, Step 2, r-[(1S,2S)-2,3-dihydroxy-1-phenylpropyl]-4',5'-difluorospiro[cyclohexane-1 ,3'-indol]-2'(1 W)-one was prepared from 4\5' Example 113: (1 S.2RH-O-chloro-S-fluorophenvIM-(2.3-dihvdro-1 H-indol-1 -vl)-3-(methylamino>propan-2-ol hvdrochloride (Formula Removed) — . In an analogous manner to Example 25, Step 5, (1S,2R)-1-(3-chloro-5-fluorophenyl)-1-(2,3-clihydro-1H-indol-1-yl)-3-(methylamino)propan-2-ol hydrochloride was prepared from (2S,3S)-3-(3~chlorc~5-fluorophenyl)-3-(2,3-dihydro-1H-indol-1-yl)propane*-1,2-diol (from Example 70, Step 4) as a white powder. HRMS: calculated for Ci8H2oCIFN2O + H+, 335.1321; found (ESI, [M+HD, 335.1318. 1 >•-*• Example 114: (1S.2R)-1-(3-chloro-5-fluorophenvl)-1-(7-fluoro-3.3-dimethvl-2.3-dihvdro-1 H-indo\-'\ -vl)-3-(methvlamino)propan-2-ol hvdrochloride (Formula Removed) In an analogous manner to Example 52, Step 2, 7-fluoro-3,3-dimethylindoline was prepared from 7-fluoro-3,3-dimethyl-1,3-dihydro-2fY-indol-2-one (from Example 69, Step 4) as a white powder. MS (ES) m/z 166.1 ([M+H]*); HRMS: calculated for C10Hi2FN + H+, 166.1032; found (ESI, [M+H]+), 166.1040. In an analogous manner to Example 1, Step 3, (2S,3«S)-3-(3-chloro-5-fluorophenyl)-3-(7-fluoro-3,3-dimethyl-2,3-dihydro-1 H-indol-1 -yl)propane-1,2-diol was prepared from 7--fluoro-3,3-dimethylindoline and [(2R3/?)-3-(3-chloro-5-fluorophenyl)oxiran-2-yl]methanol (from Example 70, Step 3) as an amber gum. MS (ESI) m/z 368.1 flM+H]*); HRMS: calculated for Ci9H2oCIF2NO2 + H+, 368.1223; found (ESI, [M+HD, 368.1234. In an analogous manner to Example 25, Step 5, (1S,2R)-1-(3-chloro-5-fluorophenyl)-1 -(7-fluoro-3,3-dimethyl-2,3-dihydra-1 H-indol-1 -yl)-3-(methylamino)propan-2-ol hydrochloride was prepared from (2S,3S)-3-(3-chloro-5-fluorophenyl)-3-(7-fluoro-3,3-dimethyl-2,3-dihydro-1H-indot-1-yl)propane-1,2-diol as an ivory solid. MS (ES) m/z 381.1 ([M+Hf); HRMS: calculated for CaoHzsCI H*. 381.1540; found (ESI, [M+H]4), 381.1533. Example 115: (1S.2f?)-1-(3-chloro-5-fluorophenvl)-1-(3.3-dimethvl-2.3- dihvdro-1 H-indol-1 -vl)-3-(methvlamino)propan-2-ol hvdrochloride (Formula Removed) In an analogous manner to Example 1, Step 3, (2S,3S)-3-(3-chloro-5- fluorophenyl)-3-(3,3-dimethyl-2,3-dihydro-1 H-indol-1-yl)propane-1,2-diol was prepared Trom a.a-dimiethyiindoline and [(2f?,3K)-3-(3-chloro-5-fluorophenyl)oxiran-2-yl]methanol (from Example 70, step 3) as a light brown gum. MS (ESI) m/z 350.0 ([M+HD; HRMS: calculated for Ci9H2iCIFNO2 + H*, 350.1318; found (ESI, [M+HD, 350.1293. In an analogous manner to Example 25, Step 5, (1S,2R)-1-(3-chloro-5-fluorophenyl)-1-(3)3-dimethyl-2,3-dihydro-1H-indol-1-yl)-3-(methylamino)propan-2-ol hydrochloride was prepared from (2S,3S)-3-(3-chloro-5-fluorophenyl)-3-(3,3-dimethyl-2,3-dihydro-1H-indol-1-yl)propane-1,2-diol as a white powder. MS (ES) m/z 363.1 ([M+H]+); HRMS- calculated for CooHo-sOIFNoO -f H*. 363.1634; found (ESI, [M+Hf), 363.1622. Example 116: 7'-fluoro-1'-f(1.S.2f?)-1-(3-fluorophenvl)-2-hvdroxv-3- (methvlamino)proDvnspirofcvclobutane-l .3'-indon-2'(1 'H)-one hvdrochloride (Formula Removed) In an analogous manner to Example 62, Step 4, 7'-fluorospiro[cyc!obutane-1,3'-indol]-2'(1'W)-one was prepared from 7-fluoro-1,3-dihydro-2Wndol-2-one (from Example 62, Step 3), substituting 1,3-dibromopropane in place of methyl iodide. MS (ES) mfr 192 [(M+H)1. In an analogous manner to Example 62, Step 5, 7'-fluoro-1'-((1S,2S)-1-(3- fluorophenyO^.S-dihydroxypropyOspiroIcyclobutane-l.a'-indolinJ^'-one was prepared from 7'-fluorospiro[cyclobutane-1,3l-indol]-2l(1'/-/)-one, substituting [(2R,3R)-3-(3-fluorophenyl)oxiran-2-yl]methanol (from Example 24, Step 1) in place of [(2/?,3R)-3-(3,5-difluorophenyl)oxiran-2-yl)methanol. MS (ES) m/z 360 l(M+H)+]. In an analogous manner to Example 62, step 6, 7'-fluoro-1'-f(1S.2ffl-1-(3-fluorophenvn-2-hvdrow-3-(methvlamino^Dropvl1spirorcvclobutane-1.3'-indon-2'(1'H)-one hvdrochloride was prepared from 7'-fluoro-1'-(('lS,2S)-1-(3-fluorophenyl)-2l3-dihydroxypropyl)spiro[cyclobutane-1 ,3'-indolin]-2'-one. MS (ES) m/z 373 Example 1 17: 7'-fluoro-1'-fnS.2ffl-1-(3-fluorophenvl)-2-hvdroxv-3-f methvlamino)propvl1spirofcvclopentane-1 13'-indon-2'(r/-fl-one _ hvdrochloride (Formula Removed) In an analogous manner to Example 62, Step 4, 7'-fluorospiro[cyclopentane-1,3'-indol]-2l(1lH)-one was prepared from 7-fluoro-1,3- dihydro-2H-indol-2-one (from Example 62, Step 3), substituting 1,4-dibromobutane in place of methyl iodide. MS (ES) m/z 206 [(M+H)*]. In an analogous manner to Example 62, Step 5, 7'-fluoro-1I-((1S,2S)-1-(3- fluorophenyl)-2,3-dihyclroxypropyl)spiro[cyclopentane-1,3'-indolin]-2'-one was prepared from 7'-fluorospiro[cyclopentane-1,3'-indol]-2'(1'H)-one, substituting [(2R,3R)-3-(3-fluorophenyl)oxiran-2-yl]methanol (from Example 24, Step 1) in place of [(2R,3f?)-3-(3.5-difluorophenyl)oxiran-2-yl]methanol. MS (ES) m/z 374 [(M+H)+J. In an analogous manner to Example 62, Step 6, 7'-fluoro-1 '-f(1 S.2R)-1 -(3-fluorophenvn-2-hvdrox'/-3-fmethvlamino)proDvnsDirofcyclopentane-1.3'-indoll-2'n'H)-one hvdrochloride was prepared from 7l-fluoro-1'-((1S,2S)-1-(3-fluorophenyl)-2,3-dihydroxypropyl)spiro[cyclopentane-1,3'-indolin]-2'-one. MS (ES) m/z 387 [(M+H)+J. Example 118: 6-fluoro-1 -f(1 S.2ffl-1 -f3-fluorophenvl)-2-hvdroxv-3-(methvlamino)propvn-3.3-dimethvl-1.3-dihvdro-2H-indol-2-one hvdrochloride (Formula Removed) To a hexanes-washed (2x) suspension of sodium hydride (60 % in oil, 14 g, 350 mmol) in dimethyl sulfoxide (300 ml) was added dimethyl malonate (46 g, 350 mmol) dropwise at 23°C. The reaction mixture was heated at 100°C for 45 minutes, then cooled to 23°C and 2,5-difluoronitrobenzene (25 g, 160 mmol) was added. The mixture was stirred at 23°C for 30 minutes, than heated at IOO°C for I hour. The cooled mixture was poured into a mixture of saturated aqueous ammonium chloride (1.2 L), ethyl acetate (250 ml) and hexanes (250 mL). The organic phase was separated and washed with saturated aqueous ammonium chloride (500 ml), water (3 x 500 mL) and saturated brine (500 mL), and dried over anhydrous magnesium sulfate. Concentration under reduced pressure gave an oily yellow solid (47 g) that was recrystallized from boiling 20 % ethyl acetate-hexanes (ca. 300 mL) to provide dimethyl (4-fluoro~2-nitrophenyl)malonate (35 g, 81 %) as shiny white prisms. MS (ES) m/z 270 [(M-H)']. Dimethyl (4-fluoro-2-nitrophenyl)malonate (5.0 g, 18 mmol), lithium chloride (1.6 g, 38 mmol) and water (0.33 g, 18 mmol) were combined in dimethyl sulfoxide (100 mL) and heated at 100°C. After 21 hours, the cooled solution was poured into a stirred mixture of saturated brine (200 mL) and ethyl acetate (200 mL). The phases were separated and the aqueous phase was extracted with ethyl acetate (200 rhL). The combined organic extracts were washed with saturated brine (2 x 200 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a dark oil (4.0 g) that was dissolved in dichloromethane and pre-adsorbed on silica gel (10 g). Flash column chromatography (silica 190 g, 5 %, 10 %, 20 % ethyl acetate/hexanes) provided methyl (4-fluoro-2-nitrophenyl)acetate (2.1 g, 54 %) as a yellow oil. MS (ES) m/z 212 f(M-H)-]. Metnyi (4-tiuoro-2-nitrophenyl)acetate (7.1 g, 33 mmol) and iron powder (7.4 g, 130 mmol) were combined in glacial acetic acid (65 ml) and heated at 100°C. After 2 hours, the cooled mixture was concentrated under reduced pressure. The residue was dissolved in hot ethyl acetate (100 ml), filtered through Celite and washed with hot ethyl acetate (100 ml). The filtrate was washed with 1 N aqueous hydrochloric acid (3 x 100 ml) and saturated brine (100 ml), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a brown solid. Trituration with 5 % ethyl acetate-hexanes (100 mL) provided 6-fluoro-1 ,3-dihydro-2H-indol-2-one (4.8 g, 96 %) as a tan solid. MS (ES) m/z 150 [(M-H)']. In an analogous manner to Example 62, Step 4, 6-fluoro-3,3-dimethyl-1 ,3-dihydro-2H~indol-2-one was prepared from 6-fluoro-1 ,3-dihydro-2H-indol-2-one. MS In an analogous manner to Example 62, Step 5, 6-fluoro-1-((1S,2S)-1-(3- fluorophenyl)-2,3-dihydroxypropyl)-3,3-dimethylindoHn-2-one was prepared from 6- fluoro-3,3-dimethyl-1 ,3-dihydro-2H-indol-2-one, substituting [(2R,3R)-3-(3- fluorophenyl)oxiran-2-yl]methanol (from Example 24, step 1) in place of [(2R,3R)-3-(3,5-difluorophenyl)oxiran-2-yl]methanol. MS (ES) m/z 348 [(M+H)*]. A solution of 6-fluoro-1-((1S,2S)-1-(3-fluorophenyl)-2,3-dihydroxy propyl)-3,3-dimethylindolin-2-one (0.32 g, 0.92 mmol) in tetrahydrofuran (4.5 mL) was treated with triphenylphosphine (0.30 g, 1.1 mmol) at 23°C. When a solution had formed, /V-ch!orosuccinimide (0.15 g, 1.1 mmol) was added. After a further 1 hour, the reaction solution was concentrated under vacuum to a small volume and pre-adsorbed on silica gel (1 g). ISCO CombiFlash Companion chromatography (12 g RediSep silica, 30 miL/min, 0-30 % ethyl acetate/hexane) provided 1-((1S,2S)-3-chloro-1 -(3-fluorophenyl)-2-hydroxypropyl)-6-fluoro-3,3-dimethylindolin-2-one (0. 1 2 g, 35 %) as a clear, almost colorless oil. MS (ES) m/z 366 In an analogous manner to Example 1, Step 6, 6-fluoro-1-[(1S,2R)-1-(3-fluorophenyl)-2-hydro>cy-3-(methylamino)propyl]-3,3-dimethyl-1,3-dihydro-2H-indol-2- ori'e "hydrochloride was prepared from 1-((1S,2S)-3-chloro-1-(3-fluorophenyl)-2-hydroxypropyl)-6-fluoro-3,3-dimethylindolin-2-one. MS (ES) m/z 361 [(M+H)+]. Example 119: (1 S.2ffl-1 -(7-Fluoro-2.3-dihvdro-1 H-indol-1 -vl)-3-(methvlamino)-l -phenvlpropan-2-ol hvdrochloride In an analogous manner to Example 1, Step 2, 7-fluoroindoline was prepared from 7-fluoroindole as a clear liquid. MS (ESI) m/z 138 ([M+H]*). In an analogous manner to Example 1, Step 3, (2S,3S)-3-(7-fluoroindolin-1-yl)-3-phenylpropane-1,2-diol was prepared from 7-fluoroindoline as a white solid. MS (ESI) m/z 288.1 A mixture of (2S,3S)-3-(7-fluoroindolin-1-yl)-3-phenylpropane-1,2-diol (1.09 g, 3.8 mmol) and triphenylphosphine (1.49 g, 5.7 mmol) was dissolved in tetrahydrofuran (30 ml.). To this was added N-chlorosuccinimide (0.76 g, 5.7 mmol) and the reaction mixture was further stirred at room temperature for 30 minutes. The mixture was then concentrated under reduced pressure and the residue was purified via Biotage Horizon (FlasH 40 M, silica, gradient from 0% ethyl acetate/hexane to 40% ethyl acetate/hexane) to give (1S,2S)-3-chloro-1-(7-fluoroindolin-1-yl)-1-phenylpropan-2-ol as a clear oil. MS (ESI) m/z 306 ([M+H]+). (1S,2S)-3-chloro-1-(7-fluoroindolin-1-yl)-1-phenylpropan-2-ol (0.49 g, 1.6 mmol) was treated with a solution of methylarnine in ethanol (2.0 M, 8 ml, 16 mmol) and the solution was stirred in a sealed vessel at room temperature for 15 hours. After dilution with a saturated aqueous solution of sodium bicarbonate, the mixture was extracted with a solution of dichloromethane/isopropanol (3/1). The extract was washed with water arid brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was crystallized from dichloromethane by adding minimum amount of ethyl acetate and diethyl ether to anora the title compound (1S,2R)-1-(7-fluoro-2,3-dihydro-1H-indol-1-yl)-3-(methylamino)-1-phenylpropan-2-ol hydrochloride as a white solid. MS (ES) m/z 300.9 ([M+H]+); HPLC purity 92.9% at 210-370 nm, 7.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for 10min, hold 4min. HRMS: calculated for C18H2iFN2O + H+, 301.17107; found (ESI, [M+H]+), 301.1695. Example 120: 4-fluoro-3-r(1S.2ffl-1-(3-fluorophenvl)-2-hvdroxv-3-(methvlarnino)propvll-l -phenvl-1.3-dihydro-2H-benzimidazol-2-one hvdrochloride (Formula Removed) 'Step 1: To a solution of 2,5-difluoronitrobenzene (2.6 g, 6.28 mmol) and aniline (d 1.022, 1.15 mL, f2.6 mmol) in dry A/./V-dimethylformamide (10 mL) was added potassium tert-butoxide (1.40 g, 12.5 mmol) in portions. After 16 hours at room temperature, the reaction mixture was poured into saturated aqueous ammonium chloride solution and extracted with dichloromethane (2 x 50 mL). The combined organic layers were washed with water (1 x 50 mL), dried over anhydrous magnesium surfate, filtered and concentrated under reduced pressure to afford crude 3-fluoro-2-nrtro-N-phenylaniline (1.15 g, 78 %), which was used in the next step without further purification. .. Step 2: A mixture of 3-fluoro-2-nitro-N-phenylaniline (1.15 g, 4.9 mmol) and palladium on charcoal (10 %, ca. 200 mg) in methanol (30 mL) was hydrogenated (50 psi H2) in a Parr shaker apparatus. After 2 hours, the catalyst was removed by filtration through a pad of celite, and the cel'rte washed with fresh methanol (20 mL). The combined methanol layers were concentrated under reduced pressure and the residue purified by column chromatography (silica, 1:0 to 9:1 hexanes:ethyl acetate) to afford" S-fl'd6r:mi-p7rei1ylbenzene-1,2-diarnine (0.47 g, 47 %). MS (ES) m/z 203.2 Step 3: To a stirred solution of 3-fluoro-N1-phenylbenzene-1,2-diamine (0.247 g, 1.22 mmol) in dry tetrahydrofuran (10 ml) was added carbonyl diimidazole (0.21 g, 1.30 mmol) under nitrogen. After 30 minutes, 4-dimethylaminopyridine (catalytic amount) was added and the reaction stirred over night. After 16 hours a further portion of carbonyl diimidazole was added (0.21 g, 1.3 mmol) and stirring continued. After 48 hours, the reaction mixture was diluted with ethyl acetate (ca. 50 mL) and extracted with sodium hydroxide solution (?N, 2 x 25 ml). The combined basic extracts were washed with ethyl acetate and then acidified (hydrochloric acid, pH 1). The product was collected by filtration and was then washed with water, hexanes and air dried to afford 4-fluoro-1-phenyl-1H-benzo[d]imidazol-2(3H)-one (0.1 17 g, 42 %) as a white solid. MS (ES) m/z 228.9 ([M+H]+). Step 4: Sodium hydride (60 % in oil, 33 mg, 0.89 mmol) was added to 4-fluoro-1-phenyl-1H~benzo[d]imidazol-2(3H)-one (0.102 g, 0.447 mmol) in dry N,N-dimethylformamide (3 mL) under nitrogen, and the mixture stirred for 20 minutes. In a separate flask, [(2R1l3R)-3-(3-fluorophenyl)oxiran-2-yl]methanol (from Example 24, Step 1, 0.15 g, 0.89 mmol) in dry dimethylformamide (3 ml) was treated with titanium tetra /so-propoxide (0.26 mL, 0.89 mmol). After 20 minutes this mixture was added to that prepared first. After 16 hours the reaction mixture was quenched by the addition of 2 N aqueous hydrochloric acid solution, extracted with ethyl acetate, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was then purified by column chromatography (silica, 1:0 to 0:1 hexanes:ethyl acetate), to afford 4-fluoro-3-((1S,2S)-1-(3-fluorophenyl)-2,3-dihydroxypropyl)-1-phenyl-1H-benzo[d]imidazol-2(3H)-one (0.146 g, 82%), which was used without further evaluation. Step 5: To a solution of 4-fluoro-3-((1S,2S)-1-(3-fluorophenyl)-2,3-dihydroxypropyl)-1-phenyl-1H-benzo[d]imidazol-2(3H)-one (0.146 g, 0.37 mmol) in dry pyridine (3 mL) was added p-toluenesulfonyl chloride (0.076 g, 0.39 mmol). After 3 hours, a further portion of p-toluenesulfonyl chloride (0.050 g, 0.27 mmol) was aaea and me reaction stirred over night. After 16 hours the mixture was diluted with ethyl acetate and washed with saturated aqueous copper II sulfate solution (x 2) and water, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was then dissolved in methylamine solution (8M in ethanol, 10 mL) and stirred over night. After 16 hours, the mixture was evaporated under reduced pressure and the residue dissolved in ethyl acetate, washed with 2 N aqueous sodium hydroxide solution (10 ml), and water, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography (silica, 100:0 to 95:5 dichloromethane: methanol saturated with ammonia) to afford 4-f!uoro-3-[(1S,?R)-1-(3-fluorophenyl)-2-hydroxy-3-(methylamino)propyl]-1-phenyl-1,3-dihydro-2H-benzimidazol-2-one (0.027 g, 16%). The solid was then dissolved in ethanol and treated with 2 N hydrochloric acid solution (01 ml) concentrated under reduced pressure and triturated with diethyl ether to afford 4-fluoro-3-[(1S,2R)-1-(3-fluorophenyl)-2-hydroxy-3-(methylamino)propyl]-1-phenyl-1,3-dihydro-2H-benzimidazol-2-one hydrochloride (6 mg) as a white solid. HRMS: calculated for + H+, 410.16746; found (ESI, [M+H]+), 410.1662. Example 121 : 4-fluoro-1-(3-fluoroDhenvn-3-fnS.2ffl-1-(3-fluorophenvlV-2-hvdroxy-3-(methvlamino)propvn-1.3-dihydro-2H-benzimidazol-2-one hvdrochloride (Formula Removed) 2,6-difluoronitrobenzene (5 g, 31.4 mmol), potassium tert-butoxide (3.5 g, 31.3 mmol), and 3-fluoroaniline (3.47 g, 31.3 mmol) in anhydrous dimethylsulfoxide (20 mL) was stirred at room temperature. Upon completion, the reaction was partitioned between saturated ammonium chloride solution (50 mL) and ethyl acetate (50 mL). The organic phase was separated, dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The product was purified on silica gel to give (a--riuoro-2-nitro-phenyl)-(3-fluoro-phenyl)-amine that was directly in the next step. A solution of (3-Fluoro-2-nitro-phenyl)-(3-fluoro-phenyl)-amine (3.27 g, 13 mmol) in methanol (50 ml) was hydrogenated over 10 % palladium-on-carbon (ca. 200 mg) at 50 psi. Upon complete reduction, the reaction was filtered through a pad of celite and concentrated onto silica gel. The product was purified on silica gel to give 3-fluoro-N1-(3-fluorophenyl)benzene-1,2-diamine (1.26 g, 44%). MS (ES) m/z 221 ([M+H]+); HRMS: calculated for C12HioF2N2 + H+, 221.08848; found (ESI, [M+Hf), 221.0858 3-Fluoro-N1-(3-fluorophenyl)benzene-1,2-diamine (1.15 g, 5.22 mmol) and carbonyl diimidazole (1.46 g, 9 mmol) in dioxane (20 ml_) was stirred at room temperature for 16 hours. Upon completion, the reaction was partitioned between 1 N hydrochloric acid (100 mL) and ethyl acetate (100 mL). The organics were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give 4-fluoro-1-(3-fluorophenyl)-1,3-dihydro-2H-benzimidazol-2~one (0.75 g, 59%). MS (ES) m/z 247.0 ([M+H]+). In an analogous manner to Example 120, Step 4, 4-fluoro-1-(3-fluorophenyl)-3-[(1 S, 2S)-1 -(3-fluorophenyl)-2,3-dihydroxypropyl]-1,3-dihydro-2H-benzimidazol-2-one was prepared from 4-fluoro-1-(3-fluorophenyl)-1,3-dihydro-2H-benzimidazol-2-one and [(2R,3R)-3-(3-fluorophenyl)oxiran-2-yl]methanol. MS (ES) m/z 415.0 ([M+H]*); HRMS: calculated for C^H^FsNaOs + H*. 415.12640; found (ESI, [M-HHD, 415.1263. In an analogous manner to Example 25, Step 5, 4-fluoro-1-(3-fluorophenyl)-3-[(1 S,2/?)-1-(3-fluorophenyl)-2-hydroxy-3-(methylamino)propyl]- 1,3-dihydro-2AY-benzimidazol-2-one hydrochloride was prepared from 4-fluoro-1-(3-fluorophenyl)-3-[(1S,2S)-1-(3-fluorophenyl)-2,3-dihydroxypropyl]-1,3-dihydro-2/-/-benzimidazol-2-one. HRMS: calculated for C^oFaNaOa + H+, 428.15804; found (ESI, [M+H]+), 428.1581. Example1122: 1-K1 S.2R)-3-amino-1 -f 3.5-difluoroDhenvl)-2-hvdroxvpropvl1- 7-fluoro-3.3-dimethvl-1.3-dihvdro-2H-indol-2-one (Formula Removed) To a solution of 7-fluoro-1-[(1S,2S)-1-(3,5-difluorophenyl)-2,3-dihydroxypropyl]-3,3-dimethyl-1,3-dihydro-2H-indol-2-one (2.21g, 6.05 mmol, from Example 62, Step 5) in tetrahydrofuran (30 ml) was added triphenylphosphine (1.98g, 7.56 mmol). The mixture was stirred at ambient temperature until all the triphenylphosphine was dissolved. To this solution was then added N-chlorosuccinimide (1.01 g, 7.56 mmol) and the resultant mixture was allowed to stir at ambient temperature for 50 minutes. The mixture was concentrated under reduced pressure and residue purified using silica gel column (eluting with a gradient of 0% to 40% ethyl acetate in hexane) to afford the chloride intermediate (1.85g, 80%). To a solution of the above chloride (0.35 g, 0.9 mmol) in dry N,N-dimethylformamide (5 mL) was added sodium iodide (0.15 g, 1 mmol) and sodium azide (0.16g, 2.3 mmol). The mixture was heated at 70°C for 18 hours, then poured into a saturated solution of ammonium chloride (80 mL). The aqueous mixture was extracted with ethyl acetate (3x20 mL), the combined organic extracts dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The residue obtained was then taken up in methanol (20 mL) and 5% palladium on carbon added. The mixture was subject to hydrogenation (40 psi HZ) for 2 hours and then filtered through a pad of celite to remove palladium on carbon. The filtrate was concentrated and purified on a silica gel column (9% of methanol in methylene chloride) to give 1-[(1S,2R)-3-amino-1-(3,5-difluorophenyl)-2-hydroxypropyl]~7-fluoro-3,3-dimethyl-1,3-dihydro-2H-indol-2-one as an oil. The freebase was dissolved in ether (10 mL) and treated with hydrogen chloride solution (1.0 M in diethyl ether, 1.0 equivalent). The white precipitate was collected and dried under vacuum then dissolved in 10 mL of water and lyophilized to 1-[(1S,2R)-3-amino-1-(3,5- -2-r^^ hydrochloride. MS (ES) m/z 364.9 ([M+Hf). CelLLines. Culture Reagents, and Assays MDCK-Net6 cells, stably transfected with human hNET (Pacholczyk, T., R.D. Blakely, and S.G. Amara, Nature, 1991, 350(6316): p. 350-4) were cultured in growth medium containing high glucose DMEM (Gibco, Cat. No. 11995), 10% FBS (dialyzed, heat-inactivated, US Bio-Technologies, Lot FBD1129HI) and 500 Dg/ml G418 (Gibco, Cat. No. 10131). Cells were plated at 300.000/T75 flask and cells were split twice weekly. The JAR cell line (human placental choriocarcinoma) was purchased from ATCC (Cat. No. HTB-144). The cells were cultured in growth medium containing RPMI 1640 (Gibco, Cat. No. 72400), 10% FBS (Irvine, Cat. No. 3000), 1% sodium pyruvate (Gibco, Cat. No. 1136) and 0.25% glucose. Cells were plated at 250,000 cells/T75 flask and split twice weekly. For all assays, cells were plated in Wallac 96-well sterile plates (PerkinElmer, Cat. No. 3983498). Norepinephrine (NE) Uptake Assay On day 1, cells were plated at 3,000 cells/well in growth medium and maintained in a cell incubator (37CC, 5% CO2). On day 2, growth medium was replaced with 200 nl of assay buffer (25 mM HEPES; 120 mM NaCI; 5 mM KCI; 2.5 mM CaCI2; 1.2 mM MgSO4; 2 mg/ml glucose (pH 7.4, 37°C)) containing 0.2 mg/ml ascorbic acid and 10 ^M pargyline. Plates containing cells with 200 y.l of assay buffer were equilibrated for 10 minutes at 37°C prior to addition of compounds. A stock solution of desipramine was prepared in DMSO (10 mM) and delivered to triplicate wells containing cells for a final test concentration of 1 uM. Data from these wells were used to define non-specific NE uptake (minimum NE uptake). Test compounds were prepared in DMSO (10 mM) and diluted in assay buffer according to test range (1 to 10,000 nM). Twenty-five microliters of assay buffer (maximum NE uptake) or test compound were added directly to triplicate wells containing cells in 200 u.l of assay buffer. The cells in assay buffer with test compounds were incubated for 20 minutes at 37°C. To initiate the NE uptake, [3H]NE diluted in assay buffer (120 nM final assay concentration) was delivered in 25 p.1 aliquots to each well and the plates were incubated for 5 minutes (37°C). The reaction was terminated by decanting the supernatant from the plate. The plates containing cells were washed twice with 200 JA! assay buffer (37°C) to remove free radioligand. The plates were then inverted, left to dry for 2 minutes, then reinverted and air-dried for an additional 10 minutes. The cells were lysed in 25 |jJ of 0.25 N NaOH solution (4"C), placed on a shake table and vigorously shaken for 5 minutes. After cell lysis, 75 jil of scintillation cocktail was added to each well and the plates were sealed with film tape. The plates were returned to the shake table and vigorously shaken for a minimum of ID minutes to ensure adequate partitioning of organic and aqueous solutions. The plates were counted in a Wallac Microbeta counter (PerkinElmer) to collect the raw cpm data. 5erotbrM75-HTr Uptake Assay The methods for 5-HT functional reuptake using the JAR cell line were modified using a previous literature report (Prasad, et a/., Placenta, 1996. 17(4): 201-7). On day 1, cells were plated at 15,000 cells/well in 96-well plates containing growth medium (RPMI 1640 with 10% FBS) and maintained in a cell incubator (37°C, 5% CO2). On day 2, cells were stimulated with staurosporine (40 nM) to increase the expression of the 5-HT transporter [17]. On day 3, cells were removed from the cell incubator two hours prior to assay and maintained at room temperature to equilibrate the growth medium to ambient oxygen concentration. Subsequently, the growth medium was replaced with 200 ^l of assay buffer (25 mM HEPES; 120 mM NaCI; 5 mM KCI; 2.5 mM CaCI2; 1.2 mM MgSO4; 2 mg/ml glucose (pH 7.4, 37°C)) containing 0.2 mg/ml ascorbic acid and 10 nM pargyline. A stock solution of paroxetine (AHR-4389-1) was prepared in DMSO (10 mM) and delivered to triplicate wells containing cells for a final test concentration of 1 uM. Data from these wells were used to define non-specific 5-HT uptake (minimum 5-HT uptake). Test compounds were prepared in DMSO (10 mM) and diluted in assay buffer according to test range (1 to 1,000 nM). Twenty-five microliters of assay buffer (maximum 5- HT uptake) or test compound were added directly to triplicate wells containing cells in 200 (il of assay buffer. The cells were incubated with the compound for 10 minutes (37°C). To initiate the reaction, [3H]hydroxytryptamine creatinine sulfate diluted in assay buffer was delivered in 25 ^l aliquots to each well for a final test concentration of 15 mM. The cells were incubated with the reaction mixture for 5 minutes at 37°C. The 5-HT uptake reaction was terminated by decanting the assay buffer. The cells were washed twice with 200 |ul assay buffer (37°C) to remove free radioligand. The plates were inverted and left to dry for 2 minutes, then reinverted and air-dried for an additional 10 minutes. Subsequently, the cells were lysed in 25 jj of 0.25 N NaOH (4"C) then placed on a shaker table and shaken vigorously for 5 minutes. After cell lysis, 75 \il of scintillation cocktail was added to the wells, the plates were sealed with film tape and replaced on the shake table for a minimum of 10 minutes. The plates were counted in a Wallac Microbeta counter (PerkinElmer) to collect the raw cpm data. Evaluation of Results For each experiment, a data stream of cpm values collected from the Wallac Microbeta counter was downloaded to a Microsoft Excel statistical application program. Calculations of ECso values were made using the transformed-both-sides logistic dose response program written by Wyeth Biometrics Department. The statistical program uses mean cpm values from wells representing maximum binding or uptake (assay buffer) and mean cpm values from wells representing minimum binding or uptake ((1 uM desipramine (hNET) or 1 uM paroxetine (hSERT)). Estimation of the ECso value was completed on a log scale and the line was fit between the maximum and minimum binding or uptake values. All graphic data representation was generated by normalizing each data point to a mean percent based on the maximum and minimum binding or uptake values. The ECso values reported from multiple experiments were calculated by pooling the raw data from each experiment and analyzing the pooled data as one experiment. S-HT?A FL1PR Assay Cell Conditions: CHO cells transfected with cDNA expressing the human 5-HT2A receptor are cultured in Dulbecco's modified Eagle's medium (Gibco #11995-065) supplemented with 10% fetal bovine serum, non-essential amino acids and selection markers. Cells are washed with PBS without Ca2* and 3 ml_ Trypsin is added to dissociate cells. After 3 minute incubation, 7 mL Trypsin Neutralizing Solution is added. Cells are then aspirated from flask and mixed in a 50 ml conical tube. 10 |il_ sample is used to count cells on a hemacytometer. Cells are then plated at 40,000 cells per well into sterile black 96 well plates with dear bottoms (VWR #29443-152) for 24 hours. Drug Hate" Preparation; Two 96-well drug plates are prepared for each cell plate. Plate 1 will contain compounds to be tested and plate 2 will contain the agonist DOI (3 nM) to activate a calcium response. Specific details of compound preparation are listed below. All compounds are made in 1X HBSS (Gibco #14175-095) supplemented with 20 mM HEPES (Gibco #15630-080). Outside wells are not used due to an edge effect seen in these cells. The reference compounds DO! and 5-HT are used gs standard 5HT agonists. MDL and Mianserin are used as standard 5HT2A selective receptor antagonists. Preparation of Plate 1: Test Compound Plate For screening test compounds at 1 jaM, a 1 mM stock is diluted to 19 ^M (FLIPR will make final dilution) and added to 4 wells in the test plate at 50 ^L per well. Standards for plate one are Vehicle, 1 u.M DOI, and 3 nM MDL. For ICso value determination, concentrations are generated by serial dilution of a 1 mM stock solution. On the day of the assay, test compound solutions of appropriate concentrations are diluted in assay buffer as described for single concentration testing, This procedure is followed to ensure that the solvent concentration is consistent across dilutions. The typical concentration testing range of compounds is 10"10 - 10"5 M in half log or full log increments. Preparation of Plate 2: Agonist (DOI) Plate. A 10 uM DOI stock is diluted to 60 nM and added to the respective wells. The pipeting station of the FLIPR will make an additional 20-fold dilution for a final concentration of 3 nM. Standards for this plate include Vehicle and 3 nM DOI. Calcium Dve preparation: Contents of dye vial (Molecular Devices #R8090) are dissolved in 100 mL of 1X HBSS supplemented with 20 mM HEPEiS. Aliquots can be frozen at -20°C for up to one week for future use. On the day of assay, dye is thawed and diluted to half concentration. Probenecid (Sigma #P-8761), a calcium anion exchange inhibitor, is made fresh from powder on the day of the experiment and added to the Calcium Buffer at a 2.5 mM final concentration prior to addition to the cells. FLIPR Machine Loading: Cells are allowed to adhere for 24 hours in 96-well plates. At time of assay, the cultured media is removed from the cells and replaced with 180 jjl. per well of Calcium 3 Assay Buffer and incubated for 1 hour at 37°C with 5% CO2. Cell, compound and DO! plates are loaded into the FLIPR machine. The baseline s> fluorescence level is read once every second for 1 minute. Compound (10 \iL) is transferred from the compound plate to the cells and the fluorescence level recorded every 6 seconds for 2 minutes to determine any agonist activity. Baseline fluorescence is recorded again every second for 10 seconds. For antagonist determination, 10 \iL of 3 nM DOI is transferred from the DOI plate to the cells and the fluorescence level recorded every 6 seconds for 5 minutes. The pipetting unit of the FLIPR machine completes all transfers. Analysis of Results: Single concentration , Agonist stimulation is expressed as a percentage of the response observed with 1 uM DOI. Antagonist inhibition of 3 nM DOI stimulation is expressed as a percentage of the response observed with 3 nM DOI alone. Concentration curve A 4-parameter logistic function is used to generate the EC50 values. The data are log transformed prior to analysis. The results of the standard experimental test procedures described in the preceding paragraphs are shown in Table 1: Table 1 (Table Removed) Percentage inhibition at ND = Not determined [t. ^7] When ranges are used herein for physical properties, such as molecular weight, or chemical properties, such as chemical formulae, all combinations arid subcornbinations of ranges specific embodiments therein are intended to be included. The disclosures of each patent, patent application and publication cited or described in this document are hereby incorporated herein by reference, in its entirely. Those skilled in the art will appreciate that numerous changes and Woaifica'Mflsrcari"Be made to the preferred embodiments of the invention and that such changes and modifications can be made without departing from the spirit of the invention. It is, therefore, intended that the appended claims cover all such equivalent variations as fall within the true spirit and scope of the invention. "What is Claims: 1. A compound of formula I: (Formula Removed) or a pharmaceutically acceptable salt thereof; wherein: the dotted line between Y and Z represents an optional second bond; the dotted line between the two R4 groups represents an optional heterocyclic ring of 4 to 6 ring atoms that may be formed between the two R* groups, together with the nitrogen through which they are attached; X is ~CC(Ri2)2)o-, -0(C(R12)2)o-, - or -C^C-; Y is N, C(RB)2, CRe, or C=O; Z is O, S(0)p, N, NR7, CRs, or C(R5)2; Rt is, independently at each occurrence, alkyl, alkoxy, halo, CF3, OCF3, hydroxy, alkanoyloxy, nitro, cyano, alkenyl, alkynyl, alkylsulfoxide, alkylsulfone, alkylsulfonamide, or slkylamido; or two adjacent R-[ also represent methytenedioxy; R2 is aryl substituted with 0-3 R14 or heteroaryl substituted with 0-3 R14; R3 is H or Ci-C4 alkyl; R4 is, independently at each occurrence, H, Ci-C4 alkyl, C3-Ce cycloalkyl, ar/lalkyl, heteroarylmethyl, t^doheptylmethyl, cyclohexylmethyl, cyclopentylmethyl, or cyclobutylmethyl, or both R4 groups, together with the nitrogen through which they are attached, form a heterocyclic ring of 4 to 6 ring atoms, where one carbon may "&e~<3pflWaflyTepiaced witn N- O» S, or SO2l and where any carbon ring atom or additional N atom may be optionally substituted with CrC4 alkyl, F, or CF3; Rsis, independently at each occurrence, H, Ci-C4 alkyl, aryl substituted with 0-3 Ri4( heteroaryl substituted with 0-3 R14, or cyano; or when two R8 are present, they may form a carbocyclic ring of 3-5 carbons; R6 is, independently at each occurrence, H, Ci-C4 alkyl, or cyano; R7 is H, Ci-C6 alkyl, C3-Ce cycloalkyl, aryl substituted with 0-3 R14; or heteroaryl substituted with 0-3 R14; Re is HI, or CrC4 alkyl; R9 is H, or CrC4 alkyl; R10 is, independently at each occurrence, H, or Ci-C4 alkyl; or RIO and R4 together with the nitrogen to which R* is attached form a nitrogen-containing ring containing 3-6 carbon atoms; Rti is aryl substituted with 0-3 RI or heteroaryl substituted with 0-3 RI; R12 is, independently at each occurrence, H, CrC4 alkyl; Ris is H or Ci-C4 alkyl; RH is, independently at each occurrence, alkyl, alkoxy, halo, CF3, OCFs, arylalkyloxy substituted with 0-3 RI, aryloxy substituted with 0-3 R1t aryl substituted with 0-3 RI, heteroaryl substituted with 0-3 RI, hydroxy, alkanoyloxy, nrtro, cyano, alkenyl, alkynyl, alkyteulfoxide, phenylsulfoxide substituted with 0-3 R1( alkylsulfone, phenylsulfone substituted with 0-3 RI, alkyisulfonamide, phenylsulfonamide substituted with 0-3 RI, heteroaryloxy substituted with 0-3 RI, heteroarylmethyloxy substituted with 0-3 R1t alkyiamklo, or aryiamido substituted with 0-3 Rr, or two adjacent R1 also represent methytenedioxy; m is an integer from 0 to 3; n is an integer from 1 to 2; o is an integer from 0 to 3; and p is an integer from 0 to 2; wherein 1-3 carbon atoms in ring A may optionally be replaced with N. 2. A compound according to claim 1, wherein: "OYe oSfled line""between Y and Z represents a second bond. 3. A compound according to claim 1 , wherein: X is -y, alkanoyloxy, nitro, cyano, alkenyl, alkynyl, alkylsulfoxide, alkylsulfone, alkylsulfonamide, or alkylamido; or two adjacent R\ also represent methylenedioxy; R2 is aryl substituted with 0-3 Ri4 or heteroaryl substituted with 0-3 Ri4; R3 is H or Ci-C4 alkyl; R« is, independently at each occurrence, H, d-C4 alkyl, Ca-Ce cycloalkyl, arylalkyl, heleroarylmethyl; cycioheptylmethyl, cyclohexylmelhyl, cyclopentylmeithyl, or cydobutylmethyl, or both R4 groups, together with the nitrogen through which they are attached, form a heterocyclic ring of 4 to 6 ring atoms, where one carbon may be optionally replaced with N, O, S, or SO2, and where any carbon ring atom or additional N atom may be optionally substituted with Ci-C4 alkyl, F, or CF3; Re is, independently at each occurrence, H, Ci-C4 alkyl, or cyano; R7 is H, Ci-C6 alkyl, Cz-Ce cycloalkyl, aryl substituted with 0-3 Ri4; or heteroaryl substituted with 0-3 R8 R9 is H, or Ci-C4 alkyl; . Rio is, independently at each occurrence, H, or Ci-C4 alkyl; or R10 and R4 together with the nitrogen to which R4 is attached form a nitrogen-containing ring containing 3-6 carbon atoms; Rn is, independently at each occurrence, alkyl, alkoxy, halo, CFa, OCF3, arylalkyloxy substituted with 0-3 Ri, aryloxy substituted with 0-3 Ri, aryl substituted with 0-3 RI, heteroaryl substituted with 0-3 RI, hydroxy, alkanoyloxy, nitro, cyano, alkenyl, alkynyl, aikylsulfoxide, phenylsulfoxide substituted with 0-3 R1t alkylsulfone, phsnylsulfone substituted with 0-3 RI, alkylsulfonamide, phenylsulfonamide substituted with 0-3 R1t heteroaryloxy substituted with 0-3 RI, heteroarylmethyloxy substituted with 0-3 R1( alkylamido, or arylamido substituted with 0-3 RI; or two adjacent RI also represent methylenedioxy; n is an integer from 1 to 2; p is an integer from 0 to 2; and q is an integer from 0 to 4; wherein 1-3 carbon atoms in ring A may optionally be replaced with N. 23. A compound according to daim 22, wherein: RI is, independently at each occurrence, alkyl, alkoxy, halo, OCF3, hydroxy, alkanoyloxy, nitro, or cyano. 24. A compound according to daim 22 or 23, wherein: Rz is aryl substituted with 0-2 25. A compound according to claim 22 or 23, wherein: R2 is phenyl, fluorophenyl, or difluorophenyl. 26. A compound according to any one of daims 22 to 25, wherein: Rs is H. 27. A compound according to any one of claims 22 to 26, wherein: 28. A compound according to any one of claims 22 to 27, wherein: Re is, independently at each occurrence, H, methyl, ethyl, n-propyl, or isopropyl. 29. A compound according to any one of claims 22 to 28, wherein: R7 is H, Ci-C6 alkyl, or aryl substituted with 0-3 R14. 30. A compound according to any one of claims 22 to 29, wherein: R8 is H. 31. A compound according to any one of claims 22 to 30, wherein: R9 is H. 32. A compound according to any one of claims 22 to 31, wherein: Rio is H. 33. A compound according to any one of claims 22 to 32, wherein Ri4 is, independently at each occurrence, alkyl, alkoxy, halo, CF3| OCF3l hydroxy, alkanoyloxy, nitro, oi cyano. 34. A compound according to any one of claims 22 to 33, wherein n te 1. 35. A compound according to any one of claims 22 to 34, wherein pisOor 1. 36. A compound of formula III: Ill or a pharmaceutically acceptable salt thereof; wherein: the dotted line between Y and Z represents an optional second bond; the dotted line between the two R» groups represents an optional heterocyciic ring of 4 to 6 ring atoms that may be formed between the two R4 groups, together with the nitrogen through which they are attached; Y is N, C(R6)2, CRe, or C=O; Z is O, S(0)p> N, NR7, CRs, or C(R5)2; Ri is, independently at each occurrence, alky I, alkoxy, halo, CFa, OCF3, hydroxy, alkanoyloxy, nitro, cyano, alkenyl, alkynyl, alkylsulfoxide, alkylsulfone, alkylsulfonamide, or alkyiamido; or two adjacent RI also represent methylenedioxy; R2 is aryl substituted with 0-3 R14 or heteroaryl substituted with 0-3 R14; Ra is H or Ci-C4 alkyl; R< is, independently at each occurrence, H, Ci-C4 alkyl, Cs-Ce cycloalkyl, arylalkyl, heteroarylmethyl, cydoheptylmethyl, cydohexylmethyl, cydopentylmetlriyl, or cyclobutylmethyl, or both R4 groups, together with the nitrogen through which they are attached, form a heterocyciic ring of 4 to 6 ring aioms, where one carbon may be optionally replaced with N, O, S, or SO2, and where any carbon ring atom or additional N atom may be optionally substituted with CrC4 alkyl, F, or CF3; R5is, independently at each occurrence, H, CrC4 alkyl, aryl substituted with 0-3 R14, heteroaryl substituted with 0-3 Ri4i or cyano; or when two R5 are present, they may form a carbocyclic ring of 3-5 carbons; Re is, independently at each occurrence, H, Ci-C4 alkyl, or cyano; R7 is H, Ci-C6 alkyl, Ca-Ce cycloalkyl, aryl substituted with 0-3 Rt4, or heteroaryl substituted with 0-3 Ri4; R8 is H, or CrC4 alkyl; R9isH,orCrC4alkyl; Rio is, independently at each occurrence, H, or Ci-C4 alkyl; or R10 and R4 together with the nitrogen to which R4 is attached form a nitrogen-containing ring containing 3-6 carbon atoms; R14 is, independently at each occurrence, alkyl, alkoxy, halo, CF3, OCF3, arylalkyloxy substituted with 0-3 RI, aryloxy substituted with 0-3 Ri, aryl substituted with 0-3 R1( heteroaryl substituted with 0-3 RI, hydroxy, alkanoyloxy, nitro, cyano, alkenyl, alkynyl, alkylsulfoxide, phenylsulfoxide substituted with 0-3 Ri, alkylsulfone, phenylsulfone substituted with 0-3 R1f alkylsulfonamide, phenylsulfonamide substituted with 0-3 RI, heteroaryloxy substituted with 0-3 Ri, heteroarylmethyloxy substituted with 0-3 R1f alkylamido, or arylamido substituted with 0-3 RI; or two adjacent R1 also represent methylenedioxy; n is an integer from 1 to 2; and q is an integer from 0 to 4; wherein 1-3 carbon atoms in ring A may optionally be replaced with N. 37. A compound according to claim 36, wherein: the dotted line between Y and Z represents a second bond. 38. A compound according to claim 36 , wherein: YisC(R6)2,CR6,orC=0. 39. A compound according to claim 36 or 37, wherein: Z is CR5 or C(R5)2. 40. A compound according to any one of claims 36 to 39, wherein: Ri is, independently at each occurrence, alkyl, alkoxy, halo, CF3, OCF3, hydroxy, alkanoyloxy, nitro, or cyano. 41. A compound according to any one of claims 36 to 40, wherein: R2 is aryl substituted with 0-2 R14. 42. A compound according to any one of claims 36 to 40, wherein: R2 is phenyl, fluorophenyl, or difluorophenyl. 43. A compound according to any one of claims 36 to 42, wherein: Ra is H. 44. A compound according to any one of claims 36 to 43, wherein: R4 is H or methyl. 45. A compound according to any one of claims 36 to 44, wherein: R5 is, independently at each occurrence. H, CrC< alkyl, aryl substituted with 0-3 R14. 46. A compound according to any one of claims 36 to 45, wherein: Rs is, independently at each occurrence, H, methyl, ethyl, n-propyl, isopropyl, aryl substituted with alkoxy, aryl substituted with aryloxy or phenyl substituted with 1-2 halo. 47. A compound according to any one of claims 36 to 46, wherein: Re is, independently at each occurrence, H, methyl, ethyl, n-propyl, or isopropyl. 48. A compound according to any one of claims 36 to 47, wherein: R7 is H, Ci-C6 alkyl, or aryl substituted with 0-3 R-H. 49. A compound according to any one of claims 36 to 48, wherein: ReisH. 50. A compound according to any one of daims 36 to 49, wherein: R9 is H. 51. A compound according to any one of claims 36 to 50, wherein: 52. A compound according to any one of claims 36 to 51, wherein: n is 1. 53. A compound according to any one of claims 36 to 52, wherein: q is an integer from 0 to 2. 54. A compound selected from the group consisting of: 1-[5-(benzy!oxy)-1 H-indol-1 -yl]-3-{methylarnino)-1-phenylpropan-2-o!; 1-[4-(benzyloxy)-1H-indoM-y^3-(methylamino)-1-phenylpropan-2-ol; 1 -[6-(benzyloxy)-1 H-indol-1 -yl]-3-(methylamino)-1 -phenylpropan-2-ol; 1-{7-{benzyloxy)-1 H-indol-1 -yl]-3-(methylamino)-1 -phenylpropan-2-ol; 1 -{5-[(2-rnethoxybenzyl)oxy]-1 H-indol-1 -yl}-3-{methylamino)-1 -phenylpropan-2-ol; 1 -{5-[(3-rnethoxybenzyl)oxy]-1 H-indol-1 -yl}-3-(methylamino)-1 -phenylpropah-2-ol; 1 -{5-[(4-rnethoxybenzyl)oxy]-1 H-indol-1 -yl}-3-(methylamino)-1 -phenylpropan-2-ol; 1-{5-{(2-chlorobenzyl)oxy]-1 H-indol-1 -yl}-3-(methylamino)-1 -phenylpropan-2-ol; 1 -{5-[(3-chlorobenzyl)oxy]-1 H-indol-1 -yl}-3-(methylamino)-1 -phenylpropan-2-ol; 1 -{5-{(4-1'-[2-hydroxy-3-(methylamino)-1-phenyipropyl]spiro[cydohexane-1,3'-indc!]-2'(1'H)-one; 5'-fluoPO-1 '-{2-hydroxy-3-(methylamino)-1 -phenylpropyl]spiro[cyclohexane-1,3'-indol]-2'(1 'H)-one; 7'-chloro-1 '-[2-hydroxy-3-(methylarnino)-1 -phenylpropyl]spiro[cyclohexane-1,3'-indol]-2'(1 'H)-one; 6'-fluoPo-1'-[1-(3-fluorophenyl)-2-hydroxy-3-(methylamino) propyl]spirofc)/clohexane-1,3'-indol]-2'(1 'H)-one; 3-(methylamino)-1 -phenyl-1 -spirolcyclohexane-1,3'-i ylpropan-2-ol; 1-(3=flQtiropnenyi)-3-(methylamino)-1-{3-[2-(trifluoromethoxy)phenyl]-H-indol-1 -yl}piropan-2-ol; 1 -(3-fluorophenyl)-1 -[3-(2-isopropoxyphenyl)-1 H-indol-1 -yl]-3~ rnethylamino)propan-2-ol; 1 -(3-fluorophenyl)-1-[3-(4-fluorophenyl)-1 H-indol-1-yl]-3-(methylamino)propan-2-ol; 1 -(3-fluorbphenyl)-3-(methylamino)-1 -[3-(2-phenoxyphenyl)-1 H-indol-1 -yl]propan-2-ol:; H3-(2,4-difluorophenyl)-1H-indol-1-yll-1-(3-fluorophenyl)-3-(methylamino')propan-2-ol; 1 -{3-(2,5-difluorophenyl)-1 H-indol-1 -yl]-1 -(3-fluorophenyl)-3-(methylamino)propan-2-ol; H3-(2,3-dirnethoxyphenyl)-1H-indol-1-yl]-1-(3-fluorophenyl)-3-(methylamino)propan-2-ol; 1 -[3-{2,4-dichlorophenyl>-1 H-indol-1 -yl]-1 -(3-fluorophenyl)-3~ (methylamino)propan-2-ol; 1 -[3-(2-ethoxyphenyi)-1 H-indol-1 -yl]-1 -(3-fluorophenyl)-3-(methylamino)propan-2-ol; 1 -(7-ctiloro-5-methoxy-1 H-pyrrolo[2,3-c]pyridin-1 -yl)-1 -(3-fluorophenyl)-3-(methylamino)propan-2-ol; 1-(7-<^loro-5-methyl-1H-pynrolot2,3-c]pyridin-1-yl)-3-(methylamino)-1-phenylpropan-2-ol; 1 -{5-ii>ethoxy-1 H-pyrrolo[2,3-clpyridin-1 -y l)-3r(methylamino)-1 -phenylpropan-2-ol; indol-1 -yl]propan-2-ol; 1-(3-fluorophenyl)-1-(3-isopropyl-2,3-dihydro-1H-indol-1-yl)-3-(methylamino)propan-2-ol; 1-<3-ethyl-2,3-dihydro-1 H-indol-1 -yl)-1-(3-fluorophenyl)-3-(methylamino)propan-2-ol; 1 -<3-ethyl-2,3-dihydro-1 H-indol-1 -yl)-3-(methylamino)-1 -phenylpropan-2-ol; 1 -(3-isopropyl-2,3-dihydro-1 H-indoH-yl)-3-(mettiylamino)-1 -phenylpropari-2-ol; 3-amino-1-(3,5-difIuorophenyl)-1-(3,3-dimethyl-2,3-dJhydro-1 H-indol-1 -yl)propan-2-ol; 1 -[1 -(3,5-difluorophenyl)-2-hydroxy-3-(methylamino)propyl]-7 -fluorb-3,3-dimethyl-1l3-dihydro-2H-indol-2-one; 5,7-di1luoro-1-[1-(3-fluorophenyl>-2-hydroxy-3-(iTiethylamino)propyn-3,3-dimethyl-1,3-dihydro-2H-indol-2-one; Hl^S.S-dJfluorophenyl^-hydroxy-S^inethylaminoJpropyll-S.S-dimethyl-1 ,3~dihydro-2H-indol-2-one; 1 -[2-hydroxy-3-(methylamino)-1 -phenylpropyQ-1 H-indol-5-ol; 1 -[1 -(3-fluorophenyl)-2-hydroxy-3-(methylamino)propyl]-1 H-indol-5-ol: r-'l 42-hydroxy-3-(methylamino)-1 -phenylpropyl]spiro [cyclohexane-1,3'-indol]-2'(1 'H)-one; 5-(benz;/loxy)-1-[2-hydroxy-3-(methylamino)-1-phenylpropyl]-3,3- dimethyl-1,3-dihydro-2H-indol-2-one; and pharmaeeutically acceptable salts thereof. 55. A compound selected from the group consisting of: 1 -[1 -<3-chlorophenyl)-2-hydroxy-3-(methylamino)propyt]-7-f luoro-3,3-dimethyl-1,3-dihydro-2H-indol-2-one; 1 -(3-ch!oro-5-fluorophenyl)-1 -{1 H-indol-1 -yl)-3-(methylamino)propan-2- ol; 3-chloro-N-{H2-hydroxy-3-(methylamino)-1-phenylpropyl]-1H-indol-5-yl}-4-methylbenzamide; 3-chloroN-{1 -t2-hydroxy-3-(methylamino)-1 -phenylpropyl]-2,3-dihydro-1 H-indol-5-yl}l5enzamide; 3-chloro-N-{H2-hydroxy-3-(methylamino)-1-phenylpfopyl]-1H-indol-5-yl}benzamide; N-{1 -[2-hydroxy-3-(methylamino)-1 -phenylpropyl]-2,3-dihydro-1 H-indol- 5-yl}benzamicle; ' N-{1 -l2-hydroxy-3-(methylamino)-1 -phenylpropyl]-1 H-indol-5-yQbenzamide; N-{1 -[2:-hydroxy-3-(methylamino)-1 Hphenylpropyl]-2l3-dihydro-1 H-indol-5-yi}cyclohexanecarboxamide; ^1H[2:4iydroxy-3-{methylarnino)-1-phenylpropyl]-1H-indol-5-yljcyclohexanecarboxamide; N-(3-chlorophenyl)-1-[2-hydroxy-3-(methylamino)-1-phenylpropyl]indoline-5-carboxamide; N-(3-clilorophenyl)-1-[2-hydroxy-3-(methylamino)-1-phenylpropyl]-1H-indole-5-carboxamide; 3-(methylamino)-1-(6-phenoxy-1H-indol-1-yl)-1-phenylpropan-2-ol; 3-(methylamino)-1 -(7-phenoxy-1 H-indol-1 -yl)-1 -phenylpropan-2-ol; 3-amino-1-[5-(benzyloxy)-1H-indol-1-yl]-1-phenylpropan-2-ol; xy)-1 H-indol-1 -yl]-3-(ethylamino)-1 -phenylpropan-2-ol; 1 -[5-(benzyloxy)-1 H-indol-1 -yl]-1 -phenyl-3-(propylamino)propan-2-ol; 1 -[5-(benzyloxy)-1 H-indol-1 -yl]-3-(isopropylamino)-1 -phenylpropan-2- ol; 1 -[5-(benzyloxy)-1 H-indol-1 -yl]-3--142-hydroxy-3-(isopropylamino)-1 -phenylpropyl]!>piro[cydohexane-1,3'-i 6'-fluoro-1 H2-hydroxy-1 -phenyl-3-(propylamino)propyqspiro[cyclohexane-1 .S'-i 1 l-[3-amino-2-hydroxy-1-phenylpropyl)-5l-fluorospiro[cyclohexane-1,3'-indol]-2'(1'H)-one; 1 '-{3-(ethylamino)-2-hydroxy-1 -phenylpropyl]-5'-fluorospiro[cyclohexane-1 .S'-indol^XI 'H)-one; 5'-fluoro-1 '-[2-hydroxy-3-(isopropy!amino)-1 -phenylpropyl]spiro[cyclohexane-1,3'-indol]-2'(1 'H)-one; (propylamino)propyl]spirolcyclohexane-1)3'-indol]-2t(VH)-one; 1 '-[3-(dimethylamino)-2-hydroxy-1 -phenylpropyl]-5'-fluorospiro[cyclohexane-1,3'-indol]-2'(1 'H)-one; 5'-fluoro-1 '-[2-hydroxy-3-morpholin-4-yl-1 -phenylpropyl]spiro[cydohexane-1,3'-indol]-2'(1 'H)-one; 1 '-t2-hydroxy-3-(methylamino)-1 -phenylpropyl]-5'-methoxyspiro[eyclohexane-1,3'-indol]-2'(1 'H)-one; 1 '-[2-hydroxy-3-(methylamino)-1 -phenylpropyl]-6r-methoxyspiro[cyc!ohexane-1,3'-indol]-2'(1 'H)-one; 1 '-[2-hydroxy-3-(methylamino)-1 -phenyipropyl]-2'-oxo-1 ',2'-dihydrospirolcyclohexane-I.S'-indolej-S'-carbonitrile; 1 '-[2-hydroxy-3-(methylamino)-1 -phenylpropyl]-2'-oxo-1 ',2'-dihydrospiro[cydohexane-1,3'-jndole]-6'-carbonitrile; 4', 5'-dif luoro-142-hydroxy-3-(methylamino)-1 -phenylpropyljspiro[cyclohexane-1,3'-indol]-2'(1 'H)-one; 7'-nuoro-1'-[1-(3-fluorophenyl)-2-hydroxy-3-(methyla(nino)propyl] spiro[cydohe>oane-1,3'-indol]-2'(1 'H)-one; 1 '-[1 -(3-chlorophenyl)-2-hydroxy-3-(methylamino)propyl]-6'-fluorospiro[cydohexane-1,3'-indol]-2'(1 'H)-one; 1 -{1 -(3-chloro-5-fluorophenyl)-2-hydroxy-3-(methylamino)propyl]-7-fluoro-3,3-dimethyl-i,3-dihydro-2H-indol-2-one; 1 -{3-ch toro-5-fluorophenyl)-1 -<2,3 -dihydro-1 H-indoU -yl)-3-(methylamino)propan-2-ol; 1 -{3-chloro-5-fluorophenyl)-1-(7-fluoro-3,3-dimethyl-2,3-dihydro-1 H-indol-1-yl)-3-(imethylannino)propan-2-ol; 1 -(3-diloro-5-fluorophenyl)-1 -(3,3-dimethyl-2,3-dihydro-1 H-indol-1 -yl)-3-(methylamino)propan-2-ol; 7'-fluoro-1 '-[1 -(3-fluorophenyl)-2-hydroxy-3-(methylamino)propyl]spiro[cydobutane-1,3'-indol]-2'(1 'H)-one; 7'-fluoro-1'-[1-(3-f!uoropheny!)-2-hydroxy-3-(methylamino)propyflspiro[cydopentane-1,3'-indol]-2'(1 'H)-one; ^-flu6rbr1-[1-(3-fluorophenyl)-2-hydroxy-3-(methy!amino)propyl]-3,3-dimethyl-1,3-dihydro-2H-indol-2-one; 1-(7-fluorc»-2,3-dihydro-1H-indol-1-yl)-3-(methylamino)-1-ph6nylpropai 2-ol; 4-fluoro-3-[1-(3-fluorophenyl)-2-hydroxy-3-(methylamino)propyl]-1-phenyl-1,3-dihydro-2H-benzimidazol-2-one; 4-fluoro-1 -(3-fluorophenyl)-3-[1 -(S^fluoropheny l)-2-hydroxy-3-(methylamino)propyl]-1,3-dihydro-2H-benzimidazol-2-one; 1-t3-amino-1-(3,5-difluorophenyl)-2-hydroxypropy!]-7-fluoro-3,3-dimsthyl-1,3-dihydro-2H-indo!-2-one; and pharmaceutically acceptable salts thereof. 56. A compound according to claim 54 or 55, wherein said pharmaceuticaily acceptable salt is hydrochtoride. 57. A pharmaceutical composition, comprising: a. at least one compound according to any one of claims 1 to 55, o; pharmaoeutically acceptable salt thereof; and b. at least one pharmaceuticaily acceptable carrier. 58. A method for treating or preventing a condition ameliorated by monoam reuptake in a subject in need thereof, comprising the step of: administering to said subject an effective amount of a compoi according to any one of claims 1 to 56, or pharmaceuticaily acceptable ; thereof. 59. A method according to claim 58, wherein said condition ameliorated by monoamine reuptake is selec from the group consisting of vasomotor symptoms, sexual dysfunct gastrointestinal and genitourinary disorders, chronic fatigue syndro fibromylagis syndrome, nervous system disorders, and combinations there 60. A method according to claim 59, wnerem saia conaition ameliorated by monoamine reuptake is selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof. 61. A method for treating or preventing at least one vasomotor symptom in a subject in need thereof, comprising the step of: administering to said subject an effective amount of a compound according to any one of claims 1 to 56, or pharrnaceutically acceptable salt thereof. 62. A method according to claim 61, .wherein said vasomotor symptom is hot flush. 63. A method according to daim 62, wherein said subject is human. 64. A method according to claim 63, wherein said human is a female. 65. A method according to claim 64, wherein said female is pre-menopausal. 66. A method according to claim 64, wherein said female is peri-menopausai. 67. A method according to claim 64, wherein said female is post-menopausal. 68. A method according to claim 63, wherein said human is a male. 69. A method according to claim 68, wnereTn'said'male is naturally, chemically or surgically andropausal. 70. A method for treating or preventing at least one depression disorder in a subject in need thereof, comprising the step of: administering to said subject an effective amount of a compound according to any one of claims 1 to 56, or pharmaceutically acceptable salt thereof. 71. A method according to claim 70, wherein said depression disorder is major depressive disorder, anxiety, sleep disturbance, or social phobia. 72. A method according to claim 71, wherein said subject is human. 73. A method for treating or preventing at least one sexual dysfunction in a subject in need thereof, comprising the step of: administering to said subject an effective amount of a compound according to any one of claims 1 to 56, or pharmaceutically acceptable satt thereof. 74. A method acconiing to claim 73, wherein said sexual dysfunction is desire-related or arousal-related. 75. A method according to daim 73, wherein said subject is human. 76. A method for treating or preventing pain in a subject in need thereof, comprising the step of: administering to said subject an effective amount of a compound according to any one of claims 1 to 56, or phsrmaceuticsffy acceptable salt thereof. 77.' A'tfetfiScf arcBrdlriglo claim 76, wherein said pain is acute centralized pain, acute peripheral pain, or a combination thereof. 78. A method according to claim 76, wherein said pain is chronic centralized pain, chronic peripheral pain, or a combination thereof. 79. A method according to claim 76, wherein said pain is neuropathic pain, viscera! pain, musculoskelsta! pain, bony pain, cancer pain, inflammatory pain, or a combination thereof. 80. A method according to claim 79, wherein said neuropathic pain is associated with diabetes, post traumatic pain of amputation, lower back pain, cancer, chemical injury, toxins, major surgery, peripheral nerve damage due to traumatic injury compression, post-herpetic neuralgia, trigeminal neuralgia, lumbar or cervical radiculopathies, fibromyalgia, glossopharyngeal neuralgia, reflex sympathetic dystrophy, casualgia, thalamic syndrome, nerve root avulsion, reflex sympathetic dystrophy or post thoracotomy pain, nutritional deficiencies, viral infection, bacterial infection, metastatic infiltration, adiposis dolorosa, bums, central pain conditions related to thalamic conditions, and combinations thereof. 81. A method according to daim 79, wherein said visceral pain is associated with ulcerative colitis, irritable bowel syndrome, irritable bladder, Crohn's disease, rheumatologic (arthralgias), tumors, gastritis, pancreatitis, infections of the organs, biliary tract disorders, and combinations thereof. 82. A method according to claim 76, wherein said pain is female-specific pain. :83 WTfiBBWa seeoraing'to claim 82, wherein said subject is human. 84. A method for treating or preventing gastrointestinal or genitourinary disorder in a subject in need thereof, comprising the step of: administering to said subject an effective amount of a compound according to any one of claims 1 to 56, or pharmaceutically acceptable salt thereof. 85. A method according to claim 84, wherein said disorder is stress incontinence or urge urinary incontinence. 86. A method according to claim 84, wherein said subject is human. 87. A method for treating or preventing chronic ratigue syndrome in a subject in need thereof, comprising the step of: administering to said subject an effective amount of a compound according to any one of claims 1 to 56, or pharmaceutically acceptable salt thereof. 88. A method according to daim 87, wherein said subject is human. 89. A method for treating or preventing fibromylagia syndrome in a subject in need thereof, comprising the step of: administering to said subject an effective amount of a compound according to any one of claims 1 to 56, or pharmaceutically acceptable salt thereof. 90. A method according to claim 89, wherein said subject is human. 91. A method for treating or preventing schizophrenia in a subject in need thereof, comprising the step of: administering to said subject an effective amount of a compound according to any one of claims 1 to 56, or pharmaceutically acceptable salt thereof. 92. A method according to claim 91, wherein said subject is human. 93. Use of a compound according to any one of claims 1 to 56 in the manufacture of a medicament for administration in a method according to any one of claims 58 to 92. 94. The Invention substantially such as herein before described.